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ABSTRACT  
 
This research assessed the cognitive functioning of several different drug and alcohol 
samples, with a specific focus on individuals in methadone maintenance treatment. 
Additionally, this research assessed the relation between cognitive functioning and 
adherence to treatment in these populations. This is a link that has been suggested by 
research in this area previously. The present research consisted of five experiments. 
Experiment 1 assessed the application, within New Zealand, of the normative data for 
a number of psychometric tests with a non- substance using sample of New Zealand 
university students. The results from this study showed that the scores for the 
university sample were generally similar to the normative means, suggesting that the 
existing normative data could be used in New Zealand. Experiment 2 assessed the 
cognitive functioning of university students who reported regular use of alcohol 
and/or cannabis. The results from this study showed that the frequency of alcohol use 
was positively correlated with problem solving ability, while frequency of cannabis 
use was positively correlated with memory functioning. Cannabis use was also 
associated with poorer problem solving ability. These findings showed that casual use 
of alcohol and/or cannabis was associated with poorer functioning on some 
psychometric tests, and that these tests were sensitive to the effects of substance use. 
Experiment 3 assessed the cognitive functioning of a sample of individuals in 
methadone maintenance treatment in relation to their adherence to treatment. The 
results from this study showed deficits in memory, divided attention and cognitive 
flexibility, and poor mathematical ability when compared to the normative data. 
Treatment adherence was found to be associated with lower levels of treatment 
satisfaction, and findings also suggested a possible relation between poor treatment 
adherence and better scores on the psychometric test scores. Due to difficulties in 
recruiting participants, Experiment 4 assessed the cognitive functioning of a second 
sample of individuals in methadone maintenance in relation to treatment adherence. 
This sample completed a reduced battery of psychometric tests, and results showed 
deficits in memory, attention, and problem solving abilities compared to the 
normative data. Treatment adherence was not found to be associated with lower levels 
of treatment satisfaction in this sample. A possible relation between poor treatment 
adherence and better psychometric test scores was identified for this sample also, 
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although the relation was between different test scores than those in Experiment 3. To 
assess whether the obtained results for Experiment 3 and Experiment 4 were specific 
to methadone, Experiment 5 assessed the cognitive functioning of several different 
drug and alcohol samples in relation to treatment adherence. The study examined the 
cognitive functioning of alcohol, drug and alcohol, and other opiate users, and showed 
that all samples had difficulty recalling information in a visual format, that a large 
percentage showed impairments in divided attention and cognitive flexibility, and that 
the drug and alcohol, and other opiate samples had deficits in problem solving ability. 
Treatment adherence in this study was assessed for the alcohol sample, with results 
showing a relation between poor treatment adherence and verbal memory ability, and 
divided attention and cognitive flexibility. Overall, the cognitive deficits found in the 
samples for each experiment were not related to treatment adherence as measured in 
this research. However, results for the alcohol sample suggested that there may be a 
link between poor adherence and impairments in verbal memory and divided 
attention. The findings from this research suggest that cognitive deficits and treatment 
adherence are not related, but this finding may be the result of limitations in this 
research (i.e., recruitment difficulties, adherence measures used). The clinical and 
research implications of the results of the research are discussed. In particular, 
recommendations for treatment services dealing with the drug and alcohol population 
are provided. 
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INTRODUCTION 
 
 
The cost of both licit and illicit substance use is high. Estimates from England place 
the societal cost from illicit substance use alone at over £11,000 per head of 
population per year (equivalent to NZ$19,719 per person), which is mainly 
attributable to criminal behaviour (Healey, Knapp, Astin, Gossop, Marsden, Stewart, 
Lehmann, & Godfrey, 1998). Within New Zealand, sources estimate the value of the 
New Zealand illicit drug market as being between $340 million (Nippert, 2005) and 
$1 billion per year (Anonymous, 2005b). While this is substantially lower that that 
seen in many overseas countries (Bramley-Harker, 2001; Caulkins & Reuter, 1998), 
substance use is still a serious concern within New Zealand.  
In addition to the cost to society, the cost for the individuals themselves is 
hard to estimate as this cost incorporates many factors. These include: financial 
expenditure; health consequences; the impact on family/friends; loss of productivity 
from job absenteeism; lost employment; and premature death to name but a few.  
However, while the societal and personal costs of substance use are high, the services 
that are provided to reduce these costs often have poor attendance rates, and it is 
common for individuals seeking treatment to have several treatment episodes during 
their lifetimes (National Institute on Drug Abuse, 1999; Substance Abuse and Mental 
Health Services Administration Office of Applied Studies, 2007). The reasons for 
poor attendance at such services are varied, however recent research has suggested 
that poor attendance could be a result of cognitive impairments in this population (e.g. 
Aharonovich, Nunes, & Hasin, 2003; Fals-Stewart, 1993; Fals-Stewart & Lucente, 
1994; Fals-Stewart & Schafer, 1992; Fals-Stewart, Schafer, Lucente, Rustine, & 
Brown, 1994; Teichner, Horner, Roitzsch, Herron, & Thevos, 2002; Verdejo-Garcia, 
Lopez-Torrecillas, Orozco, & Perez-Garia, 2004). 
 
Substance Use Overseas and in New Zealand 
 
Overseas research has suggested that up to 25% of individuals seen in primary 
care clinics (e.g. general practices) have an alcohol or drug disorder (Jones, Knutson, 
& Haines, 2003; Sullivan & Fleming, 1997). Additionally, over 50% of adolescents in 
the United States are likely to have experimented with illicit substances by the time 
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they graduate from high school (Gordon, Kinlock, & Battjes, 2004). While the 
majority do not continue to use substances, substance use prior to the age of 15 has 
been linked to problems with alcohol, tobacco and other substances in later life.  
Within New Zealand, the rates of illicit substance use per head of population 
appear to be similar to those seen in Australia and the United States (Black & 
Casswell, 1993), however, the substances that are available in New Zealand differ to 
those available in other countries due to the isolated nature of the country. A 
nationwide survey conducted between 1998 and 2001 (Wilkins, Casswell, Bhatta, & 
Pledger, 2002) reported rates of cannabis use (54%), and other illicit substances (4% 
opiates, 15% hallucinogens, 11.9% stimulants) in a sample of individuals aged 15-45, 
with greatest rates found for individuals aged 18-24 years (almost 60% having used 
illicit substances at least once).  Of this sample, 12.5% met the criteria for cannabis 
dependence, and 3.6% for other illicit substance dependence by the age of 25 years 
(equivalent to almost one in seven individuals). Similarly, a longitudinal study in 
Christchurch (Boden, Fergusson, & Horwood, 2006) reported that 76.1% of the 
individuals in their sample had tried cannabis and 43.5% had used other illicit 
substance on at least one occasion by the age of 25 years. The estimated prevalence 
rates of substance use disorders in New Zealand are higher than many overseas 
countries (with the exception of Australia), with 3.5% of the population having a 
substance use disorder in any 12 month period (Wells, Oakley Browne, Scott, McGee, 
Baxter, & Kokaua, 2006). Greatest prevalence rates were noted for the 16-24 year 
(9.6%) and 25-44 year (4.2%) samples, which suggests that a greater percentage of 
New Zealanders develop substance use disorders over their lifetimes.   
In addition to the societal cost of alcohol and drug use, there are a number of 
risk factors associated with the use of substances, in regards to both the method of 
substance use, and the impacts of substance use on an individual’s health. Prolonged 
use can have long-term impacts on an individuals health, with organ damage and 
cancer of particular concern (Iversen, 2001; NZPA, 2005). The manufacture of 
substances may also have detrimental effects on the individual’s health in other ways. 
For example, the manufacture of substances such as methamphetamine in clandestine 
labs produce a number of dangerous & poisonous chemicals that are harmful if 
inhaled, and also have a high risk of combustion, fire and explosion (Dann, 2005).  
Substance use has also been linked to detrimental effects on brain functioning, 
however, the long term effects of substance use on the brain are still unclear. While 
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there is no definitive answer regarding the effects of substance use on brain 
functioning, research is increasingly suggesting that while there may be some 
recovery following abstinence, this recovery may be limited (Verdejo-Garcia, Lopez-
Torrecillas, Orozco, & Perez-Garia, 2004). Impairments in functioning, either as a 
precursor to, or as a result of substance use, are increasingly being studied as this is an 
area that could be targeted with the aim of improving treatment programmes, and 
educating individuals about the harm of substance use. 
Given the number of potential health related issues and impairments in daily 
functioning that individuals may experience, due to their substance use, many 
individuals will eventually seek treatment, or may be mandated to by legal authorities. 
However, the success rates of treatment programmes vary substantially. A number of 
the available treatment approaches in the alcohol and drug field are outlined below.   
 
Treatment Approaches to Alcohol and Drug Use 
In New Zealand there are over 100 agencies that specialise in alcohol and drug 
treatment, with most services catering to both drug and alcohol populations. As at 
2005, the government contributed $72 million towards these alcohol and drug services 
(Anonymous, 2005a). Research has suggested that the majority of clients in these 
services are male (60%), and approximately 28% are Maori (Adamson, Sellman, 
Futterman-Collier, Huriwai, Deering, Todd, & Robertson, 2000). The most common 
reasons for seeking treatment are alcohol related issues (45%), cannabis use (27%), 
and opioid use (17%). These services use a wide variety of approaches to the 
treatment of alcohol and drug related problems ranging from the well know 12 step 
programmes and abstinence based treatment through to the, more recently developed, 
harm reduction approach. For a more detailed review of drug and alcohol treatment 
services see Gossop (2006) and Raistrick, Heather and Godfrey (2006).  
Of particular interest in this research were the treatment services available for 
opiate users. At the present time, the only substitution treatment option for opiate 
dependence that is available in New Zealand is Methadone Maintenance Treatment 
(MMT). Further details on MMT are provided in the following section.  
 
Treatment Services for Opiate Users 
MMT has long been provided as a treatment option for heroin dependence, 
although it is also used for other opiate use diagnoses with equal success. Within New 
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Zealand, this includes individuals who have been using substances such as temgesic, 
morphine sulphate tablets (MST), poppy extract morphine, methadone tablets, 
homebake, pethidine and palfium (Thornton, 1991). MMT is the most popular 
treatment option for opiate dependence, with overseas research suggesting that 
approximately 42.6% of individuals in treatment for drug dependence are enrolled in 
a MMT programme (Gossop, Marsden, & Stewart, 1998). Despite the high percentage 
of opioid dependent individuals in alcohol and drug treatment in general, overseas 
estimates suggest that only 15% – 25% of opioid users are in treatment at any given 
time, and that long-term treatment programmes have trouble retaining individuals 
(Rosenblum, Magura, & Joseph, 1991).  
The main objective of MMT is to improve the health of opiate users by 
minimising the harm associated with opiate use, in order for these individuals to 
maintain some stability in their daily lives. Over 500 studies have demonstrated the 
effectiveness of MMT in achieving these aims (Bryne & Newman, 1999; Ward, 
Mattick, & Hall, 1998). 
MMT programmes have been shown to decrease the risks associated with 
opiate use. Reductions in mortality, overdoses, and substance related health problems 
have been reported in MMT populations when compared to individuals who continue 
with illicit use (e.g. Collins, Hubbard, & Valley Rachal, 1985; Desmond & Maddux, 
2000; Digiusto, Shakeshaft, Ritter, O'Brien, Mattick, & NEPOD Research Group, 
2004; Gronbladh, Ohlund, & Gunne, 1990; Hall, Lynskey, & Degenhardt, 2000; 
Hickman, Madden, Henry, Baker, Wallace, Wakefield, Stimson, & Elliott, 2003; 
Milroy & Forrest, 2000; Rosinger, Finkbeiner, Krings, & Gastpar, 1998; Sheerin, 
Green, Sellman, Adamson, & Deering, 2004; Sung-Yeon, 1993; Warner-Smith, 
Lynskey, Darke, & Hall, 2001). MMT has also been linked to improved employment 
status, reduction in illicit drug use of all types, reduction in criminal behaviour, and 
overall improvement in quality of life (Latowsky & Kallen, 1997). Long-term 
maintenance on MMT has been associated with continued improvements in 
functioning (Kandel, Huang, & Davies, 2001).  
The overall costs to society additionally appear to decrease for those on MMT. 
For example, in 1996 the estimated cost per annum for an individual on MMT in New 
Zealand was $4,400 compared to the estimated $50,000 for an opioid dependent 
individual in the correctional system (Sellman, Hannifin, Deering, & Borren, 1996). 
Such comparisons in terms of cost are made as the current rate of opioid use in New 
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Zealand prisoners is estimated to be at least 10-20 times higher than the general 
population (Sellman, Hannifin, Deering, & Borren, 1996).  
 
Methadone Maintenance in New Zealand 
In 2003, it was estimated that between 13,500 and 26,000 New Zealanders 
were addicted to opiates, with a predicted increase of 15% per year (Fleming, 2003). 
To cater for this population, approximately 4000 individual MMT places are funded 
by the New Zealand Government (Sell & Zador, 2004). The cost of providing this 
treatment is estimated at $4,400 per annum per individual (Sellman, Hannifin, 
Deering, & Borren, 1996; Sheerin, Green, Sellman, Adamson, & Deering, 2004).  
In general, New Zealand MMT programmes adhere to a harm reduction rather 
than an abstinence based philosophy. Essentially, this means that methadone is 
prescribed with the aim of reducing the harm/risks associated with illegal use of 
opioids (e.g. HIV, hepatitis, unsafe injecting practices, and overdose). This is not to 
say that illegal use is condoned, although this approach generally allows for the use of 
some illegal substances while maintaining the individual’s safety.  
While methadone maintenance has been shown to be effective in reducing the 
risks associated with illicit opiate use, attendance and adherence at drug and alcohol 
services is poor. For example, it is estimated that of the appointments scheduled with 
MMT population at the Community Alcohol and Drug Service in Hamilton, 
approximately 66% of appointments are attended (Barratt, personal communication, 
2004). Possible reasons for the poor retention and adherence to treatment are outlined 
below.  
 
Retention and Adherence  
Literature in the drug and alcohol field has focused on the relationship 
between demographic factors and treatment outcomes for a number of years. 
Primarily, studies have attempted to determine the reasons why some people stay in 
treatment while others drop out. Studies have looked at several areas, including the 
retention, and adherence of individuals in treatment, however, although retention and 
adherence can be classified as distinctly different areas of treatment outcome, the 
terms are often used interchangeably.  
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Retention  
Drop-outs and poor retention have been identified as a major limitation of 
substance abuse/dependence treatments. Retention in treatment, typically defined as 
remaining in the treatment programme (Esteban, Gimeno, Barril, Aragones, Climent, 
& de la Cruz Pellin, 2003; Fals-Stewart & Lucente, 1994), has been of particular 
interest as retention rates have been repeatedly shown to be the worst in the first few 
weeks and months of drug and alcohol treatment.  
MMT retention rates, in particular, have generally been lower than those seen 
for treatment programmes that target other substances, although the retention rates 
reported in different studies vary greatly. Overseas research and service reviews 
suggest that retention and adherence rates in MMT are between 10% and 88% (e.g. 
Babst, Chambers, & Warner, 1971; Craig, 1980; D'Ippoliti, Davoli, Perucci, 
Pasqualini, & Bargagli, 1998; Del Rio, Mino, & Perneger, 1997; Dore, Walker, Paice, 
& Clarkson, 1999; Esteban et al., 2003; Gossop, Marsden, Stewart, Edwards, 
Lehmann, Wilson, & Seger, 1997; Gutierrez, Ballesteros, Gonzalez-Oliveros, & Ruiz 
de Apodaka, 1995; Maremmani, Zolesi, Aglietti, Marini, Tagliamonte, Shinderman, 
& Maxwell, 2000; Saxon, Wells, Fleming, Jackson, & Calsyn, 1996; Torrens, 
Castillo, & Perez-Sola, 1996). Within New Zealand, retention rates may vary from 
those seen overseas, although little research has been conducted in this area. Dore, 
Walker, Paice and Clarkson (1999), in the first New Zealand study of MMT 
individuals, reported a high retention rate with 86% remaining on the programme for 
6 months or longer.  
Research has suggested that the poor retention rates seen in drug and alcohol 
populations, and MMT populations specifically, may be related to treatment or 
treatment population characteristics. For example, several research studies have 
reported a relationship between methadone dose and outcome, with higher doses 
generally predictive of better treatment attendance and retention (Borg, Broe, Ho, & 
Kreek, 1999; D'Ippoliti, Davoli, Perucci, Pasqualini, & Bargagli, 1998; Farre, Mas, 
Torrens, Moreno, & Cami, 2002; Maxwell & Shinderman, 2002; Strain, Stitzer, 
Liebson, & Bigelow, 1993; Torrens, Castillo, & Perez-Sola, 1996). However, others 
have found no relationship between methadone dose and treatment retention (Blaney 
& Craig, 1999; Del Rio, Mino, & Perneger, 1997). 
Other factors that have been associated with retention include: length and 
severity of drug use (Babst, Chambers, & Warner, 1971; Del Rio, Mino, & Perneger, 
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1997); counselling attendance, and opiate abstinence at 2 weeks (Morral, Belding, & 
Iguchi, 1999); and free treatment, greater contact with treatment, and increased rating 
of client cooperation by staff (Booth, Corsi, & Mikulich-Gilbertson, 2004). Drop-out, 
or failure to remain in treatment, has been associated with increased alcohol 
dependence, cocaine dependence, decreased legal status, increased number of 
previous treatment episodes, and increased number of psychiatric problems (Simpson, 
Joe, Broome, Hiller, Knight, & Rowan-Szal, 1997). However, other studies have 
found no relationship between retention and cannabis use (Epstein & Preston, 2003).  
With retention rates in drug and alcohol services lower than many funding 
agencies would like, the possible reasons for poor retention have been examined in 
relation to adherence to treatment. The aim of assessing these factors is to identify 
those individuals who are more or less likely to succeed in treatment so that services 
can be tailored to the needs of this population. 
 
Adherence 
Adherence is defined by the American Heritage Stedman's Medical Dictionary 
(2002) as “the extent to which the patient continues the agreed-upon mode of 
treatment under limited supervision when faced with conflicting demands, as 
distinguished from compliance or maintenance”. Adherence has, however, often been 
interchangeably defined as compliance “The degree of constancy and accuracy with 
which a patient follows a prescribed regimen, as distinguished from adherence or 
maintenance” (Editors of the American Heritage Dictionaries, 2002). In the interests 
of this review both adherence and compliance have been reviewed, and defined as 
adherence.  
Research has focused on adherence in an attempt to outline the characteristics 
of individuals who do well in treatment (Gilmore, Lash, Foster, & Blosser, 2001). 
More recently, research has suggested that adherence rates are similar across 
substance disorders which may aid us in understanding the reasons for the different 
levels of adherence (Morrison, 2004). 
Adherence criteria in drug and alcohol populations have been based on a 
number of factors as outlined in Table 0.1. The criteria used to assess adherence, as 
shown in Table 0.1, have varied greatly with no preferential approach to assessment 
evident in this area. Reviews of the literature on adherence suggest that poor 
adherence is associated with lower levels of education, (Kalichman, Ramachandran, 
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& Catz, 1999; Sofuoglu, Gonzalez, Poling, & Kosten, 2003), being from an ethnic 
minority (Agosti, Nunes, & Ocepeck-Wellkson, 1996); psychiatric comorbidity (e.g. 
Alterman, McDermont, Cacciola, Rutherford, Boardman, McKay, & Cook, 1998; 
Cacciola, Alterman, Rutherford, McKay, & Mulvaney, 2001; Caplehorn, Reilly, & 
Wodak, 1993; Fals-Stewart & Lucente, 1994; Grella, 1997; McLellan, Alterman, 
Metzger, Grissom, Woody, Luborsky, & O'Brien, 1994; Messina, Farabee, & 
Rawson, 2003; Ross, Dermatis, Levounis, & Galanter, 2003; Weiss, 2004), and 
unemployment (Mutasa, 2001). Positive correlations have been found between 
adherence and motivation to seek treatment, social stability, previous treatment 
Table 0.1
Example of Treatment Adherence measures used
Study Measure/s used
(Ferrando, 1996) Mean change in biological markers in urinalysis results
Mean percentage of drug positive urinalysis results 
(Gilmore et al., 2001) Mean number of days in treatment
Completing 28 days of treatment
Mean comprehension rating
Mean motivation rating
Mean participation rating
Beginning aftercare group therapy
Mean number attended after care groups
Readmittance at 3 months
Readmittance at 6 months 
(Golin et al., 2002) Composite score from electronic medication bottle  
caps, pill count and self-report
(Morrison, 2004) Electronic monitoring
Prescription filling
Continuation in clinical studies
Percentage of patients discontinuing medication
Proportion of days on which treatment medication is taken
(Saxon et al., 1996) Illicit substance use as reflected by urinalysis results 
(Weiss, 2004) Patient interviews
Collateral reports
Rates of prescription refill
Pill counts
Serum or urine drug level monitoring
Urinary medication markers
Electronic event system monitoring systems
Daily diaries 
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(Simpson & Joe, 1993), alcohol related diagnoses (Veach, Remley, Kippers, & Sorg, 
2000); and in opiate treatment higher use of Buprenorphine (a substitute treatment for 
opioid use), lower levels of pre-treatment use prior to admission and lower doses of 
methadone while in treatment (Tremeau, Darreye, Khidichian, Weibel, Kempf, Greth, 
Schneider, Wantz, Weber, Stepien, & Macher, 2002). In particular, individuals 
seeking treatment for cocaine and opiate use have higher rates of non-adherence than 
other substance using individuals (Agosti, Nunes, & Ocepeck-Wellkson, 1996; Grella, 
1997).  
In relation to MMT specifically, research has identified a number of factors 
that may be predictive of treatment adherence. Poor adherence has been associated 
with a lack of choice in treatment options (Bell, Digiusto, & Byth, 1992), conflicts 
between treatment goals and the norms and values of the substance using population 
(Rosenblum, Magura, & Joseph, 1991), and poor treatment satisfaction (National 
Treatment Agency for Substance Misuse, 2007; Simpson, Joe, & Brown, 1997; 
Villafranca, McKellar, Trafton, & Humphreys, 2005). Additionally, it has been 
suggested that it is more difficult to maintain polysubstance users in MMT as, while 
methadone helps to treat opioid dependence, the use of other drugs or alcohol may 
interfere with an individuals ability to adhere to treatment protocols/policies (Babst, 
Chambers, & Warner, 1971).  
As can be seen, previous research has shown that there are number of possible 
predictors of adherence and retention. However, no one factor has been singled out as 
more predictive of adherence and retention across studies. A possible reason for the 
inconsistent findings in the research on adherence and retention, are the limitations 
associated with many of the studies. The major limitation is the variation in the 
measures and definitions used across studies. For example completion of treatment 
may refer to discharge based on meeting service based treatment goals, based on 
clients perception of goals achieved and therefore leaving treatment, or completion of 
time limited treatment program irrespective of current dependence; while drop-out 
can include those expelled due to poor cooperation or poor compliance, poor 
treatment attitude, client choice, poor treatment satisfaction, unsuitability of client or 
program, or lack of motivation (Lewis & Ross, 1994). Studies have also been limited 
by failing to deal with complex relationships among variables such as individual 
characteristics and program goals; differences in programs (i.e. harm reduction versus 
abstinence based, fee versus free, inpatient versus outpatient, medical versus 
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therapeutic models, qualifications of staff running program); differences in ways in 
which treatment approaches are applied; lack of control samples; issues with 
recruitment or sample selection; differences in follow-up procedures; issues with self-
report measures; changes in treatment approaches over time; small sample sizes; poor 
definitions of what treatment involves, what is required for adherence and retention, 
what constitutes ‘success’ in programs; under what circumstances individuals leave 
programs; and how regularly reviews are conducted to check individuals are 
complying with treatment, to name but a few of the factors (Condelli, 1994; Gowing, 
2001; Lewis & Ross, 1994). 
More recent studies, such as Peles, Schreider and Adelson (2006) have begun 
to use large sample sizes to address issues of power, however limitations still exist. In 
this research the treatment requirements (regular personal therapist appointments, 
therapy groups, daily dosing, take-home doses (up to 14) dependent on no drug use) 
were very specific to the treatment service which makes comparison to other studies 
difficult; treatment was fee based which may have affected participant engagement 
(i.e. more likely to engage due to cost paid/more likely to drop out as not affordable 
over time); may not be applicable to female users (almost 73% of participants were 
male); no information was provided about how retention was assessed (appears to 
have been based on those who remained in treatment but it is unclear over what time 
period) and under what circumstances individuals were not retained in treatment (I.e. 
they dropped out, they completed treatment, they were discharged for failing to 
following treatment protocols). Bell, Burrell, Indig and Gilmour (2006) in an 
Australian study, analysing predictors of retention in treatment in three cohorts in 
New South Wales over 10 year period, addressed many of the failings of previous 
studies. This study included a large sample size, across several treatment settings, 
differences in treatment approaches over time, differences in free versus fee treatment 
program, and reasons for drop-out. Even with such intensively designed research, 
limitations however still exist, such as limited information routinely collected for 
clients, differences in what ‘successful treatment’ means across treatment settings,  
differences in treatment modalities (i.e. abstinence based or harm reduction based), 
and no information on the effects of methadone dose on results. However, such 
studies are a step in the right direction, make generalization to the wider population 
more applicable, and may begin to address the inconsistencies previously seen in the 
literature. 
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As discussed above, there are a number of possible reasons why literature to 
date has been inconsistent in this area, such as the ways in which adherence and 
retention have been assessed, however it may also be due to the number of cognitive 
skills that are required to adhere to treatment. For example, individual skills needed to 
comply with treatment, such as attending weekly appointments, complying with 
treatment rules, and social interaction skills may be impaired in this group thus 
leading to poor adherence rates (Kleber, Weiss, Anton, Rounsaville, George, Strain, 
Greenfield, Ziedonis, Kosten, Hennesey, O'Brien, Smith Connery, McIntyre, Charles, 
Anzia, Nininger, Cook, Summergrad, Finnerty, Woods, Johnson, Yager, Pyles, Cross, 
Walker, Peele, Barnovitz, Hafler Gray, Shemo, Saxena, Tonnu, Kunkle, Albert, 
Fochtmann, Hart, & Regier, 2006; Weinstein & Shaffer, 1993). The majority of 
treatment approaches also include cognitive components that require attention and 
conceptual understanding which may be impaired. Recent research into this area has 
suggested that cognitive deficits may be a causal factor in poor adherence and 
retention as a number of studies have identified greater levels of cognitive impairment 
in drug and alcohol populations than in the general population.  
Cognitive impairments have been associated with shorter treatment length, 
poorer programme participation, more frequent rule violations, more frequent removal 
from treatment (Fals-Stewart & Lucente, 1994), early drop-out from treatment 
(Teichner, Horner, Roitzsch, Herron, & Thevos, 2002; Woods, Freitas, & Fas-
Stewart, 1999), higher relapse rates (Miller, 1991), continued substance use (Blume, 
Schmalinga, & Marlatt, 2005), and less treatment success (Cooney, Kadden, Litt, & 
Getter, 1991).  
Given that a number of the factors and characteristics outlined as predictive of 
retention and adherence in treatment could be a result of underlying cognitive 
impairment or difficulty, for example impulse control and decision making, further 
research is needed to better understand what, if any, cognitive impairments this 
population is likely to present with, and how these impairments might affect treatment 
outcomes. Previous research has suggested that impairments in cognitive functioning 
are likely to result in increased rule violations, difficulty maintaining abstinence, 
difficulty achieving treatment goals, and poorer clinical estimates and outcomes (e.g. 
Aharonovich, Nunes, & Hasin, 2003; Fals-Stewart, 1993; Fals-Stewart & Lucente, 
1994; Fals-Stewart & Schafer, 1992; Fals-Stewart, Schafer, Lucente, Rustine, & 
 
 12
Brown, 1994; Teichner, Horner, Roitzsch, Herron, & Thevos, 2002; Verdejo-Garcia, 
Lopez-Torrecillas, Orozco, & Perez-Garia, 2004). 
 
Relation between adherence, retention and cognitive functioning 
In order to assess how cognitive impairments may impact on MMT treatment 
in New Zealand, the cognitive skills that are needed by individuals enrolling in, and 
already on the MMT programme at CADS in Hamilton were assessed. 
In most cases, MMT requirements differ from those which individuals have 
experienced previously (e.g. picking up doses daily, not receiving a “high” from 
methadone as it is a long acting opiate – 24-36 hours, limitations on substance and 
alcohol use). Individuals that are new to the MMT programme are faced with a 
number of changes in their daily lives, including having to organise holidays/travel 
well in advance, the possible side effects of methadone, the interaction of methadone 
with other substances and/or prescription medications, and the effects of methadone 
on present medical conditions. Adapting to these changes requires a large number of 
skills, some of which consumers may not have needed previously. Therefore, 
underdevelopment of these skills may have an effect on the success of the treatment. 
The MMT programme provided by CADS Hamilton requires individuals to 
attend appointments when scheduled, and pick up their methadone dose daily. In 
addition, individuals are expected to demonstrate stability in other areas of their lives, 
which encompass cognitive skills associated with daily living to be eligible for 
‘takeaway’ doses. As individuals on MMT can choose, to a certain extent, how much 
interaction they have with CADS Hamilton, only those skills that are needed to 
comply with the minimum requirements (those skills absolutely necessary) are 
discussed here.  
In order for individuals to pick-up there methadone on a daily basis, it is 
expected that they will: 
 
1) Be told that they need to pick up their methadone daily from a specific 
pharmacy, which requires listening and attention skills; 
2) Remember that they are expected to pick up their methadone daily which 
requires short and long term memory, and recall skills (although these skills 
may be superseded by opioid withdrawal); 
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3) Be expected to attend the pharmacy during opening hours on a daily basis, 
which requires additional planning and problem solving skills.  
 
Additionally, there are a number of steps involved with regard to appointment 
attendance. Firstly, consumers must be told about the appointment, which means they 
must be able to attend and listen. Once having been told of the appointment, it is 
expected that the consumer will: 
 
1)  Comprehend the need to attend the scheduled appointment, which indicates a 
need for insight, reasoning and judgement skills;  
2)  Remember that they have an appointment, which requires short and long-term 
verbal and/or visual memory depending on the methods used to remember, 
and later recall the appointment;  
3)  Be able to form an association between the scheduled appointment and the 
date, which requires working memory skills; and  
4)  Attend the appointment on time and at the correct location, requiring 
additional planning and problem solving skills.   
 
Over time, consumers are expected to reduce their illicit drug use or face 
possible discharge from the methadone programme. It is expected, therefore, that 
consumers will, at a minimum, be able to manage impulsiveness, and also have skills 
associated with problem solving skills when faced with a situation which they have 
associated with prior opiate use. While reducing their illicit drug use, consumers are 
expected to follow guidelines regarding non-intoxication at appointments and when 
picking up methadone. This requires additional problem solving and planning skills, 
as well as the, previously mentioned, ability to control impulsiveness. 
In addition, consumers are expected to behave appropriately while at the 
service or pharmacy, with violent or threatening behaviour a criteria for review and/or 
discharge from the MMT programme. It is therefore expected that consumers will 
have appropriate social interaction skills, and have cognitive skills in areas of 
executive functioning. It is expected that consumers would need similar cognitive 
skills in order to comply with the service criteria (e.g. no involvement in serious 
criminal activity and diversion of methadone, reduction in harmful or hazardous use 
of other drugs). 
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Therefore, individuals enrolled in the MMT programme need skills in the 
following areas in order to comply with different aspects of the programme: short 
term memory; retention/recall; long term memory; working memory; listening & 
attention skills; reading skills (minimum level of 9th grade/4th form equivalent); the 
ability to control impulsivity; insight, reasoning and judgement skills; the ability to 
problem solve; and planning skills. Impairments in these cognitive areas are likely to 
lead to missed doses, poor attendance at appointments, rule violation, difficulty 
maintaining abstinence, and difficulty achieving treatment goals, all of which have 
previously been associated with poor treatment adherence.  
While cognitive impairments may be associated with treatment adherence and 
retention, the cause of these impairments remains unclear. These cognitive deficits 
may occur as a result of substance use, or they may be related to a pre-existing 
disorder, although, recent research has reported impairments associated with specific 
drug use. A further description of the cognitive impairments reported in substance 
using populations is outlined below. 
 
Cognitive functioning of substance users 
 
Previous research has suggested that a significant percentage of individuals 
with a substance use history have some type of cognitive impairment. Gillen, 
Kranzler, Kadden and Weidenman (1991) found that 25% of individuals seeking 
substance use treatment were classified as impaired on the basis of a 
neuropsychological exam. Research into the area of cognitive functioning in 
substance using populations has, however, been inconsistent, and much of the 
research that is available is limited in its application to general drug and alcohol 
populations due to stringent inclusion and exclusion criteria. 
As mentioned previously, several research studies have suggested that 
individuals with cognitive impairments are more likely to drop out of treatment, and 
have increased difficulties compared to cognitively intact individuals if they remain in 
treatment (e.g. Cooney, Kadden, Litt, & Getter, 1991; Fals-Stewart & Lucente, 1994; 
Miller, 1991; Teichner, Horner, Roitzsch, Herron, & Thevos, 2002; Woods, Freitas, & 
Fas-Stewart, 1999). Research also suggests that impairments may be a perpetuating 
factor in the continued use and or abuse of alcohol and other substances (e.g. 
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Goldman, Brown, Christiansen, & Smith, 1991; Kleber et al., 2006). However, the 
specific cognitive impairments that individuals who seek alcohol and drug treatment 
experience remain unclear. A summary of the findings in relation to cocaine, opiates, 
and polysubstance use are outlined below. 
 
Cocaine 
In many countries cocaine is one of the most widely used illicit substances 
after cannabis (Smart & Ogborne, 2000). However, cocaine dependence is not often 
seen within the New Zealand setting due to the complexities of manufacture and 
customs checks (Wilkins, Girling, & Sweetsur, 2006). As such, the number of 
referrals for the treatment of cocaine abuse/dependence is small to almost non-
existent in comparison to nearby countries such as Australia where cocaine and heroin 
use are often treated concurrently. Therefore, cocaine use was not considered to be 
relevant in the current research. 
 
Opiates 
Illicit opiates are used by an estimated 13.5 million people worldwide. This 
includes an estimated 9.2 million using heroin (World Health Organisation, 2002). In 
1996, estimates placed opiate dependence in New Zealand at 13,500-26,600 
individuals with an estimated increase of 15% a year (Sellman, Hannifin, Deering, & 
Borren, 1996).  Boden, Fergusson and Horwood (2006) in a New Zealand 
longitudinal study found that 3.7% of individuals had used opiates by the age of 25 
years.  
Heroin and injecting drug use first became widespread during the 1970’s, and 
subsequently during this time many countries first introduced MMT programmes 
(Thornton, 1991). Since the 1970’s, the supply of heroin in New Zealand has reduced 
substantially due to the increased interception of imports by police and customs 
officials. To replace this ‘lack of supply’, heroin manufacture became another ‘Kiwi 
invention’ using over the counter products containing codeine as a base to convert to 
morphine, and subsequently heroin – commonly known as ‘homebake’ (Bedford, 
Nolan, Onrust, & Siegers, 1987; Carnwath & Smith, 2002; Hannifin, 1997; Thornton, 
1991). More recently, opium poppies have been grown and cultivated in New 
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Zealand, and overseas heroin has become increasingly available, however, the large 
majority of is still ‘homebake’ (Carnwath & Smith, 2002).  
While heroin remains the main opiate used in many overseas countries, in 
New Zealand the most common opiates of abuse are methadone and morphine 
(Geevasinga, Moriarty, & Robinson, 2003). Other opiate forms that are commonly 
seen are pharmaceutical based drugs, such as codeine. 
As with other substances, opiates have been linked to deficits in cognitive 
functioning. For example, Lyvers & Yakimoff (2003), using the Wisconsin Card 
Sorting Test (WCST), found that opioid dependence, like alcohol and cocaine 
addiction is associated with a disruption of executive cognitive functions and with 
possible changes in brain function that could lead to long-term deficits. Heroin users 
(in various types of substitution treatment programmes) have also been reported to 
have deficits in abstraction and learning, spatial working memory, and to make more 
perseverative errors on tasks when using the Cambridge Neuropsychological Test 
Automated Battery (CANTAB), however, they obtained above average scores on the 
National Adult Reading Test (NART) (108.9) (Ornstein, Iddon, Baldacchino, 
Sahakian, London, Everitt, & Robbins, 2000). Overall, however, as with other 
substances, the literature on the impairments in opiate users is inconsistent. The 
impairments that have been reported in individuals following the use of Heroin, 
Methadone, and other Opiates are outlined below.  
 
Heroin 
The prevalence of heroin dependence is estimated at between 3 –8 per 1000 
adults in many overseas countries including Australia, Britain and wider Europe 
(Hall, Ross, Lynskey, Law, & Degenhardt, 2000). Estimates in New Zealand suggest 
that the prevalence of lifetime heroin use in individuals aged 13-65 years is 0.5% 
(Ministry of Health, 2007), although, as with overseas populations, this figure may be 
increasing, which could be as a result of a number of factors including increases in 
purity and availability (Hall, Ross, Lynskey, Law, & Degenhardt, 2000). As with the 
variation in access to heroin, the method of taking heroin tends to differ across 
countries with patterns in the UK showing more smoking and ‘chasing’ (approx 40% 
in treatment smoked heroin prior to entry) rather than injecting of heroin, which was 
the sole route of administration in Australia until the late 1990’s (Maher, Dixon, Hall, 
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& Lynskey, 1998). The route of heroin administration in New Zealand does not 
appear to have been researched. 
Heroin is viewed as a highly addictive drug, and recent evidence suggests this 
may be due to chemical changes that occur in the brain of the individual after initial 
experimentation. Research suggests that individuals develop a cognitive processing 
bias where by individuals excessively focus on drug-related cues (Franken, Kroon, 
Weirs, & Jansen, 2000; Franken, Stam, Hendriks, & van der Brink, 2003). Research 
also suggests that heroin users often have little insight into their own risks of 
overdosing, in fact they appear to underestimate this risk significantly (Warner-Smith, 
Lynskey, Darke, & Hall, 2001). In addition to this, heroin users have been reported as 
showing other cognitive deficits such as impairment in attention (e.g. Guerra, Solé, 
Camí, & Tobeña, 1987; Prosser, Cohen, Steinfeld, Eisenberg, London, & Galynker, 
2006; Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 2005), but not all research 
agrees with this (Fields & Fullerton, 1975; Guerra, Solé, Camí, & Tobeña, 1987; Pau, 
Lee, & Chan, 2002; Roberts & Horton, 2000). Perception abilities have been reported 
as unimpaired in heroin users (e.g. Galski, Williams, & Ehle, 2000; Wang, Liu, Chen, 
Sun, Fu, Ma, He, Wang, Wilson, Carlson, & Ma, 2007). 
Memory deficits have been more consistently reported in heroin using 
populations. Deficits in verbal and visual memory (Ersche, Clark, London, Robbins, 
& Sahakian, 2006; Fishbein, Hyde, Eldreth, London, Matochik, Ernst, Isenberg, 
Steckley, Schech, & Kimes, 2005; Fishbein, Krupitsky, Flannery, Langevin, 
Bobashev, Verbitskaya, Augustine, Bolla, Zvartau, Schech, Egorova, Bushara, & 
Tsoy, 2007; Prosser et al., 2006), and working memory (Fishbein et al., 2005; 
Fishbein et al., 2007; Guerra, Solé, Camí, & Tobeña, 1987; Verdejo, Toribio, Orozco, 
Puente, & Perez-Garcia, 2005) have been reported. However, findings are 
inconsistent, with some studies reporting no deficits in memory (Guerra, Solé, Camí, 
& Tobeña, 1987), while other studies have reported memory abilities superior to 
controls (Fields & Fullerton, 1975). 
The verbal functioning of heroin users has been reported to be both impaired 
(e.g. Guerra, Solé, Camí, & Tobeña, 1987; Prosser et al., 2006) and not impaired 
(Guerra, Solé, Camí, & Tobeña, 1987; Verdejo, Toribio, Orozco, Puente, & Perez-
Garcia, 2005), while intellectual functioning has been reported as lower, on average, 
than the general population (e.g. Fishbein et al., 2005; Fishbein et al., 2007; Kirby & 
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Petry, 2004; Mintzer, Copersino, & Stitzer, 2005; Prosser et al., 2006; Verdejo, 
Toribio, Orozco, Puente, & Perez-Garcia, 2005). 
Cognitive flexibility deficits have been inconsistently reported in heroin users. 
Deficits have been reported with regard to impulsivity (e.g. Fishbein et al., 2005; 
Fishbein et al., 2007; Heyman & Dunn, 2002; Kirby & Petry, 2004; Lee & Pau, 2002; 
Pau, Lee, & Chan, 2002; Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 2005), 
and decision making and problem solving (e.g. Fishbein et al., 2005; Fishbein et al., 
2007; Petry, Bickel, & Arnett, 1998). In contrast, other studies have found no deficits 
in impulsivity (Fishbein et al., 2007), decision making and problem solving (Ersche, 
Roiser, Clark, London, Robbins, & Sahakian, 2005; Mintzer, Copersino, & Stitzer, 
2005; Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 2005), mental flexibility and 
abstraction (Pau, Lee, & Chan, 2002), and cognitive flexibility (Verdejo, Toribio, 
Orozco, Puente, & Perez-Garcia, 2005). Psychomotor speed has been reported as both 
impaired (Fishbein et al., 2005; Fishbein et al., 2007) and not impaired in heroin users 
(Fishbein et al., 2005; Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 2005). 
As with many other substances, the cognitive functioning of both current and 
abstinent heroin users varies across studies, although in general, memory, impulse 
control and inhibition appear to be impaired in the majority of studies. The 
inconsistent results to date could be attributed to a variety of factors including other 
substance use, measures used, and exclusion and inclusion criteria. Another factor that 
is likely to have influenced results that have been obtained in recent years is the 
increase of heroin use by middle class populations, where traditionally heroin has 
been seen as a ‘poor mans drug’ (Carnwath & Smith, 2002).  
 
Methadone 
Methadone is a synthetic substance that is chemically different from 
morphine, but has similar chemical actions and effects (Milroy & Forrest, 2000). 
When taken orally in a liquid form, methadone is absorbed well by the gastrointestinal 
tract, and has a typical half life of 10 to 18 hours, although it can last as long as 25 
hours or more. Because of the long half life of methadone, it lends itself readily to the 
treatment of opiate dependence as individuals are not left feeling uncomfortable soon 
after they have consumed their dose (which can occur when methadone is injected, or 
with other opiate treatment options). Methadone has also been considered useful in 
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the treatment of opiate dependence as it does not create an instant euphoria and rush 
that many individuals associate with the pleasurable rush from heroin.  
In addition to being a prescription medication, methadone is often used illicitly 
by opiate dependent individuals. Illicit methadone is usually methadone that has been 
prescribed and then diverted, either through the methadone being held in the mouth 
during observed consumption and then regurgitated, or through diversion of a 
prescribed ‘takeaway’ methadone dose. The impact of methadone on cognitive and 
neuropsychological functioning has not received as much attention as other 
substances such as alcohol, cannabis, cocaine or heroin and the research that does 
exist in this area has been inconsistent, as with other opiates. 
 Attention deficits have been reported in individuals on MMT programmes 
(e.g. Darke, Sims, McDonald, & Wickes, 2000; Mintzer & Stitzer, 2002; Prosser et 
al., 2006; Specka, Finkbeiner, Lodemann, Leifert, Kluwig, & Gastpar, 2000; Verdejo, 
Toribio, Orozco, Puente, & Perez-Garcia, 2005), but not all research agrees with this 
finding (Kelley, Welch, & McKnelley, 1978). Deficits in perception have also been 
reported, although not in distance perception and time estimation (Kelley, Welch, & 
McKnelley, 1978; Mintzer & Stitzer, 2002). 
  Memory deficits have been reported more consistently in individuals on MMT 
programmes. Deficits in memory in general (Ersche, Clark, London, Robbins, & 
Sahakian, 2006; Grevert, Masover, & Goldstein, 1977; Mason, Kocsis, Melia, Khuri, 
Sweeney, Wells, Borg, Millman, & Kreek, 1998; Prosser et al., 2006), working 
memory (Mintzer & Stitzer, 2002; Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 
2005), meta memory (Mintzer & Stitzer, 2002), and long-term visual and verbal 
memory (Darke, Sims, McDonald, & Wickes, 2000) have been reported. Results have 
been less consistent when assessing short-term visual and verbal memory with studies 
both reporting both deficits (Curran, Kleckham, Bearn, Strang, & Wanigaratne, 2001; 
Darke, Sims, McDonald, & Wickes, 2000; Gritz, Shiffman, Jarvik, Haber, Dymond, 
Coger, Charuvastra, & Schlesinger, 1975; Kelley, Welch, & McKnelley, 1978) and no 
deficits (Kelley, Welch, & McKnelley, 1978). No impairments have also been 
reported when assessing long-term episodic memory (Mintzer & Stitzer, 2002). 
Impairments in verbal functioning (Prosser et al., 2006), and learning (Gritz et 
al., 1975) have been reported, however, other research has disagreed with this finding 
(Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 2005). Overall, assessments of 
intellectual functioning in individuals on MMT programmes have reported lower 
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levels of intellectual functioning than found in the general population (e.g. Avants, 
Margolin, Warburton, Hawkins, & Shi, 2001; Darke, Sims, McDonald, & Wickes, 
2000; Gruber, Tzilos, Silveri, Pollack, Renshaw, Kaufman, & Yurgelun-Todd, 2006; 
Mintzer, Copersino, & Stitzer, 2005; Prosser et al., 2006). 
Deficits in the executive functioning of individuals on MMT programmes 
have been reported by the majority of studies in this area. Impairments in cognitive 
flexibility (Avants, Margolin, Warburton, Hawkins, & Shi, 2001; Verdejo, Toribio, 
Orozco, Puente, & Perez-Garcia, 2005), planning, problem solving and analogue 
reasoning (Darke, Sims, McDonald, & Wickes, 2000; Ersche, Clark, London, 
Robbins, & Sahakian, 2006; Heyman & Dunn, 2002; Mintzer & Stitzer, 2002; 
Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 2005), and impulsivity and 
inhibition (Ersche et al., 2005; Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 
2005) have been reported. In contrast, some studies have found no impairments in 
cognitive flexibility (Gruber et al., 2006).  
Psychomotor functioning deficits have been inconsistently reported. Some 
studies have reported deficits in psychomotor speed/cognitive speed (Mintzer & 
Stitzer, 2002), while others have found none (Gordon, 1970; Kelley, Welch, & 
McKnelley, 1978). Additionally, psychomotor functioning has been shown to 
improve after two months on methadone maintenance (Gruber et al., 2006). 
To date, the research assessing the cognitive functioning of individuals on 
methadone maintenance has been inconsistent; however, findings generally suggest 
that impairments in attention, memory and cognitive flexibility are more likely when 
compared to both controls and other substance using samples. The inconsistency in 
findings could be the result of the wide variety of substances that are generally used 
by opiate populations, as well as comorbid alcohol and other drug issues. The time of 
the last methadone dose, the amount of time on methadone and whether an individual 
has stabilised on their methadone dose may have affect assessment results also.  
 
Other Opiates 
At least one study has examined the cognitive effects of Buprenorphine (an 
alternative treatment option to methadone). Madden, Petry, Badger and Bickel (1997) 
reported on a sample of 18 individuals receiving Buprenorphine treatment for a 
average of 3.7 months. Results indicated that individuals, when compared to controls, 
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showed impairments in impulsivity, but obtained intellectual functioning scores that 
were similar to the normal population.  
 
In summary, the findings with opiate populations have been inconsistent; 
however, research generally suggests that impairments in attention, memory, and 
cognitive flexibility are more likely in opiate users than in the general population. 
Variations in the impairments noted above, differ with the type of opiate being used, 
and may have been influenced by ease of access (for example, individuals on MMT 
programmes have a constant supply of an opiate of a known quantity and quality). 
Therefore, further research is needed to ascertain the cognitive impairments that are 
present in opiate populations, and how these impairments may influence treatment 
adherence and retention.  
Polysubstance Use 
Increasingly, literature is suggesting that treatment of singular substance using 
individuals is rare, with the majority of individuals using at least one other substance 
in additional to their primary substance of choice (Campbell, 2001; Darke & Hall, 
1995; Kandel, Huang, & Davies, 2001). Opiate users in particular, use a wide variety 
of substances such as alcohol, benzodiazepines, amphetamines and cocaine (Ward, 
Bell, Mattick, & Hall, 1997), and research suggests that they are likely to continue to 
do so even after they have enter treatment programmes such as MMT (Stitzer, 
Bigelow, Liebson, & Hawthorne, 1982). Research from South London suggests that 
polysubstance use is a major issue in opiate users seeking treatment, with 70% 
reporting concurrent heroin and crack cocaine use, and some individuals also 
reporting the use of diazepam (11%), methadone (9%) and cocaine powder (8%) in 
combination with heroin (Beswick, Best, Rees, Coomber, Gossop, & Strang, 2001). 
Within New Zealand, and in some overseas countries, benzodiazepine use, in 
particular, is often seen in individuals receiving MMT (Stitzer, Bigelow, Liebson, & 
Hawthorne, 1982). Cannabis and alcohol use are also commonly seen (Campbell, 
2001). Polysubstance use, as outlined above, does not always cease when individuals 
enter treatment. For example, Anglin (1989) assessed the use of alcohol by 375 
individuals in treatment for heroin addiction, and found that alcohol and heroin use 
were inversely related, with individuals increasing their use of alcohol as heroin use 
decreased. Anglin (1989) also proposed that this is a lifelong pattern, with individuals 
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substituting other substances to compensate for the decrease in their primary 
substance of choice.  
Research, such as that outlined in the previous sections, has suggested that 
there are greater levels of cognitive deficits in substance using populations than the 
general population. Similarly, this is likely to be true for polysubstance users; 
however, research has often excluded polysubstance users from samples, and has 
focused instead on individuals with a history of using only one substance. Research 
studies that have included polysubstance users have reported higher rates of 
impairments. For example, Bruhn and Maage (1975) found that 37% of polysubstance 
users were impaired two to three weeks after they entered treatment and 34% at three-
month follow-up when assessed using the Halstead-Reitan. This is much higher than 
the rates reported earlier for individuals using single substances. The cognitive 
impairments reported, to date, with polysubstance users are summarised below. 
 The majority of studies that have included polysubstance users have reported 
no impairments in attentional abilities (e.g. Amir & Bahri, 1999; Barker, Bigler, 
Johnson, Anderson, Russo, Boineau, & Blatter, 1999; Beatty, Blanco, Hames, & 
Nixon, 1997; Bruhn & Maage, 1975; Horner, 1997; Kelly, Johnson, Knoller, 
Drubach, & Winslow, 1997; Reay, Hamilton, Kennedy, & Scholey, 2006). However, 
there are some studies that disagree with this finding (Heishman, Weingartner, & 
Henningfield, 1999; Lisdahl Medina, Shear, & Schafer, 2006). Few studies have 
assessed perception in polysubstance users, however, the studies that have, reported 
impairment in this area (Heishman, Weingartner, & Henningfield, 1999). 
 Reported memory deficits in polysubstance users have varied. Studies have 
found no impairments in visual memory (Bruhn & Maage, 1975), semantic memory 
(Bruhn & Maage, 1975; Horner, 1997), working memory and explicit recall (Bruhn & 
Maage, 1975; Nixon, Paul, & Phillips, 1998), and in memory and learning (Heishman, 
Weingartner, & Henningfield, 1999). Other studies have reported no impairments in 
verbal learning and memory (Horner, 1997; Lisdahl Medina, Shear, & Schafer, 2006), 
visuospatial learning and memory (Beatty, Blanco, Hames, & Nixon, 1997; Fishbein 
et al., 2007; Nixon, Paul, & Phillips, 1998; Reay, Hamilton, Kennedy, & Scholey, 
2006; Selby & Azrin, 1998; Verdejo-Garcia, Lopez-Torrecillas, Aguilar de Arcos, & 
Perez-Garcia, 2005), and short-term memory (Bruhn & Maage, 1975; Croft, Mackay, 
Mills, & Gruzelier, 2001; Kelly, Johnson, Knoller, Drubach, & Winslow, 1997). 
However, the majority of studies with polysubstance users have reported deficits in 
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memory, including implicit memory (Gonzalez, Vassileva, Bechara, Grbesic, 
Sworowski, Novak, Nunnally, & Martin, 2005), verbal learning and memory (Barker 
et al., 1999; Horner, 1997; Kelly, Johnson, Knoller, Drubach, & Winslow, 1997; 
Reay, Hamilton, Kennedy, & Scholey, 2006; Selby & Azrin, 1998; Verdejo-Garcia, 
Lopez-Torrecillas, Aguilar de Arcos, & Perez-Garcia, 2005), short and long term 
memory (Bruhn & Maage, 1975; Fillmore & Rush, 2006; Fishbein et al., 2007; Grant, 
Contoreggi, & London, 2000; Heishman, Weingartner, & Henningfield, 1999; 
Horner, 1997; Kelly, Johnson, Knoller, Drubach, & Winslow, 1997; Nixon, Paul, & 
Phillips, 1998; Verdejo-Garcia, Lopez-Torrecillas, Aguilar de Arcos, & Perez-Garcia, 
2005), working memory (Croft, Mackay, Mills, & Gruzelier, 2001; Fishbein et al., 
2007; Horner, 1997; Nixon, Paul, & Phillips, 1998; Reay, Hamilton, Kennedy, & 
Scholey, 2006; Selby & Azrin, 1998), and general memory (Kandel, Huang, & 
Davies, 2001; Weaver, Madden, Charles, Stimson, Renton, Tyrer, Barnes, Bench, 
Middleton, Wright, Paterson, Shanahan, Seivewright, & Ford, 2003). 
 Studies assessing intellectual functioning in polysubstance users have reported 
scores well above the normative data (Callaly, Trauer, Munro, & Whelan, 2001; 
Kokkevi & Stefanis, 1995; Marsden, Gossop, Stewart, Rolfe, & Farrell, 2000; Milby, 
Sims, Khuder, Schumacher, Huggins, McLellan, Woody, & Haas, 1996; Ministry of 
Health, 2001b), similar to the normative data (Callaly, Trauer, Munro, & Whelan, 
2001; Kokkevi & Stefanis, 1995; Rounsaville, Weissman, Kleber, & Wilber, 1982; 
Sellman, Hannifin, Deering, & Borren, 1996), and lower than the normative data 
(Callaly, Trauer, Munro, & Whelan, 2001; Gilewski, Zelinski, & Schaie, 1990; 
Kokkevi & Stefanis, 1995; Kosten, Rounsaville, & Kleber, 1982; Rounsaville, 
Weissman, Kleber, & Wilber, 1982; Sellman, Hannifin, Deering, & Borren, 1996; 
Zakzanis, Leach, & Kaplan, 1998).  
 Reported deficits in the cognitive flexibility of polysubstance users have 
varied also. Impairments have been reported in cognitive flexibility (e.g. Adrian & 
Barry, 2003; Aharonovich, Hasin, Brooks, Liu, Bisaga, & Nunes, 2005; Landro, 
Stiles, & Sletvold, 2001; Lezak, Howieson, Loring, Hannay, & Fisher, 2004; Porter, 
Gallagher, Thompson, & Young, 2003; Thakker, Ward, & Strongman, 1999), 
decision making and problem solving (e.g. Comijs, Deeg, Dik, Twisk, & Jonker, 
2002; , 2000; Gilewski, Zelinski, & Schaie, 1990; Hilsabeck, Hassanein, Ziegler, 
Carlson, & Perry, 2005; Jones, 2001; Lezak, Howieson, Loring, Hannay, & Fisher, 
2004; Ministry of Health, 2001a; Rehm, Bondy, Sempos, & Vuong, 1997; Single, 
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Robson, Rehm, & Xi, 1999), and impulsivity and inhibition (e.g. Corrigan, 2004; 
Darke, Ross, Hando, Hall, & Degenhardt, 2000; Degenhardt & Topp, 2003; Gossop, 
Stewart, Treacy, & Marsden, 2002; Strain, Brooner, & Bigelow, 1991). Conversely, 
some studies have found no impairments in decision making and problem solving 
(e.g. Avants, Warburton, & Margolin, 2000; Berglund, Leijonguist, & Horlen, 1977; 
Fals-Stewart, 1993; Fals-Stewart & Lucente, 1994; Fals-Stewart & Schafer, 1992; 
Field & Casswell, 1999; Katz, King, Schwartz, Weintraub, Barksdale, Robinson, & 
Brown, 2005; New Zealand Health Information Service, 2001; O'Leary, Donovan, 
Chaney, & Walker, 1979; Wilkins, Casswell, Bhatta, & Pledger, 2002), inhibition and 
impulse control (e.g. Barker-Collo, 2001; NZPA, 2005; Shepherd & Leathem, 1999; 
Tanaka-Matsumi, Seiden, & Lam, 1996; van de Vijver & Tanzer, 2004). 
 Psychomotor functioning has been studied less frequently in polysubstance 
populations; and the little research that has been done is inconclusive. The 
psychomotor functioning of polysubstance users has been reported as both impaired 
(Knight, 1984, , 1997; McKerracher, Rich, & Niven, 1988) and not impaired 
(Hammersley, 1995; Nelson, 1991; Strauss, Sherman, & Spreen, 2006). 
  
Overall Findings on the Cognitive Functioning of Substance Users  
Overall, research suggests that the use of substances or alcohol can result in 
short-term, if not long-term permanent damage to the brain. However, despite 
numerous research articles assessing the relationship between substance use and 
cognitive functioning impairments, results have been inconsistent and are often very 
unclear as to the relationship between the substance use and exact impairments. The 
findings to date, while being inconsistent, suggest that a large percentage of the drug 
and alcohol using population have some type of cognitive impairment that is likely to 
impact on the daily functioning of these individuals, and that these deficits are not 
commonly seen in the general population. At this time, more research is needed to 
assess the cognitive deficits that this population experiences, the impact of these 
deficits on daily functioning, and the impact of these deficits on treatment outcomes.  
Firstly, however, the reasons for the inconsistency in the results, to date, need to be 
identified. The reported impairments in the cognitive functioning of substance users 
could be influenced by a number of factors, including psychiatric disorders, health 
problems, head injuries and overdoses. Specifically in relation to opioid use and 
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cognitive functioning, reviews have highlighted issues regarding: absence of 
demographic information for comparison and small number of measures; measures 
not validated or reliable; lack of comparison samples; samples using other substances 
in addition to methadone (i.e. benzodiazepines); high number of head injuries; testing 
conducted prior to dosing therefore individuals may have been in withdrawal; limited 
information about current drug use; difficulties in differentiating between 
impairments attributable to acute dosing, chronic dosing, poly-drug abuse, and other 
confounding factors versus impairments that predated the opioid abuse (Mintzer, 
2007).  
While many studies aim to control for at least some of these confounding 
variables, the remaining uncontrolled variables could account for some of the 
inconsistency in the results reported. The most commonly identified confounding 
variables are discussed below. 
 
Psychiatric Comorbidity 
Substance using populations have been consistently shown to present with 
high rates of comorbid psychiatric disorders (Kandel, Huang, & Davies, 2001; 
Weaver et al., 2003), with research commonly suggesting a link between substance 
use and self-medicating behaviour. New Zealand research and service provision 
suggests that similarly high rates of comorbidity exist in the New Zealand population 
(Sunderland, Watts, Baddeley, & Harris, 1986).  
Opiate populations, in particular, have been shown to have higher rates of 
comorbid psychiatric disorders than the general population with estimates suggesting 
up to 90% of individuals have a current or lifetime psychiatric disorder other than 
substance use disorders (Callaly, Trauer, Munro, & Whelan, 2001; Kokkevi & 
Stefanis, 1995; Marsden, Gossop, Stewart, Rolfe, & Farrell, 2000; Milby et al., 1996). 
The comorbid disorders identified most commonly include depression (Callaly, 
Trauer, Munro, & Whelan, 2001; Kokkevi & Stefanis, 1995; Rounsaville, Weissman, 
Kleber, & Wilber, 1982; Sellman, Hannifin, Deering, & Borren, 1996), anxiety 
(Callaly, Trauer, Munro, & Whelan, 2001; Kokkevi & Stefanis, 1995; Rounsaville, 
Weissman, Kleber, & Wilber, 1982), and personality disorders (in particular antisocial 
personality disorder) (Kokkevi & Stefanis, 1995; Kosten, Rounsaville, & Kleber, 
1982; Rounsaville, Weissman, Kleber, & Wilber, 1982; Sellman, Hannifin, Deering, 
& Borren, 1996). Comorbid substance use disorders are also common, particularly 
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alcohol use (Rounsaville, Weissman, Kleber, & Wilber, 1982; Sellman, Hannifin, 
Deering, & Borren, 1996).  
While comorbid psychiatric disorders may increase the complexities of 
treatment provision for individuals with alcohol and substance use disorders, 
psychiatric disorders have also been associated with poorer performance on a number 
of psychometric measures. For example, a number of studies have associated 
depression with memory deficits (e.g. Gilewski, Zelinski, & Schaie, 1990; Zakzanis, 
Leach, & Kaplan, 1998), as well as impairments in attention, executive functioning 
and other aspects of cognitive functioning (Aharonovich et al., 2005; Landro, Stiles, 
& Sletvold, 2001; Porter, Gallagher, Thompson, & Young, 2003). Impairments have 
also been associated with test anxiety, as well as higher levels of general anxiety 
(Lezak, Howieson, Loring, Hannay, & Fisher, 2004).  
 
Health Impacts 
Health related problems have been suggested as a confounding variable in the 
studies reporting cognitive impairments in alcohol and substance users. These health 
problems largely result from substance use, and include liver function abnormalities, 
gastrointestinal disorders, cardiovascular problems, and neurological problems in 
individuals in treatment for alcohol abuse/dependence (Adrian & Barry, 2003; 
Thakker, Ward, & Strongman, 1999). Health related consequences associated with 
alcohol and other substance use can also include blood born viruses such as Hepatitis 
C, Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency 
Syndrome (AIDS), respiratory diseases, heart disease, cancer and stroke (Jones, 2001; 
Ministry of Health, 2001a; Rehm, Bondy, Sempos, & Vuong, 1997; Single, Robson, 
Rehm, & Xi, 1999).     
A link between memory complaints and health problems has been suggested, 
and this have influenced the results reported in the literature to date (Gilewski, 
Zelinski, & Schaie, 1990). The numerous different medications that are used to treat 
these health related problems could impact on functioning levels, which in turn could 
influence how and when treatment is sought, how treatment can be delivered, what 
diagnoses are given, and how treatment results are analysed. For example, research 
has suggested that interferon treatment for Hepatitis C may impact cognitive 
functioning, at least during the time that the individuals is on the treatment regime 
(Hilsabeck, Hassanein, Ziegler, Carlson, & Perry, 2005). 
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Other health related concerns that occur prior to treatment, such as head 
injuries or overdoses, may also influence psychometric assessment in this population, 
both in choice of measures and in results obtained. Given the number of possible 
comorbid problems, and that in many cases there are no visible signs of disability, 
staff may interpret these behaviours as being intentionally difficult on the behalf of 
the client group (Corrigan, 2004).  
 
Polysubstance Use 
As mentioned earlier, exclusive substance use has become less common 
among individuals seeking treatment for drug and alcohol use (Darke, Ross, Hando, 
Hall, & Degenhardt, 2000; Degenhardt & Topp, 2003; Gossop, Stewart, Treacy, & 
Marsden, 2002). In particular, individuals seeking treatment for opioid use often have 
a history of polysubstance use, which appears to increase the number of issues that 
these individuals experience. For example, Strain, Brooner & Bigelow (1991) found 
that, in a sample of 66 individuals enrolled in a methadone maintenance programme, 
the majority of individuals met the criteria for multiple substance use disorders, and 
that a greater number of substance use disorders were noted in individuals with other 
comorbid non-substance psychiatric disorders.  
The use of a combination of different substances is likely to had lead to 
different impairments being reported by different individuals, in some of the studies 
mentioned previously. Differences in the substances that are available for 
consumption, the way these substances are produced, or the potency of substances, 
are also likely to have affected the impairments that have been reported. For example, 
within New Zealand research has suggested that the use of LSD and marijuana occur 
at similar rates to overseas countries; however, New Zealand has higher rates of 
ecstasy and amphetamine use; and lower rates of cocaine and tranquilliser use (New 
Zealand Health Information Service, 2001; Wilkins, Casswell, Bhatta, & Pledger, 
2002). By comparison, other research has suggested that New Zealand has rates of 
alcohol, cannabis, and other drugs use that are similar to other countries, with the 
exceptions of hallucinogens which are used more frequently in New Zealand, and 
heroin and cocaine which are used more frequently in Australia (Field & Casswell, 
1999). Given that substances use in New Zealand differs from that reported overseas, 
an important step in understanding the impact of substance use on cognitive 
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functioning with the New Zealand population is to examine what differences exist 
between drug use in this country and overseas. 
 
Psychometric measures 
A large number of different psychometric measures have been used to assess 
the cognitive functioning of individuals with alcohol and/or substance use. 
Psychometric tests that purport to measure the same areas of cognitive functioning 
often produce different results when administered to the same individual. This 
disparity in results suggests that these measures that may be measuring slightly 
different aspects of the same cognitive ability. 
 In addition, psychometric measures with poor validity and reliability are 
sometimes used, as are tests that have not been developed for the purposes for which 
they are used. A more thorough discussion of the influence of psychometric measures 
on research outcomes is included in the section titled The Present Research. 
 
The Cause of Impairments 
Despite the high rate of comorbidity between substance use disorders and 
psychiatric disorders, it is often unclear which precedes the other – are substances 
used as a coping mechanism, or as self-medication of a psychiatric disorder or other 
difficulty, or does the substance use occur first with psychiatric comorbidity occurring 
as a result? To the individuals themselves, this distinction may not appear to be 
important, however, an increasing amount of research is showing a link between 
maladaptive coping and substance use (Avants, Warburton, & Margolin, 2000).   
 The cause of substance related impairments is similarly complicated. As the 
majority of studies are conducted with individuals who have a long using history, and 
with limited available information regarding their cognitive functioning prior to 
substance use, it remains unclear whether cognitive impairments precede substance 
use, occur as a result of substance use, or are the result of a more complicated mixture 
of variables. As such, it may be difficult to ascertain the cognitive functioning of drug 
and alcohol populations with any clear certainty. Therefore, further research is needed 
to assess this possibility.  
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The Present Research 
As outlined in the previous sections, research has suggested that alcohol 
and/or substance use is associated with cognitive impairments. However, the literature 
available, to date, has been unclear as to what form, exactly, these impairments take. 
Putative links are also being made between cognitive impairments and the poor 
adherence, retention and treatment outcomes that are often seen in services that cater 
to these populations.  
A review of the services provided at the Community Alcohol & Drug Service 
(CADS) in Hamilton suggested that a number of cognitive skills are required for 
successful treatment adherence, and retention. These are: short term memory, 
retention/recall, long term memory, working memory, listening and attention skills, 
reading skills (minimum level of 9th grade/4th form equivalent), planning, insight, 
reasoning and judgement skills, and the ability to problem solve and control 
impulsivity. Similarly, previous research has suggested that individuals must be able 
to learn new information, and incorporate it into behaviour change (Fals-Stewart, 
1993; Fals-Stewart & Lucente, 1994; Fals-Stewart & Schafer, 1992; Katz et al., 
2005).  
However, only a few studies in the United Kingdom and the United States 
have assessed the link between the cognitive skills needed and adherence, retention 
and treatment outcomes. Results from these studies suggest that cognitive impairment 
is associated with poorer treatment engagement, higher drop-out rates, faster relapse, 
poorer long-term outcomes, lower levels of motivation and higher levels of 
hopelessness (Berglund, Leijonguist, & Horlen, 1977; Fals-Stewart, 1993; Fals-
Stewart & Schafer, 1992; Katz et al., 2005; O'Leary, Donovan, Chaney, & Walker, 
1979). Cognitive impairment has also been associated with higher rates of psychiatric 
disorders, poor programme participation, increased rule violations, removal from 
programmes and shorter treatment episodes (Fals-Stewart & Lucente, 1994; Lyvers & 
Yakimoff, 2003). 
 As mentioned previously, adherence and retention in treatment has been poor. 
The current research aimed to assess possible reasons for poor adherence to treatment 
further. Specifically, the research aimed to assess the cognitive functioning of 
individuals receiving MMT in relation to their adherence to the treatment programme.  
To date, no research in New Zealand has examined this connection.  
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 This research was carried out for a number of reasons. Firstly, studies have 
suggested that the use of substances within New Zealand varies from many overseas 
countries, due primarily to New Zealand’s isolated geographical location. This 
isolation means that substances such as heroin and cocaine are not commonly 
accessible, and that alternative substances are either made, such as home bake heroin, 
or substituted, for example the use of cannabis is New Zealand in thought to be 
particularly high (NZPA, 2005). This difference in substance access and use may have 
affected the from and frequency of impairments observed in drug and alcohol 
populations in New Zealand.  
 A second factor involves how treatment services within a New Zealand 
context are managed and run. While many New Zealand services such as the 
Community Alcohol & Drug Service in Hamilton follow a harm reduction model to 
reducing substance use, New Zealand has specific guidelines that document the 
implementation of this service. Therefore, requirements for adherence to treatment 
programmes in New Zealand may differ from the requirements in many overseas 
services due to variations in how treatment protocols and requirements are 
implemented. As such, individuals may need different cognitive skills in order to 
comply with treatment regulations in New Zealand than those skills reported as 
necessary by studies overseas.  
 As mentioned previously, there has been much inconsistency in the 
impairments noted in substance using populations; however, the literature to date has 
suggested that impairment tends to increase with an increase in the number of 
substances that an individual uses regularly. The inconsistent, and often contradictory, 
findings regarding the cognitive functioning of substance using populations may be 
due to a number of factors including previous head injuries, overdoses and other 
health related issues. In addition to these factors, different psychometric measures 
have been used to assess the cognitive functioning of these populations. As such, 
comparison across studies is difficult, as psychometric tests purporting to measure the 
same cognitive ability produce differing results. As such, the first step in the present 
research was to identify appropriate psychometric measures to assess the cognitive 
functioning of these populations. 
As discussed above, it is difficult, if not impossible in many cases, to 
disentangle the possible causes of cognitive impairment, in a population as diverse as 
that seen in the drug and alcohol field. Therefore, the present research intended to 
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look at the impact of drug and alcohol use on cognitive functioning, and aimed to 
draw some conclusions regarding a possible causal relationship. More importantly, 
however, this research examined the impact of cognitive impairments on treatment 
adherence. Essentially, this research aimed to identify the cognitive deficits present in 
this population, and strategies to improve the functioning of these individuals, both in 
treatment and in their daily lives. 
Much previous research has used stringent exclusion criteria, which, while 
helpful in trying to pinpoint the cause of difficulties has given us little useful 
information for the population as a whole. This research, therefore, endeavoured to 
keep exclusion criteria to a minimum to allow for a truer representation of the 
population. 
 In order to assess the cognitive functioning of individuals in MMT at CADS in 
Hamilton, normative data for a New Zealand population needed to be obtained. The 
majority of measures that assess psychological functioning have been developed in 
the United States and the United Kingdom and these tests have not often been normed 
with other populations. As a result, research has suggested that many of the tests that 
are available may not be culturally appropriate. For example, New Zealand research 
assessing the use of the Boston Naming Test (BNT) and the California Verbal 
Learning Test (CVLT) found that New Zealand participants scored between 1.0 and 
1.5 standard deviations below the American norms for these measures (Barker-Collo, 
2001). Research with indigenous cultures that was carried out during colonisation also 
found that indigenous populations performed more poorly on measures of intellectual 
ability which at the time was used as an argument that European populations were 
superior, and gave some justification to the slavery movement. Since this time, 
however, it has become increasingly clear that the reason for this difference in 
performance is that these psychometric tests measured constructs that were 
unimportant in the cultural context (e.g. Shepherd & Leathem, 1999; Tanaka-
Matsumi, Seiden, & Lam, 1996; van de Vijver & Tanzer, 2004). 
Few studies have focused on psychometric measures that are appropriate for 
use with New Zealand populations. Indeed, there is little advice in the literature 
originating from New Zealand on measures that are even recommended. The most 
recent recommendations the researcher could find were provided by Knight and 
Godfrey (1984) who listed 20 most recommended psychometric measures for training 
and administration purposes, and McKerracher, Rich and Niven (1988) who listed 
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several measures that have previously been examined in New Zealand. Many of the 
measures recommended in these articles are no longer published and have been 
superseded by other measures.  
Therefore, given the lack of normative data available for New Zealand, the 
first aim of this research was to determine the appropriateness of overseas 
psychometric norms for use in the New Zealand context, by recruiting a control 
sample from the University of Waikato. As part of this data collection, participants 
were questioned regarding their alcohol and substance use history in order to obtain a 
sample of non-using controls. In addition, those that reported current alcohol and drug 
use were included in a separate study to allow for further comparison.  
Descriptions of the psychometric measures administered to the University 
Control sample are given below. 
 
Psychometric Measures for Present Research 
 As mentioned previously, a review of the MMT programme at CADS 
Hamilton identified a number of skills that were required in order to comply with 
different aspects of the treatment programme. These were: short term memory, 
retention/recall, long term memory, working memory, listening & attention skills, 
reading skills (minimum level of 9th grade/4th form equivalent), insight, planning 
skills, reasoning and judgement skills, ability to problem solve and control 
impulsivity. As the present research was interested in the link between cognitive 
impairments and treatment adherence, the above cognitive skills were chosen for 
assessment. 
Previous research in the substance use area has used a large number of 
different measures to assess cognitive functioning. However, concerns have been 
raised over the measures that have been used, in regards to both their validity and 
reliability, and to the use of these measures to assess different areas of functioning. 
For example, Knight (1997), in a review of the Wechsler Intelligence Scale-Revised, 
noted that the interpretation of WAIS profiles should always be informed by the 
individuals life history as well as results on other psychometric measures. Knight 
(1997) also noted that subscales of the WAIS should be read with extreme caution as 
the WAIS subscales were not made as stand alone measures, that individual scatter 
among subscales tests is common, and that a low or high score on one subscale means 
little without other background information. A number of research studies have also 
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developed their own assessment tools that, in many cases, have not been assessed or 
validated appropriately, while others have used measures which have been largely 
denounced as unreliable or unsuitable to measure particular aspects of functioning 
(Hammersley, 1995). Additionally, administration time has been criticised. Many test 
batteries require several hours to complete, and this can make the use of such batteries 
impractical. The costs associated with the administration of these test batteries 
(usually including substantial incentives) have been criticised also, as have the 
increased risks of finding a significant difference by chance, or finding contradicting 
results across measures (Hammersley, 1995).  
For the present research, a review of the relevant literature was conducted to 
identify those psychometric measures that would be most appropriate to assess the 
cognitive functioning of an alcohol and drug population in New Zealand. In 
particular, the measures were assessed for their ease of administration and the time 
required for administration, the frequency of use in the literature to date, and their 
reliability and validity. The selected measures are outlined below.   
The National Adult Reading Test – 2nd Edition (Nelson, 1991) was included in 
the test battery to assess premorbid IQ, as this is the most commonly used measure of 
intelligence in the area of alcohol and substance use research. The use of a common 
measure in this area, allowed for greater comparison across studies. The NART was 
selected over the Vocabulary subtest of the WAIS and demographic estimates as the 
NART is considered to be more accurate (Strauss, Sherman, & Spreen, 2006).  
The Wechsler Memory Scale-III-Abbreviated (WMS-III-A) (Wechsler, 2002) 
was included in the battery as a measure of short and long-term visual and verbal 
memory. The WMS-II-A was chosen to assess memory functioning in this population 
as story recall (as demonstrated in the recall task required in the Logical Memory 
subtest) has been considered one of the strongest predictors of everyday memory 
performance, due possibly to the reconstructive process playing an important role in 
information retrieval in everyday life (Sunderland, Watts, Baddeley, & Harris, 1986). 
The WMS-III-A was chosen over other memory measures due to its shorter 
administration time (approximately 15-20 minutes with a 25-35 minute delay between 
subtests), validity and reliability data, and because it is a well recognised and 
commonly used measure. 
The Wisconsin Card Sorting Test-Abbreviated (WCST-A) (Kongs, 
Thompson, Iverson, & Heaton, 2000) was selected to assess problem solving ability 
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and abstract reasoning ability. The WCST has been the measure used most commonly 
to assess this area of functioning, and the WCST-A is thought to measure the same 
construct while allowing for a reduced administration time (approximately 10 – 15). 
The WCST is also thought to measure working memory skills similar to those 
measured by the Wechsler Memory Scale-III, as measures on the WMS-III Working 
Memory Index and scores on the WCST (number correct, number errors, number of 
perseverative errors and conceptual level responses) have been reported as correlating 
significantly (Mahrou, Devaraju-Backhaus, Espe-Pfeifer, Dornheim, & Golden, 
2000). 
The Stroop Color and Word Test (Golden & Freshwater, 2002) was selected 
as a measure of impulse control and inhibition. The Stroop is one of the few measures 
available to measure impulse control and inhibition, and has been used in research 
with drug and alcohol populations often. Previous research has suggested that 
impairments in impulse control and inhibition are more likely in drug and alcohol 
populations, and that impairments in these areas may account for ongoing substance 
use by this population (Verdejo-Garcia, Lopez-Torrecillas, Orozco, & Perez-Garia, 
2004). The Stroop requires approximately 5 minutes to administer.  
The Trail Making Test (TMT) (Reitan, 1986) has been used to assess 
cognitive flexibility, attention, scanning and visuomotor tracking. The TMT was 
selected for this research as a measure of attention, both simple and divided, and 
cognitive flexibility as it is measure of these cognitive functions that is used most 
commonly in drug and alcohol populations. The TMT was also selected as a measure 
due to its short administration time, approximately 5 minutes. 
Reading ability was also identified as an important component in the review of 
the CADS MMT programme. As such, the Wechsler Individual Achievement Test-II-
Abbreviated (WIAT-II-A) (Wechsler, 2001) was included as a measure of reading and 
academic ability. Few research studies have assessed the reading ability of drug and 
alcohol populations, so the WIAT-II-A was selected as it is a well validated and 
commonly used measure to assess academic ability. It has a short administration time 
also (10-20 minutes).  
The Beck Anxiety Inventory (BAI) (Beck & Steer, 1990) and Beck 
Depression Inventory-II (BDI-II) (Beck, Steer, & Brown, 1996) were included in the 
assessment battery to assess for the confounding effects of anxiety and depression. 
Previous research has suggested that anxiety and depression symptoms may affect 
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cognitive functioning negatively (Lezak, Howieson, Loring, Hannay, & Fisher, 2004). 
The BAI requires approximately 5 minutes to administer.  
In addition to the assessment of cognitive functioning in this population, 
perceptions of treatment were assessed with regards to treatment adherence. To assess 
this area, the Treatment Perceptions Questionnaire (TPQ) (Marsden, Bacchus, 
Stewart, Griffiths, Clarke, Gossop, & Strang, 1998) was included in the test battery. 
The TPQ is a short self-report questionnaire that was developed for use with 
substance use populations, and has often been used in the literature to assess treatment 
satisfaction. The TPQ requires approximately 5 minutes to administer. 
 
Outline of Studies 
As discussed above, the first aim was to determine the appropriateness of 
overseas psychometric norms for use in New Zealand context, by recruiting a control 
sample of New Zealand university students who did not report current use of drugs or 
alcohol. Results of this study are presented in Experiment 1. In recruiting participants 
for this study, a large number of participants reported current alcohol use. As such, 
the second aim of this research was to explore the cognitive deficits of a group of 
university students that used alcohol. In addition to the University Alcohol Use 
sample, a sample of University Cannabis users was later recruited to explore the 
cognitive deficits of a group of university students that used alcohol and/or cannabis. 
The results of these studies are presented in Experiment 2. 
The third aim of this research was to explore the cognitive deficits of a group 
of opiate dependent participants enrolled in MMT (Experiment 3). Recruitment for 
this sample was slow, so following the recruitment of only 15 participants over a one 
year period; the number of psychometric measures was reduced. Following the 
reduction in psychometric measures, a second sample of individuals in MMT was 
recruited. The findings from this study are reported in Experiment 4.  
Given the difficulties in recruiting participants in Experiment 3, a concurrent 
sample of individuals, both in and out of treatment, with alcohol and substance use 
were recruited to explore the cognitive deficits of drug and alcohol participants, and to 
compare these groups’ performances on the cognitive measures. The findings from 
the drug and alcohol sample are reported in Experiment 5, along with a comparison to 
the obtained MMT samples. In addition to the above aims, Experiment 3, Experiment 
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4, and Experiment 5 aimed to assess the association between cognitive outcomes and 
adherence to treatment.  
Following Experiment 5, a general discussion on the findings from this 
research is provided. 
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EXPERIMENT 1 
 
Research has suggested that many psychometric assessment measures 
(measurement of psychological constructs, including personality, intelligence, and 
aptitudes (Reber & Reber, 2001)) used in recent times are culture specific in one way 
or another. For example, measures developed for predominately white European 
populations are unlikely to be generalisable to non-white non-European populations  
(Gopaul-McNicol & Amrmour-Thomas, 2001). Reynolds (1998) suggests that there 
could, therefore, be problems when using such measures and their normative data for 
populations other than those used for their development.  
In more recent years, a number of studies have assessed the cross-cultural 
applicability of psychometric measures (e.g. Barker-Collo, 2001; Naglieri, Rojahn, 
Matto, & Aquilino, 2005; Shepherd & Leathem, 1999; Tanaka-Matsumi, Seiden, & 
Lam, 1996; van de Vijver & Tanzer, 2004), however, little research has assessed the 
use of such measures and their normative data in the New Zealand population. The 
limited findings available suggest that the normative data for psychometric measures 
developed overseas in countries such as America and the United Kingdom may have 
limited application in New Zealand. For example, Barker-Collo (2004) found that on 
the mean performance of New Zealand students on the Boston Naming Test was 1.2 
standard deviations below the published American norms, and on the California 
Verbal Learning Test, a sample of 17 to 81 year old participants obtained scores 
between 1 and 1.5 standard deviations below the published American norms. 
Similarly, Fernando, Chard, Butcher and McKay (2003) found that a New Zealand 
sample differed significantly from the American normative data on the Rey Complex 
Figure Test. These differences may be the result of a cultural bias. 
 In contrast, other research has suggested that New Zealand scores do not differ 
significantly from the published American or United Kingdom norms. McKerracher, 
Rich and Niven (1988), assessed the use of the Eysenck Personality Questionnaire in 
a sample of New Zealand students, and found that obtained scores were comparable 
with British norms. Similarly, Rodriguez, Treacy, Sowerby and Murphy (1998) 
assessed the use of the Wechsler Intelligence Scale for Children-Third Edition and the 
Stanford-Binet Intelligence Scale and found results comparable to American norms.  
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As explained in the Introduction, the aim of this study was to determine the 
appropriateness of overseas psychometric norms for use in New Zealand context by 
obtaining a control sample of New Zealand university students who did not report 
current use of drugs or alcohol, and to assess the normative data of the psychometric 
measures selected, for later studies. At the time of this research, none of the chosen 
psychometric measures had been validated with a New Zealand population. Prior to 
any further studies, information on the use of these measures with a New Zealand 
population was required. 
 
 
METHOD 
 
Participants 
Forty-eight participants, recruited from undergraduate and graduate courses at 
the University of Waikato, were interviewed, one of these was excluded due to poor 
level of English as they were unable to read and understand tests administered. Of the 
remaining research participants, 7 were male and 40 female. Their ages ranged from 
17 to 61 (mean = 24.49, SD 9.28). The majority of participants self-identified as New 
Zealand European/Pakeha (48.93%), with the remaining participants identifying as  
Other European (12.76%), New Zealand Maori (10.64%), Maori/European (6.38%) 
and Other (21.29%). Forty participants (85.1%) had English as a first language with 
the remaining 7 participants having learned English as a second language as part of 
their school education.  
 
Materials 
 The psychometric measures administered in this study were those chosen 
following a review of the MMT programme at CADS Hamilton. This review 
highlighted a number of cognitive skills required to adhere to treatment, and the 
psychometric tests chosen to assess these cognitive skills in later studies were the 
same as outlined in this study. A summary of each of the measures is provided below. 
 
Beck Anxiety Inventory (1990, 1993) 
The Beck Anxiety Inventory (BAI) (Beck & Steer, 1990) is a 21-item self-
report inventory that broadly assesses the symptoms of both physiological and 
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cognitive anxiety. This measure requires the individual to read each question and rate 
their anxiety on a scale of 0 to 3 based on their experiences during the week prior to 
administration. Scores for overall anxiety are provided, as well as means and standard 
deviations for obsessive-compulsive disorder, panic disorder with agoraphobia, 
generalised anxiety disorder, panic disorder without agoraphobia and social phobia. 
The BAI requires approximately 5 - 10 minutes to administer and can be used with 
individuals 17 through 80 years.  
The BAI was standardised on a sample of 1086 psychiatric outpatients, and, 
additionally, on a sample of 160 outpatients. Internal consistency for this measure has 
been shown to be high (Cronbach coefficient alpha = .92), as has content validity, 
concurrent validity  and discriminate validity, and compares well with other measures 
of anxiety (Beck & Steer, 1990). However, research suggests that scores are 
significantly related to gender, with women scoring higher than men, and to age, with 
younger individuals reporting more severe levels of anxiety (Beck & Steer, 1990). In 
the current study, obtained data were compared to the non-clinical sample referred to 
in the manual. 
 
Beck Depression Inventory – Second Edition (1996) 
The Beck Depression Inventory – Second Edition (BDI-II)(Beck, Steer, & 
Brown, 1996) is a 21-item self-report inventory that assesses the symptoms of 
depression, including affective, behavioural, somatic, cognitive, and motivational 
components, and suicidal ideation. The measure requires the individual to read each 
question and rate their level of depression on a scale of 0 to 3 for the two weeks prior 
to administration. The BDI-II requires approximately 5 minutes to administer and can 
be used with individuals 13 through 80 years. Versions of the BDI have commonly 
been used as a measure of depressive symptomology since the items correlate with the 
Diagnostic and Statistical Manual Fourth Edition (DSM-IV) criteria for depression 
(Bjork et al., 1999).  
The BDI-II was standardised on a large clinical sample (N=500), and 120 
controls and has shown improved clinical sensitivity compared to previous versions of 
the test, with the BDI-II reliability coefficient alpha/internal consistency of 0.92 
(Beck, Steer, & Brown, 1996). The BDI-II has been shown to have good test-retest 
reliability (0.93) also. The BDI-II has been shown to be more closely related to the 
DSM criteria for depression than the previous BDI, however, the two versions are 
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largely comparable with a correlation of .93 (Beck, Steer, & Brown, 1996). In the 
current study, obtained data were compared to the university sample referred to in the 
manual. 
 
National Adult Reading Test – Second Edition (1991) 
The National Adult Reading Test – Second Edition (NART-II) (Nelson, 1991) 
was developed to assess the premorbid intelligence levels of individuals suspected of 
suffering from a dementing process, however, it has been more commonly used to 
assess the premorbid intelligence of individuals (Crawford, 1992). As a result, the 
NART is the most widely used test to estimate premorbid intelligence, and has been 
used to provide a comparison standard for client performance on the Wechsler Scales 
(Wechsler Adult Intelligence Scale, Wechsler Memory Scale) (Crawford, Allan, 
Cochrane, & Parker, 1990; Crawford, Deary, Starr, & Whalley, 2001). The NART has 
also been used in research with the drug and alcohol population when testing 
cognitive functioning due to its relative imperviousness to brain damage (which is 
seen with a higher frequency in this population) (Darke, Sims, McDonald, & Wickes, 
2000; Kelly, Johnson, Knoller, Drubach, & Winslow, 1997; Taylor, Kreutzer, Demm, 
& M, 2003). The NART is often considered one of the best measures of premorbid 
intelligence and research suggests it is a better indicator of premorbid functioning 
than the commonly used demographic measures approach (Pickholtz & Williams, 
1997). However, it should be noted that the NART-II has not been validated against 
recent versions of the Wechsler Memory Scale and Wechsler Adult Intelligence Scale, 
although recent research suggests that the NART-II correlates highly with the WAIS-
III (Mathias, Barrett-Woodbridge, & Bowden, 2004; Sullivan, Senior, & Hennessy, 
2000). 
The NART gives an accurate measure of intelligence by assessing the 
participants ability to read 50 non-phonetic words - an intellectual function that 
remains largely intact after dementia, strokes or head injury (Strauss, Sherman, & 
Spreen, 2006). The individual’s responses are scored as correct or incorrect according 
to pronunciation. The overall score can be used to derive an estimate of premorbid IQ 
(from 69 to 131), as well as provide estimates of verbal and performance skills. The 
NART has been developed to be used with individuals 20 – 70 years, and takes 
approximately 5 minutes to administer.  
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Reliability and validity information is sparse in the NART manual. Reliability 
is reported as high for split (.93), interscorer (.96 – .98) and test–retest (.98). 
Similarly, validity is reported as loading highly on g (.85) (Nelson, 1991). 
 
The Stroop Color & Word Test (1978, 2002) 
The Stroop Color and Word Test (Golden & Freshwater, 2002) has had many 
reincarnations since its first development but all versions assess an individual’s ability 
to read out words in ink colours different from the colour that the word exemplifies. 
This measure is used most commonly to assess attention and concentration (Lezak, 
Howieson, Loring, Hannay, & Fisher, 2004; Strauss, Sherman, & Spreen, 2006), 
however, it is also used as a measure of impulse control and inhibition (Mitrushima, 
Boone, & D'Elia, 1999; Strauss, Sherman, & Spreen, 2006).  
The Stroop task consists of a page with colour words printed in black ink, a 
page with 'Xs' printed in colour, and a page with words from the first page printed in 
colours from the second page (the colour and the word do not match). The examinee 
looks at each sheet and moves down the columns, reading words or naming the ink 
colours as quickly as possible within a time limit. The test yields three scores based 
on the number of items completed on each of the three stimulus sheets. In addition, an 
interference score, which is useful in determining the individual's cognitive flexibility, 
creativity, and reaction to cognitive pressures can be calculated.  
The 2002 Examiner's Manual (Golden & Freshwater, 2002) provides updated 
scoring, norms, and interpretations for ages 15-90 years. The Adult version was 
developed for individuals 15 years and over (with a child version available) and takes 
approximately 5 minutes to administer. The normative data provided in the 2002 
manual was used for analysis.  
There are a number of versions of the Stroop available (e.g. Delis, Kaplan, & 
Kramer, 2001; Golden & Freshwater, 2002; Spreen & Strauss, 1998; Trenerry, 
Crosson, DeBoe, & Leber, 1989), and research suggests that reliability across the 
different versions is high. Test-retest reliability ranges from .70 to .89 (Golden, 1978). 
Other reliability and validity information is not provided in either of the Stroop 
Manuals (Golden, 1978; Golden & Freshwater, 2002). Gender differences have been 
commonly reported on the colour naming aspect of this measure, with women 
demonstrating superior colour naming skills (Golden, 1978).  
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Trail Making Test (1944) 
The Trail Making Test (TMT) (Reitan, 1986) was originally developed as part 
of the Army Individual Test Battery (1944) and has since been used as a stand-alone 
measure to assess speed, attention and mental flexibility (Strauss, Sherman, & Spreen, 
2006). The TMT has been used to measure a wide variety of cognitive functions 
including scanning, visual search, psychomotor functions, sequencing abilities, mental 
tracking, mental flexibility, and concentration (Mitrushima, Boone, & D'Elia, 1999), 
but it has been used most commonly to assess cognitive flexibility, divided attention, 
scanning and visuomotor tracking (Lezak, Howieson, Loring, Hannay, & Fisher, 
2004; Strauss, Sherman, & Spreen, 2006).  
The TMT consists of two parts, composed of 25 circles containing numbers in 
Part A and numbers and letters in Part B. On Part A the individual is instructed to 
draw a line to connect the numbers in sequence as quickly as possible. On Part B the 
individual is instructed to connect the numbers 1-13 and the letters in alternating order 
(e.g. 1-A-2-B-3-C) as quickly as possible. Scoring is based on the time taken to 
complete each part. This measure has an administration time of approximately 5 
minutes and can used with individuals 15 years and older. A children’s version is 
available for individuals aged 9 –14 years.  
Normative data for the TMT was originally provided in relation to cut-off 
scores (Reitan, 1986) although more recently research studies have provided more 
accurate normative data which accounts for age, gender, ethnicity and IQ. 
Mitrushima, Boone, and D’Elia (1999) list over 40 studies that have assessed the 
validity and reliability of the TMT, although studies often use different criteria for 
analysing the results. The TMT has been shown to have reliability and validity in the 
0.90 to 0.98 range, however, this varies with differences in test administration (Spreen 
& Strauss, 1998), and has been reported to be sensitive to closed head injuries, alcohol 
abuse and poly-substance abuse (Spreen & Strauss, 1998).   
Currently, the only New Zealand normative data available for the Trail 
Making Test are for older adults (Siegert & Cavana, 1997), however a number of 
different scoring options are available for the Trail Making Test based on overseas 
populations (Lezak, Howieson, Loring, Hannay, & Fisher, 2004; Mitrushima, Boone, 
& D'Elia, 1999; Strauss, Sherman, & Spreen, 2006). For the purposes of this research, 
the normative data provided by Tombaugh (2004) were used for analysis. These data 
were based on 911 individuals aged 18-89 years. The normative data from Tombaugh 
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(2004) were chosen over other normative data available as they include a large non-
clinical sample which controlled for mental state and depression using the Mini 
Mental Status Exam and the Geriatric Depression Scale respectively. The normative 
data provided by Tombaugh are also relatively recent, are readily accessible, and are 
considered to be of a higher standard than other normative data provided for this 
measure (Strauss, Sherman, & Spreen, 2006) 
 
Wechsler Intelligence Achievement Test–II–Abbreviated (2001) 
The Wechsler Intelligence Achievement Test–II–Abbreviated (WIAT-II-A) 
(The Psychological Corporation, 2001) was developed to identify and track basic 
academic skills, and as a tool to develop interventions for children and adults. The 
WIAT–II–A consists of three subtests (Spelling, Word Reading, and Numerical 
Operations) from the full version of the Wechsler Individual Achievement Test–
Second Edition (WIAT–II). The WIAT–II–A requires approximately 10 to 20 minutes 
to administer and can be used with individuals 4 to 89 years. 
Reliability and validity measures for the WIAT-II-A have been assessed for 
each of the ages/age groups for which norms are provided, with split-half and inter-
item reliability coefficients ranging from 0.71 to 0.99, and test-retest reliability 
ranging from 0.91 to 0.99. Validity measures suggest that the WIAT-II-A assesses 
similar constructs of achievement to other tests in the area, and correlates well with 
the original WIAT measure, with correlations ranging from 0.78 to 0.86 (Wechsler, 
2001). 
 
Wechsler Memory Scale–III–Abbreviated (1997) 
The Wechsler Memory Scale–III–Abbreviated (WMS-III-A) (Wechsler, 2002) 
was developed as a shortened version of the WMS-III, and is used to assess auditory 
and visual memory, and provides an overall indication of memory functioning. The 
test provides scores for immediate and delayed auditory memory, immediate and 
delayed visual memory as well as index scores for immediate memory, delayed 
memory and a general memory index. As the name suggests, the Immediate Memory 
score indicates how individuals perform on tasks that require immediate recall. The 
Delayed Memory score indicates how individuals perform on tasks that required 
delayed recall – after a delay of approximately 30 minutes. The WMS-III-A was 
designed for use with individuals 16-89 years, and can be administered in 
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approximately 15-20 minutes with a 25-35 minute delay between administration of 
Logical Memory I and Family Pictures I, and Logical Memory II and Family Pictures 
II. 
Reliability and validity of the WMS-III-A has been assessed for each of the 
age groups for which norms are provided (13 age bands from 16-89 years), with split-
half and inter-scorer reliability coefficients ranging from 0.72 to 0.95, and test-retest 
reliability ranged from 0.61 to 0.80 on the subtest scores and 0.71 to 0.81 for the 
index scores. Validity measures suggest that the WMS-III-A assesses similar memory 
constructs to other tests in the area, and compares well with other measures that assess 
the recall of visually complex information (Wechsler, 2002). More recently, research 
has also suggested that the Family Pictures subtests heavily rely on verbal abilities, 
and may be a better measure of general memory and aspects of working memory 
(Chapin, Busch, Naugle, & Najm, 2008; Dulay, Schefft, Testa, Fargo, Privitera, & 
Yeh, 2002; Lezak, Howieson, Loring, Hannay, & Fisher, 2004; Lichtenberger, 
Kaufman, & Lai, 2001). 
 
Wisconsin Card Sorting Test – Abbreviated (1981, 1993, 2000) 
The Wisconsin Card Sorting Test (WCST) (Kongs, Thompson, Iverson, & 
Heaton, 2000) was developed as a measure of executive functioning, including 
abstract reasoning ability, mental flexibility and problem solving ability in particular, 
while requiring an individual to keep track of correct/incorrect responses. The WCST 
is also commonly used as a measure to gain evidence of frontal lobe lesions and other 
forms of brain dysfunction (Kongs, Thompson, Iverson, & Heaton, 2000), and has 
been used as a measure of working memory. 
The full version of the WCST is one of the most commonly used psychometric 
measures, and has been used to assess the cognitive functioning of individuals in the 
drug and alcohol field (Aharonovich, Hasin, Brooks, Liu, Bisaga, & Nunes, 2005; 
Bartzokis, Lu, Beckson, Rapoport, Grant, Wiseman, & London, 2000; Bechara & 
Martin, 2004; Hoff, Riordan, Morris, Cestaro, Wieneke, Alpert, Wang, & Volkow, 
1996; Lezak, Howieson, Loring, Hannay, & Fisher, 2004; Pirastu, Fais, Messina, 
Bini, Spiga, Falconieri, & Diana, 2006). The WCST-Abbreviated and the WCST full 
version require the same cognitive skills, and the majority of what is known about the 
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full version of the WCST can be applied to the abbreviated version (Kongs, 
Thompson, Iverson, & Heaton, 2000; Mitrushima, Boone, & D'Elia, 1999).  
The full and abbreviated version of the WCST employs four stimulus cards 
and 64 (abbreviated) and 128 (full version) response cards with varying colours, 
shapes and forms. Participants are required to match the response cards with the four 
stimulus cards across changing conditions and are only told if they have responded 
correctly or incorrectly. Conditions including matching the four stimulus cards on 
colour, form, and shape.  Scores are recorded for: total number of correct responses, 
total number of errors; number of perseverative responses; number of 
nonperserverative errors; number of perseverative errors; and number of categories 
completed. The WCST was developed to be used with individuals 6.5 – 89 years. The 
abbreviated version of the WCST has 64 cards and takes approximately 10 – 15 
minutes to administer, although there is no time limit.  
Reliability and validity data for the WCST-A, which are based on the full 
version of the WCST, show good internal consistency (ranging from 0.60 to 0.85), 
and good construct and cross-cultural validity which suggest the WCST-A is a useful 
measure for differentiating brain dysfunction (Kongs, Thompson, Iverson, & Heaton, 
2000).  
 
Procedure 
Prior to the commencement of this research, ethical approval was obtained 
from the Psychology Department Human Research Ethics Committee at the 
University of Waikato. 
Recruitment of participants took place between June 2004 and December 2005 
within the Psychology Department at the University of Waikato. Participants were 
recruited through sign up sheets posted on notice boards within the Psychology 
Department at the University of Waikato. The information sheet (see Appendix I) 
gave details of the research and also explained that the research was both voluntary 
and confidential. Participants who agreed to participate were asked to leave their 
contact details for the researcher to contact them. Participants were allowed to claim a 
small course credit if they were presently enrolled in a first year psychology course. 
Once individuals had agreed to be contacted, the researcher either emailed or called 
participants to arrange a time to meet to complete the research. 
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At the time of the interview, participants were again provided with the 
information sheet stating that the research was both voluntary and confidential, and 
were asked to sign a consent form, after the details of the research had been explained 
and participants had any questions about the research answered (See Appendix II). 
Participants were also informed of the limits of confidentiality surrounding harm to 
self or others. Individuals who agreed to take part in the research were firstly 
administered a brief demographic questionnaire, and then were administered the 
neuropsychological tests as outlined in the Materials Section. The demographic 
questionnaire included information on education level, previous substance use, and 
previous head injuries and overdoses (See Appendix III).  
The neuropsychological tests were administered in a fixed sequence by the 
researcher as listed below. 
 
Wechsler Memory Scale III – Abbreviated (WMS-III-A) (Logical Memory I and 
Family Pictures I) 
Trail Making Test (TMT) 
Stroop Color and Word Test 
National Adult Reading Test (NART) 
Wechsler Memory Scale III – Abbreviated (WMS-III-A) (Logical Memory II and 
Family Pictures II) 
Wechsler Individual Achievement Test II - Abbreviated (WIAT-II-A) 
Beck Anxiety Inventory (BAI) 
Beck Depression Inventory (BDI-II) 
Wisconsin Card Sorting Test – Abbreviated (WCST-A) 
 
All interviews were conducted on a one on one basis in a room within the 
Psychology Department at the University of Waikato. As required by the ethics 
committee, at the completion of the research participants were provided with a list of 
drug and alcohol agencies, and mental health services should they have any questions, 
or wish to obtain assistance with any of the issues discussed in the research (See 
Appendix IV). Test administration took approximately 1.5 hours and was completed 
in one session. 
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Scoring and data entry 
The neuropsychological tests were hand scored according to the respective 
manuals. The one exception to this was the Trail Making Test, where the results were 
scored according to the normative data provided by Tombaugh (2004). Participants 
were not provided feedback on their individual results. The one exception to this was 
high suicidal ideation scores on the BDI-II, as these were discussed with participants 
to further assess risk issues. 
Analysis was conducted using SPSS Version 12. Analysis was based on the 
following scores for each measure: Wechsler Memory Scale-III-Abbreviated subtest 
and index scores; Wechsler Individual Achievement Test-II-Abbreviated scaled 
scores; Trail Making Test percentile scores; Stroop Color and Word Test T-Scores; 
National Adult Reading Test predicted IQ scores; Beck Anxiety Inventory Total score 
and severity rating; Beck Depression Inventory-II Total score and severity rating; and 
Wisconsin Card Sorting Test standard scores. All results were compared to the 
predetermined significance level of p = 0.05. 
In the case of missing data, if only one answer was missing from a scale or 
subscale, an average value was calculated by the researcher. Otherwise data was 
coded as missing, and was not included in that section of the analysis. 
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RESULTS 
 
This study was conducted to determine the appropriateness of overseas 
psychometric norms for use in New Zealand context, by recruiting a control sample of 
New Zealand university students who did not report current use of drugs or alcohol. A 
sample of 48 university students who reported no current use of alcohol or drugs were 
recruited from undergraduate and graduate courses at the University of Waikato. One 
participant was excluded due to a poor level of English, which left a final sample of 
47 participants.  
 As shown in Table 1.1, the participants had a mean age of 24.49 years, were 
predominately female and had completed the equivalent of 7th Form or Year 
13/NCEA Level 3. Almost half of the University Control sample were New Zealand 
European/Pakeha, followed by Other European, Maori, Maori/European and Other 
which included African American, Asian, Fijian Indian, Indian, Phillipino, 
Polynesian, Samoan and Sri Lankan.  
 
Table 1.1
Demographic details of University Control sample
Age 24.49 SD 9.28, Range 17-61
Gender
Male 7 14.9
Female 40 85.1
Handedness
Left 8 17
Right 39 83
Education 13.68 years SD 1.42, Range 12-17
  
Ethnicity
NZ European 23 48.93
Maori 5 10.64
Maori/European 3 6.38
Other European 6 12.76
Other 10 21.29
Control Sample
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Performance on the psychometric tests 
 Prior to any analysis, Shapiro-Wilks tests were conducted to assess the 
distribution of the data for normality. Results from this analysis suggested that for the 
University Control Sample, the scores from the following measures were not normally 
distributed: WMS Family Pictures I (W = 0.95, df = 47), WIAT-II-A Word Reading 
Score (W = 0.90, df = 44), TMT Part A Percentile Score (W = 0.93, df = 47), Stroop 
Color T-Score (W = 0.94, df = 46), BAI (W = 0.88, df  = 45) and BDI-II (W = 0.79, 
df = 45), WCST-A Standard Total Number of Errors (W = 0.92, df = 45) and the 
WCST-A Conceptual Level Responses (W = 0.92, df = 45) (all at p < 0.05). 
Subsequently, transformations were conducted on the scores from these measures. 
Square-root and inverse square-root transformations normalised the 
distribution of the scores for the following measures: WIAT Word Reading, Stroop 
Color T-Score, BDI-II, and WCST-A Standard Total Number of Errors and 
Conceptual Level Response. However, transformation using the Square-root, Log and 
Inverse Transformations did not normalise the distribution of the scores for the TMT 
Part A and Part B and BAI.  
Where applicable, the normative population scores were transformed in the 
same way as the data to allow for comparison using a one-sample t-test. Data that 
were not normalised by transformation were compared using the standard t-test. 
While these data were not normally distributed, one sample t-tests were conducted as 
there is no non-parametric equivalent measure and t-tests are considered to be quite 
robust. However, the results from these measures should be interpreted with caution. 
One sample t-tests were then conducted to compare this sample’s data to the 
published norms for each measure. 
 These one sample t-tests showed significant differences between the obtained 
and normative data for a number of the measures. A summary of these results is 
presented in Table 1.2. Significant differences between the obtained and normative 
data were found for the WIAT Word Reading and Spelling subtests, WIAT 
Composite Score, TMT Part A Percentile Score, all of the NART Scores (Full Scale, 
Verbal and Performance), the Stroop Color-Word T Score and Stroop Interference 
Score, as well as the WCST-A Standard Total Number of Errors and Conceptual 
Level Responses. Medium effect sizes using Cohen’s d were obtained on the WIAT-
II-A Composite Score and Stroop Interference T-Score, and large effects on the 
WIAT-II-A Spelling substest, and all measures of the NART-II. While large effect 
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sizes are recommended as the standard effect size to report (Cohen, 1992), both 
medium and large effect sizes have been reported in the current study due to the 
relatively small sample size. For all of these measures, the mean scores were higher 
than the normative data. Results for all other measures were not significantly different 
from the normative sample. 
Given that this sample’s scores differed from the normative means on several 
measures, the results were compared to the standard deviation ranges provided for 
each measure. The mean scores for this sample fell within one standard deviation of 
the test norm on all measures. Mean scores on the Beck Anxiety Inventory fell in the 
mild range and scores on the Beck Depression Inventory-II fell within the minimal 
range. A summary of the mean and standard deviation scores for each measure is 
provided in Table 1.3.  
 
Relation between demographic and psychometric test results 
It has been suggested that neuropsychological tests scores can be influenced 
by various factors including anxiety and depression, age, years of education, 
handedness and gender (Kennedy, 1981; Lezak, Howieson, Loring, Hannay, & Fisher, 
2004; Mitrushima, Boone, & D'Elia, 1999; Stanton, Savageau, Aucion, Jenkins, & 
Zyzanski, 1984; Strauss, Sherman, & Spreen, 2006). In order to investigate these in 
this sample, a series of correlations were calculated. 
As shown in Table 1.4, there was a significant correlation between the BDI-II 
and Stroop Word-T Score (positive correlation), and between the BAI and the BDI-II 
(positive correlation). The significant correlation between the BAI and BDI-II was 
similar to that reported by Beck and Steer (1990) in the Beck Anxiety Inventory 
Manual (r = 0.60). Based on the Pearson Correlations, anxiety and depression did not 
relate to the scores obtained on any of the measures. As such anxiety and depression 
were not included as covariates in any further analysis. 
The correlation between age and obtained scores for the NART-II was 
calculated as this was the one measure that did not provide age adjusted normative 
data. As shown in Table 1.4, there was no significant correlation between age and the 
NART-II scores. The correlations between reported level of years of education and 
the WMS-III-A and the TMT were also calculated as these measures do not provide 
academically adjusted normative data. As shown in Table 1.4, these correlations were 
not statistically significant. 
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The correlation between handedness and the various TMT scores were 
calculated, as previous research has suggested that left handed individuals may 
perform more poorly on this measure (Tupper & Cicerone, 1990). As shown in Table 
1.4, no significant correlations were found between any of the measures and 
handedness; however there were only a small number of left handed individuals in the 
sample. None of the correlations between gender and any of the psychometric 
measures were statistically significant.  
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TABLE 1.2
One sample t-test comparing University Control Sample to Normative Data, including means, standard deviations and Cohen's d
WCST Perseverative Errors 100 15 97.60 12.01 -1.45 44 NS -0.16
WCST Nonperseverative Errors 100 15 100.35 17.03 0.03 44 NS 0.02
WCST Conceptual Level Responses 10 3.87 9.80 4.06 -20.91 44 * -0.07
* Significant at p< 0.05
Normative One Standard University University Cohens
Mean Deviation Control Control Significance d
Mean SD
WMS Logical Memory I 10 3 10.33 2.68 0.52 46 NS 0.11
WMS Family Pictures I 10 3 10.93 2.63 0.73 46 NS 0.31
WMS Logical Memory II 10 3 10.47 3.01 1.69 45 NS 0.16
WMS Family Pictures II 10 3 10.19 3.21 0.00 45 NS 0.06
WMS Immediate Memory 100 15 102.26 14.89 0.67 46 NS 0.15
WMS Delayed Memory 100 15 104.77 15.27 1.58 45 NS 0.32
WMS Total Memory 100 15 102.70 15.10 0.77 45 NS 0.18
WIAT Word Reading 10 3.87 10.45 2.86 -38.69 43 * 0.12
WIAT Numerical Operations 100 15 100.30 15.10 -0.08 43 NS 0.02
WIAT Spelling 100 15 114.14 9.69 9.43 43 * 0.94
WIAT Composite 100 15 108.66 10.96 5.24 43 * 0.58
TMT Part A Percentile 50 16 53.72 29.29 2.01 46 * 0.11
TMT Part B Percentile 50 16 52.91 31.87 0.20 46 NS 0.09
Stroop Word T-Score 7.07 3.16 7.22 3.13 1.22 45 NS 0.02
Stroop Colour T-Score 50 10 50.19 9.93 0.44 45 NS 0.02
Stroop Colour-Word T-Score 50 10 54.60 9.38 2.89 45 * 0.46
Stroop Interference T-Score 50 10 54.16 7.66 3.58 45 * 0.42
NART Full Scale IQ 100 15 113.51 5.70 18.19 44 * 0.90
NART Verbal IQ 100 15 112.60 3.95 16.06 44 * 0.84
NART Performance IQ 100 15 113.70 5.09 21.48 44 * 0.91
Beck Anxiety Inventory 11.08 9.1 9.02 6.61 1.18 44 NS -0.23
Beck Depression Inventory 3.54 3.15 2.93 2.62 1.40 46 NS -0.28
WCST Total Number of Errors 10 3.87 9.97 4.08 -21.05 44 * 0.01
WCST Perseverative Responses 100 15 98.77 11.43 -0.83 44 NS -0.08
t df
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TABLE 1.3
Means and Standard Deviations for Normative and University Control Sample
Normative One Standard
Mean Deviation Mean SD
WMS Logical Memory I 10 3 10.33 2.68
WMS Family Pictures I 10 3 10.93 2.63
WMS Logical Memory II 10 3 10.47 3.01
WMS Family Pictures II 10 3 10.19 3.21
WMS Immediate Memory 100 15 102.26 14.89
WMS Delayed Memory 100 15 104.77 15.27
WMS Total Memory 100 15 102.70 15.10
WIAT Word Reading 100 15 109.21 8.16
WIAT Numerical Operations 100 15 100.30 15.10
WIAT Spelling 100 15 114.14 9.69
WIAT Composite 100 15 108.66 10.96
TMT Part A Percentile 50 16* 53.72 29.29
TMT Part B Percentile 50 16* 52.91 31.87
Stroop Word T-Score 50 10 52.16 9.82
Stroop Colour T-Score 50 10 50.19 9.93
Stroop Colour-Word T-Score 50 10 54.60 9.38
Stroop Interference T-Score 50 10 54.16 7.66
NART Full Scale IQ 100 15 113.51 5.70
NART Verbal IQ 100 15 112.60 3.95
NART Performance IQ 100 15 113.70 5.09
Beck Anxiety Inventory 11.08 9.10 9.02 6.61
Beck Depression Inventory 12.56 9.93 8.58 6.87
WCST Total Number of Errors 100 15 99.42 16.65
WCST Perseverative Responses 100 15 98.77 11.43
WCST Persevertive Errors 100 15 97.60 12.01
WCST Nonperseverative Errors 100 15 100.35 17.03
WCST Conceptual Level Responses 100 15 96.56 16.49
* TMT results are presented in percentile scores. 1 SD below the 50th percentile is the 16th percentile
University Control
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Table 1.4
Correlations between demographic and psychometric test results in the University Control Sample
WCST Perseverative Errors 0.018 -0.214 -0.240
WCST Nonperseverative Errors -0.143 0.097 -0.085
WCST Conceptual Level Responses -0.128 -0.232 -0.246
* Significant at p < 0.05
Correlation Coeffient (r) 
Pearsons Point Biserial Point Biserial Pearsons Pearsons Pearsons
Age Gender Handedness Years of Beck Beck
Education Anxiety Depression
WMS Logical Memory I 0.011 0.067 -0.082 -0.163
WMS Family Pictures I -0.166 -0.257 0.067 -0.059
WMS Logical Memory II -0.045 0.063 0.035 -0.027
WMS Family Pictures II -0.207 -0.205 0.023 -0.069
WMS Immediate Memory -0.073 -0.085 0.004 -0.120
WMS Delayed Memory -0.127 -0.069 0.037 -0.066
WMS Total Memory -0.112 -0.071 0.015 -0.101
WIAT Word Reading 0.020 0.074 0.045
WIAT Numerical Operations 0.090 -0.093 -0.088
WIAT Spelling -0.129 -0.070 -0.074
WIAT Composite -0.015 -0.073 -0.080
TMT Part A Percentile 0.144 -0.187 0.010 0.194 0.013
TMT Part B Percentile -0.164 -0.220 0.089 0.135 -0.103
Stroop Word T-Score 0.057 0.230 0.305*
Stroop Colour T-Score -0.003 0.010 -0.022
Stroop Colour-Word T-Score 0.044 0.065 0.024
Stroop Interference T-Score 0.110 0.000 0.056
NART Full Scale IQ 0.292 0.173 0.082 0.082
NART Verbal IQ 0.274 0.166 0.074 0.065
NART Performance IQ 0.282 0.194 0.075 0.069
Beck Anxiety Inventory -0.123 0.687*
Beck Depression Inventory 0.044 0.687*
WCST Total Number of Errors -0.059 -0.161 -0.132
WCST Perseverative Responses 0.037 -0.080 -0.006
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DISCUSSION 
 
 The sample was recruited to compare the normative data for the psychometric 
measures to a New Zealand population. The sample obtained scores either in 
accordance with the normative means, or in several cases, significantly higher than 
the normative means. In particular, there were higher scores on the WIAT-II-A Word 
Reading and Spelling subtests, WIAT-II-A Composite Score, TMT Part A Percentile 
Score, all of the NART-II Scores (Full Scale, Verbal and Performance), the Stroop 
Color-Word T Score and Stroop Interference T-Score, as well as the WCST-A 
Standard Total Number of Errors and Conceptual Level Responses. While the 
findings on these measures were significantly different from the normative data, the 
obtained results were within one standard deviation of the normative data mean. The 
results for each of the measures are discussed below. 
One of the difficulties in interpreting results from psychometric tests is that 
statistical significance may not equate to clinical significance. A result that is 
statistically significant may not be considered as impaired in the traditional sense 
(usually one or two standard deviations below the normative mean), and may not 
result in a noticeable change in behaviour compared to the normative population. 
Additionally, research suggests that it is relatively common for normally functioning 
individuals to obtain scores that fall higher or lower than the normative mean, but 
within one standard deviation (e.g. Kongs, Thompson, Iverson, & Heaton, 2000; 
Nelson, 1991). For this reason, psychometric results are usually interpreted in terms of 
clinical significance. 
Clinically significant results are, by contrast to statistically significant results, 
considered to be of practical importance, as for a result to be considered clinically 
significant, a noticeable difference in behaviour must be apparent (McBurney & 
White, 2004). In psychometric test results, clinical significance is either discussed in 
relation to noticeable impairments in behaviour, or to noticeable improvements in 
behaviour, when behaviour is assessed over an extended period. Previously, research 
has suggested that one standard deviation below the normative mean is generally 
considered as indicative of clinically significant impairment (Kongs, Thompson, 
Iverson, & Heaton, 2000; Lezak, Howieson, Loring, Hannay, & Fisher, 2004; 
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Wechsler, 2002). As such, the scores obtained by the current sample did not differ in 
terms of clinical significance compared to the normative data. 
Obtained results for the WIAT-II-A Word Reading and Spelling subtests, and 
WIAT-II-A Composite score were higher than the normative mean. It was expected 
that the sample would obtain results comparable to the normative data, as conversion 
of raw scores for this measure accounts for years of education and age, which may 
have differentiated the current sample from the normative sample otherwise. The 
significantly higher scores on these measures could suggest a difference in the 
educational standards in New Zealand compared to the American education system, 
on which the normative data are based. Overall, the results on the WIAT-II-A suggest 
that the sample had reading, spelling and mathematics abilities within the expected 
range. 
Results for the TMT, while statistically significant from the normative mean 
for Part A, were within one standard deviation of the normative mean. As the means 
for both Part A and Part B of the TMT were higher than the normative data, this 
suggests that the sample was unlikely to have difficulties in simple attention, or 
divided attention and cognitive flexibility. Significantly higher results on the TMT 
Part A were unexpected, as Tombaugh (2004) reported that the normative data were 
unaffected by education in the comparative normative sample. It was expected that the 
current sample would be comparable to Tombaugh’s (2004) sample, as Tombaugh 
(2004) also included university students in the normative sample, although scores 
from community dwellers were included in the normative analysis also.  
The present sample obtained significantly higher scores on the NART-II, 
however, the means were within one standard deviation of the normative data. The 
findings for the current sample are higher than expected in comparison to the 
normative data. This may be due to the high level of education in the current sample. 
The influence of education on the obtained results for this measure are difficult to 
determine, as the test manual (Nelson, 1991) does not provide information on the 
education level of the normative sample. 
Overall, the scores for the current sample were generally similar to the 
normative means, and in some cases slightly higher (although this may have been 
influenced by the education level of the sample). Given the similar results it appeared 
that were no large differences between the different populations and so the existing 
norms could be used in New Zealand. The normative data provided in the test 
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manuals (and by Tombaugh (2004) for the TMT) were therefore used in analysis in 
the other studies conducted as part of this research.   
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EXPERIMENT 2 
 
As discussed previously, the aim of Experiment 2 was to explore the cognitive 
deficits of a group of university students that used alcohol and/or cannabis who were 
recruited during Experiment 1. Previous research has suggested that there is a high 
prevalence of hazardous drinking (defined as six drinks for males and four drinks for 
females on one occasion (Alcohol Advisory Council of New Zealand, 2004))  among 
New Zealand tertiary students (Kypri, Langley, McGee, Saunders, & Williams, 2002), 
and illicit substance use also appears to occur on a regular basis in this population 
(Smart & Ogborne, 2000; Webb, Ashton, Kelly, & Kamali, 1996). The effect of 
alcohol and cannabis use by university students on their cognitive functioning has 
received some attention. A summary of the findings is provided below. 
 
Alcohol Use 
A recent New Zealand study by Kypri, Langley, McGee, Saunders and 
Williams (2002) showed that, in a sample of 1480 tertiary students, 83.2% had 
consumed at least one alcoholic drink in the last four weeks and that 60% of males 
and 58.2% of females typically drank more than the recommended level outlined by 
the Alcohol Advisory Council of New Zealand (ALAC) more than twice per week on 
average. In addition, 52% of males and 46% of females reported binge drinking 
(seven or more drinks on one occasion, and five or more drinks on one occasion for 
males and females respectively) in the last four weeks. 
Previous research has suggested that impairments in the cognitive functioning 
of regular alcohol users may be noticeable even after short-term use (e.g. Fillmore, 
Carscadden, & Vogel-Sprott, 1998; Hannon, Butler, Day, Khan, Quitoriano, Butler, & 
Meredith, 1987; Sher, Martin, Wood, & Rutledge, 1997; Weissenborn & Duka, 2000, 
, 2003), with impairments being reported more consistently in long-term alcohol users 
(e.g. Clifford, 1990; Evert & Oscar-Berman, 1995; Fals-Stewart, Schafer, Lucente, 
Rustine, & Brown, 1994; Fein, Bachman, Fisher, & Davenport, 1990; Gruber & 
Yurgelun-Todd, 2001; Jones, Knutson, & Haines, 2003; McCrady & Smith, 1986; 
Moselhy, Georgiou, & Kahn, 2001; Oscar-Berman & Marinkovic, 2003). The short-
term effects of alcohol have been assessed frequently in casual and regular drinkers, 
with research typically focusing on the drinking habits of college and university 
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students. Little research exists on the cognitive effects of alcohol use on university 
students in New Zealand, however, several studies have assessed the effects of 
alcohol in overseas populations. Some of these studies are outlined below. 
In one such study, Hannon, Day, Butler, Larson and Casey (1983) found, in a 
sample of 92 university students who were casual drinker, that there was a relation 
between cognitive impairments as measured by the WCST and the length of 
consumption over a lifetime, for both males and females. These data suggest that 
there was a greater impairment with increased used. However, a later study by 
Hannon, Butler, Day, Khan, Quitoriano, Butler, and Meredith (1987) failed to 
replicate these findings. 
In another study, Fillmore, Carscadden and Vogel-Sprott (1998) assessed the 
cognitive functioning of 27 male university students who were social drinkers. Results 
showed impaired information processing. This study did not assess other aspects of 
cognitive functioning. Similarly, Weissenborn and Duka (2000, 2003) found 
impairments in both memory and executive functioning for 96 acutely intoxicated 
university students with a history of alcohol use. 
Others have studied students who are alcohol dependent. For example, Sher, 
Martin, Wood and Rutledge (1997) found impairments in visuospatial ability and 
motor speed of severely alcohol-dependent university students. Brown, Tapert, 
Granhol and Delis (2000), in a study involving alcohol dependent adolescents, 
reported a relation between performance on verbal and nonverbal retention tests and 
alcohol use, with poorer performance associated with greater use. In this same study, 
recent alcohol withdrawal was also associated with poor visuospatial functioning, and 
longer-term withdrawal was associated with poorer retrieval of both verbal and 
nonverbal information. Similarly, Moss, Kirisci, Gordon and Tarter (1994) reported 
poorer performance on measures of reading recognition, total reading, spelling 
achievement, and verbal and full-scale IQ in adolescents with alcohol abuse and 
dependence. 
Binge drinking has also been associated with poorer performance on tests of 
cognitive functioning. For example, Goudriaan, Grekin, and Sher (2007) reported an 
associated between increased use/binge drinking and impaired decision making, on 
the IOWA Gambling Task, in university students. Findings also suggest that alcohol 
using adolescents made less perseverative and commission errors, obtained better 
scores on a visual memory measure, and that alcohol using males performed better 
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and alcohol using females performed worse than controls on the Wisconsin Card 
Sorting Test.  
Other studies have, however, reported no impairments in short-term alcohol 
users. Eckardt, Stapleton, Rawlings, Davis and Grodin (1995) reported no 
impairments in the language skills, attention, motor skills, intelligence, or memory 
ability of alcohol dependent individuals during detoxification. Similarly, Fadardi and 
Cox (2006) reported no impairment in interference in social drinking university 
students compared to dependent alcohol users. 
 The above studies suggest that impairments, while not consistently reported, 
have been associated with greater alcohol consumption. Poorer performance has been 
reported on psychometric measures of memory, information processing, executive 
functioning, and academic abilities; however, further research is needed to assess the 
effects of short-term and casual alcohol use as most studies have focused on alcohol 
use in more severe users. 
 
Cannabis Use  
In addition to alcohol use, New Zealand research suggests that cannabis use is 
common in adolescents and young adults, with the Christchurch Health and 
Development Study (Fergusson & Horwood, 2000) reporting that 69% had tried 
cannabis by the age of 21 years. Within this sample, 24% had used cannabis on less 
than 10 occasions, while 9% met the criteria for cannabis dependence. 
Long-term cannabis use has been reported as impacting upon cognition, 
memory, reward, pain perception and motor coordination areas of the brain, with 
larger deficits noted in tasks that require sustained attention (Hall & Solowij, 1998). 
The effects of cannabis appear to be most pronounced within 12-24 hours of ingestion 
with impairments during this time reported in attention, psychomotor skills and short 
term memory (Pope Jr., Gruber, & Yurgelun-Todd, 1995). Long-term impairment in 
functioning have been reported most frequently in individuals with an extensive 
history of cannabis use (Hall & Solowij, 1998).  
In addition to the research with long-term cannabis users, there is some 
research on the effects of cannabis use in the cognitive functioning of casual users. 
Research with adolescents and university students has generally reported no 
impairments in casual users, however, regular to heavy use does appear to be related 
to impairment in cognitive functioning.  
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Jacobson, Mencl, Westerveld and Pugh (2004), assessed the cognitive 
functioning of 7 cannabis using individuals who were in their last year of high-school. 
The results for this study showed that these participants made more incorrect 
responses on the Conners Continuous Performance Test, a measure of sustained 
attention, and performed less accurately on a 2-back task, which assessed working 
memory, compared to a non-using control sample. No impairment was reported in 
selective and divided attention as measured by a computerised word recognition test. 
Harvey, Sellman, Porter and Frampton (2007), in a more comprehensive 
assessment, administered the Wechsler Abbreviated Scale of Intelligence, several 
subtests of the Cambridge Neuropsychological Battery (motor screening, rapid visual 
information processing, spatial working memory, intradimensional extradimensional 
shift, paired associates learning, spatial span), the Rey Auditory Verbal Learning Test, 
the Digit Span, and the Symbol Digit Modalities Test to a New Zealand sample of 70 
non-regular and regular cannabis using adolescents. They found that the regular users 
had significantly poorer performance than the non-regular users on all measures of 
executive functioning and working memory (i.e. the Rapid Visual Information 
Processing A, Spatial Working Memory total errors, Spatial Working Memory 
strategy, and the sum of Trials A1 to A5 on the Rey Auditory-Verbal Learning Test). 
Similarly, Schwartz, Gruenewald, Klitzner and Fedio (1989) assessed the 
cognitive functioning of 8 cannabis dependent adolescents and found impairments in 
memory when assessed using the Benton Visual Retention Test and Wechsler 
Memory Scale Prose Passages. Pope and Yurgelun-Todd (1996) assessed cognitive 
functioning in university students who were categorised as regular (maximum of 9 
days in last 30) or heavy users (minimum of 22 days in last 30). Impairments were 
reported for heavy users, but not light users, on the preservation measures of the 
WCST, in memory on the delayed recall of figures on the WMS, in learning ability on 
the California Verbal Learning Test, and in immediate recall on the Rey-Osterreith 
Complex Figure Test. No significant differences were reported between the two 
groups on the Stroop when used as a measure of attention and interference. 
By contrast, Fried, Watkinson and Gray (2005) assessed the cognitive 
functioning of 113 young adults who used cannabis, and found no impairment in 
memory, general functioning, vocabulary or concept formulation/abstract reasoning 
when assessed with the WMS-III, WAIS-III, Peabody Picture Vocabulary Test and 
Category Test respectively. Carlin and Trupin (1977) also reported no impairments on 
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the Halstead Reitan Neuropsychological Battery in a sample of 10 young adults who 
used cannabis. Similarly, Schaeffer, Andrysiak and Ungerleider (1981) found no 
impairment in the cognitive functioning of 10 cannabis using individuals when 
assessed with the Benton Visual Retention Test, Rey Auditory-Verbal Learning Test, 
Hooper Visual Modalities Test, Raven’s Progressive Matrices Test and Trail Making 
Test. 
 As demonstrated by the studies outlined above, research has suggested that 
impairments in memory, attention and executive functioning appear to occur more 
frequently in cannabis using adolescents and university student populations compared 
to non-users, however, there have been some exceptions to these findings. Therefore, 
further research is needed to assess the effects of casual and short-term use of 
cannabis on cognitive functioning.  
As mentioned previously, the aim of this study was to explore the cognitive 
deficits of a group of university students that used alcohol and/or cannabis. 
 
 
METHOD 
 
Participants 
Forty-five of the participants recruited from the student population at the 
University of Waikato during Experiment 1 met the requirements for this study. 
Thirty-nine of these reported using alcohol on a regular basis (at least once weekly) 
and were included in the University Alcohol sample. The 6 participants who reported 
using cannabis on a regular basis (at least once weekly) were included in the 
University Cannabis sample. Of these 6 participants, 2 reported using only cannabis, 
and 4 reported using both cannabis and alcohol on a regular basis (at least once per 
week). According to self report, none of the participants had used alcohol or cannabis 
in the 12 hours prior to assessment, and given the low frequency of use it is unlikely 
that these participants were dependent. 
 The University Alcohol sample included 10 male and 29 females. Their ages 
ranged from 17 to 52 (mean = 23.41, SD 7.33). The majority of participants self-
identified as New Zealand European/Pakeha (46.15%), and the remaining participants 
identified as Other European (17.95%), New Zealand Maori (17.95%), 
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Maori/European (10.26%) and Other (7.69%). Thirty-three (84.6%) had English as a 
first language and the remaining 6 participants had learnt English as a second 
language as part of their school education.  
 The University Cannabis sample included 1 female and 5 males, ranging in 
age from 18 to 22 years (20.50, SD 1.517). The participants self-identified as 
European (83.3%) or Other European (16.7%). Participants had completed 14 years of 
education on average. Five of these 6 participants had English as a first language, and 
1 participant had learnt English as a second language as part of their school education. 
 
Materials 
The psychometric measures administered to the University Alcohol sample 
were identical to those administered in Experiment 1. For further details on the 
neuropsychological tests administered please refer to the Method section for 
Experiment 1. 
The University Cannabis sample was administered a reduced battery of 
psychometric tests. These were the Stroop Color & Word Test, Trail Making Test, 
Wechsler Memory Scale-III-Abbreviated and the Wisconsin Card Sorting Test-
Abbreviated. For further information regarding the reduction in measures please see 
the Introduction to Experiment 3. 
 
Procedure 
The procedure for the University Alcohol sample was identical to that in 
Experiment 1. The procedure for the University Cannabis sample is outlined below. 
Prior to the commencement of this research, ethical approval was obtained 
from the Psychology Department Human Research Ethics Committee at the 
University of Waikato. 
Recruitment of participants for the University Cannabis sample took place 
between January and October 2007. Participants were recruited through sign up sheets 
posted on notice boards within the Psychology Department at the University of 
Waikato. The information sheet stated that the researcher was interested in contacting 
individuals who currently used substances; that the research involved tests of 
cognitive functioning; and that questions would be asked about current alcohol and/or 
drug use. The information sheet (see Appendix V) gave details of the research and 
explained that the research was both voluntary and confidential. The information 
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sheet provided the researcher’s contact details (email, phone number and room 
number), and potential participants were asked to either make contact with the 
researcher, or leave their contact details and that the researcher would contact them. 
Participants were allowed to claim a small course credit if they were presently 
enrolled in a first year psychology course. Once individuals had agreed to be 
contacted or had contacted the researcher, the researcher either emailed or called 
participants to arrange a time to meet to complete the research. 
At the time of the interview, participants in the University Cannabis sample 
were provided once again with the information sheet stating that the research was 
both voluntary and confidential, and were asked to sign a consent form after the 
details of the research had been explained and any questions about the research had 
been answered (See Appendix II). Participants were also informed of the limits of 
confidentiality surrounding harm to self or others. Individuals who agreed to take part 
in the research were administered a brief demographic questionnaire, and the 
neuropsychological tests as outlined previously. The demographic questionnaire 
collected information on education level, previous substance use, head injuries, and 
overdoses (See Appendix III).  
The neuropsychological tests were administered in a fixed sequence by the 
researcher as listed below. 
 
Wechsler Memory Scale III – Abbreviated (WMS-III-A) (Logical Memory I & 
Family Pictures I) 
Trail Making Test (TMT) 
Stroop Color and Word Test 
Wisconsin Card Sorting Test – Abbreviated (WCST-A) 
Wechsler Memory Scale III – Abbreviated (WMS-III-A) (Logical Memory II & 
Family Pictures II) 
 
All interviews were conducted on a one on one basis in a room within the 
Psychology Department at the University of Waikato. As required by the Ethics 
Committee, at the completion of the research participants were provided with a list of 
drug and alcohol agencies and mental health services should they have any questions, 
or wish to obtain assistance with any of the issues discussed in the research (See 
Appendix IV).  
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Scoring and data entry 
Scoring and data entry was identical to Experiment 1. For further details 
please see the Procedure section of Experiment 1. 
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RESULTS 
 
A sample of 39 university students who used alcohol regularly (at least once 
weekly) were recruited from undergraduate and graduate courses at the University of 
Waikato. An additional sample of six university students who reported regular 
cannabis use (at least once weekly) were also recruited from undergraduate and 
graduate courses at the University of Waikato. 
As can be seen in Table 2.1, the participants in the University Alcohol sample 
had a mean age of 23.41 years, were predominately female and had completed the 
equivalent of 7th Form or Year 13. Close to half of the sample were New Zealand 
European/Pakeha, followed by Other European, Maori, Maori/European, and Other 
which included English Fijian, African and European/Nuean. 
The participants in the University Cannabis sample had a mean age of 20.5 
years, were predominately male, and had completed the equivalent of 14 years of 
education (which is equivalent to one year of tertiary training). The participants in the 
University Cannabis sample were predominantly of New Zealand European descent. 
 
Table 2.1
Demographic details of University Alcohol & University Cannabis samples
Age 23.41 SD 7.33, Range 17-52 20.5 SD 1.517, Range 18-22
Gender
Male 10 25.6 5 83.3%
Female 29 74.4 1 16.7%
Handedness
Left 2 5.1 1 16.7%
Right 37 94.9 5 83.3%
Education 13.38 years SD 1.50, Range 11-17 14.17 years SD 1.17, Range 13-16
 
Ethnicity
NZ European 18 46.15 5 83.3%
Maori 7 17.95
Maori/European 4 10.26
Other European 7 17.95 1 16.7%
Other 3 7.69
Regular Alcohol Use Sample Cannabis Use Sample
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An independent samples t-test showed that the two samples differed 
significantly in age (t = -2.194, df = 43, p < 0.05), but not in years of education (t = 
1.219, df = 43, p > 0.05). A chi squared test showed that gender was related to sample 
membership (χ 2 = 7.788, p < 0.05), while ethnicity (χ 2 = 3.565, p > 0.05) was not 
related to sample membership.   
 
Performance on the psychometric tests 
Prior to any analysis, Shapiro-Wilks tests were conducted to assess the 
distribution of the data for normality. Using this test, the distribution of scores from 
the following measures were found to be significantly different from normal for the 
University Alcohol sample: WMS Logical Memory Score I (W = 0.94, df = 39), 
WMS Immediate Memory Index (W = 0.93, df = 39), WIAT Word Reading (W = 
0.91, df = 36), Trail Making Part A Percentile (W = 0.93, df = 39) and Part B 
Percentile Score (W = 0.88, df = 39), Beck Anxiety Inventory Score (W = 0.93, df = 
36), Beck Depression Inventory (W = 0.90, df = 36), WCST Total Number of Errors, 
(W = 0.93, df = 38) WCST Conceptual Level Responses (W = 0.92, df = 38) (all at p 
< 0.05). Square-root and inverse square root transformations normalised the 
distribution of the scores for the following measures: BAI, BDI-II, and WCST-A 
Standard Total Number of Errors and Conceptual Level Response. However, 
transformations did not normalise the distribution of the data for the WMS Logical 
Memory Score I, WMS Immediate Memory Index, WIAT Word Reading, Trail 
Making Part A Percentile and Part B Percentile Score. Obtained scores for the 
University Cannabis sample were shown to adhere to a normal distribution for all 
measures.  
Where applicable, the normative population scores were transformed in the 
same way as the data to allow for comparison using a one-sample t-test. Data that 
were not normalised by transformation were compared using the standard t-test. One 
sample t-tests were then conducted to compare this sample to the published norms for 
each measure. 
The one sample t-tests showed significant differences between the obtained 
and normative data for a number of measures for both samples. As shown in Table 
2.2, significant differences were found between the University Alcohol sample and 
the normative data on all measures of the WIAT-II-A, Trail Making Test Part A, all 
NART measures (Verbal, Performance, Full Scale), and on the Stroop Color-Word 
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and Stroop Interference measures. Significant differences between the obtained and 
normative data were found on the Beck Depression Inventory-II, and on the WCST-A 
Standard Total Number of Errors and Conceptual Level Response also. Medium 
effects sizes were obtained when using Cohen’s d for the WIAT-II-A Word Reading 
and Spelling subtests, and NART-II Performance IQ, while large effect sizes were 
obtained for the NART-II Full Scale and Verbal IQ scores. While large effect sizes 
are recommended as the standard effect size to report (Cohen, 1992), both medium 
and large effect sizes have been reported in the current study due to the relatively 
small sample size. The University Alcohol sample mean scores were higher than the 
normative data for all of these measures, with the exception of the WIAT-II-A 
Numerical Operations subtest. Scores for all other measures were not significantly 
different from the normative sample.  
The one sample t-tests for the University Cannabis sample, as shown in Table 
2.3, showed statistically significant differences compared to the normative mean for 
the Stroop Interference T-Score (significantly higher than the normative mean) and all 
measures of the WCST-A (significantly lower than the normative mean). Medium 
effect sizes were obtained on the WMS-III-A Logical Memory II, and TMT Part A 
Percentile Score, while large effect sizes were obtained on all of the WCST-A 
measures. Performance on all other measures was not significantly different from the 
normative sample at p < 0.05. 
Given that the University Alcohol and University Cannabis sample’s scores 
differed from the normative means on several measures, the results were compared to 
the standard deviation ranges provided for each measure to assess where the obtained 
results fell in regards to the normative mean. The mean scores for the University 
Alcohol sample fell within one standard deviation of the test norm on all measures. 
Mean scores on the Beck Anxiety Inventory for the University Alcohol sample fell 
within the mild range and scores on the Beck Depression Inventory-II fell within the 
minimal range. A summary of the mean and standard deviation scores for each 
measure is provided in Table 2.4. As mentioned previously, higher scores indicated 
better performance on all measures, with the exception of the BAI and BDI-II on 
which higher scores indicated increased symptomlogy. 
Similarly, the results obtained for the University Cannabis sample fell within 
one standard deviation of the normative mean on most measures, with the exception 
of the Stroop Interference T-Score, which was one standard deviation higher than the 
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normative mean, and the WCST-A Conceptual Level Response, score which was one 
standard deviation lower than the normative mean. A summary of the mean and 
standard deviation scores is provided in Table 2.5. 
 
Relation between demographic and psychometric test results 
As discussed in Experiment 1, it has been suggested that psychometric tests 
may be influenced by various factors including anxiety and depression, age, years of 
education, handedness and gender. As in Experiment 1, correlations were calculated 
to examine these relations further. 
As shown in Table 2.6, there was a significant positive correlation for the 
University Alcohol sample between the Beck Anxiety Inventory and the Beck 
Depression Inventory-II. Anxiety and depression did not appear to relate to the scores 
obtained on any of the other measures. As such, anxiety and depression were not 
included as covariates in any further analysis. 
With regard to gender, there was a significant correlation with the Stroop 
Interference T-score (females scored higher) in the University Alcohol sample. There 
were no significant correlations between age, years of education, or handedness and 
the administered psychometric measures.  
Due to the small sample size, correlations were not conducted with the 
University Cannabis sample to assess the effects of age, years of education, 
handedness or gender. 
 
The relation between frequency of use and psychometric results 
The relation between frequency of alcohol and cannabis use was assessed in both 
samples using Pearson Correlations. Frequency of alcohol use in the University 
Alcohol sample ranged from once weekly to daily, with the mean number of days of 
alcohol consumption per week being 1.90 (SD 1.25).  Frequency of cannabis use in 
the Cannabis sample ranged from three times weekly to daily, with the mean number 
of days of cannabis use per week being 6.00 (SD 1.67).  
As shown in Table 2.7, frequency of alcohol use was found to positively 
correlate with all measures from the NART-II (increased use associated with higher 
scores) and to negatively correlate with the WCST-A Total Number of Errors and 
Conceptual Level Responses (increased use associated with lower scores) in the 
University Alcohol sample. As shown in Table 2.8, frequency of cannabis use was 
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found to negatively correlate with the WMS-III-A Delayed Memory and Total 
Memory scores (increased use associated with lower scores), and positively correlate 
with the Stroop Word T-Score and Stroop Colour-Word T-Score (increased use 
associated with higher scores) in the University Cannabis sample. 
 
Group Comparisons 
In order to examine the effects of regular alcohol and regular cannabis use, 
comparisons were made between the University Control sample (described in 
Experiment 1), the University Alcohol, and the University Cannabis samples. 
Independent sample t-tests were used to compare the samples on measures that were 
normally distributed (as mentioned earlier). The data for the remaining measures, 
which were not normally distributed, were compared using the non-parametric 
equivalent to the independent samples t-test, the Mann-Whitney U test. 
An independent samples t-test showed that the University Control sample and 
the University Alcohol sample did not differ significantly in age (t = 0.589, df = 84, p 
> 0.05) or years of education (t = 0.941, df = 84, p > 0.05). A chi squared test results 
showed that gender (χ 2 = 1.552, p > 0.05) and ethnicity (χ 2 = 4.224, p > 0.05) were 
not related to sample membership.   
Similarly, an independent samples t-test showed that the University Control 
sample and the University Cannabis sample did not differ significantly in age (t = 
2.679, df = 51, P > 0.05) or years of education (t = -0.804, df = 51, p > 0.05). Chi 
squared analyses showed that gender was related to sample membership (χ 2 = 14.229, 
p < 0.05), and ethnicity was not related to sample membership (χ 2 = 3.551, p > 0.05). 
As shown in Table 2.9 and Table 2.10, the University Control sample and the 
University Alcohol sample did not differ significantly on any of the administered 
measures. Medium effect sizes were obtained on the WMS-III-A Family Pictures I 
subtest. Table 2.11 and Table 2.12 show that the University Control sample differed 
significantly from the University Cannabis sample on the WCST-A Perseverative 
Responses and Perseverative Errors, as well as on the WCST-A Total Number of 
Errors. Medium effect sizes using Cohen’s d were obtained on the WCST-A 
Perseverative Responses and Perseverative Errors. On all of these measures, the 
University Control sample obtained higher scores. The University Control and 
University Cannabis samples did not significantly differ on any other measures.  
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As shown in Table 2.13 and Table 2.14, the University Alcohol sample 
differed significantly from the University Cannabis sample on the Stroop Interference 
T-Score, and all measures of the WCST-A. Medium effect sizes were obtained on the 
all measures of the WCST-A. On the Stroop Interference T-Score, the University 
Cannabis sample obtained higher scores, while on the WCST-A the University 
Cannabis sample obtained lower scores.  
  
72TABLE 2.2
One sample t-test comparing University Alcohol Sample to Normative Data, including means, standard deviations, and Cohen's d
WCST Nonperseverative Errors 100 15 103.00 16.76 1.10 37 NS 0.20
WCST Conceptual Level Responses 10 3.87 9.94 4.06 -19.45 37 * -0.02
* Significant at p< 0.05
Cohens
Mean SD Mean SD Significance d
WMS Logical Memory I 10 3 10.00 2.40 0.00 38 NS 0.00
WMS Family Pictures I 10 3 9.54 2.60 -1.11 38 NS -0.15
WMS Logical Memory II 10 3 10.54 2.49 1.35 38 NS 0.18
WMS Family Pictures II 10 3 9.28 2.36 -1.90 38 NS -0.24
WMS Immediate Memory 100 15 98.18 11.47 -0.99 38 NS -0.12
WMS Delayed Memory 100 15 100.44 10.50 0.26 38 NS 0.03
WMS Total Memory 100 15 98.49 11.19 -0.84 38 NS -0.10
WIAT Word Reading 100 15 107.94 7.50 6.36 35 * 0.53
WIAT Numerical Operations 100 15 94.94 12.44 -2.44 35 * -0.34
WIAT Spelling 100 15 110.86 8.93 7.30 35 * 0.72
WIAT Composite 100 15 104.11 9.25 2.67 35 * 0.27
TMT Part A Percentile 50 16 58.87 25.08 2.21 38 * 0.26
TMT Part B Percentile 50 16 46.87 30.81 -0.63 38 NS -0.09
Stroop Word T-Score 50 10 49.71 10.90 -0.16 37 NS -0.03
Stroop Colour T-Score 50 10 46.89 9.68 -1.98 37 NS -0.31
Stroop Colour-Word T-Score 50 10 53.39 6.79 3.08 37 * 0.34
Stroop Interference T-Score 50 10 54.58 6.13 4.60 37 * 0.46
NART Full Scale IQ 100 15 112.64 4.22 17.96 35 * 0.84
NART Verbal IQ 100 15 112.28 4.76 15.47 35 * 0.82
NART Performance IQ 100 15 111.75 3.36 20.99 35 * 0.78
Beck Anxiety Inventory 3.33 3.02 3.24 2.71 -1.53 35 NS -0.03
Beck Depression Inventory 3.54 3.15 3.04 2.78 -3.60 35 * -0.16
WCST Total Number of Errors 10 3.87 10.05 3.84 21.50 37 * 0.01
WCST Perseverative Responses 100 15 100.50 14.03 0.22 37 NS 0.03
WCST Perseverative Errors 100 15 98.55 12.72 -0.70 37 NS -0.10
t df
Normative University  Alcohol 
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TABLE 2.3
One sample t-test comparing University Cannabis Sample to Normative Data, including means, standard deviations and Cohen's d
Cohens
Mean SD Mean SD Significance d
WMS Logical Memory I 10.00 3 10.50 1.76 0.70 5 NS 0.17
WMS Family Pictures I 10.00 3 9.33 1.97 -0.83 5 NS -0.22
WMS Logical Memory II 10.00 3 11.50 2.35 1.57 5 NS 0.50
WMS Family Pictures II 10.00 3 9.00 1.67 -1.46 5 NS -0.33
WMS Immediate Memory 100.00 15 99.00 8.41 -0.29 5 NS -0.07
WMS Delayed Memory 100.00 15 102.00 9.36 0.52 5 NS 0.13
WMS Total Memory 100.00 15 99.67 9.00 -0.09 5 NS -0.02
TMT Part A Percentile 50.00 16th 68th 22.75 1.88 5 NS 0.51
TMT Part B Percentile 50.00 16th 55th 36.91 0.30 5 NS 0.13
Stroop Word T-Score 50.00 10 48.67 13.85 -0.24 5 NS -0.13
Stroop Colour T-Score 50.00 10 50.67 7.99 0.20 5 NS 0.07
Stroop Colour-Word T-Score 50.00 10 54.50 11.19 0.99 5 NS 0.45
Stroop Interference T-Score 50.00 10 60.33 8.04 3.15 5 * 1.03
WCST Total No Errors 100.00 15 85.67 9.71 -3.62 5 * -0.96
WCST Perseverative Responses 100.00 15 87.50 7.66 -4.00 5 * -0.83
WCST Persevertive Errors 100.00 15 86.17 8.89 -3.81 5 * -0.92
WCST Nonperseverative Errors 100.00 15 87.33 10.01 -3.10 5 * -0.84
WCST Conceptual Level Response 100.00 15 84.83 10.98 -3.38 5 * -1.01
* Significant at p< 0.05
t df
Normative University Cannabis
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TABLE 2.4
Means and Standard Deviations for Normative and University Alcohol Sample
Mean SD Mean SD
WMS Logical Memory I 10 3 10.00 2.40
WMS Family Pictures I 10 3 9.54 2.60
WMS Logical Memory II 10 3 10.54 2.49
WMS Family Pictures II 10 3 9.28 2.36
WMS Immediate Memory 100 15 98.18 11.47
WMS Delayed Memory 100 15 100.44 10.50
WMS Total Memory 100 15 98.49 11.19
WIAT Word Reading 100 15 107.94 7.50
WIAT Numerical Operations 100 15 94.94 12.44
WIAT Spelling 100 15 110.86 8.93
WIAT Composite 100 15 104.11 9.25
TMT Part A Percentile 50th 16th 59th 25.08
TMT Part B Percentile 50th 16th 47th 30.81
Stroop Word T-Score 50 10 49.71 10.90
Stroop Colour T-Score 50 10 46.89 9.68
Stroop Colour-Word T-Score 50 10 53.39 6.79
Stroop Interference T-Score 50 10 54.58 6.13
NART Full Scale IQ 100 15 112.64 4.22
NART Verbal IQ 100 15 112.28 4.76
NART Performance IQ 100 15 111.75 3.36
Beck Anxiety Inventory 11.08 9.10 10.53 7.36
Beck Depression Inventory 12.56 9.93 9.22 7.72
WCST Total Number of Errors 100 15 101.08 14.76
WCST Perseverative Responses 100 15 100.50 14.03
WCST Perseverative Errors 100 15 98.55 12.72
WCST Nonperseverative Errors 100 15 103.00 16.76
WCST Conceptual Level Responses 100 15 98.71 16.48
TMT results are presented in percentile scores. 1 SD below the 50th percentile is the 16th percentile
University Regular UseNormative
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TABLE 2.5
Means and Standard Deviations for Normative and University Cannabis Samples
Mean SD Mean SD
WMS Logical Memory I 10 3 10.50 1.76
WMS Family Pictures I 10 3 9.33 1.97
WMS Logical Memory II 10 3 11.50 2.35
WMS Family Pictures II 10 3 9.00 1.67
WMS Immediate Memory 100 15 99.00 8.41
WMS Delayed Memory 100 15 102.00 9.36
WMS Total Memory 100 15 99.67 9.00
TMT Part A Percentile 50th 16th 68th 22.75
TMT Part B Percentile 50th 16th 55th 36.91
Stroop Word T-Score 50 10 48.67 13.85
Stroop Colour T-Score 50 10 50.67 7.99
Stroop Colour-Word T-Score 50 10 54.50 11.19
Stroop Interference T-Score 50 10 60.33 8.04
WCST Total No Errors 100 15 85.67 9.71
WCST Perseverative Responses 100 15 87.50 7.66
WCST Persevertive Errors 100 15 86.17 8.89
WCST Nonperseverative Errors 100 15 87.33 10.01
WCST Conceptual Level Response 100 15 84.83 10.98
T T results are presented in percentile scores. 1 SD below the 50th percentile is the 16th percentile
University CannabisNormative
M
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Table 2.6
Correlations between demographic and psychometric test results for the University Alcohol Sample
Correlation Coeffient (r) 
WCST Nonperseverative Errors 0.173 -0.128 -0.287
WCST Conceptual Level Responses 0.305 -0.020 -0.033
* Significant at p < 0.05
Pearsons Point Biserial Point Biserial Pearsons Pearsons Pearsons
Age Gender Handedness Years of Beck Beck
Education Anxiety Depression
WMS Logical Memory I 0.025 -0.125 116.000 0.006
WMS Family Pictures I 0.105 -0.233 -0.036 0.005
WMS Logical Memory II -0.153 -0.136 0.049 0.008
WMS Family Pictures II 0.231 -0.021 -0.013 -0.004
WMS Immediate Memory 0.089 -0.021 0.047 0.027
WMS Delayed Memory 0.032 -0.228 0.029 0.002
WMS Total Memory 0.075 -0.225 0.040 0.021
WIAT Word Reading 0.213 0.148 0.026
WIAT Numerical Operations 0.181 0.073 0.085
WIAT Spelling -0.035 0.013 -0.001
WIAT Composite 0.148 0.121 0.052
TMT Part A Percentile 0.292 0.154 -0.143 0.156 -0.004
TMT Part B Percentile 0.223 0.140 0.035 0.036 -0.088
Stroop Word T-Score 0.299 -0.031 -0.083
Stroop Colour T-Score 0.044 0.207 0.022
Stroop Colour-Word T-Score -0.205 -0.086 -0.138
Stroop Interference T-Score -0.383* -0.039 -0.018
NART Full Scale IQ 0.107 0.050 0.193 0.123
NART Verbal IQ 0.097 0.061 0.207 0.128
NART Performance IQ 0.070 0.063 0.186 0.123
Beck Anxiety Inventory 0.020 0.656*
Beck Depression Inventory -0.177 0.656*
WCST Total Number of Errors 0.259 -0.252 -0.136
WCST Perseverative Responses 0.311 -0.281 -0.174
WCST Perseverative Errors 0.236 -0.258 -0.146
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Table 2.7
Correlations between frequency of alcohol use and psychometric test 
results for the University Alcohol Sample
Pearsons
Frequency
of Use
WMS Logical Memory I -0.105
WMS Family Pictures I -0.209
WMS Logical Memory II -0.058
WMS Family Pictures II -0.212
WMS Immediate Memory -0.187
WMS Delayed Memory -0.163
WMS Total Memory -0.177
WIAT Word Reading -0.255
WIAT Numerical Operations -0.048
WIAT Spelling 0.116
WIAT Composite 0.097
TMT Part A Percentile -0.081
TMT Part B Percentile -0.298
Stroop Word T-Score 0.051
Stroop Colour T-Score 0.030
Stroop Colour-Word T-Score -0.059
Stroop Interference T-Score -0.162
NART Full Scale IQ 0.362*
NART Verbal IQ 0.342*
NART Performance IQ 0.332*
Beck Anxiety Inventory 0.218
Beck Depression Inventory 0.000
WCST Total Number of Errors -0.472*
WCST Perseverative Responses -0.192
WCST Perseverative Errors -0.248
WCST Nonperseverative Errors -0.054
WCST Conceptual Level Responses -0.474*
* Significant at p < 0.05
Correlation Coeffient (r) 
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 Table 2.8
Correlations between frequency of cannabis use and psychometric test 
 results for the University Cannabis Sample
Pearsons
Frequency
of Use
WMS Logical Memory I 0.131
WMS Family Pictures I -0.517
WMS Logical Memory II -0.784
WMS Family Pictures II -0.536
WMS Immediate Memory -0.789
WMS Delayed Memory -0.844*
WMS Total Memory -0.834*
TMT Part A Percentile -0.030
TMT Part B Percentile -2.259
Stroop Word T-Score 0.896*
Stroop Colour T-Score 0.779
Stroop Colour-Word T-Score 0.838*
Stroop Interference T-Score 0.253
WCST Total Number of Errors 0.210
WCST Perseverative Responses 0.029
WCST Persevertive Errors 0.130
WCST Nonperseverative Errors -0.505
WCST Conceptual Level Responses -0.089
* Significant at p < 0.05
Correlation Coeffient (r) 
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Table 2.9
Independent Samples t-test Comparing University Control and University Alcohol Samples, including means, standard deviations and Cohen's d
t df Significance Cohens
Mean SD Mean SD d
WMS Logical Memory 2 10.47 3.01 10.54 2.49 0.33 84.00 NS -0.03
WMS Family Pictures 2 10.19 3.21 9.28 2.36 1.18 84.00 NS 0.32
WMS Delayed Memory 104.77 15.27 100.44 10.50 1.13 83.00 NS 0.33
WMS Total Memory 102.70 15.10 98.49 11.19 1.13 83.00 NS 0.31
WIAT Numerical Operations 100.30 15.10 94.94 12.44 1.54 78.00 NS 0.38
WIAT Spelling 114.14 9.69 110.86 8.93 1.42 78.00 NS 0.35
WIAT Composite 108.66 10.96 104.11 9.25 1.98 78.00 NS 0.44
Stroop Word T-Score 52.16 9.82 49.71 10.90 0.92 82.00 NS 0.24
Stroop Colour-Word T-Score 54.60 9.38 53.39 6.79 0.35 82.00 NS 0.15
Stroop Interference T-Score 54.16 7.66 54.58 6.13 -0.43 82.00 NS -0.06
NART Full Scale IQ 113.51 5.70 112.64 4.22 0.90 79.00 NS 0.17
NART Verbal IQ 112.60 3.95 112.28 4.76 0.96 79.00 NS 0.07
NART Performance IQ 113.70 5.09 111.75 3.36 0.90 79.00 NS 0.44
WCST Perseverative Responses 98.77 11.43 100.50 14.03 0.68 81.00 NS -0.14
WCST Perseverative Errors 97.60 12.01 98.55 12.72 0.44 81.00 NS -0.08
WCST Nonperseverative Errors 100.35 17.03 103.00 16.76 0.80 81.00 NS -0.16
* Signficant at p < 0.05
University Control University Alcohol
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Table 2.10
Mann-Whitney U Test Comparing University Control and University Alcohol Samples, including Cohen's d
Mann-Whitney U Wilcoxon W Z Asymp. Sig Cohens d
WMS Logical Memory 1 875.50 1655.50 -0.36 NS 0.13
WMS Family Pictures I 793.00 1573.00 -1.08 NS 0.53
WMS Immediate Memory 770.50 1550.50 -1.27 NS 0.30
WIAT Word Reading 742.50 1408.50 -0.48 NS 0.16
TMTAPercentile 865.00 1993.00 -0.45 NS -0.19
TMTBPercentile 884.00 1664.00 -0.28 NS 0.19
Stroop Colour T-Score 696.00 1437.00 -1.60 NS 0.24
Beck Anxiety Inventory 729.00 1764.00 -0.77 NS 0.12
Beck Depression Inventory 780.00 1815.00 -0.29 NS -0.09
WCST Total Number of Errors 819.50 1854.50 -0.32 NS -0.10
WCST Conceptual Level Responses 777.50 1812.50 -0.71 NS -0.13
* Signficant at p < 0.05
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Table 2.11
Independent Samples t-test Comparing University Control and University Cannabis Samples, including means, standard deviations and Cohen's d
t df Significance Cohens
Mean SD Mean SD d
WMS Logical Memory 1 10.33 2.68 10.50 1.76 -0.24 51 NS 0.02
WMS Logical Memory 2 10.47 3.01 11.50 2.35 -0.60 50 NS 0.12
WMS Family Pictures 2 10.19 3.21 9.00 1.67 0.74 50 NS -0.13
WMS Immediate Memory 102.26 14.89 99.00 8.41 0.39 51 NS -0.11
WMS Delayed Memory 104.77 15.27 102.00 9.36 0.25 50 NS -0.10
WMS Total Memory 102.70 15.10 99.67 9.00 0.32 50 NS -0.11
TMT Part B Percentile 52.91 31.87 54.50 36.91 -0.26 51 NS -0.44
Stroop Word T-Score 52.16 9.82 50.67 7.99 0.69 50 NS -0.20
Stroop Colour-Word T-Score 54.60 9.38 54.50 11.19 -0.11 50 NS -0.01
Stroop Interference T-Score 54.16 7.66 60.33 8.04 -1.96 50 NS 0.39
WCST Perservation Responses 98.77 11.43 87.50 7.66 2.27 49 * -0.50
WCST Perservation Errors 97.60 12.01 86.17 8.89 2.16 49 * -0.50
WCST Nonperservation Errors 100.35 17.03 87.33 10.01 1.81 49 NS -0.42
* Significant at p< 0.05
University Control University Cannabis
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Table 2.12
Mann-Whitney U Test Comparing University Control and University Cannabis Samples, including Cohen's d
Mann-Whitney U Wilcoxon W Z Asymp. Sig Cohens d
WMS Family Pictures I 114.50 135.50 -0.75 NS -0.21
TMT Part A Percentile Score 109.50 1237.50 -0.89 NS 0.35
Stroop Colour T-Score 133.50 1214.50 -0.13 NS -0.20
WCST Total No Errors 67.50 88.50 -1.98 * -0.45
WCST Conceptual Level Response 80.00 101.00 -1.61 NS -0.40
* Significant at p< 0.05
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Table 2.13
Independent Samples t-test Comparing University Alcohol and University Cannabis Samples, including means, standard deviations and Cohen's d
t df Significance Cohens
Mean SD Mean SD d
WMS Family Pictures 1 9.54 2.60 9.33 1.97 0.18 43 NS 0.03
WMS Logical Memory 2 10.54 2.49 11.50 2.35 -0.89 43 NS -0.15
WMS Family Pictures 2 9.28 2.36 9.00 1.67 0.28 43 NS 0.04
WMS Delayed Memory 100.44 10.50 102.00 9.36 -0.34 43 NS -0.08
WMS Total Memory 98.49 11.19 99.67 9.00 -0.25 43 NS -0.06
Stroop Word T-Score 49.71 10.90 48.67 13.85 0.21 42 NS 0.06
Stroop Colour-Word T-Score 53.39 6.79 54.50 11.19 -0.34 42 NS -0.09
Stroop Interference T-Score 54.58 6.13 60.33 8.04 -2.05 42 * -0.48
WCST Perservation Responses 100.50 14.03 87.50 7.66 2.20 42 * 0.51
WCST Perservation Errors 98.55 12.72 86.17 8.89 2.29 42 * 0.56
WCST Nonperservation Errors 103.00 16.76 87.33 10.01 2.21 42 * 0.56
* Significant at p< 0.05
University CannabisUniversity Alcohol
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Table 2.14
Mann-Whitney U Test Comparing University Alcohol and University Cannabis Samples, including Cohen's d
Mann-Whitney U Wilcoxon W Z Asymp. Sig Cohens d
WMS Logical Memory I 108.50 888.50 -0.29 NS -0.08
WMS Immediate Memory 114.00 894.00 -0.10 NS -0.04
TMT Part A Percentile Score 97.50 877.50 -0.65 NS -0.27
TMT Part B Percentile Score 104.00 884.00 -0.44 NS -0.24
Stroop Colour T-Score 88.00 829.00 -0.89 NS -0.21
WCST Standard Total No Errors 43.50 64.50 -2.41 * 0.62
WCST Standard Score for Conceptual Level Response 49.50 70.50 -2.21 * 0.52
* Significant at p< 0.05
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DISCUSSION 
 
The present study was conducted to assess the effects of regular alcohol and 
cannabis use on the cognitive functioning of a sample of university students. As 
outlined in the Results section, overall findings showed that the University Alcohol 
sample obtained scores similar to the normative means, and in several cases, obtained 
scores better than the normative means. In particular, the University Alcohol sample 
obtained higher scores on all measures of the WIAT-II-A with the exception of 
Numerical Operations, the Trail Making Test Part A, all NART-II measures, and the 
Stroop Color-Word and Stroop Interference measures. The University Cannabis 
sample obtained higher scores on the Stroop Interference T-Score and lower scores on 
all measures of the WCST-A compared to the normative data. Results for the 
University Cannabis sample on all other measures were similar to the normative 
means. 
When compared to the University Control sample from Experiment 1, the 
University Alcohol sample did not differ significantly on the psychometric measures, 
however, the University Cannabis sample scored lower on the WCST-A Perseverative 
Responses and Perseverative Errors, as well as on the WCST-A Total Number of 
Errors. Comparing the University Alcohol and University Cannabis samples showed 
that the University Alcohol sample obtained higher scores on all measures of the 
WCST-A than the University Cannabis sample, however, the University Alcohol 
sample obtained significantly lower Stroop Interference T-Scores than were obtained 
by the University Cannabis sample. 
These findings are discussion further below. 
  
Wechsler Memory Scale-III-Abbreviated 
No impairments in memory functioning were found for either the University 
Alcohol sample or the University Cannabis sample in the current study, although a 
medium effect size was found on the WMS-III-A Logical Memory II subtest when 
comparing the University Cannabis sample to the normative mean. Neither sample 
differed from the University Control sample. Thus the measures of short- and long-
term memory for both samples were within the normative range, indicating there was 
no impairment in the short- or long-term verbal and visual memory of either sample. 
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This suggests that neither of the samples would have difficulty remembering 
information in their daily lives, as mean scores on these measures were not more than 
one standard deviation below the normative mean (Wechsler, 2002).  
These findings for the University Alcohol sample contrast with those reported 
by Weissenborn and Duka (2000, 2003) who found that acutely intoxicated 
adolescents with a history of alcohol use had impairments in short-term memory. 
However, the results of the present study are similar to those reported by Moss, 
Kirisci, Gordon and Tarter (1994) and Eckardt, Stapleton, Rawlings, Davis and 
Grodin (1995). The findings for the alcohol sample in this study are likely to have 
differed from those reported by Weissenborn and Duka (2000, 2003), as while the 
current sample had a history of alcohol use, they were not acutely intoxicated at the 
time of the assessment.  
The scores of the University Cannabis sample on the WMS-III-A, while not 
significantly different from the other university samples, were found to be associated 
with frequency of cannabis use. Results showed that participants with a greater 
frequency of cannabis use obtained lower scores on the WMS-III-A Delayed Memory 
and Total Memory scores. This finding suggests that more frequent cannabis use may 
result in increased memory impairments as has been reported in the literature 
previously (Pope Jr. & Yurgelun-Todd, 1996; Schwartz, Gruenewald, Klitzner, & 
Fedio, 1989).  
 The findings from the current studies suggest that while casual alcohol use in 
university students is not associated with impairments in memory, increased 
frequency of cannabis use is associated with increased impairments in long-term 
memory and overall memory functioning. The noted low scores for the cannabis 
sample suggests that university students with regular and frequent cannabis use may 
have difficulty remembering information in their daily functioning, and this is likely 
to negatively impact on their academic studies (Fergusson, Horwood, & Beautrais, 
2003; Lynskey & Hall, 2000). 
 
Wisconsin Card Sorting Test-Abbreviated 
In the current study, the University Alcohol sample obtained results in the 
normal range, however, increased frequency of use was associated with lower scores 
on the WCST-A Total Number of Errors and Conceptual Level Responses. 
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The overall findings for the University Alcohol sample contrast with the 
impairments reported by Hannon, Day, Butler, Larson and Casey (1983) on the 
WCST in a sample of acutely intoxicated adolescents with a history of alcohol use; 
and also differ from those reported by Moss, Kirisci, Gordon and Tarter (1994) who 
reported poor performance in female adolescents, although concur with the 
unimpaired performance in male adolescents that was reported in this same study. The 
findings regarding the association between increased frequency of use and scores on 
the WCST-A Total Number of Errors and Conceptual Level Responses are similar to 
those reported by Hannon, Day, Butler, Larson and Casey (1983), who reported an 
association between increased use and poorer performance on the WCST 
Nonperseverative Errors measure. 
The results of the current alcohol sample may differ from those reported by 
Hannon, Day, Butler, Larson and Casey (1983) as the current sample was not acutely 
intoxicated at the time of assessment, and may have differed in regards to drinking 
history. Similarly, the University Alcohol sample may have differed from that 
reported on by Moss, Kirisci, Gordon and Tarter (1994) as the current sample 
consisted of university students who were not assessed for alcohol dependence, and 
therefore the amount and frequency with which they were consuming alcohol may not 
be comparable. 
The University Cannabis sample obtained lower scores than the normative 
mean on all of the WCST-A measures, however, obtained results were within one 
standard deviation of the normative mean on most measures. The one exception to 
this were the scores on the WCST-A Conceptual Level Response which were one 
standard deviation lower than the normative mean on average. As scores on the 
Conceptual Level Responses are said to indicate the individuals understanding of the 
correct sorting principles (Lezak, Howieson, Loring, Hannay, & Fisher, 2004; Strauss, 
Sherman, & Spreen, 2006), this finding suggests that the University Cannabis sample 
has difficulty identify ways to solve a problem. As this results is more that one 
standard deviation below the normative mean, this finding represents a clinically 
significant impairment, and may impact on their ability to cope with problems in their 
daily lives.  The findings for the University Cannabis sample are similar to Pope Jr. 
and Yurgelun-Todd (1996) who found impairment on the preservative measures in 
university students with heavy cannabis use, although the same impairments were not 
found in light cannabis users.  
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Overall, the findings on the WCST-A suggest that casual alcohol use is not 
associated with impairments in problem solving ability, however increased frequency 
of use is associated with an increase in errors on problem solving tasks, and difficulty 
continuing with a problem solving strategy. This suggests that increased alcohol use 
in university students is associated with poorer problem solving skills. Overall 
findings for the cannabis sample suggest that university students who use cannabis 
have difficulty identifying ways in which to solve a problem, and this may impact on 
their ability to cope with problems in their daily lives (Kongs, Thompson, Iverson, & 
Heaton, 2000). 
 
Trail Making Test 
 In the current study, neither the University Alcohol sample nor the University 
Cannabis sample, were found to have poorer scores on the TMT compared to the 
normative data. These findings suggest that the two samples are unlikely to have 
difficulties with simple attention (as measured by the TMT Part A), or with divided 
attention and cognitive flexibility (as measures by the TMT Part B).  
The findings for the University Alcohol sample concur with the literature, 
which have reported results comparable to the normative data in individuals with a 
short history of alcohol use (Eckardt, Stapleton, Rawlings, Davis, & Grodin, 1995). 
The findings for the University Cannabis sample are similar to those that have been 
reported previously on the cognitive functioning of young cannabis users when 
assessed with the TMT (Carlin & Trupin, 1977; Schaeffer, Andrysiak, & Ungerleider, 
1981). Interestingly, the findings for the University Cannabis sample on the TMT 
contrast with the poorer scores obtained on the WCST-A, another measure said to 
assess cognitive flexibility. The difference in the results from these two measures 
suggests that the TMT and the WCST-A measure different aspects of cognitive 
flexibility. Previous research has also suggests that these two measures may measure 
different aspects of functioning, with the TMT said to be more sensitive to 
impairments in cognitive flexibility (Strauss, Sherman, & Spreen, 2006). Given the 
different findings on these two measures, future research may be better to use the 
TMT to assess cognitive flexibility, while using the WCST-A to measure problem 
solving specifically. 
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Stroop Colour Word Test 
In the current study, the University Alcohol sample performed at a similar 
level to the normative mean, while the University Cannabis sample performed better 
than the normative mean, on the Stroop Interference T-Score.  
The findings for the University Alcohol sample are similar to those reported 
by Fadardi and Cox (2006), who administered the Stroop task to university students 
who identified as social drinkers. The findings for the University Cannabis sample are 
similar to those reported by Pope Jr. and Yurgelun-Todd (1996), however, the higher 
Stroop Interference T-Score in the current sample was unexpected. The Stroop 
Interference T-Score is derived from the word, colour and colour-word raw scores and 
is said to be a measure of an individual’s ability to inhibit responses. Previous 
research has suggested that impairments in impulse control and inhibition are more 
likely in substance using populations (Verdejo-Garcia, Lopez-Torrecillas, Orozco, & 
Perez-Garia, 2004), but this was not seen for the current cannabis sample.  
Similarly unexpected was the association shown between the Stroop Word T-
Score and Stroop Colour-Word T-Score and frequency of cannabis use. This relation 
suggests that word reading ability improves with frequency of cannabis use. Previous 
research has suggested that learning is impaired in casual cannabis users (e.g. Pope Jr. 
& Yurgelun-Todd, 1996), however, the findings on the Stroop and WMS-III-A 
suggest that this is not the case in this cannabis sample. Further research is needed to 
examine this finding. 
The findings for both samples indicate good cognitive flexibility and the 
ability to respond to task demands, and that casual use does not appear to affect 
impulse control and inhibition. The results on the Stroop task coincide with those 
obtained by the samples on the TMT which is also said to measure cognitive 
flexibility. This suggests that the two measures are likely to measure similar 
constructs. 
 
National Adult Reading Test-II 
The NART-II was used with only the University Alcohol sample. The 
University Alcohol sample obtained higher scores on all measures from the NART-II 
compared to the normative data. The scores were comparable to those obtained by the 
University Control sample. Findings did, however, suggest an association between 
frequency of use and NART-II scores, with higher frequency of alcohol use associated 
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with better scores. The correlation between these measures and frequency of alcohol 
use was, however, relatively small, and scores were only slightly above one standard 
deviation from the normative mean. This finding may however suggest that alcohol 
may be used as a coping mechanism in those with higher IQ, which has been 
previously reported in the literature (Batty, Deary, Schoon, Emslie, Hunt, & Gale, 
2008). Overall, these results suggest that intellectual functioning was not impaired in 
the University Alcohol sample.  
 
Wechsler Individual Achievement Test-Abbreviated 
As with the NART-II, the WIAT-II-A was conducted with only the University 
Alcohol sample. On the WIAT-II-A, the University Alcohol sample results were 
comparable to the normative data, with the exception of the Numerical Operations 
subtest which was lower. This finding is somewhat unexpected given the high 
functioning of the sample in the word reading and spelling subtests, however, it is still 
within the normative standard deviation range for this test. The lower score on the 
Numerical Operation subtest may be a factor of the New Zealand education system in 
which mathematics education following 5th Form is not compulsory. In the current 
sample the effect of mathematics education on the obtained Numerical Operations 
score was unable to be determined as this was not assessed. 
Overall, the findings on the WIAT-II-A suggest that regular alcohol use in 
university students is not associated with impairments in reading, spelling, or 
mathematical ability. 
 
Beck Anxiety Inventory & Beck Depression Inventory-II 
The BAI and BDI-II were conducted with only the University Alcohol sample. 
The University Alcohol sample completed the BAI and BDI-II to assess anxiety and 
depression respectively. Results on these measures suggested anxiety symptoms in the 
mild range, and in the minimal range for depression. The low occurrence of anxiety 
and depression symptoms in the University Alcohol sample are similar to those 
reported by a number of previous studies (Creamer, Foran, & Bell, 1995; Fisher, 
1996; Gorenstein, Andrade, Filho, Tung, & Artes., 1999; Lam, Pepper, & 
Ryabchenko, 2004; Troup, 2001; Whisman, Pere, & Ramel, 2000; Wiebe & Penley, 
2005).  
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The scores for the BAI and BDI-II for the University Alcohol sample were 
highly correlated, as has been reported previously in both clinical and non-clinical 
populations, including student samples (Gotlib, 1984). The correlation reported 
between the BAI and BDI-II was similar to that reported in the normative data (Beck 
& Steer, 1990) and is also similar to that reported by Troup (2001) who used these 
measures in a NZ university sample. This suggests that the two measures assess 
similar constructs, as has been reported previously (Beck & Steer, 1990; Beck, Steer, 
& Brown, 1996). 
As discussed, the University Alcohol sample obtained scores similar to those 
reported in research both overseas and in New Zealand, and the results on these 
measures were not found to relate to the results obtained on any of the psychometric 
measures. As levels of anxiety and depression were low these were unlikely to have 
affected performance on other tests. 
 
Limitations 
 The findings from the current study should be interpreted with caution for a 
number of reasons. Both samples were of individuals who reported consuming 
alcohol or cannabis at least once weekly (and therefore unlikely to be dependent); 
however, information on the amount consumed on each occasion was not obtained. 
This was because participants were generally unable to specify the amount consumed. 
The amount of alcohol and cannabis consumed by each participant on a regular basis 
was, therefore, unavailable, and may account for some of the findings which do not 
concur with the literature in this area.  
Frequency of alcohol and cannabis use reported by participants may have also 
been an influencing factor in the current research, as individuals potentially under- or 
over-reported their use. In addition, individuals may not have reported on all 
substances they were using at the time of the interview. As the research was both 
voluntary and anonymous it was hoped that the likelihood of false reporting would be 
reduced, however, this cannot be determined. 
As outlined, only six individuals were recruited for the University Cannabis 
sample over the period of January to December 2007. Therefore, extrapolation of data 
from this sample to the wider population is  difficult, although previous studies have 
reported similar sample sizes (e.g. Carlin & Trupin, 1977; Jacobson, Mencl, 
Westerveld, & Pugh, 2004; Schaeffer, Andrysiak, & Ungerleider, 1981; Schwartz, 
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Gruenewald, Klitzner, & Fedio, 1989). The small cannabis sample could suggest that 
there are few cannabis using students at the University of Waikato. This, however, is 
unlikely, as the literature suggests that cannabis is the most commonly used illicit 
substance in New Zealand, and overseas studies have reported high rates of cannabis 
use in college and university populations (Smart & Ogborne, 2000; Webb, Ashton, 
Kelly, & Kamali, 1996). A more likely explanation for the small number of 
participants is the stigma that is associated with admitting substance use, and potential 
concerns around admitting to participation in an illegal activity (Sullivan, 2007). 
While the information was anonymised from all participants, other potential 
participants may have been concerned as to the dissemination of any information they 
provided, and, that this could potentially identify them to other individuals.  
The current samples were recruited through only the Psychology Department 
at the University of Waikato. At the time of this research, the majority of students 
enrolled in psychology were female. As such, a larger percentage of the recruited 
participants in the alcohol sample were female. In contrast, the cannabis sample was 
largely males. Therefore, recruitment in other departments at the University may have 
been useful, although generally the university student population is female biased. 
Due to the high number of female participants, this may make the generalisation of 
these results difficult.   
Recruitment for both samples may have been influenced by the limited 
reimbursement available to participants for their time (the researcher was only able to 
offer a small course credit to individuals in the first year psychology courses). This 
may have potentially limited the number of individuals who volunteered. Previous 
research has found that offering incentives, such as money, does increase participation 
in research (Edwards, Roberts, Clarke, DiGuiseppi, Pratap, Wentz, & Kwan, 2002; 
Festinger, Marlowe, Croft, Dugosh, Mastro, Lee, DeMatteo, & Patapis, 2005), 
although concerns have been raised regarding incentives as they could be considered 
as coercion to participate given some individual’s continued drug seeking behaviour 
(Cunningham, 1998; Galanter & Kleber, 1999; McCrady & Bux Jr., 1999). 
 
Overall Findings 
The findings from the current study suggest that there are no significant 
impairments in the cognitive functioning of university students who consume alcohol 
regularly, although increased frequency of alcohol use was associated with decreased 
 
  
93
problem solving ability. The findings for the University Cannabis sample suggest that 
poorer problem solving skills are more likely in university students who use cannabis 
regularly, and that difficulties in the cannabis sample are likely to represent clinically 
significant difficulties (noticeable impairments) in at least some aspects of problem 
solving ability. Additionally, increased frequency of cannabis use was shown to be 
associated with poorer performance in memory functioning. Poorer performance in 
these areas may be associated with noticeable deficits in daily functioning, and may 
negatively effect achievement at university in this population. Further research is 
needed to assess the cognitive functioning of university students who use substances 
and/or alcohol.  
The findings from this study suggest that increased alcohol and cannabis use 
may be associated with poorer performance on several psychometric measures. This 
suggests that the administered psychometric measures are sensitive to the effects of 
alcohol and drug use even for casual users. In the next study these psychometric 
measures were administered to a sample of individuals on Methadone Maintenance 
Treatment at the Community Alcohol and Drug Service to assess the longer term 
effects of substance use. 
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EXPERIMENT 3 
 
Following the completion of Experiment 1, and as discussed in the Introduction the 
aims of this experiment were to explore the cognitive deficits of a group of opiate 
dependent participants enrolled in MMT, and to assess the association between 
cognitive outcomes and adherence to treatment. 
 
 
METHOD 
 
Participants 
In order to recruit participants for this study, the Community Alcohol & Drug 
Service (CADS) in Hamilton was approached, as this service provides treatment for 
over 200 individuals on Methadone Maintenance Treatment (MMT), and is the largest 
provider of methadone treatment in the Waikato region. The CADS management staff 
agreed to participate in the research, and staff were willing to assist in recruiting 
participants for the research. In order to increase the likelihood of individuals 
participating in the research, appointments to participate in the study were, where 
possible, scheduled in conjunction with existing appointments at the service.  
 Of approximately 220 individuals on MMT at the time of this study, 46 
individuals agreed to be contacted. Of these, 2 declined to be interviewed, 22 did not 
arrive, and 7 were unable to be contacted. The final sample consisted of only 8 men 
and 7 women.  
Of the sample interviewed, 12 identified as New Zealand European, 1 as New 
Zealand Maori and 2 as European of non-New Zealand origin. The age of participants 
ranged from 25 years to 42 years (mean 35.33, SD 5.219). On average, they had 
completed 11.4 years of education (SD 2.72), which is equivalent to having 
completed 5th Form or Year 11.  
The average length of time in this episode of treatment (since most recent 
admission) for opiate dependence for the 15 participants was 5.4 years (range 3 
months to 20 years, SD 5.8), with the daily dose of methadone averaging 87.98 mg 
(range 30 mg to 150 mg, SD 37.1). Of the sample, 6 individuals had received 
treatment for opioid dependence previously.  Individuals reported that their first 
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substance use occurred between 12 and 29 years of age (mean 14.93, SD 4.32) with 
first opiate use occurring between 14 and 25 years (mean 18.36, SD 3.67). 
 
Materials 
The psychometric measures administered to each participant were identical to 
those administered in Experiment 1 but included the Treatment Perceptions 
Questionnaire. 
 
Treatment Perceptions Questionnaire (TPQ) (1998) 
The Treatment Perceptions Questionnaire (Marsden, Bacchus, Stewart, 
Griffiths, Clarke, Gossop, & Strang, 1998) is a brief 10-item likert-type scale used to 
measure satisfaction with treatment for substance abuse problems. Of the 10 scale 
items, five questions assess the nature and extent of relationships with staff, and five 
items assess how the intervention is working, including the individual’s perceptions of 
the rules and regulations. The greatest TPQ score possible is 40, with greater scores 
indicative of greater treatment satisfaction.  Each item is scored on a scale of 0-4, (0 = 
strongly disagree to 4 = strongly agree). The TPQ was developed to assess client' 
satisfaction with treatment, and takes approximately 5 minutes to complete.  
According to the authors (Marsden, Stewart, Gossop, Rolfe, Bacchus, 
Griffiths, Clarke, & Strang, 2000) the overall internal reliability for the TPQ is 0.76, 
and test-retest reliability for the items fell between 0.40 and 0.60, with the overall 
test-retest reliability being 0.57 indicating fair test-retest reliability. Discriminate 
validity results showed a difference in results for individuals in inpatient versus 
community treatment.  
 
Adherence Measures 
In addition, to the psychometric measures administered, the present study 
assessed treatment adherence. Previous research has used a number of methods to 
measure adherence, such as: missed medication; days on dose; reduced pick-up 
schedules; urinanalysis results; counsellor ratings; and programme tenure (Blaney & 
Craig, 1999). In the current research, limited information was available with regards 
to adherence, and retention in treatment at the Community Alcohol and Drug Service 
due to the limited information that was routinely collected. At the time of the 
research, the available options for the assessment of adherence were number of 
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missed doses of methadone, urinanalysis results, length of time on programme, 
number of takeaway doses of methadone prescribed, and attendance at doctor and 
keyworker appointments. Following discussion with staff at CADS, and a review of 
the MMT programme at CADS, the two adherence measures deemed to be the most 
suitable were the number of missed methadone doses, and attendance at doctors’ 
appointments. Results of urinanalysis were not considered to be appropriate as the 
CADS MMT programme is run under a harm reduction philosophy, and a reduction in 
substance use is not required to remain on the programme. Length of time on the 
MMT programme was not included as this was considered to be a retention, and not 
an adherence measure. Attendance at keyworker appointments was also excluded, as 
attendance at keyworker appointments is not compulsory. 
The selected adherence measures (number of missed methadone doses, and 
attendance at doctors’ appointments) were assessed as follows: 
 
• The number of missed doses of methadone was based on records kept by the 
service (present service criteria states that the prescription pharmacy must 
notify CADS if an individual fails to pick up their dose of methadone for the 
day). Individuals with takeaway doses (where more than one dose can be 
picked up for use on consecutive days) were considered to have consumed on 
all days if they picked up their takeaway doses and there were no reports of 
replacement doses made in the file notes. Similarly, individuals who failed to 
pick up their takeaway doses, without replacement doses prescribed, were 
considered to have missed doses on those days. 
• The number of missed doctors’ appointments was based on the two 
appointments scheduled most recently. An individual was considered to have 
missed/not attended a scheduled appointment if they failed to attend the initial 
scheduled appointment, or the replacement appointment if one was scheduled 
within two weeks of the original appointment. The percentage of appointments 
that were attended was based on the two initial appointments scheduled most 
recently (if individuals attended the replacement appointment they were 
considered to have met the criterion for attendance at the scheduled 
appointment). This approach has been used previously by Gutierrez, 
Ballesteros, Gonzalez-Oliveros, & Ruiz de Apodaka (1995) who had a 
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criterion of unjustified absence from 5 consecutive or 10 alternative follow-up 
appointments. For some participants, information on the number of doctor 
appointments attended was available for the previous two appointments only. 
Therefore, this was selected as the number of appointments for the adherence 
criterion.  
 
Procedure 
Prior to the commencement of this research, ethical approval was obtained 
from the Psychology Department Human Research Ethics Committee at the 
University of Waikato and the Northern Y Regional Ethics Committee (part of the 
Health and Disability Ethics Committee). 
Participants were recruited from the Community Alcohol/Drug Service 
(CADS) in Hamilton, New Zealand between January 2005 and December 2005. All 
individuals were on the MMT programme run by this service. Participants were 
recruited through information fliers posted at CADS (see Appendix VII), and through 
information provided by staff to consumers of the service. Individuals were eligible to 
participate in the research if they had been enrolled in the methadone programme at 
CADS Hamilton for at least 3 months and were over the age of 18 years. Individuals 
were excluded from participation if they were deemed to be intoxicated by staff at the 
service (either alcohol or substance induced) at the time of the interview or if they had 
a current major mental illness (judged on a case by case basis).  
All individuals on the MMT programme were given the opportunity to 
participate, and provided that they meet the established criteria they were invited to 
take part in the research. Exclusion criteria were kept to a minimum to allow for a 
truer representation of this population, with the aim of producing results that were 
meaningful for the entire population, and not just a select minority. The minimum 
requirement of three months on the MMT programme was required to ensure 
stabilisation on methadone, as previous research has suggested that individuals should 
not be tested within 2 to 4 weeks of admission to treatment as results during this time 
may be affected by residual intoxication effects (Woods, Freitas, & Fas-Stewart, 
1999). Exclusion due to intoxication or substance impairment was assessed on the day 
of the interview, as research has suggested that impaired individuals may not 
comprehend fully what they are agreeing to participate in (McCrady & Bux Jr., 1999). 
The initial interview was also used to assess each participant’s eligibility to 
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participate, in relation to the other inclusion/exclusion criteria. No limitations were 
placed on how recently the participants had consumed their most recent dose of 
methadone; however, the recency of methadone dose was added as a covariate in the 
analysis of that data that was obtained.  
Individuals who agreed to take part in the research, were provided with the 
information sheet about the research (see Appendix VIII), and once they had 
completed the necessary consent forms (see Appendix IX) they were administered the 
neuropsychological tests, and asked a short series of questions regarding recent 
substance/alcohol use, and previous head injuries (see Appendix X). The 
neuropsychological tests were administered in the same order as Experiment 1. The 
Treatment Perceptions Questionnaire was administered at the end of the test sequence. 
All interviews were conducted on a one on one basis in a room at the Community 
Alcohol & Drug Service and took approximately 1 ½ to 2 hours to complete. 
Individuals were provided with a refreshment break during the assessment. Following 
the completion of the assessment, individual participation was recorded in the 
individuals file at CADS (see Appendix XI). 
Individuals were required to consent to a review of their file in order to assess 
their adherence to MMT, and to gain further demographic information (i.e. current 
diagnoses, or information unable to be obtained during the assessment). Results of the 
participant’s most recent urinanalysis (this was already a requirement for inclusion on 
the MMT programme) were reviewed in order to determine the possible influence of 
other substances on the validity of the test results. While exclusion criteria minimised 
the chance that individuals were intoxicated at the time of testing, residual effects of 
recent substance use may have affected results. As this was difficult to guard against, 
the aim was to include positive urine analysis results as a covariate when analysing 
the data. 
Participants were provided with refreshments and tea/coffee when they 
participated in the research, as it was considered to be inappropriate to give them a 
financial incentive. Previous research in this area has suggested that financial 
incentives could be considered as coercion to participate (Cunningham, 1998; 
Galanter & Kleber, 1999; McCrady & Bux Jr., 1999).  
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Demographic Information 
Demographic information was collected through the short demographic 
questionnaire completed by participants, and through file reviews (e.g., previous drug 
use, DSM diagnoses). This information is collected for all individuals on initial 
assessment for admission to the MMT programme. The length of time an individual 
had been using opiates was excluded from analysis as many participants could not 
give specific details in this area and insufficient information could be obtained from 
files regarding years of use, previous admissions, and ‘clean years’. 
 
Scoring and data entry 
Scoring and data entry were conducted as outlined in Experiment 1. 
Participants in the current study were given the option of receiving feedback on the 
results of the testing, and if participants agreed, this information was provided for 
inclusion in their case notes at CADS. The feedback consisted of general information 
regarding their overall functioning on each measure (e.g., the results of the memory 
test suggest that you are unlikely to have difficulty remembering information that you 
hear and information that you see) and also general skills for improvement of 
functioning (e.g., you may find that having information repeated is helpful, and 
writing down information, keeping a diary, or leaving post-it notes on the fridge 
might also be useful). In cases where there were significant concerns regarding the 
impairments found on the conducted measures, these were discussed with staff at 
CADS. In cases where there were concerns regarding harm to self or others (i.e. 
suicidal ideation question on BDI-II) these were further discussed with the participant 
to further ascertain risk issues, and where applicable risk issues were discussed with 
staff at CADS. If consultation with staff had not been available, and where there were 
ongoing concerns regarding risk, the researcher had the necessary Crisis Assessment 
and Treatment Team (CATT) contact details for the Hamilton region so that further 
advice could be accessed. 
 Analysis was conducted using SPSS Version 12, and was based on the same 
psychometric scores outlined in Experiment 1. Analysis of the Treatment Perception 
Questionnaire was based on the total score obtained from this scale, responses to 
individual questions, and on the two factors identified in the development of the TPQ 
– staff perceptions and program perceptions (Marsden et al., 2000). In the case of 
missing data, if only one answer was missing from a scale or subscale, an average 
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value was calculated by the researcher. Otherwise, data was coded as missing, and 
was not included in that section of the analysis. 
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RESULTS 
 
 
This study was conducted to assess the occurrence of cognitive impairments in 
individuals receiving MMT in New Zealand. A sample of 15 individuals in MMT 
were recruited from the CADS in Hamilton, New Zealand.  
 As shown in Table 3.1, the sample had a mean age of 35.33 years, and were 
predominantly of New Zealand European descent. There were a similar number of 
male and female participants, and on average they had completed the equivalent of 5th 
Form or Year 11/NCEA Level 1. 
 
Table 3.1
Demographic details of Methadone Sample
Age 35.33 SD 5.219, Range 25-42
Gender
Male 8 53.30%
Female 7 46.70%
Education 11.4 SD 2.72, Range 9-17
Handedness
Left 3 20%
Right 12 80%
  
Ethnicity
NZ European/Pakeha 12 80%
Maori 1 6.7%
Other European 2 13.3%
Methadone Maintenance
Time in Methadone Program 5.44 years SD 5.802, Range 3 months-20 years
Present dose of Methadone 87.98mg SD 37.10, Range 30-150
Previous Treatment Episodes 1.07 SD 1.58, Range 0-4
Substance History
First Drug Use 14.93 SD 4.323, Range 12-29
First Opiate Use 18.36 SD 3.67, Range 14-25
 
As previously mentioned, the participants had been in the current episode of 
treatment for opiate dependence 5.44 years on average, and were prescribed a 
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methadone dose of 87.98 mg daily on average. Six participants had received treatment 
for opioid dependence previously, with the mean number of treatment episodes being 
1.07. Participants reported that their first substance use occurred between 12 and 29 
years with first opiate use occurring between 14 and 25 years. 
 
Performance on the psychometric tests 
Prior to any analysis, Shapiro-Wilks tests were conducted to assess the 
distribution of the data for normality. Results from this analysis suggested that data 
for the TMT Part B Percentile Score (W = 0.706, df = 15, p < 0.05) were not normally 
distributed. Subsequently, transformations were conducted on these data, however, 
these failed to normalise the distribution of the data. As there are no non-parametric 
equivalents to the one sample t-test, the standard one sample t-test was used.  
A series of one sample t-tests was conducted to compare the results obtained 
with the normative data provided in the administration manuals for each test, with the 
exceptions of the BAI and BDI-II. The BAI data were compared to the non-student 
sample described in the BAI Manual (Beck & Steer, 1990), and the BDI-II data were 
compared to the university student sample described in the BDI-II Manual (Beck, 
Steer, & Brown, 1996), as other non-clinical data are not provided. 
The one sample t-tests showed significant differences between the obtained 
and normative data for a number of measures. A summary of these results is shown in 
Table 3.2. The Methadone sample obtained significantly lower scores than the 
normative sample for the Family Pictures I and II subtests, for all index score 
measures of the WMS-II-A, WIAT-II-A Numerical subtest and Composite Score, 
Trail Making Part B Percentile Score, and for all measures of the WCST-A with the 
exception of nonperseverative errors. However, they scored significantly higher than 
the normative data for the WIAT-II-A Word Reading subtest, Stroop Interference 
measure, and all NART-II measures. Significantly higher scores were also found for 
the BAI, which is indicative of increased anxiety symptomology. Medium effect sizes 
were obtained for the WMS-III-A Immediate Memory and Delayed Memory, all 
measures of the NART-II, and all measures of the WCST-A with the exception of 
Nonperseverative Errors. Large effect sizes were obtained when using Cohen’s d for 
the WMS-III-A Family Pictures I and II subtests and Total Memory, the WIAT-II-A 
Numerical Operations subtest, and the BAI. Results from all other measures were not 
statistically different from the normative sample.  
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 A comparison of the obtained results to the normative standard deviation 
ranges provided for each measure showed that, while the sample differed significantly 
from the normative data on a number of measures, the mean scores fell within one 
standard deviation for all measures, with the exception of the WIAT-II-A Numerical 
operations subtest and the BAI. The mean score on the BAI for the Methadone sample 
fell in the moderate range, with the majority of participants (33.33%) obtaining scores 
in the severe range, followed by the moderate and mild (both 26.67%), and minimal 
(13.33%) ranges. The mean score for the Methadone sample on the Beck Depression 
Inventory-II fell within the mild range, with the majority of participants obtaining a 
result in the minimal range (40%) followed by the mild (26.67%), severe (20%) and 
moderate (13.33%) ranges. A summary of the mean and standard deviations for each 
measure is provided in Table 3.3.  
As the mean scores obtained by the sample may not reflect the score of any 
one individual, the sample data were analysed for each participant to assess overall 
impairment at one and two standard deviations below the normative mean for each 
measure. The number of individuals who obtained scores either one or two standard 
deviations below the normative mean is given in Table 3.4. Only one standard 
deviation (16th Percentile) is given for the Trail Making test as normative data are not 
provided for two standard deviations. It should be noted that while 13 participants 
attempted the Wisconsin Card Sorting Test, only 12 participants completed the task. 
This suggests that the score of the one individual who failed to complete the task 
might have fallen more than one or two standard deviations below the normative 
mean had they finished the task. On closer examination it was found that one 
participant obtained a score two standard deviations below the normative mean on all 
measures of the WMS-III-A. Obtained scores more than two standard deviations 
below the normative mean on all other measures, were not the data from a single 
participant. 
 
Relation between demographic and psychometric test results 
As in Experiment 1, possible relations between psychometric test results and 
anxiety, depression, age, years of education, handedness and gender were assessed. 
Table 3.5 shows that the BAI negatively correlated with the Stroop Colour T-Score 
and Stroop Colour-Word T-Score (greater anxiety symptoms associated with poorer 
Stroop performance). The Beck Depression Inventory-II positively correlated with the 
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Logical Memory I and II subtests of the WMS-III-A (greater depression symptoms 
associated with better WMS-III-A scores), and correlated negatively with the Stroop 
Colour-Word T-Score (greater depression symptoms associated with worse Stroop 
scores).  
The relation between age and obtained score was assessed for the NART-II, as 
this did not provide age adjusted normative data. Table 3.5 shows that age did not 
significantly correlate with scores obtained on the NART-II. Years of education was 
positively correlated with the Trail Making B (higher scores on TMT associated with 
more years of education), but did not correlate with any other measure.  
Gender did not correlate with any of the measures, while handedness 
correlated with the Trail Making Test Part B Percentile Score (left handedness 
associated with a better result). This result should be interpreted with caution as the 
distribution differed significantly from normal, and only 3 participants were left 
handed.  
As well as these moderating factors, the literature has suggested that 
methadone itself may affect cognitive ability (e.g., Rapeli, Fabritius, Alho, Salaspuro, 
Wahlbeck, & Kalska, 2007). Thus, a series of correlations was conducted to assess the 
relation between psychometric test results and dose of methadone, length of time on 
MMT (years), and time since last methadone dose. As shown in Table 3.6, methadone 
dose did not correlate significantly with any of the psychometric measures, and time 
on MMT was negatively correlated with Nonperseverative Errors on the WCST-A 
(increased time in MMT associated with poorer scores on Nonperseverative Errors).  
Length of time since last dose was positively correlated with the WMS-III-A 
Family Pictures I and Family Pictures II scores; however, this correlation was due to 
one outlier who had not consumed a dose of methadone in the previous 24 hours. 
When this participant was excluded from analysis the correlation was not significant 
(r = 0.319, p < 0.05 and r = 0.277, p < 0.05 respectively). 
 As discussed in the Method section, participants were not excluded if they had 
experienced a head injury or overdose previously. Pearson Correlations were 
conducted to assess the relation between the number of head injuries reported and the 
number of previous overdoses in relation to the psychometric tests. Number of head 
injuries was negatively correlated with all measures from the NART-II. Number of 
overdoses was positively correlated with the TMT Part B Percentile score and Beck 
Anxiety Inventory score. However, the significant correlations obtained for number of 
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head injuries and number of overdoses should be interpreted with caution as these 
were based on self-report and these data may be inaccurate.  
 
Other Drug Use 
Of the 15 individuals in this sample, 11 individuals reported using other 
substances within the prior 48 hours. Of these, 5 reported cannabis use, 4 reported 
benzodiazepine use, one reported alcohol and cannabis use, and one participant 
reported using benzodiazepines, morphine, cannabis and alcohol in the previous 48 
hours.  
In order to determine the influence of other drug use on psychometric tests 
results, the sample was split into five groups based on what other drugs the 
individuals identified as using. Group membership was as follows: no other drug use; 
benzodiazepine use; alcohol and cannabis use; and benzodiazepine, morphine, 
cannabis and alcohol use. 
The obtained scores on each of the psychometric tests were assessed using 
Kruskal-Wallis tests across the five groups within the Methadone sample. The results 
of these tests are outlined in Table 3.7, and show that performance on the 
psychometric tests was not influenced by the other substances use that was reported. 
 
Satisfaction with Treatment 
The Treatment Perceptions Questionnaire (TPQ) was used to assess 
satisfaction with treatment. Scores on the TPQ were variable (mean 23.15, SD 5.82, 
range 14 – 33), however, general themes regarding the methadone programme were 
evident from the personal opinion section that was included in the questionnaire. 
Individuals felt that MMT as a treatment option resulted in a loss of freedom (e.g., 
requirement to consume dose under supervision on a regular basis); they were 
condemned for attempts to reduce illicit use; they were ‘treated like children’; and the 
consequences of not complying with the treatment programme were inconsistent.  
The data from the TPQ were analysed further to assess for trends in treatment 
satisfaction. The TPQ was analysed in regards to both individual questions, and to the 
two factors identified in the development of the TPQ – staff perceptions and program 
perceptions (Marsden et al., 2000). An analysis of the individual questions indicated 
lower mean scores (lower satisfaction) on three questions: ‘The staff have not always 
understood the kind of help I wanted’ (1.62, SD 1.45), ‘The staff and I have had 
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different ideas about what my treatment objectives should be’ (1.69, SD 0.85) and ‘I 
have not liked some of the treatment rules or regulations’ (1.23, SD 1.16). Higher 
scores (greater satisfaction) were noted on two questions: ‘I think the staff have been 
good at their jobs’ (3.23, SD 0.60) and ‘I have received the help that I was looking 
for’ (3.00, SD 1.08). Analysis using the two factors identified by Marsden et al. 
(2000) found similar mean scores on both the Staff Perceptions factor (11.62, SD 
3.48) and the Program Perceptions factor (11.54, SD 3.02).  
 Pearson Correlations were conducted to assess the relation between TPQ 
scores and length of time in the MMT programme and methadone dose. No 
significant correlations were found between length of time in the MMT programme 
and TPQ Total Score (r = -0.056), Staff Perceptions (r = -0.207), or Program 
Perceptions (r = 0.132) factors. Similarly, no significant correlations were found 
between methadone dose and TPQ Total Score (r = 0.001), Staff Perceptions (r = 
0.003) or Program Perceptions (r = -0.001) factors. 
 
Neuropsychological Performance & Treatment Adherence 
Adherence to treatment in the current sample was measured by attendance at 
scheduled doctors’ appointments and number of missed doses of methadone. As 
mentioned in the Method section, individuals were deemed to have adhered to the 
treatment programme if they had not missed a dose of methadone, and had attended 
their last two appointments (or replacement appointments if scheduled within two 
weeks). Nine of the 15 individuals in the Methadone sample had attended their two 
most recent appointments, while the remaining 6 had attended one of the last two 
most recent appointments. None of the participants had missed consumption of their 
dose of methadone within the last month. 
To determine if there were differences between those who adhered to 
treatment requirements and those that had not, a series of independent sample t-tests 
and Mann-Whitney U tests were conducted. Both an independent samples t-test and a 
Mann Whitney U test were conducted for each psychometric measure, as data for both 
groups on several of the measures were not normally distributed. In all cases, both 
tests showed the same result. Therefore, the independent sample t-test results only, are 
reported here. These results are outlined in Table 3.8, and show no statistically 
significant differences for any of the psychometric measure, although significant 
differences were found for the TPQ Total score and TPQ Program Perceptions factor 
 
  
107
score. The individuals who attended only one of their last two appointments obtained 
lower scores (lower satisfaction) than the other individuals on both of these measures. 
Medium effect sizes were obtained for the WMS-III-Logical Memory II 
subtest, WIAT-II-A Word Reading and Numerical Operations subtests, BDI-II, 
NART Verbal IQ score, WCST-A Conceptual Level Responses and TPQ Staff 
Perceptions score. Large effect sizes were obtained for the WIAT-II-A Composite 
score, TMT Part A Percentile Score, WCST-A Total Number of Errors, and the TPQ 
Total and Program Perceptions scores.  
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TABLE 3.2
One sample t-test comparing Methadone Sample to Normative Data, including means, standard deviations and Cohen's d
Cohens
Significance d
WCST Nonperseverative Errors 100 15 92.83 11.99 -2.07 11 NS -0.48
WCST Conceptual Level Response 100 15 89.67 7.69 -4.65 11 * -0.69
* Significant at p< 0.05
t dfMethadoneNormative 
Mean SD Mean SD
WMS Logical Memory I 10 3 9.00 3.23 -1.20 14 NS -0.33
WMS Family Pictures I 10 3 7.40 2.50 -4.03 14 * -0.87
WMS Logical Memory II 10 3 8.80 3.34 -1.39 14 NS -0.40
WMS Family Pictures II 10 3 7.27 3.13 -3.38 14 * -0.91
WMS Immediate Memory 100 15 89.53 14.03 -2.89 14 * -0.70
WMS Delayed Memory 100 15 89.73 14.81 -2.68 14 * -0.68
WMS Total Memory 100 15 88.73 14.14 -3.09 14 * -0.75
WIAT Word Reading 100 15 105.69 5.48 3.74 12 * 0.38
WIAT Numerical Operations 100 15 82.54 16.51 -3.81 12 * -1.16
WIAT Spelling 100 15 98.54 9.47 -0.56 12 NS -0.10
WIAT Composite 100 15 93.00 8.38 -3.01 12 * -0.47
TMT Part A Percentile 50 16 49 th 26.15 -0.20 14 NS -0.04
TMT Part B Percentile 50 16 22nd 18.19 -6.03 14 * -0.83
Stroop Word T-Score 50 10 46.21 11.27 -1.26 13 NS -0.38
Stroop Colour T-Score 50 10 45.57 8.16 -2.03 13 NS -0.44
Stroop Colour-Word T-Score 50 10 54.93 9.59 1.92 13 NS 0.49
Stroop Interference T-Score 50 10 54.86 6.74 2.70 13 * 0.49
NART Full Scale IQ 100 15 111.00 5.32 8.01 14 * 0.73
NART Verbal IQ 100 15 111.87 6.91 6.65 14 * 0.79
NART Performance IQ 100 15 111.40 7.74 5.71 14 * 0.76
Beck Anxiety Inventory 7.78 5.65 19.20 10.81 4.09 14 * 2.02
Beck Depression Inventory 12.56 9.93 17.40 11.06 1.70 14 NS 0.49
WCST Total Number of Errors 100 15 90.92 7.025 -4.48 11 * -0.61
WCST Perseverative Responses 100 15 91.33 8.63 -3.48 11 * -0.58
WCST Persevertive Errors 100 15 90.00 9.47 -3.66 11 * -0.67
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TABLE 3.3
Means and Standard Deviations for Normative and Methadone Sample
Normative One Standard Methadone Methadone
Mean Deviation Mean SD
WMS Logical Memory I 10 3 9.00 3.23
WMS Family Pictures I 10 3 7.40 2.50
WMS Logical Memory II 10 3 8.80 3.34
WMS Family Pictures II 10 3 7.27 3.13
WMS Immediate Memory 100 15 89.53 14.03
WMS Delayed Memory 100 15 89.73 14.81
WMS Total Memory 100 15 88.73 14.14
WIAT Word Reading 100 15 105.69 5.48
WIAT Numerical Operations 100 15 82.54 16.51
WIAT Spelling 100 15 98.54 9.47
WIAT Composite 100 15 93.00 8.38
TMT Part A Percentile 50th 16th 49 th 26.15
TMT Part B Percentile 50th 16th 22nd 18.19
Stroop Word T-Score 50 10 46.21 11.27
Stroop Colour T-Score 50 10 45.57 8.16
Stroop Colour-Word T-Score 50 10 54.93 9.59
Stroop Interference T-Score 50 10 54.86 6.74
NART Full Scale IQ 100 15 111.00 5.32
NART Verbal IQ 100 15 111.87 6.91
NART Performance IQ 100 15 111.40 7.74
Beck Anxiety Inventory 7.78 5.65 19.20 10.81
Beck Depression Inventory 12.56 9.93 17.40 11.06
WCST Total Number of Errors 100 15 90.92 7.025
WCST Perseverative Responses 100 15 91.33 8.63
WCST Persevertive Errors 100 15 90.00 9.47
WCST Nonperseverative Errors 100 15 92.83 11.99
WCST Conceptual Level Response 100 15 89.67 7.69
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Table 3.4
Number of individuals obtaining scores One and Two Standard Deviations below norm
n 1 SD 2 SD
WMS Logical Memory I 15 5 1 h
WMS Family Pictures I 15 7 1 h
WMS Logical Memory II 15 5 1 h
WMS Family Pictures II 15 6 2 b,h
WMS Immediate Memory 15 4 1 h
WMS Delayed Memory 15 4 1 h
WMS Total Memory 15 5 1 h
WIAT Word Reading 13 0 0
WIAT Numerical Operations 13 7 2 i,k
WIAT Spelling 13 1 0
WIAT Composite 13 2 0
TMT Part A Percentile 15 2
TMT Part B Percentile 15 9
Stroop Word T-Score 14 0 2 a,k
Stroop Colour T-Score 14 2 1 a
Stroop Colour-Word T-Score 14 0 0
Stroop Interference T-Score 14 0 0
NART Full Scale IQ 15 0 0
NART Verbal IQ 15 0 0
NART Performance IQ 15 0 0
WCST Total Number of Errors 12 2 0
WCST Perseverative Responses 12 2 0
WCST Persevertive Errors 12 2 1 k
WCST Nonperseverative Errors 12 4 0
WCST Conceptual Level Response 12 5 0
a, b, h, i, k = Participants 1, 2, 8, 9 and 11 respectively
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Table 3.5
Correlations between demographic and psychometric test results for the Methadone Sample
Correlation Coeffient (r) 
WCST Persevertive Errors -0.131 0.182 -0.369
WCST Nonperseverative Errors 0.267 -0.310 -0.130
WCST Conceptual Level Response 0.306 -0.215 -0.377
* Significant at p < 0.05
Pearsons Point Biserial Point Biserial Pearsons Pearsons Pearsons
Age Gender Handedness Years of Beck Beck
Education Anxiety Depression
WMS Logical Memory I 0.428 0.114 0.285 0.534*
WMS Family Pictures I 0.288 0.006 0.147 -0.109
WMS Logical Memory II 0.472 0.222 0.395 0.536*
WMS Family Pictures II 0.315 0.045 -0.029 -0.092
WMS Immediate Memory 0.446 0.082 0.228 0.240
WMS Delayed Memory 0.419 0.107 0.224 0.238
WMS Total Memory 0.429 0.092 0.250 0.237
WIAT Word Reading 0.122 0.180 0.027
WIAT Numerical Operations 0.294 0.219 -0.077
WIAT Spelling 0.513 0.012 0.402
WIAT Composite 0.383 0.145 0.095
TMT Part A Percentile -0.294 0.191 0.028 -0.055 0.332
TMT Part B Percentile 0.177 0.759* 0.541* 0.105 0.245
Stroop Word T-Score -0.243 -0.326 -0.105
Stroop Colour T-Score 0.400 -0.676* -0.329
Stroop Colour-Word T-Score 0.131 -0.560* -0.587*
Stroop Interference T-Score 0.198 -0.148 -0.428
NART Full Scale IQ -0.069 0.338 -0.224 0.187
NART Verbal IQ -0.088 0.339 -0.204 0.192
NART Performance IQ -0.078 0.325 -0.212 0.195
Beck Anxiety Inventory 0.059 0.389
Beck Depression Inventory 0.328 0.389
WCST Total Number of Errors 0.366 0.067 -0.302
WCST Perseverative Responses 0.157 0.485 -0.065
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Table 3.6
Correlations between methadone and psychometric results for the Methadone Sample
Correlation Coeffient (r) 
Pearsons Pearsons Pearsons Point Biserial Point Biserial
Time in Methadone Time Since Head Overdose
Treatment Dose Dose Injury
WMS Logical Memory I 0.1 0.415 0.222 -0.262 0.506
WMS Family Pictures I 0.47 -0.076 0.663* -0.046 0.087
WMS Logical Memory II 0.062 0.098 0.152 -0.088 0.318
WMS Family Pictures II 0.451 0.097 0.663* -0.251 -0.127
WMS Immediate Memory 0.312 0.236 0.499 -0.205 0.298
WMS Delayed Memory 0.307 0.076 0.486 -0.181 0.075
WMS Total Memory 0.32 0.150 0.507 -0.198 0.199
WIAT Word Reading 0.101 -0.541 0.227 -0.512 -0.066
WIAT Numerical Operations 0.094 -0.477 -0.133 -0.333 0.284
WIAT Spelling 0.119 -0.140 0.019 -0.550 -0.255
WIAT Composite 0.122 -0.463 -0.038 -0.532 -0.006
TMT Part A Percentile 0.291 -0.096 -0.165 -0.166 -0.122
TMT Part B Percentile 0.281 -0.101 -0.147 -0.334 0.607*
Stroop Word T-Score -0.065 -0.427 -0.008 -0.349 -0.273
Stroop Colour T-Score 0.067 -0.489 0.433 -0.476 -0.473
Stroop Colour-Word T-Score -0.104 -0.256 0.495 -0.191 -0.482
Stroop Interference T-Score -0.187 -0.042 0.476 0.093 -0.189
NART Full Scale IQ 0.445 -0.033 0.215 -0.621* -0.317
NART Verbal IQ 0.446 0.037 0.208 -0.643* -0.282
NART Performance IQ 0.453 0.016 0.196 -0.624* -0.292
Beck Anxiety Inventory -0.175 0.007 -0.077 0.048 0.751*
Beck Depression Inventory -0.208 0.238 -0.316 -0.217 0.402
WCST Total Number of Errors -0.37 -0.029 0.233 0.174 0.066
WCST Perseverative Responses -0.044 0.045 0.204 0.453 0.490
WCST Persevertive Errors 0.162 0.000 0.343 0.438 0.228
WCST Nonperseverative Errors -0.719* 0.117 -0.186 -0.139 0.015
WCST Conceptual Level Response -0.363 -0.027 0.458 0.084 -0.197
* Significant at p < 0.05
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Table 3.7
Kruskal Wallis Test for effects of other substance use for the Methadone Sample
* Signficant at p < 0.05
n Mean SD n Mean SD n Mean n Mean SD
WMS Logical Memory I 4 10.25 3.95 5 8.20 1.64 1 12.00 4 8.00 4.69
WMS Family Pictures I 4 9.25 3.30 5 6.60 1.82 1 9.00 4 6.75 2.22
WMS Logical Memory II 4 9.25 2.06 5 7.80 2.17 1 14.00 4 8.75 5.44
WMS Family Pictures II 4 9.50 3.42 5 6.80 2.59 1 8.00 4 5.50 3.70
WMS Immediate Memory 4 98.50 15.02 5 85.40 6.54 1 102.00 4 84.25 19.92
WMS Delayed Memory 4 97.50 12.82 5 84.40 10.01 1 106.00 4 85.75 21.93
WMS Total Memory 4 96.75 13.89 5 83.80 7.98 1 104.00 4 84.50 20.40
WIAT Word Reading 4 104.50 5.74 5 106.60 6.66 1 109.00 2 101.50 0.71
WIAT Numerical Operations 4 72.50 10.50 5 83.80 21.48 1 108.00 2 84.00 1.41
WIAT Spelling 4 99.00 6.73 5 98.00 10.54 1 99.00 2 92.50 16.26
WIAT Composite 4 89.50 7.19 5 93.60 10.64 1 100.00 2 90.50 6.36
TMT Part A Percentile 4 57.50 18.93 5 42.00 28.42 1 80.00 4 32.50 23.98
TMT Part B Percentile 4 16.25 9.46 5 21.00 15.17 1 75.00 4 12.50 5.00
Stroop Word T-Score 4 43.75 1.71 5 48.80 17.17 1 50.00 3 42.67 13.05
Stroop Colour T-Score 4 47.00 6.98 5 50.00 7.71 1 45.00 3 37.33 9.07
Stroop Colour-Word T-Score 4 57.00 8.49 5 57.60 12.24 1 46.00 3 52.33 10.07
Stroop Interference T-Score 4 56.50 7.33 5 54.20 8.23 1 49.00 3 56.33 7.09
NART Full Scale IQ 4 113.25 7.54 5 113.40 4.62 1 112.00 4 106.25 7.80
NART Verbal IQ 4 113.00 8.04 5 113.00 5.43 1 112.00 4 105.00 8.68
NART Performance IQ 4 112.25 5.56 5 112.20 3.83 1 111.00 4 106.50 5.80
WCST Total Number of Errors 3 86.67 10.69 5 91.60 6.88 1 92.00 2 95.50 4.95
WCST Perseverative Responses 3 91.67 2.89 5 89.80 7.22 1 101.00 2 98.50 9.19
WCST Persevertive Errors 3 90.33 5.86 5 86.00 11.53 1 98.00 2 97.50 10.61
WCST Nonperseverative Errors 3 84.67 7.51 5 102.60 11.67 1 80.00 2 91.50 0.71
WCST Conceptual Level Response 3 88.67 12.06 5 90.60 8.35 1 85.00 2 93.50 0.71
No Other Use Benzodiazepine UseAlcohol & Cannabis UseCannabis Use
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Table 3.8
Independent Samples t-test comparing attendence at doctors appointments in Methadone Sample, including means, standard deviations and 
Cohen's d
 Cohens
TPQ Total Score 19.20 5.07 25.63 5.01 -2.24 11 * -1.28
TPQ Staff Perceptions 10.20 3.96 12.50 3.07 -1.18 11 NS -0.67
TPQ Program Perceptions 9.00 1.73 13.13 2.53 -3.18 11 * -1.81
* Significant at p< 0.05
Two appointmentsOne appointment
Mean SD Mean SD t df Significance d
WMS Logical Memory 1 9.83 1.72 8.44 3.94 0.81 13 NS 0.42
WMS Family Pictures 1 7.67 3.08 7.22 2.22 0.33 13 NS 0.17
WMS Logical Memory 2 9.67 2.80 8.22 3.70 0.81 13 NS 0.50
WMS Family Pictures 2 7.67 3.72 7.00 2.87 0.39 13 NS 0.21
WMS Immediate Memory 93.00 13.13 87.22 14.89 0.77 13 NS 0.41
WMS Delayed Memory 93.33 15.47 87.33 14.76 0.76 13 NS 0.40
WMS Total Memory 92.17 14.36 86.44 14.36 0.76 13 NS 0.40
WIAT Word Reading 107.40 5.41 104.63 5.60 0.88 11 NS 0.50
WIAT Numerical Operations 90.00 16.91 77.88 15.47 1.33 11 NS 0.76
WIAT Spelling 101.20 11.97 96.88 7.97 0.79 11 NS 0.45
WIAT Composite 97.40 9.50 90.25 6.80 1.59 11 NS 0.91
TMT Part A Percentile 36.67 28.93 56.67 22.22 -1.52 13 NS -0.80
TMT Part B Percentile 19.17 11.14 23.33 22.22 -0.42 13 NS -0.22
Stroop Word T-Score 46.50 10.13 46.00 12.75 0.08 12 NS 0.04
Stroop Colour T-Score 45.00 11.47 46.00 5.40 -0.22 12 NS -0.12
Stroop Colour-Word T-Score 56.67 10.09 53.63 9.66 0.57 12 NS 0.31
Stroop Interference T-Score 58.00 6.36 52.50 6.37 1.60 12 NS 0.86
Beck Anxiety Inventory 21.17 10.55 17.89 11.40 0.56 13 NS 0.30
Beck Depression Inventory 13.33 6.25 20.11 12.99 -1.18 13 NS -0.62
NART Full Scale IQ 112.50 5.24 110.00 5.43 0.88 13 NS 0.47
NART Verbal IQ 114.00 6.45 110.44 7.20 0.98 13 NS 0.51
NART Performance IQ 113.67 7.45 109.89 7.98 0.92 13 NS 0.49
WCST Total Number of Errors 94.40 3.51 88.43 8.06 1.54 10 NS 0.90
WCST Perseverative Responses 89.20 12.32 92.86 5.37 -0.62 10 NS -0.41
WCST Persevertive Errors 91.80 9.42 88.71 10.03 0.54 10 NS 0.32
WCST Nonperseverative Errors 94.40 12.46 91.71 12.51 0.37 10 NS 0.21
WCST Conceptual Level Response 93.00 5.34 87.29 8.58 1.31 10 NS 0.77
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DISCUSSION 
 
 
In this study, the cognitive functioning of 15 individuals in an MMT 
programme was assessed. This sample obtained lower scores than the normative 
sample for the Family Pictures I and II subtests and index scores of the WMS-III-A, 
the WIAT-II-A Numerical Operations subtest and Composite score, TMT Part B 
Percentile Score, and all measures of the WCST-A with the exceptions of 
Nonperseverative Errors. The Methadone sample obtained higher scores than the 
normative sample for the WIAT-II-A Word Reading subtest, Stroop Interference T-
Score, and all NART-II measures. This sample also obtained a higher score than the 
normative sample on the BAI which is indicative of increased anxiety symptomology 
(Beck & Steer, 1990). The obtained scores for the sample, while statistically different 
from the normative data, fell within one standard deviation of the test norms on all 
measures, with the exception of the WIAT-II-A Numerical operations subtest and the 
BAI.  
Obtained psychometric results were not shown to differ between individuals 
that attended both of their two most recently scheduled appointments and those who 
had attended one of their two most recently scheduled appointments, however, those 
who attended only one of the appointments obtained lower scores on the TPQ Total 
and TPQ Program Perceptions factor score, which indicates lower treatment 
satisfaction. 
These findings are discussed below. 
  
Wechsler Memory Scale-III-Abbreviated 
While studies have used subtests from the WMS to assess memory functioning 
in methadone populations, no studies appear to have used the Logical Memory and 
Family Pictures subtests which comprise the WMS-III-A. Research using other 
memory measures does suggest that impairments are likely to be reported in working 
memory, and long-term visual and verbal memory (Darke, Sims, McDonald, & 
Wickes, 2000; Mintzer & Stitzer, 2002; Verdejo, Toribio, Orozco, Puente, & Perez-
Garcia, 2005), however, the results regarding impairments in short-term visual and 
verbal memory have been reported less consistently (Curran, Kleckham, Bearn, 
Strang, & Wanigaratne, 2001; Darke, Sims, McDonald, & Wickes, 2000; Gritz, 
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Shiffman, Jarvik, Haber, Dymond, Coger, Charuvastra, & Schlesinger, 1975; Kelley, 
Welch, & McKnelley, 1978).  
The current sample obtained poorer results compared to the normative sample 
on the measures of both short and long-term visual, and on overall measures of 
immediate, delayed and total memory ability. Effect sizes for all of these measures 
were either medium or large suggesting that while the sample was small, the 
statistically significant results are robust. The obtained results were, however, within 
one standard deviation of the normative mean. The results for the current sample, with 
regards to poorer results in visual memory, concur with research in this area, although 
this sample was not considered to be clinical impaired as mean results were within 
one standard deviation of the normative mean. These results contrast with previous 
research in this area. The findings for this sample may have differed from those 
reported by previous researchers due to differences in the measures used, as while 
measures often purport to measure the same are of cognitive functioning, disparity in 
results suggests that these measures that may be measuring slightly different aspects 
of the same cognitive ability. The WMS-III-A, as used in this research, has been 
shown previously to mean the same memory construct as other well validated 
measures although recent research suggests that the Family pictures subtest of the 
WMS-III-A is more likely to be a measure of general or working memory (Chapin, 
Busch, Naugle, & Najm, 2008; Dulay, Schefft, Testa, Fargo, Privitera, & Yeh, 2002; 
Lezak, Howieson, Loring, Hannay, & Fisher, 2004; Lichtenberger, Kaufman, & Lai, 
2001).  
In addition to comparing the results to the normative means, methadone dose, 
time since last dose, and time on methadone were assessed in relation to the results. 
While methadone dose or time on methadone was not found to correlate with 
performance on the WMS-III-A, there was a relation between time since dose and 
scores, with higher scores associated with increased time since dose consumption. 
While this significant finding was associated with one outlier who had not consumed 
in the previous 24 hours, this finding does possibility suggest that methadone may 
cause short-term, temporary impairments in memory which may improve when 
methadone consumption is ceased. 
The obtained differences may also be a result of the different opiates available 
in New Zealand. This may suggest that impairments seen in overseas opiate 
populations are not applicable in a New Zealand setting. As discussed previously, 
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results on tests of cognitive functioning have differed depending on the opiate used. 
As New Zealand has lower rates of heroin use than seen in many overseas countries 
(Field & Casswell, 1999), it is likely that there would be differences in the 
impairments of cognitive functioning of opiate users in New Zealand.  
Overall, the current sample had more difficulty compared to the normative 
sample recalling information in a visual format, both short-term and after a delay. The 
findings on the visual memory subtest suggest that this sample is unlikely to have 
difficulty recalling information that they have heard. While the mean results for the 
verbal memory subtests were within the normative range, one third of participants in 
the sample obtained results either one or two standard deviations below the mean. 
This third of the sample are likely to have difficulty recalling information in verbal 
and visual formats, both immediately and after a delay and these difficulties are likely 
to have a clinically significant effect on their everyday lives, and in treatment 
sessions. Situations requiring visual recall in particular are likely to be more difficult 
for this population. The obtained results should also be compared to those obtained on 
the NART for the sample, which would suggest that while the sample obtained results 
in the normal range, these are significantly lower than would be expected. This may 
mean that individuals are more likely to report subjective memory impairments, 
although memory functioning ability still falls within the normative range. 
 
Wisconsin Card Sorting Test-Abbreviated 
The Methadone sample performed more poorly on all measures of the WCST-
A with the exception of Nonperseverative Errors when compared to the normative 
data. Medium effect sizes were obtained on the same measures. The medium effect 
sizes suggest that while the sample was small, the statistically significant results are 
robust. However, while the results for the sample were statistically significant, the 
mean scores on the WCST-A all fell within one standard deviation of the normative 
mean. Similarly, individual results showed that the majority of the sample obtained 
results less than one standard deviation below the normative mean. These results 
suggest that while the sample obtained statistically significant results these were not 
clinically significant as these results did not fall more than one standard deviation 
below the normative mean (Kongs, Thompson, Iverson, & Heaton, 2000).  
While results were not clinically significant for the majority of participants, 
there were some participants who obtained results more than one standard deviation 
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below the normative means on the WCST-A. On the Nonperseverative Errors 
measure, 4 individuals obtained results that were more than one standard deviation 
below the normative mean, and on the Conceptual Level Responses measure 5 
individuals obtained a result more than one standard deviation below the normative 
mean. Those individuals, who obtained poorer scores on the Nonperseverative Errors 
measure, also obtained poorer results on the Conceptual Level Responses measure. 
This suggests that some individuals in the sample did have difficulties with problem 
solving, and specifically these individuals made more errors when solving a problem.  
The majority of previous research studies using the WCST have reported 
impairments in the problem solving ability of methadone samples (Darke, Sims, 
McDonald, & Wickes, 2000; Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 
2005), however, no studies appear to have used the WCST-A. As achievement on the 
WCST-A is thought to closely match that achieved on the WCST, comparisons 
between the two measures has been made in this research. 
 The poorer performance of the current sample is similar to that reported by 
Verdejo et al. (2005) and Darke et al. (2000), however, the mean results in the current 
study were not clinically significant (more than one standard deviation below the 
normative mean). On the WCST-A one standard deviation is the recommended 
threshold for classification of impairment as it is normal for individuals to obtain a 
score that would be considered impaired otherwise (Kongs, Thompson, Iverson, & 
Heaton, 2000). The difference in findings for the current sample when compared to 
the literature may be due to slight differences between the WCST and WCST-A, or 
may be another indication that overseas findings are not applicable in a New Zealand 
setting due to the difference in substances available. The observed differences in the 
results are unlikely to be the result of the small sample size in the current study as 
medium effect sizes were obtained on the WCST-A measures. 
 In addition to assessing the obtained scores compared to the normative data, 
correlations were conducted to assess the relation between scores obtained and 
methadone prescription. Interestingly, time on methadone was negatively correlated 
with non-perseverative errors, which suggests that the longer individuals have been on 
methadone the more non-perseverative errors they make on the WCST-A. This may 
suggest that long-term methadone use may negatively impact on problem solving 
ability, or may also suggest that those who remain in treatment are more likely to 
make mistakes in problem solving.  
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 Overall, the findings for this current sample suggest that while the majority of 
the sample had no clinically significant impairment in problem solving ability, 5 
participants had impairments in this area. This suggests that the majority of 
individuals in MMT should have no difficulty solving problems in their daily lives 
provided that they have the resources (e.g. time, money) to solve the given problem. 
Five of the participants are, however, likely to have noticeable difficulties with 
problem solving tasks.  
 
Trail Making Test 
The TMT was used as a measure of attention, both simple and divided, and 
cognitive flexibility. It is the most commonly used measure of these cognitive 
functions in drug and alcohol populations, and impairments in cognitive flexibility as 
assessed by the TMT have been reported in methadone populations (Avants, 
Margolin, Warburton, Hawkins, & Shi, 2001; Mintzer & Stitzer, 2002).  
 In the current study, the Methadone sample did not differ from the normative 
mean on Part A of the TMT, but obtained poorer scores on the TMT Part B. 
Individual results showed than 2 of the 15 individuals obtained scores that were more 
than one standard deviation below the normative mean on TMT Part A, and 9 
participants obtained scores that were more than one standard deviation below the 
normative data on Part B. While the results for the TMT Part B were not normally 
distributed and should be interpreted with caution, these findings suggest that the 
majority of individuals were not impaired on simple attention tasks (as assessed by 
Part A), although almost two thirds of the sample were impaired in their divided 
attention and cognitive flexibility.   
 The results for the current sample are comparable to those reported by Avants 
et al. (2001) and Mintzer and Stitzer (2002). Both of these studies reported 
impairments on the TMT Part B, and Mintzer and Stitzer (2002) reported impairments 
on the TMT Part A also. The findings for the current sample on Part A may have 
differed from those reported by Mintzer and Stitzer (2002) as that study reported on 
the time taken to complete the TMT Part B in seconds, while the current study used 
age adjusted normative data. Therefore, the current findings may be a more accurate 
representation of the simple attention abilities of individuals in MMT, as previous 
research has suggest that the TMT is susceptible to age effects (Mitrushima, Boone, & 
D'Elia, 1999). 
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While the current study used age adjusted normative data for the TMT, the 
effects of education were not accounted for. In the current sample, years of education 
were found to positive correlated with the Trail Making B Percentile Score (as 
number of years of education increases, so to does TMT Part B Percentile score). 
Previous research using the TMT has reported the same relation between education 
and the TMT (Strauss, Sherman, & Spreen, 2006). This finding may indicate that 
scores on the TMT are impacted by level of education. 
 In this sample there were two surprising findings from the TMT. In the current 
study significant correlations were obtained between overdoses and scores on the 
TMT Part B which suggests that, as the number of overdoses increases, individuals 
obtain better scores on the TMT Part B. This finding is surprising given that the TMT 
is commonly thought to measure organic brain damage (Reitan, 1986; Tombaugh, 
2004). On further examination, this result was found to be the result on one outlier, 
and when analysis was redone excluding this participant the result was not significant. 
Left-handedness was also associated with a better result on the TMT Part B in 
the current sample, which contradicts previous research which has suggests that left-
handed individuals perform more poorly on the TMT (Tupper & Cicerone, 1990). 
Left-handedness has previously been associated with poorer scores, as it is thought 
that left-handed individuals inadvertently cover more of the page while completing 
the TMT, therefore making it more difficult to scan the page for the next letter or 
number effectively. While the results for this current sample suggest that left-handed 
individuals obtained better scores on the TMT Part B this result should be interpreted 
with caution given that the distribution of the data differed significantly from normal, 
and only 3 participants were left handed. Additionally, given the small sample size 
this result may be an interaction between a number of variables and not handedness 
and TMT Part B scores. 
Overall, the findings suggest that the majority of individuals were not 
impaired on simple attention tasks, however, a large percentage of participants were 
impaired in their divided attention and cognitive flexibility. These impairments are 
likely to have a significant impact on the effectiveness of treatment sessions at CADS, 
as these individuals are likely to have difficulty paying attention to several things at 
once, and then relating this information to their everyday lives (Lezak, 1995). The 
impairments in attention suggest that information should be provided in a simplified 
format to allow for increased processing of important information, and that repetition 
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of this information may be useful given the reported impairments in memory. 
Treatment sessions could incorporate the use of written handouts to reduce the 
amount of information individuals need to attend to, address strategies to reduce 
distraction, and encourage the formulation of a routine to improve memory for tasks 
that need to be completed, and reduce the need to think about several tasks at once.  
 
Stroop Color & Word Test 
The Stroop Color and Word Test was administered as a measure of impulse 
control and inhibition. The Stroop is one of the few measures available to measure 
impulse control and inhibition, and has been used in research with drug and alcohol 
populations. Previous research has suggested that impairments in impulse control and 
inhibition are more likely in drug and alcohol populations, and that impairments in 
these areas may account for ongoing substance use by this population (Verdejo-
Garcia, Lopez-Torrecillas, Orozco, & Perez-Garia, 2004). Reported impairments in 
methadone samples using the Stroop have, however, varied, with some studies 
reporting impairments (Mintzer & Stitzer, 2002; Prosser, Cohen, Steinfeld, Eisenberg, 
London, & Galynker, 2006; Verdejo, Toribio, Orozco, Puente, & Perez-Garcia, 2005) 
and others reporting no impairments (Gruber, Tzilos, Silveri, Pollack, Renshaw, 
Kaufman, & Yurgelun-Todd, 2006). 
 In the current study, the Methadone sample performed significantly better than 
the published normative data on the Stroop Interference measure, and in accordance 
with the normative data on all other measures of the Stroop. These results are contrary 
to research which has reported impairments in impulse control and inhibition. The 
results in the current study also suggest that this sample may have inhibition skills 
better than the general population. As such, it is unlikely that inhibition and impulse 
control impairments contribute to poor treatment adherence and retention in this 
sample. 
 
National Adult Reading Test-II 
The National Adult Reading Test – 2nd Edition was administered to assess 
premorbid IQ as this is the most commonly used measure of intelligence in the area of 
alcohol and substance use research. Previous research has suggested that premorbid 
IQ scores in methadone samples are lower than those reported in the general 
population (Avants, Margolin, Warburton, Hawkins, & Shi, 2001; Darke, Sims, 
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McDonald, & Wickes, 2000; Gruber et al., 2006; Mintzer, Copersino, & Stitzer, 2005; 
Prosser et al., 2006), and/or may differ from those of the general population prior to 
the use of substances (Pope Jr., Gruber, & Yurgelun-Todd, 1995). 
In the current study, the Methadone sample obtained premorbid IQ scores on 
the NART-II that were higher than the normative mean, with obtained mean scores in 
the 111-112 range. These results are well above those reported in previous studies of 
methadone populations which have reported premorbid IQ scores below the 
normative means for the respective measures (e.g. Avants, Margolin, Warburton, 
Hawkins, & Shi, 2001; Darke, Sims, McDonald, & Wickes, 2000; Gruber et al., 2006; 
Mintzer, Copersino, & Stitzer, 2005; Prosser et al., 2006). 
Given the high premorbid IQ scores, previous research suggests that we would 
expect to see normal or above normal performance on the other administered 
measures (Lezak, Howieson, Loring, Hannay, & Fisher, 2004). In addition, the results 
from Experiment 1 suggested that the measures used may be suitable for use in New 
Zealand, and we would therefore expect results in line with the normative data. In the 
current, sample however, significantly poorer results were found on the WMS-III-A, 
WIAT-II Numerical Operations and Composite score, and all measures of the WCST-
A with the exception of Nonperseverative Errors. Therefore, the obtained scores on 
the NART-II therefore suggest that the poorer results obtained by this sample are 
likely to represent a significant decrease in functioning ability, even if these results 
still fall within the normal range. As such, individuals in the MMT programme may 
report a decrease in functioning ability which is not detected by psychometric tests as 
this population may have had superior functioning at a prior time. 
One particularly interesting finding in this study was the relation between the 
number of head injuries, and all measures of the NART-II. This relation is surprising 
given that previous research has suggested that the NART-II is relatively impervious 
to the effects of brain damage (Darke, Sims, McDonald, & Wickes, 2000; Kelly, 
Johnson, Knoller, Drubach, & Winslow, 1997; Taylor, Kreutzer, Demm, & M, 2003). 
This finding suggests that scores on the NART-II may be affected by the number of 
head injuries, although this result should be interpreted with caution given the small 
sample size and as the number of head injuries was based on self report which may 
not be reliable. Recent research also suggests that the NART is not impervious to the 
effects of sustained TBI, and similar effects have been reported on the WTAR  (Bate, 
Mathias, & Crawford, 2001; Freeman, Godfrey, Harris, & Partridge, 2001; Mathias, 
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Bigler, Jones, Bowden, Barrett-Woodbridge, Brown, & Taylor, 2004; Mathias, 
Bowden, Bigler, & Rosenfeld, 2007). This could suggest that measures such as the 
NART may also be impacted upon by other brain insults, such as substance misuse. 
Further research is needed to assess this finding.  
 
Wechsler Individual Achievement Test-Abbreviated 
In the initial research for this study, reading ability was highlighted as being 
necessary to understand and comprehend the information provided prior to entry into 
the MMT programme provided by CADS. Specifically, individuals enrolling in the 
MMT programme provided by this service are given two documents to read - the 
CADS Methadone Contract (see Appendix VI) and the New Zealand Methadone 
Handbook (Howieson, Koning, Burgess, Nixon, & Keays, 2003), which outline the 
terms and conditions of enrolling in the programme. In addition, information about 
the methadone programme and consumer responsibilities is provided verbally by 
staff. However, there are no set guidelines as to what consumers should be told about 
MMT by staff at CADS, and therefore, the verbal information provided to consumers 
is likely to vary. Based on the written information provided, it is expected that new 
consumers to MMT have a Flesch-Kincaid Grade Level reading score of 8.7 for the 
Methadone Contract and a reading level of 9.4 for the Methadone Handbook 
(equivalent of a 4th form/Year 10 education level).  
 As reading ability was considered an important component, the WIAT-II-A 
was included as a measure of reading and academic ability. Few research studies have 
assessed the reading ability of drug and alcohol populations, so the WIAT-II-A was 
selected as it is a well validated and often used measure to assess academic ability. 
Additionally, it has a short administration time.  
The Methadone sample obtained higher scores compared to the normative data 
on the Word Reading subtest, with the mean score equal to a 7th Form or Year 11 
reading level. This was higher than the mean number of years that the sample had 
completed of formal education (11.4 years, equivalent to having completed 5th Form 
or Year 11). Analysis of individual results showed that all participants met the 
minimum 4th Form/Year 10 education level required to read the information provided 
by CADS. These results indicate that the sample were unlikely to have difficulty with 
reading and comprehension of the information provided about the MMT programme.  
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 In addition to the Word Reading measure, the WIAT-II-A also assessed 
mathematics and spelling abilities. On the Numerical Operations subtest the 
Methadone sample obtained poorer scores compared to the normative data, with a 
mean score indicating that the sample had a Form 1/Year 7 mathematics 
understanding. On the Spelling subtest, the Methadone sample did not differ from the 
normative data, and obtained a mean score indicating that the sample had a 5th 
Form/Year 11 understanding of spelling. The overall Composite score for the 
Methadone sample was significantly lower than the normative mean, however, this 
was largely due to the Numerical Operations scores.  
Overall, the results for the WIAT-II-A suggest that the current sample is 
unlikely to have difficulty reading information provided by CADS, and is unlikely to 
have difficulty participating in aspects of the MMT programme that require reading 
ability. The findings on the Word Reading subtest are comparable to those obtained 
on the NART-II, also a measure of reading, which further supports the higher 
premorbid functioning ability in this sample. However, the sample is likely to have 
difficulty with tasks requiring mathematics skills above a Form 1/Year 7 level. Given 
that the sample had basic mathematics skills (e.g. addition and subtract) these skills 
are unlikely to have a significantly impacted on the daily requirements of the MMT 
programme. 
 
Beck Anxiety Inventory & Beck Depression Inventory-II 
In the current study, the Methadone sample obtained a mean BDI-II score of 
17.4 (SD 11.06), with the largest percentage of the sample falling in the minimal 
range for symptomology (40%), followed by mild (26.67%), severe (20%), and 
moderate (13.33%). The mean BDI-II score obtained by the Methadone sample is 
similar to those reported by Wasserman et al. (2001) and Ersche et al. (2006). The 
obtained BDI-II results were also significantly higher than those obtained by the 
University Control sample reported in Experiment 1 (8.53, SD 6.87), which concurs 
with the research suggesting higher psychiatric rates in alcohol and drug populations 
(Callaly, Trauer, Munro, & Whelan, 2001; Kokkevi & Stefanis, 1995; Marsden, 
Gossop, Stewart, Rolfe, & Farrell, 2000; Milby, Sims, Khuder, Schumacher, Huggins, 
McLellan, Woody, & Haas, 1996). 
One surprising finding on the BDI-II was the positive correlation with the 
Logical Memory I and II subtests of the WMS-III-A, which suggests that the more 
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depressed someone is, the better they perform at short-term verbal recall. This finding 
contrasts with previous research that suggests that depression is usually associated 
with a decrease in memory ability (e.g. Gilewski, Zelinski, & Schaie, 1990; Zakzanis, 
Leach, & Kaplan, 1998), and as such may be the result of an interaction between a 
number of variables and not the depression and memory scores.   
BDI-II scores were also found to negatively correlate with the Stroop Colour-
Word T-Score. This finding suggests that the more depressed an individual is, the 
more difficulty they have in naming the colour of a word when it is different from the 
word that is printed. The finding regarding colour-word naming ability coincides with 
the research that depression affects neuropsychological performance (Aharonovich, 
Hasin, Brooks, Liu, Bisaga, & Nunes, 2005; Landro, Stiles, & Sletvold, 2001; Porter, 
Gallagher, Thompson, & Young, 2003), although no studies with MMT populations 
appear to have reported a relationship between depression and impairment in colour-
naming ability. It should be noted that participants with lower scores on the Stroop 
Colour-Word T-Score did, however, still obtain scores within the normal range. 
No studies appear to have assessed the use of the BAI in MMT populations. In 
the current study, the Methadone sample obtained a mean BAI score of 19.20 (SD 
10.81), with the largest percentage of the sample falling in the severe range for 
symptomology (33.33%), followed by the mild and moderate ranges (both 26.67%) 
and the minimal range (13.33%). The BAI mean score was higher than that reported 
in the normative data, and higher than that obtained by the University Control sample 
in Experiment 1 (11.08, SD 9.10). This concurs with the research regarding higher 
rates of psychiatric disorders in alcohol and drug populations compared to the general 
population (Kandel, Huang, & Davies, 2001; Sunderland, Watts, Baddeley, & Harris, 
1986; Weaver, Madden, Charles, Stimson, Renton, Tyrer, Barnes, Bench, Middleton, 
Wright, Paterson, Shanahan, Seivewright, & Ford, 2003). 
Previous research with opiate dependent populations has typically used the 
State-Trait Anxiety Inventory (STAI) to assess anxiety, and have reported higher 
anxiety rates of anxiety in these populations compared to the general population 
(Adamson, 1997; Darke, Swift, & Hall, 1994). In particular, Darke et al. (1994) 
reported that more than 50% of their methadone sample obtained a score that was 
more than one standard deviation above the normative mean. While the STAI was not 
used in the current research due to the criticisms surrounding the ability of the STAI 
to differentiate between anxiety and depression, and findings which also suggest that 
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the BAI provides a better measure of anxiety (Creamer, Foran, & Bell, 1995), the 
findings in this study using the BAI concur with the literature to date.  
In addition to the analysis of the BAI results in comparison to the normative 
data, the relation between anxiety and the administered psychometric measures was 
assessed. The BAI was shown to negatively correlate with the Stroop Colour T-Score 
and Stroop Colour-Word T-Score. This finding was unexpected, as no previous 
research appears to have suggested a link between anxiety and the Stroop task in 
methadone populations. This finding suggests that anxiety may impair colour naming 
ability in the Methadone sample, although this finding may be at least partially 
attributable to the impairments in divided attention noted earlier.  Alternatively, this 
finding may suggest that anxiety interferes with the ability to complete the Stroop 
rather than indicating a specific relationship between colour-naming and anxiety.  
Number of overdoses was found to positively correlate with the BAI score. 
This finding suggests that as the number of overdoses increases, so do the symptoms 
of anxiety. This could suggest that individuals that overdose are more anxious, or 
alternatively that overdosing results in higher levels of anxiety. However, as 
correlations are not evidence of causality, further research is needed to assess this 
finding. These results should also be interpreted with caution given the small sample 
size, and as reported overdoses were based on self-report.  
While the above results suggest elevated rates of both anxiety and depression 
in the current Methadone sample, caution should be taken in the interpretation of the 
results. Following the literature review, and in consultation with the participants in 
this study, it was found that a number of the common side effects of methadone 
resemble those asked about in relation to anxiety in the BAI and depression in the 
BDI-II. For example, commonly reported side-effects of methadone include sweating,  
shallow breathing, constipation, dizziness, dry mouth, sexual dysfunction, body aches, 
bone problems, appetite loss, nausea, insomnia, weight changes, and 
tiredness/drowsiness (Goldsmith, Hunt, Lipton, & Strung, 1984; Medsafe, 2005). 
Similarly, the BAI assesses the symptoms of sweating, difficulty breathing, dizziness 
or light-headedness, while the BDI-II assesses aspects such as changes in sleep 
patterns, and loss of interest in sex.  
Thus, it is difficult to determine if the symptoms that individuals report are 
side-effects of methadone, or are symptoms of an underlying anxiety disorder. The 
side-effects commonly reported may also account, at least in part, for the high rates of 
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benzodiazepine prescription in this population if the side-effects of methadone are 
mistakenly attributed to an anxiety disorder. 
 
Treatment Perceptions Questionnaire 
In addition to the psychometric measures, individuals in the Methadone 
sample completed the Treatment Perceptions Questionnaire (TPQ) to assess 
satisfaction with treatment. On this measure, the Methadone sample obtained a mean 
score of 23.15 (SD 5.82) from a possible maximum score of 40 (higher scores indicate 
greater treatment satisfaction). This finding is similar to that reported by Deering et al. 
(2003) who reported a mean TPQ score of 22.7 (SD 8.6) in a sample of 93 individuals 
in MMT in Christchurch New Zealand. Similarly, Strang, Marsden, Cummins, Farrell, 
Finch, Gossop, Stewart and Welch (2000) reported an average TPQ score of 22.6 (SD 
7.7) in a sample of 15 individuals, in South London, who were receiving oral 
methadone. 
Overall, the results from the TPQ suggested dissatisfaction with the MMT 
programme, with participants in this sample reporting that they had not received the 
type of help they wanted; that staff had different ideas about what treatment should 
involve; and that they did not like the treatment rules and regulations. Participants 
also reported that MMT as a treatment option resulted in a loss of freedom (e.g., 
requirement to consume dose under supervision on a regular basis); that they were 
condemned for attempts to reduce illicit use as they were ‘treated like children’; and 
that the consequences of not complying with the treatment programme were 
inconsistent. These findings are similar to those reported by Deering et al. (2003). 
In the current study, perceptions of treatment as outlined in the TPQ total 
score and TPQ Program Perceptions factor differed between those who attended both 
of their two most recently scheduled appointments, and those who attended only one 
of their two most recently scheduled appointments. This suggests that satisfaction 
with treatment may be related to appointment attendance, however, it is unclear if 
individuals do not attend their appointments due to dissatisfaction with the treatment 
service and the type of treatment that is available, or if individuals are less satisfied 
with the treatment service and the type of treatment available due to lack of 
attendance at appointments. Further research is needed to assess the relation between 
client dissatisfaction with treatment services and poor adherence in programmes run 
by these services. 
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Neuropsychological Performance & Treatment Adherence 
As discussed previously, one of the aims of the research was to assess the 
cognitive functioning of individuals in MMT in relation to their adherence to the 
treatment programme. In the current study, treatment adherence was measured by 
attendance at scheduled doctors’ appointments and the number of missed doses of 
methadone. As mentioned in the Results section, of the 15 individuals in the 
Methadone sample, 11 had attended their two most recent appointments while the 
remaining 6 had attended one of the two most recently scheduled appointments. None 
of the sample had missed consumption of their dose of methadone within the last 
month. 
In the current study, there were no significant differences found between those 
participants who had attended their two most recent appointments, and those 
participants who had attended one of the last two most recent appointments on any of 
the psychometric measures. Scores on the TPQ total score and TPQ Program 
Perceptions factor score were, however, found to be lower for those participants who 
had attended 1 of the 2 most recently scheduled appointments. While there were no 
statistically significant differences found on any of the psychometric measures, there 
were medium and large effect sizes obtained for a number of the measures. These 
effect sizes suggest that, with a larger sample, differences may have been seen on the 
measures on long-term verbal memory, academic ability with the exception of 
spelling, impulse control, depression, verbal intelligence, and some aspects of 
problem solving. Interestingly, the participants who had attended only one of the two 
most recently scheduled appointments obtained higher (better) mean scores compared 
to those participants who attended both the last two scheduled appointments on all of 
these measures, with the exception of the depression score. The depression score in 
this group also indicated that this group had lower levels of depression that the 
participants who had attended both of their appointments.  
The findings for the current study suggest that poorer cognitive functioning is 
not related to poorer treatment adherence. In fact, the findings suggest that better 
cognitive functioning is associated with poorer treatment adherence. This finding 
contrasts with previous literature which has suggested that cognitive impairments are 
likely to be associated with poorer treatment adherence (Aharonovich, Nunes, & 
Hasin, 2003; Blume, Schmalinga, & Marlatt, 2005; Fals-Stewart, 1993; Fals-Stewart 
& Lucente, 1994; Fals-Stewart & Schafer, 1992; Fals-Stewart, Schafer, Lucente, 
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Rustine, & Brown, 1994; Kleber, Weiss, Anton, Rounsaville, George, Strain, 
Greenfield, Ziedonis, Kosten, Hennesey, O'Brien, Smith Connery, McIntyre, Charles, 
Anzia, Nininger, Cook, Summergrad, Finnerty, Woods, Johnson, Yager, Pyles, Cross, 
Walker, Peele, Barnovitz, Hafler Gray, Shemo, Saxena, Tonnu, Kunkle, Albert, 
Fochtmann, Hart, & Regier, 2006; Miller, 1991; Teichner, Horner, Roitzsch, Herron, 
& Thevos, 2002; Verdejo-Garcia, Lopez-Torrecillas, Orozco, & Perez-Garia, 2004; 
Weinstein & Shaffer, 1993; Woods, Freitas, & Fas-Stewart, 1999). The contrasting 
results reported in the current study could be a result of a bias sample as only those 
individuals who arrived for the research assessment were included in analysis, and as 
such may not be representative of the larger MMT population. The fact that the 
participation in the research was voluntary may also mean that the sample is not 
representative. Previous research has addressed the issue of recruitment by offering 
incentives (e.g., Block, Erwin, & Ghoneim, 2002), or by incorporating research as a 
compulsory component of treatment (e.g. Blaney & Craig, 1999; Fals-Stewart & 
Bates, 2003; Fals-Stewart, 1997). These approaches were not possible in the current 
research. The obtained results could also suggest that those with increased difficulties 
were more likely to attend the service in the aim of receiving assistance, hence the 
better treatment attendance in those with poorer cognitive functioning. 
The adherence measure used in the research was additionally limited by the 
information that is routinely collected by the Community Alcohol and Drug Service, 
and as such may not truly represent treatment adherence in this population. This is 
likely to have particularly influenced the current results, given that poorer adherence 
as measured in this study was associated with higher scores on the psychometric 
measures. Future studies aiming to assess adherence may find that using a number of 
adherence measures may produce a different result. Ultimately, the best way to 
achieve this is through a longitudinal approach that is incorporated in initial enrolment 
in treatment, and therefore able to assess several aspects of predefined adherence. 
 
Relation between methadone and psychometric results 
The relation of methadone dose to the neuropsychological test results was 
assessed as some previous research has suggested that higher doses of methadone may 
be associated with greater impairment (e.g. Rapeli et al., 2007). In contrast, other 
research has reported no correlation between methadone dose and impairment (Darke, 
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Sims, McDonald, & Wickes, 2000).  In the current study, the dose of methadone was 
not found to correlate with the scores on any of the psychometric measures.  
Time on MMT was negatively correlated with Nonperseverative Errors on the 
WCST-A. This finding suggests that longer treatment episodes are associated with 
less non-perseverative errors, which in the context of a problem solving task could 
suggest a greater understanding of the task. However, as a similar pattern was not 
evident on the perseverative errors measure, interpretation of this result is difficult. 
This finding may also be a result of other factors, such as increased time to learn 
problem solving strategies, as individuals who have been in methadone treatment for 
a longer duration are invariably older. 
In addition the length of time on methadone was assessed as previous research 
has suggested a link between cognitive impairment and time of methadone dose 
administration also (e.g. Curran, Kleckham, Bearn, Strang, & Wanigaratne, 2001). In 
the current study, significant correlations were found between the length of time since 
last dose and the WMS-III-A Family Pictures I and Family Pictures II subtests. This 
finding suggests that methadone itself may contribute to impairments in the memory 
functioning of this population, and as such memory may improve once individuals are 
no longer in an MMT programme. Research assessing the cognitive functioning of 
individuals both in treatment, and following cessation of treatment could explore this 
finding further.  
 
Limitations 
The current sample was recruited from CADS in Hamilton which, at the time 
of the research, provided a MMT programme for approximately 220 individuals. The 
research was available to all individuals who had been on the methadone programme 
provided by this service for at least three months. While this encompassed almost all 
of the individuals on the methadone programme at this service, only 15 individuals 
were interviewed, from a total of 46 individuals who agreed to be contacted.  
 Therefore, the Methadone sample includes less than 10% of the population 
being studied, making it a small sample which may not be representative of the wider 
population for several reasons. Firstly, individuals were recruited on a voluntary basis 
through the treatment service so it only included those individuals who visited the 
service (turned up for appointments within the recruitment period) or who heard about 
the research from other individuals at the treatment service. Secondly, while 46 
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individuals agreed to be contacted about participation in the research, only those 
individuals who arrived for the appointments were interviewed. Comparing the 
present Methadone sample with individuals who did not arrive for appointments, and 
with the greater population would have been useful in determining whether the 
sample was representative of the wider population. However, this was not possible 
due to the need for informed consent. As such, it is possible that the Methadone 
sample in this study only included those individuals who attended the service on a 
regular basis, and who may, therefore, have less significant impairments. However, 
this is difficult to determine. 
Secondly, the use of financial incentives was restricted as previous research 
with drug and alcohol populations has suggested that financial incentives could aid in 
continued drug-seeking behaviour, and could, therefore, be considered to be coercion 
(Cunningham, 1998; Galanter & Kleber, 1999; McCrady & Bux Jr., 1999). Therefore, 
the limited incentives offered in the current research may have resulted in the low 
number of individuals recruited for this study.  
 Finally, the administration of the current research took approximately 1 ½ to 2 
hours to complete. This lengthy administration time may have reduced the number of 
individuals willing, or in fact able, to participate due to other commitments. While the 
required time to participate in the research was considerably shorter that other 
research studies (e.g. Fals-Stewart, 1997; Fields & Fullerton, 1975; Morris & Lawson, 
1998), these other research studies have been able to offer incentives for participation.  
 While the current study has several limitations, there are also a number of 
strengths. 
 
Strengths 
Previous research in the area of drug use and cognitive functioning has 
attempted to control for a wide range of variables which may influence the outcome 
of testing. The resulting sample is often far removed from the study population, and 
the results obtained with this sample are often not applicable to the wider population.  
In the current study, individuals were not excluded from the research unless 
they were deemed to be intoxicated at the time of administration, or were considered 
to be mentally unstable at the time of assessment. The aim of this was to obtain a 
sample that was representative of the population being sampled, while also allowing 
for confounding variables such as head injuries and overdoses to be assessed. For 
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example, results in the current study found that performance on the TMT decreased 
with number of overdoses. Another surprising finding was that the number of head 
injuries was correlated with all measures of the NART-II (all negative). These 
findings provide further information about the actual population which is seen in 
treatment services. 
In addition, the current research included a measure of premorbid functioning 
to assess for differences between expected and obtained levels of functioning. Some 
previous research has been criticised for failing to account for premorbid functioning, 
and other research has reported premorbid functioning rates lower that the general 
population, the current research found that the sample had a significantly higher 
premorbid IQ. This suggests that findings for this study even if within the normal 
range, or slightly below the normal range, when compared to the normative data, may 
represent a significant decrease in functioning for these individuals. The higher 
premorbid IQ scores in this sample may also suggest a difference in the premorbid 
functioning ability of methadone samples within New Zealand compared to those 
studied overseas. Therefore, cognitive impairments may not be reported within New 
Zealand samples populations as frequently. Further research is needed to examine the 
findings of this study. 
 
Overall Findings 
As discussed previously, the results from this study suggest that the 
Methadone sample had impairments in their memory, in divided attention and 
cognitive flexibility, and performed below the expected range for mathematical ability 
compared to the normative data. When comparing the results for these measures to the 
normative data, the overall sample means were still within one standard deviation of 
the normative means. However, the disparity between the NART-II scores (premorbid 
functioning estimate) and the psychometric measures suggests that there was a decline 
in functioning for this population even though scores  on the psychometric measures 
did not fall more than one standard deviation below the normative data mean.  
 By contrast, this sample obtained higher (better) scores on the measures of 
inhibition/impulse control, reading ability and premorbid functioning than the 
normative data. The findings concerning inhibition/impulse control were particularly 
surprising given that the literature has suggested that impulse control and inhibition in 
this population are likely to be impaired. 
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 While the current study aimed to assess the relation between adherence to 
treatment and psychometric test results, no relation was found for any of these 
measures, although effect sizes suggested that higher, and therefore better, scores on 
several psychometric measures were associated with poorer adherence. Poor 
adherence was, however, found to be related to poorer treatment satisfaction.  
 While the results from this study provide some interesting findings, the 
research findings are limited in a number of ways, as outlined previously. There are a 
number of recommendations that can be made from this present study. 
 
Recommendations 
Based on the findings of this study, further research is needed to address the 
cognitive functioning of individuals in MMT in New Zealand. Further research is 
needed due to a number of possible limitations in the current sample as outlined 
previously. The current study suggests that there may be impairments in memory, 
divided attention and cognitive flexibility.  
In order to assess the cognitive functioning of this population further, it was 
decided to extend the current study with the intention of gaining more participants to 
add further support to the results from this study. Due to the difficulties in recruiting 
participants for this study, and as a number of the psychometric measures found no 
impairments in their respective areas of functioning when compared with the 
normative data, it was decided to reduce the battery of tests administered. The 
measures that were removed from the battery were the WIAT-II-A, BAI, BDI-II and 
the NART-II. The removal of these tests is discussed below. 
 The WIAT-II-A was originally included in the test battery to assess reading 
ability in the current sample, as a review of the Community Alcohol and Drug Service 
found that individuals required a reading level equivalent to a 4th Form/Year 10 
education to read the two documents provided prior to commencing on the MMT 
programme. In the current study, all individuals in the sample obtained a Word 
Reading score on the WIAT-II-A above the minimum 4th Form/Year 10 education 
level which suggested that the methadone population is unlikely to have difficulty 
reading the information provided. Given that the individuals in the current study had 
no difficulty with reading ability and that the scores obtained on the other WIAT-II-A 
subtests (Numerical Operations and Spelling) were not considered to be relevant to 
MMT, the WIAT-II-A was removed from the test battery.  
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The BAI and BDI-II were included in the current study to assess the effects of 
anxiety and depression on the neuropsychological measures administered. Overall the 
BAI and BDI-II were not found to correlate with the psychometric measures, and in 
the few cases that they did these findings were often contrary to previous research 
findings. In addition, a number of the common side effects of methadone resemble 
symptomology that is asked about on the BAI and on the BDI-II. This made it 
difficult to assess whether these measures were assessing anxiety and depression. 
Therefore, the BAI and BDI-II were removed from the test battery.  
 The other measure removed from the test battery was the National Adult 
Reading Test-II. As discussed previously, this was included as an estimate of 
premorbid IQ as previous research has been criticised for not assessing premorbid 
functioning. In the current study, the Methadone sample obtained mean NART-II 
scores in the 111-112 range which were significantly above those of the normative 
data. Additionally, all participants obtained Full Scale IQ scores equal to or above the 
normative mean. As the sample showed no impairment in premorbid IQ, the NART-II 
was removed from the test battery. 
 The measures that remained in the test battery were the WMS-III-A, TMT, 
Stroop Colour and Word Test and the WCST-A. The total time required to administer 
the remaining measures was approximately 45 minutes.   
 In addition to the reduction in psychometric measures, the number of agencies 
through which participants were to be recruited was extended. In addition to 
recruiting participants through CADS, the Needle Exchange Service in Hamilton was 
included as a recruitment location with the aim of recruiting individuals who were 
enrolled in the MMT programme at CADS, but who were not attending their 
appointments at that service. It was hoped that this would increase the total number of 
individuals that were recruited, as well as recruiting individuals who were not 
adhering to treatment. In turn, this would allow further analysis of the relation 
between cognitive impairments and treatment adherence. The data from the Second 
Methadone sample is reported in the next study (Experiment 4).  
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EXPERIMENT 4 
 
Experiment 4 aimed to gain more participants from the MMT programme at 
CADS in order to extend the sample. As mentioned previously, it was decided that the 
research approach would be modified in a number of ways. In this study, the number 
of psychometric measures administered was reduced with the aim of recruiting more 
participants to provide a more representative sample, and to assess the cognitive 
functioning of individuals in MMT further. In addition, the Needle Exchange in 
Hamilton was included as a recruitment location in an attempt to contact those people 
enrolled in MMT who were not attending their appointments. 
 
 
METHOD 
 
Participants 
Following the completion of Experiment 3, and the modifications to the 
research approach, CADS in Hamilton was approached a second time regarding 
participation in this research. The CADS management agreed to participate in the 
research, and agreed that a reduction in the measures used and extension of the 
recruitment locations would be beneficial in recruiting more participants. In addition, 
the overall research approach was discussed with staff as there were a number of new 
staff members that had joined the service since the completion of Experiment 3.  
As a result, a total of 14 individuals were interviewed from a pool of 16 who 
agreed to be contacted. The remaining two individuals either did not arrive for an 
arranged appointment, or were unable to be contacted. All 14 participants were 
enrolled in the MMT programme at CADS, and 11 of these participants were 
recruited through this service. The remaining three participations were recruited 
through the Needle Exchange Service in Hamilton. 
 
Materials 
As discussed previously, the psychometric measures administered to each 
participant were the Stroop Color and Word Test, Trail Making Test, Wechsler 
Memory Scale-III-Abbreviated and the Wisconsin Card Sorting Test-Abbreviated. 
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Further details of these psychometric tests are provided in Experiment 1. Participants 
also completed the Treatment Perceptions Questionnaire, the details of which are 
available in Experiment 3. The adherence measures and interview outline used in 
Experiment 3 were also used with this sample. 
 
Procedure 
Prior to the commencement of this research, ethical approval was obtained 
from the Psychology Department Human Research Ethics Committee at the 
University of Waikato and the Northern Y Regional Ethics Committee (part of the 
Health and Disability Ethics Committee). 
Participants were recruited through CADS and the Needle Exchange Service 
in Hamilton between January 2007 and December 2007. All individuals were on the 
MMT programme that is run by CADS. Participants were recruited through 
information fliers posted at CADS and at the Needle Exchange Service (see Appendix 
VII), and through information provided by service staff to consumers of these 
services.  
Individuals who agreed to take part in the research, were provided with the 
information sheet about the research (see Appendix XII), and one they had completed 
the necessary consent forms (see Appendix XIII) they were administered the 
psychometric tests. They were asked a short series of questions regarding recent 
substance/alcohol use, and previous head injuries also (see Appendix X). The 
psychometric tests were administered in a fixed sequence by the researcher, as listed 
below. 
 
Wechsler Memory Scale III – Abbreviated (WMS-III-A) (Logical Memory I & 
Family Pictures I) 
Trail Making Test (TMT) 
Stroop Color and Word Test 
Wisconsin Card Sorting Test – Abbreviated (WCST-A) 
Wechsler Memory Scale III – Abbreviated (WMS-III-A) (Logical Memory II & 
Family Pictures II) 
 
The Treatment Perceptions Questionnaire was provided to participants at the 
end of the test sequence. All interviews were conducted on a one on one basis in a 
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room at CADS, or at the Needle Exchange Service and took approximately 45 
minutes to complete. All other aspects of the procedure were identical to the 
procedure in Experiment 3. Following the completion of the assessment, individual 
participation was recorded in the individuals file at CADS (see Appendix XIV). 
 
Scoring and data entry 
Scoring and data entry were conducted as outlined in Experiment 1. As in 
Experiment 3, participants in the current study were given the option of receiving 
feedback on the results of the testing, and if participants agreed, this information was 
provided for inclusion in their case notes at CADS.  
 Analysis was conducted using SPSS Version 12, and was based on the same 
psychometric scores outlined in Experiment 1. Analysis of the Treatment Perception 
Questionnaire was conducted as outlined in Experiment 3. 
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RESULTS 
 
 
This study aimed to increase the size of the sample of individuals in MMT, 
and to assess the cognitive functioning of individuals receiving MMT in New Zealand 
further. The participants in this study had a mean age of 37.72 years, and were 
predominantly of New Zealand European descent, as shown in Table 4.1. There were 
a greater number of males than females, and the sample had completed the equivalent 
of 6th Form or Year 12/NCEA Level 2. The participants had been in the current 
episode of treatment for opiate dependence 8.3 years on average, and the mean 
prescribed methadone dose was 87.36 mg daily. Nine participants had received 
treatment for opioid dependence previously, with the mean number of treatment 
Table 4.1
Demographic details of Second Methadone Sample
Age 37.72 SD 7.01, Range 28-49
Gender
Male 9 64.30%
Female 5 35.70%
Handedness
Left 2 14.30%
Right 12 85.70%
Education 12.57 years SD 3.01, Range 9-17
 
Ethnicity
NZ European/Pakeha 10 71.40%
Maori 1 7.10%
Maori/European 2 14.30%
Other European 1 7.10%
Methadone Maintenance
Time in Program 8.3 years SD 7.1, Range 3 months-22 years
Previous Treatment 2.07 SD 2.09, Range 0-6
Present dose 87.36 SD 48.97, Range 12.5-160
Substance History
First Drug Use 14.43 years SD 3.13, Range 11-22
First Opiate Use 20.14 years SD 5.14, Range 13-32
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episodes being 2.07. The age of first substance use was between 11 and 22 years of 
age, with first opiate use occurring between the ages of 13 and 32 years. 
 
Performance on the psychometric tests 
As with the data from the previous experiments, prior to any analysis, Shapiro-
Wilks tests were conducted on the data to assess for normality. Results from this 
analysis suggested that the data for the TMT Part B Percentile Score (W = 0.597, df = 
13, p < 0.05) and the WCST-A Total Number of Errors (W = 0.854, df = 11, p < 0.05) 
were significantly different from the normal distribution. Subsequently, 
transformations were conducted on these measures, and square-root transformations 
normalised the distribution of scores for both measures. For these measures, the 
normative population scores were transformed in the same way as the data to allow 
for comparison using a one-sample t-test. 
A series of one sample t-tests was conducted to compare the results obtained 
with the normative data provided in the administration manuals for each test, with the 
exception of the TMT. The TMT data were compared to the normative data provided 
by Tombaugh (2004), as discussed in Experiment 1. 
The one sample t-tests showed statistically significant differences between the 
obtained and the normative data for a number of measures. A summary of the results 
is presented in Table 4.2. The sample obtained significantly lower scores compared to 
the normative data on all measures of the WMS-III-A (with the exception of the 
Logical Memory II subtest), the TMT Part A and B Percentile Scores, Stroop Colour 
T-Score, and all measures of the WCST-A. Medium effect sizes were obtained for the 
WMS-III-A Logical Memory II subtest, and the TMT Part B, while large effect sizes 
were obtained for all other measures of the WMS-III-A, the Stroop Colour T-Score, 
and all measures of the WCST-A with the exception of Total Number of Errors. 
Results from the Second Methadone sample on all other measures were not 
statistically significant from the normative sample.  
A comparison of the obtained results to the normative standard deviation 
ranges provided for each measure showed that, while this sample differed 
significantly from the normative data on a number of measures, the mean scores fell 
within one standard deviation of the test norm for the majority of measures. The 
exceptions to this were the mean scores for the WMS-III-A Family Pictures I and 
Family Pictures II subtests and all index scores, which fell more that one standard 
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deviation below the normative means. A summary of the means and standard 
deviations for each measure is provided in Table 4.3.  
The data were analysed for each participant to assess whether their scores fell 
more that one or two standard deviations below the normative mean. Table 4.4 gives 
the number of individuals whose score fell either one or two standard deviations 
below the normative mean for each measure. The exception to this is the Trail Making 
Test where only one standard deviation (16th Percentile) was used. Individual 
participants are numbered according to the order in which they were recruited. 
Participants 1-15 were recruited in Experiment 3, and so, are not included in this 
analysis. 
This analysis showed that 2 participants obtained scores more that 2 standard 
deviations below the normative mean on all measures of the WMS-III-A, while an 
additional 2 participants obtained scores more than two standard deviations below the 
normative mean on the Family Pictures I and II subtests. Five of the 14 participants 
obtained scores one standard deviation below the normative means on the TMT Part 
A, and 9 on TMT Part B at one standard deviation. One participant obtained a score 
more than two standard deviation lower than the normative mean on the Stroop 
Colour T-Score and Stroop Colour-Word T-Score, while 3 participants obtained 
scores more than two standard deviations below the normative mean on the WCST-A 
Nonperseverative Errors measure. One of these participants also obtained scores more 
than two standard deviations below the normative mean on most measures of the 
WCST-A. Overall results showed that each participant was not impaired on more than 
two of the psychometric tests, with the exception of participant 20. 
 
Relation between demographic and psychometric test results 
As in the previous experiments, the degree of relation between psychometric 
results and gender, handedness, academic achievement, head injuries and overdoses 
were assessed. Table 4.5 shows that gender was positively correlated with the TMT 
Part B Percentile Score and the Stroop Interference T-Score (males obtained lower 
scores). Handedness and academic achievement did not correlate with any of the 
psychometric measures. Number of head injuries was negatively correlated with the 
TMT Part A Percentile Score and the WCST-A Nonperseverative Errors measure, 
while number of overdoses was negatively correlated with the Stroop Colour T-Score. 
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However, significant correlations for number of head injuries and number of 
overdoses should be interpreted with caution as these were based on self-report.  
The relation between time in methadone treatment, methadone dose, and time 
since last dose were also assessed. As shown in Table 4.6, time in methadone 
treatment, methadone dose, and time since last dose were not found to significantly 
correlate with any of the psychometric measures. 
 
Other Drug Use 
Of the 14 individuals in this sample, 4 individuals reported using other 
substances within the prior 48 hours prior to assessment. Of these 4 individuals, 2 
reported cannabis use, 1 reported benzodiazepine use, and 1 reported illicit opiate in 
the previous 48 hours.  
In order to determine the influence of other drug use on psychometric tests 
results, the sample was split into four groups based on what other drugs the 
individuals identified as using. Group membership was as follows: no other drug use; 
alcohol, benzodiazepines; and illicit opiates. 
The obtained scores on each of the psychometric test results were assessed 
using Kruskal-Wallis tests across the four groups with the Second Methadone sample. 
The results of these tests are outlined in Table 4.7, and show that performance on the 
psychometric tests were not influenced by the type of other substance used. The 
results from this analysis should, however, be interpreted with caution given the small 
number of individuals who reported other drug use. 
 
Satisfaction with Treatment 
Results from the Treatment Perceptions Questionnaire were varied (mean 23.43, 
SD 6.11, range 14-33). General themes regarding the methadone program were 
evident from the personal opinion section included in the questionnaire. These are 
outlined below: 
 
- MMT results in a loss of freedom (e.g., requirement to consume dose 
under supervision on a regular basis) which impacts on work and family 
commitments 
- Individuals in MMT are condemned for attempts to reduce illicit use and 
may face changes to treatment if illicit use is admitted 
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- Individuals felt that they were ‘treated like children’ as they were not 
provided with options regarding their treatment, and were not considered 
responsible enough to make informed choices 
- MMT provided as the ‘only option’, with referral to other services or 
count-down off methadone discouraged 
- Program rules are inconsistently applied 
- Flexible treatment rules needed to allow individuals to engage in work  
- High staff changeover created difficulties for clients 
- Difficulty contacting staff in emergencies, specifically doctors at the 
treatment service 
- No specific drug and alcohol after-hours contact available in an emergency 
 
Additionally, individuals had concerns regarding confidentiality (although 
these related to specific incidents). Some individuals stated that they would like more 
information provided regarding the side-effects of methadone. Others thought that 
staff did not understand the process of addiction as well as counsellors who were 
addicts previously.  
An analysis of the individual TPQ questions indicated a lower mean score 
(lower satisfaction) for one question: ‘I have not liked some of the treatment rules or 
regulations’ (1.22, SD 1.12). Analysis using the two factors identified by Marsden et 
al. (2000) found a slightly higher mean score on the staff perceptions factor (12.29, 
SD 3.71) compared to the program perceptions factor (11.14, SD 3.59). 
 Pearson Correlations were conducted to assess the relation between treatment 
satisfaction as measured by the TPQ and time in the MMT programme and methadone 
dose. No significant correlations were found between time in treatment and the TPQ 
Score (r = -0.456), TPQ Staff Perceptions (r = -0.516), or TPQ Program Perceptions 
(r = -0.303). Similarly, no significant correlations were found between methadone 
dose and TPQ Total Score (r = -0.294), Staff Perceptions (r = -0.263) or Programme 
Perceptions (r = -0.269) factors. 
 
Neuropsychological Performance & Treatment Adherence 
Adherence to treatment was measured by attendance at scheduled doctors’ 
appointments and the number of missed doses of methadone. Eight of the 14 
individuals in the Second Methadone sample had attended their two most recent 
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appointments, while the remaining six had attended one of the two most recent 
appointments. None of the participants had missed consumption of their dose of 
methadone within the last month. 
To determine if there were differences between those who adhered to 
treatment requirements and those that had not, a series of independent sample t-tests 
and Mann-Whitney U tests were conducted. Both an independent samples t-test and a 
Mann Whitney U test were conducted for each measure, as data for both groups on 
several of the measures were not normally distributed. In all cases, both tests showed 
the same result. Therefore, the independent sample t-test results only, are reported 
here. These results are outlined in Table 4.8, and show no significant differences, on 
any of the psychometric measures or the TPQ, between the individuals who attended 
one appointment, and those who attended two appointments. Medium effect sizes 
were obtained for the comparison between scores on the TMT Part A Percentile 
Score, all measures of the Stroop with the exception of the Stroop Interference T-
Score, and the WCST-A Perseverative Responses, Perseverative Errors, and 
Conceptual Level Responses measures.  
 
Neuropsychological Performance across samples 
As the current study was conducted to extend the methadone sample obtained 
in Experiment 3 in order to gain a more representative sample, a comparison was 
conducted between the original methadone sample and the methadone sample in this 
study to identify any differences between the two samples. An independent samples t-
test showed that the two samples did not significantly differ in age (t = -1.042, df = 
27, p > 0.05), academic achievement (t = -1.102, df = 27, p > 0.05), time in 
methadone treatment (t = -1.187, df =  27, p > 0.05), or dose of methadone (t = 0.039, 
df = 27, p > 0.05); while a chi squared test for independence showed that gender (χ 2 = 
0.358, p > 0.05) and ethnicity (χ 2 = 2.484, p > 0.05) were not related to sample 
membership. 
  As shown in Table 4.9 and Table 4.10, a series of independent sample t-tests 
and Mann-Whitney U tests were conducted to assess the difference between the two 
samples on the psychometric tests. Mann-Whitney U tests were conducted when one 
or more of the samples differed significantly from the normative distribution. The two 
Methadone samples scores did not differ significantly on any of the 
neuropsychological tests, or on the TPQ. Medium effect sizes were obtained on all 
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measures of the Stroop with the exception of the Word T-Score, and the WCST-A 
Nonperseverative Errors. On all of these measures the original methadone sample 
obtained better scores. 
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TABLE 4.3
Means and Standard Deviations for Normative and Second Methadone Samples
Normative One Standard Methadone Methadone
Mean Deviation Mean SD
WMS Logical Memory I 10 3 7.57 3.01
WMS Family Pictures I 10 3 6.57 2.44
WMS Logical Memory II 10 3 8.17 2.98
WMS Family Pictures II 10 3 6.00 2.92
WMS Immediate Memory 100 15 82.57 15.15
WMS Delayed Memory 100 15 84.75 15.20
WMS Total Memory 100 15 81.75 16.44
TMT Part A Percentile 50th 16th 38th 24.75
TMT Part B Percentile 50th 16th 25th 28.21
Stroop Word T-Score 50 10 46.67 10.73
Stroop Colour T-Score 50 10 40.83 7.72
Stroop Colour-Word T-Score 50 10 46.75 13.17
Stroop Interference T-Score 50 10 48.67 10.25
WCST Total No Errors 100 15 86.91 16.43
WCST Perseverative Responses 100 15 89.55 14.85
WCST Persevertive Errors 100 15 89.82 13.82
WCST Nonperseverative Errors 100 15 85.45 16.97
WCST Conceptual Level Response 100 15 86.27 18.45
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Table 4.4
Number of individuals obtaining scores One and Two Standard Deviations below norm
n 1 SD 2 SD
WMS Logical Memory I 14 5 2 17,22
WMS Family Pictures I 14 6 3 17,20,22
WMS Logical Memory II 12 1 2 17,22
WMS Family Pictures II 12 4 4 17,20,22,28
WMS Immediate Memory 14 4 3 17,20,22
WMS Delayed Memory 12 4 2 17,22
WMS Total Memory 12 4 3 17,20,22
TMT Part A Percentile 14
TMT Part B Percentile 14
Stroop Word T-Score 14 4 0
Stroop Colour T-Score 14 4 1 28
Stroop Colour-Word T-Score 14 3 1 28
Stroop Interference T-Score 14 3 0
WCST Total Number of Errors 12 5 1 23
WCST Perseverative Responses 12 3 1 27
WCST Persevertive Errors 12 3 1 27
WCST Nonperseverative Errors 12 3 3 19,20,23
WCST Conceptual Level Response 12 4 2 19,27
17,19,20,22,23,27,28 = Methadone Participants 17, 19, 20, 22, 23, 27 and 28 respectively
9 17,18,19,20,22,23,26,27,28
        5 18,19,23,24,27                              
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Table 4.6
Correlation between methadone and psychometric results for the Second Methadone Sample
Correlation Coeffient (r) 
Pearsons Pearsons Pearsons
Time in Methadone Time Since
Treatment Dose Dose
WMS Logical Memory I -0.024 -0.251 0.379
WMS Family Pictures I -0.073 -0.143 0.279
WMS Logical Memory II -0.036 -0.413 0.071
WMS Family Pictures II -0.181 -0.229 0.377
WMS Immediate Memory -0.032 -0.223 0.322
WMS Delayed Memory -0.092 -0.335 0.228
WMS Total Memory -0.159 -0.363 0.223
TMT Part A Percentile 0.101 0.059 -0.107
TMT Part B Percentile -0.099 -0.468 -0.039
Stroop Word T-Score -0.231 -0.103 0.170
Stroop Colour T-Score -0.111 -0.489 -0.205
Stroop Colour-Word T-Score 0.105 -0.386 -0.292
Stroop Interference T-Score 0.12 -0.469 -0.369
WCST Total Number of Errors -0.222 -0.174 0.152
WCST Perseverative Responses 0.058 -0.110 0.278
WCST Persevertive Errors 0.028 -0.224 0.166
WCST Nonperseverative Errors -0.195 -0.085 0.101
WCST Conceptual Level Response -0.106 -0.123 0.095
* Signficant at p < 0.05
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DISCUSSION 
 
Experiment 4 assessed the cognitive functioning of a second sample of 
individuals in MMT. Compared to the normative data, this sample obtained lower 
scores for all measures of the WMS-III-A with the exception of the Logical Memory 
II subtest, the TMT Part A and B Percentile Scores, Stroop Colour T-Score, and all 
measures of the WCST-A. Obtained psychometric results were not shown to differ 
between individuals who attended both of their last two scheduled appointments and 
those who had attended one of their two most recently scheduled appointments. No 
significant difference was shown between the two groups on the any of the TPQ 
scores.  
While the obtained results differed slightly from those obtained for the initial 
Methadone sample described in Experiment 3, analysis showed that the two samples 
did not statistically differ on any of the psychometric results, or on the TPQ.  
The findings from the present study are discussed below. 
 
Wechsler Memory Scale-III-A 
 In the current sample, lower scores were obtained on all measures of the 
WMS-III-A compared to the normative mean, with the exception of the Logical 
Memory II subtest. While the Logical Memory II subtest score was not significantly 
different from the normative mean, the medium effect size for this measure suggest 
that with a larger sample this result may be significant. In addition, the scores 
obtained by this sample were more than one standard deviation below the normative 
mean for all memory measures with the exception of the Family Pictures subtests.  
Thus, overall the results suggest that the sample had impairments in short and 
long-term visual memory, and in immediate, delayed and total memory ability. 
Analysis of individual results showed that more than half of the sample obtained 
scores more than one standard deviation below the normative mean on all WMS-III-A 
measures, with the exception of Logical Memory II. As mentioned previously, results 
more than one standard deviation below the normative mean are considered to 
indicate clinically significant impairment (Kongs, Thompson, Iverson, & Heaton, 
2000; Lezak, Howieson, Loring, Hannay, & Fisher, 2004; Wechsler, 2002), and that 
clinically significant impairments are likely to result in a noticeable affect on 
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behaviour (McBurney & White, 2004). Therefore, more that half of the individuals in 
this sample would be expected to have noticeable difficulties in both short and long-
term visual memory, as well as in short-term verbal memory. These impairments 
would likely result in difficulties remembering, and later recalling, information, which 
is likely to impact on their daily functioning. For example, individuals may have 
difficulty recalling appointment times, or tasks that they need to complete. 
 
Wisconsin Cart Sorting Test-Abbreviated 
 Mean scores obtained on the WCST-A, while significantly different from the 
normative data, were within one standard deviation of the normative mean for this 
sample. Analysis of individual results, however, showed that half of the participants 
obtained scores more than one standard deviation below the normative mean on the 
Total Number of Errors, Nonperseverative Errors, and Conceptual Level Responses 
measures. These findings suggest that while the overall sample obtained results within 
the normative range these were lower than expected, and a large number of 
individuals obtained results in the impaired range. The three measures on which the 
participants obtained results more that one standard deviation below the normative 
mean are said to assess errors in problem solving, as well as difficulty identifying 
ways in which to solve a problem. This suggests that half of the current sample has 
impairments in these abilities, and that these individuals may have increased difficulty 
with problem solving tasks in their daily lives. For example, individuals may have 
difficulties coping with stressors or interpersonal conflicts, and may have difficulties 
achieving goals such as those set in treatment. This may mean that these individuals 
avoid situations that require problem solving skills, or may ask others to solve 
problems for them.  In regards to treatment specifically, this may mean that 
individuals avoid appointments in which they think conflicts will arise, or do not 
complete therapy homework tasks. 
 
Trail Making Test 
 On the TMT, mean scores obtained by this sample were lower than the 
normative means on both the TMT A and B, however, these scores were within one 
standard deviation of the normative mean. An analysis of individual results showed 
that while mean results were within one standard deviation of the normative mean, 5 
individuals obtained results that were more than one standard deviation below the 
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normative mean on Part A, and 9 on Part B. These findings suggest that over one-third 
of the sample had impairments in simple attention, and almost two thirds had 
impairments in divided attention and cognitive flexibility. Therefore, these individuals 
are likely to have difficulty paying attention to tasks in their daily lives (Lezak et al., 
2004), particularly when the task has several components, and are likely to have 
difficulty attending to information in treatment sessions. These difficulties, in 
combination with the impairments noted on the WMS-III-A suggest that individuals 
may have difficulty recalling information as a result of poor attention. 
 While a significant percentage of the sample obtained scores in the impaired 
range on the TMT there was no indication of consistent, global impairments on either 
the TMT A or TMT Part B. 
 
Stroop Colour and Word Test 
 Results for this sample on the Stroop Colour and Word Test are indicative of 
no impairment in inhibition or impulse control, as although lower scores were 
obtained compared to the normative data they were within on standard deviation. 
While no impairments were shown in inhibition and impulse control, significantly 
lower scores were obtained on the Stroop Colour T-Score. This finding suggests that 
the current sample may have difficulty identifying colours, although a similar finding 
was not found in the initial methadone sample. As no previous research with 
methadone populations appears to have found impairments in colour naming ability, 
further research is needed to examine this finding. 
 
Treatment Perceptions Questionnaire 
 Similar findings to those found in Experiment 3 on the TPQ were found in this 
sample. The findings on the TPQ suggested dissatisfaction with the MMT programme 
run by CADS in Hamilton, although the obtained results on the TPQ were variable. 
Individual feedback on the TPQ in this sample was similar to that found for the initial 
methadone sample. Additionally, the current sample said that MMT was provided as 
the ‘only option’, that flexible treatment rules were needed, that high staff turnover 
created difficulties for clients, and that staff were not always contactable. The 
additional concerns raised by the Second Methadone sample may highlight changes 
that have occurred between collection of the two methadone samples, in particular, 
the number of new staff that had been employed at CADS in the intervening time 
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between the two studies. However, other concerns were similar across the two 
samples suggesting that overall service provision had not changed between the 
collection periods. 
As with Experiment 3, no significant correlations were found between the 
TPQ scores and methadone dose or time in MMT. Unlike Experiment 3, however, no 
relation was found between scores on the TPQ and the measures used to assess 
adherence to treatment which may suggest that satisfaction with treatment is not 
related to adherence. Further research is needed to examine this finding. 
 
Neuropsychological Performance & Treatment Adherence 
 In this sample, adherence to treatment was not found to relate to any of the 
psychometric scores or the TPQ. Large effect sizes were, however, obtained for the 
WMS-III-A Family Pictures II, TMT A and B, and WCST-A Total Number of Errors 
and Nonperseverative Responses. Interestingly, the large effect sizes suggest better 
performance by those individuals who had attended only one of their two most recent 
appointments. These large effects sizes suggest that these variables may influence 
treatment adherence, although not in the expected direction. The measures on which 
medium and large effect sizes were obtained differ from those found in Experiment 3. 
This may suggest that some aspects of cognitive functioning are inversely related to 
adherence to treatment, although further research is needed to assess this result fully. 
As mentioned in Experiment 3, this finding may also suggest that individuals with 
increased impairment are more likely to attend services to seek assistance. 
 
Limitations 
As with the initial Methadone sample obtained in Experiment 3, there were a 
number of limitations in the current study. Despite having reduced the number of 
psychometric measures administered in this study, and therefore the required time to 
administer the psychometric measures, recruitment of participants was slow with only 
14 participants recruited between January 2007 and December 2007. It was hoped that 
this reduction in measures would increase participation in the research, however this 
was not successful.  
As with the initial Methadone sample, individuals were recruited on a 
voluntary basis through the treatment service. As participation in the research was 
voluntary, and not a requirement of treatment, this may have limited the number of 
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participants for this sample. Inclusion of the Needle Exchange as a recruitment 
location was also unsuccessful in substantially increasing the number of participants 
that were recruited for this study. 
 Additionally, as potential participants could not be approached directly, and 
were instead recruited through notices and information provided by staff at CADS and 
the Needle Exchange Service, reliance on these methods may have affected 
participation recruitment adversely. In particular, changes in staff at CADS during the 
recruitment period may have been detrimental to recruitment for this study as was the 
case in Experiment 3. 
As with Experiment 3, limited incentives were offered for participation in this 
study. It was hoped that by reducing the time needed to participate in the research, the 
limitations regarding reimbursement would be reduced. Given the difficulty recruiting 
participants for this methadone sample, this does not appear to have been the case.  
As with the initial Methadone study, the current methadone sample may have 
only included individuals who regularly attended the service, and who may, therefore, 
have less significant impairments than the general methadone population (although 
this is difficult to determine). By including the Needle Exchange Service as a 
recruitment location it was hoped that individuals who were on the MMT programme 
but were not regularly attend the Community Alcohol and Drug Service would be 
recruited. However, of the 3 participants recruited through the Needle Exchange, 2 
were regular attendees of the CADS MMT programme. The inclusion of this service, 
therefore, was not effective in achieving this aim. 
 In the current study, no relation was found between adherence to treatment (as 
measured in this study) and obtained results on the psychometric measures or the 
TPQ. As previous research has suggested a link between treatment adherence and 
cognitive functioning (e.g. Aharonovich et al., 2003; Fals-Stewart, 1993; Fals-Stewart 
& Lucente, 1994; Fals-Stewart & Schafer, 1992; Fals-Stewart et al., 1994; Teichner et 
al., 2002; Verdejo-Garcia et al., 2004), this finding is contrary to that expected. As 
discussed in Experiment 3, this may suggest that the adherence criteria used in the 
current study was not appropriate to measure adherence to treatment in this 
population. Alternatively, this adherence measure may be appropriate although 
participants who were non-attendees were not captured in this sample. While no other 
way to assess adherence could be found here, given the data available, further 
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research with a wider range of adherence criteria, or that includes non-attendees may 
show different results. 
  
Overall Findings 
The results from this study support the conclusions of Experiment 3, as the 
findings from this Second Methadone sample are comparable to those obtained 
previously. Overall, the findings from both samples suggest impairments in short and 
long-term visual and verbal memory, divided attention and cognitive flexibility, and 
problem solving ability. In particular, impairments in short and long-term visual 
memory were especially pronounced. 
While the mean scores for the majority of measures were within one standard 
deviation of the normative mean for both samples, analysis of individual results 
showed that a significant number of individuals obtained scores that were one and two 
standard deviations below the normative mean on several of the psychometric 
measures. In particular, more than half of the individuals obtained results more than 
one standard deviation below the normative mean on the measures of short and long-
term visual memory, and divided attention and cognitive flexibility. More than a third 
of the participants in the methadone samples also obtained results more than one 
standard deviation below the normative mean on the measures of short-term visual 
memory, overall short and long-term memory, total memory ability, and problem 
solving ability. 
Results more than one standard deviation below the normative mean on the 
administered measures are said to be representative of impairment in the area that the 
psychometric tests assess (Kongs et al., 2000; Lezak et al., 2004; Wechsler, 2002). 
Therefore, the results from both methadone samples suggest that a large percentage of 
individuals had impairments in aspects of memory, divided attention and cognitive 
flexibility, and problem solving. Results more than one standard deviation below the 
normative mean are likely to represent clinically significant impairments in these 
areas. The difficulties likely to be associated with impairments in these areas are 
outlined below. 
Story recall, as assessed by the Logical Memory subtests of the WMS-III-A, 
has been considered as predictive of everyday memory functioning (Sunderland, 
Watts, Baddeley, & Harris, 1986). As such, it is expected that individuals would have 
difficulty recalling information that they have heard in their everyday lives, with 
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memory ability in this population further impacted upon by the impairments noticed 
in divided attention (Lezak et al., 2004). Difficulty recalling information in a verbal 
format was slightly better in both methadone samples after a delay suggesting that 
information processing in this population may be slower. Additionally, this suggests 
that individuals in this population may require more time to learn new information, 
and to integrate this information, which may be of particular relevance to how 
treatment services are provided. For example, repetition of information both in, and 
across treatment sessions, providing information in several formats, and encouraging 
the use of diaries may help with impairments in memory. 
Impairments in visual memory were greater than impairments in verbal 
memory for both methadone samples, suggesting that individuals had difficulty 
recalling information in a visual format. This suggests that individuals in this 
population will find that information presented in a verbal format is easier to recall 
than information presented in a visual format, although as noted above, individuals 
also had impairments in verbal memory. As such, a combination of both visual and 
verbal formats may increase recall of information in this population. This finding may 
also suggest that general/working memory is impaired in this population, given that 
recent research suggests that the Family pictures subtest of the WMS-III-A is more 
likely to be a measure of general/working memory (Chapin, Busch, Naugle, & Najm, 
2008; Dulay, Schefft, Testa, Fargo, Privitera, & Yeh, 2002; Lezak, Howieson, Loring, 
Hannay, & Fisher, 2004; Lichtenberger, Kaufman, & Lai, 2001). Impairments in 
working memory may mean that learning of new information may be difficult for this 
population, and may explain ongoing maladaptive behaviour patterns reported in 
individuals on methadone maintenance.   
Performance on the TMT suggests that less than one-third of participants in 
the methadone sample had impairments in simple attention, although a significant 
percentage had impairments in divided attention and cognitive flexibility. Impairment 
in simple attention may present as distractibility or difficulty focusing on the task at 
hand, while divided attention impairments are noticeable when tasks have several 
components that require manipulation at once, and the ability to process the 
information from these tasks simultaneously (Mitrushima, Boone, & D'Elia, 1999). 
These results suggest that individuals with impairments in divided attention will have 
difficulty paying attention to two or more tasks at once, and that information should 
be provided in a simplified format to allow for increased processing time. Repetition 
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of important information, given the impairments in memory may be useful for 
individuals in MMT. 
No impairments in inhibition or impulse control as measured by the Stroop 
Colour and Word Test were identified in either sample, which suggests that this 
population is unlikely to have difficulty in this area. This contrasts with previous 
research that has suggested a link between inhibition/impulse control, and substance 
use (Verdejo-Garcia et al., 2004). This finding may suggest that inhibition/impulse 
control is not related to ongoing substance use in opioid populations, and that other 
factors are more relevant i.e. problem solving or working memory impairments.  
Impairments on the WCST-A is indicative of impairments in concept 
formulation and reasoning, with individuals reported to have difficulty generalising 
information, forming concepts and using categories, and applying procedural rules 
and general principles (Lezak et al., 2004). Impairments in these aspects of 
functioning may result in difficulties solving problems in daily life, as well as abiding 
by rules both in, and out, of treatment settings. In both methadone samples, 
performance was within one standard deviation of the normative mean, however, at 
least 25% of individuals obtained results more than one standard deviation below the 
normative mean on the WCST-A measures which suggests impairments in these 
areas. 
Overall, impairments in the areas of memory, attention, and problem solving 
have the potential to impact on the ability of this population to adhere to and remain 
in treatment, although in the current study treatment adherence, as measured by 
attendance at doctors appointments, did not relate to impairments in any of these 
areas. Results for both samples did, however, show large effect sizes on several 
psychometric measures. This may mean that there is a relation between cognitive 
functioning and treatment adherence which was not observed in the current studies 
due to the small sample sizes. More research is needed to examine these findings.  
In order to further examine the findings from Experiment 3 and Experiment 4, 
a sample of individuals who were not in MMT, but who were drug and alcohol users 
was recruited. The intention was to see if the cognitive deficits found for both the 
MMT samples were unique to individuals on MMT, or if these cognitive impairments 
were evident in other drug and alcohol populations. In order to recruit individuals for 
this sample, the Salvation Army Bridge Programme was included as a recruitment 
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location in addition to CADS and the Needle Exchange Service. The data for the 
comparison drug and alcohol samples is reported in Experiment 5. 
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EXPERIMENT 5 
 
As discussed previously, the number of participants recruited for Experiment 3 
and Experiment 4 was lower than expected. It was hoped that in reducing the 
measures administered in Experiment 4 that the number of participants volunteering to 
participate in the research would increase, however, this was not the case. Further, 
advertising for individuals who were on MMT through the Needle Exchange Service 
did not increase the recruitment rate. However, the sample obtained in Experiment 4 
obtained similar results on the psychometric tests to the original methadone sample 
collected in Experiment 3.  
Given the difficulties in recruiting participants for both Experiment 3 and 
Experiment 4, a sample of individuals who were not in MMT, but who were alcohol 
users, drug and alcohol users, and opiate users was recruited The intention was to see 
if the cognitive deficits found for both of the MMT samples were unique to 
individuals on MMT, or were evident in other drug and alcohol populations. 
Numerous research studies have suggested that individuals who use substances 
and or alcohol are likely to experience some type of cognitive impairment. Previously, 
in the Introduction, the impacts of cocaine, opiates and polysubstance use on 
cognitive functioning were discussed in relation to the existing literature on substance 
use. Below, further information is provided about the relationship between alcohol use 
and cognitive functioning. 
 
Alcohol 
Research suggests that alcohol is the most widely used substance within New 
Zealand (Wilkins, Casswell, Bhatta, & Pledger, 2002), with an estimated 81% of adult 
consuming alcohol once per week on average. In addition, an estimated 52% of 
individuals aged 12-17 years consume alcohol fortnightly on average (Alcohol 
Advisory Council of New Zealand, 2005).  Estimates suggest that 635,000 adults 
drink at least once a week, and 785,000 adults drink regularly, often daily, with 1.2 
million New Zealanders considering binge drinking to be acceptable, and regularly 
binge drink themselves (Alcohol Advisory Council of New Zealand, 2008). 
Historically, alcohol was one of the first recreational drugs, and worldwide sales are 
now estimated at more than $300 billion per year (Iversen, 2001).  
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Current estimates suggest that as many as 5-10% of individuals are dependent 
on alcohol (Iversen, 2001), however due to the social acceptability and legality of this 
substance few individuals seek treatment unless the use of alcohol impacts 
significantly on job, family, and life in general. Alcohol consumption within New 
Zealand is of particular concern, with a large percentage of alcohol consumed in binge 
sessions. Estimates suggest that 3.8 drinks are consumed in an average drinking 
session across all ethnicities, with rates increasing in Pacific Islanders (6.3) and Maori 
(6.9) respectively (NZPA, 2005). This is consistent with previous research in the area 
of alcohol use in New Zealand which suggests that 31% of men and 14% of women 
drink enough to feel drunk at least once a month (Adamson et al., 2000). More 
recently, research by the Alcohol Advisory Council of New Zealand (2005) suggests 
that 40% of individuals over 18 years of age binge drink on a regular basis. 
While alcohol remains a socially accepted substance, the estimated social cost 
due to misuse is approximately 2-3% of New Zealand’s Gross National product 
(Howden-Chapman, Bushnell, & Carter, 1994). The direct cost of alcohol use within 
New Zealand (i.e., hospital costs, accident compensation payments, police and justice 
costs) was estimated between $341 million and $589 million in 1991; and with 
indirect costs (i.e. loss of production, reduced work efficiency) this figure was 
suggested to be much higher, between $1045 million and $4005 million (Devlin, 
Scuffham, & Bunt, 1997). These estimates do not account for some of the more 
visibly obvious costs of alcohol use such as property damage or damage from minor 
incidents that go unreported. In addition, the costs to the immediate family such as 
domestic violence and impact of child rearing practices, or use of alcohol during 
pregnancy are not included in this estimate. 
 As discussed previously in Experiment 2, research is increasingly suggesting 
that use of alcohol, especially continued and longer term use, results in impairment in 
cognitive functioning (Clifford, 1990; Evert & Oscar-Berman, 1995; Fals-Stewart, 
Schafer, Lucente, Rustine, & Brown, 1994; Fein, Bachman, Fisher, & Davenport, 
1990; Gruber & Yurgelun-Todd, 2001; Jones, Knutson, & Haines, 2003; McCrady & 
Smith, 1986; Moselhy, Georgiou, & Kahn, 2001; Oscar-Berman & Marinkovic, 
2003). The causal use of alcohol has not, however, found consistent results. A 
discussion of the findings in regards to casual alcohol use is outlined in Experiment 2. 
Cognitive impairment in alcohol users in general have been reported more 
consistently in the literature compared to substance users, and appear to be 
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particularly prevalent in individuals who have used alcohol at harmful levels for more 
that 10 years (Eckardt et al., 1998; Parsons & Nixon, 1998). For example, research by 
Glass, Chan and Rentz (2000) with 134 individuals in treatment for drinking under the 
influence (DUI) offences, found that 73% had one or more clinically significant 
cognitive impairments (2 standard deviations below the normative data on the 
measures used). 
 Some research, however, suggests that abstinence may result in some recovery 
of functioning (Munro, Saxton, & Butters, 2000), although other research suggests 
that while cognitive flexibility diminishes with age, cognitive impairments in alcohol 
dependent individuals may be more permanent (Pfefferbaum, Rosenbloom, & 
Sullivan, 2002). The findings with regards to alcohol use and cognitive functioning 
are summarised below. 
 Attention has often been reported as unimpaired in alcohol using samples 
(Beatty, Katzung, Moreland, & Nixon, 1995; Brown, Tapert, Granholm, & Delis, 
2000; Kelly, Johnson, Knoller, Drubach, & Winslow, 1997; Tedstone & Coyle, 2004), 
however, some studies have reported impairments in attention (Duka, Townshend, 
Collier, & Stephens, 2003; Glass et al., 2000; Goldstein et al., 2004). Impairments in 
perceptual abilities have been reported less consistently, with some studies finding 
perceptual impairments (Beatty, Blanco, Hames, & Nixon, 1997; Beatty et al., 1995; 
Fama, Pfefferbaum, & Sullivan, 2004; Farquhar, Lambert, Drummond, Tiplady, & 
Wright, 2002; Munro et al., 2000; Sparadeo & Butters, 1983; Tivis, Beatty, Nixon, & 
Parsons, 1995), but not all research has agreed with this finding (Alterman & Hall, 
1989; Munro et al., 2000; Nixon, Paul, & Phillips, 1998). 
 The majority of research studies have reported deficits in the memory abilities 
of alcohol using samples (Farquhar et al., 2002; Kim, Lee, Choi, & Go, 2003; 
Sparadeo & Butters, 1983), although some research suggests that memory abilities 
may improve with abstinence. Deficits have been reported in short-term memory, 
(Alterman, Kushner, & Holahan, 1990; Errico, King, Lovallo, & Parsons, 2002; 
Flannery et al., 2007; Nixon et al., 1998; Selby & Azrin, 1998; Tivis et al., 1995), 
long-term memory, (Alterman et al., 1990; Brown et al., 2000; Errico et al., 2002; 
Selby & Azrin, 1998), working memory (Ambrose, Bowden, & Whelan, 2001; 
Fishbein et al., 2007; Flannery et al., 2007), and spatial memory (Beatty et al., 1997; 
Townshend & Duka, 2005). Deficits have also been reported in both visual memory 
(Brown et al., 2000; Errico et al., 2002; Fishbein et al., 2007; Glass et al., 2000; 
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Goldstein et al., 2004; Williams & Skinner, 1990), and verbal memory (Beatty et al., 
1995; Errico et al., 2002; Tarquini & Masullo, 1981; Tivis et al., 1995; Uekermann, 
Daum, Schlebusch, Wiebel, & Trenckmann, 2003).  
While the majority of studies have reported deficits in memory, some studies 
have not agreed with these findings (Beatty et al., 1997; Beatty et al., 1995; Brown et 
al., 2000; Errico et al., 2002; Tarquini & Masullo, 1981; Uekermann et al., 2003), 
with particularly inconsistent results reported in abstinent alcohol users who have 
been reported as both impaired (Dawson & Grant, 2000; Fama et al., 2004; Munro et 
al., 2000; Zinn, Stein, & Swartzwelder, 2004) and not impaired (Dawson & Grant, 
2000; Munro et al., 2000; Zinn et al., 2004) on different memory tests. 
 The findings regarding the verbal functioning of alcohol users have been 
inconsistent, with some studies reporting impairments (Glass et al., 2000; Tivis et al., 
1995; Williams & Skinner, 1990) and others reporting no impairments (Chaney, 
O'Leary, Fehrenbach, & Donovan, 1980; Tarquini & Masullo, 1981; Uekermann et 
al., 2003; Zinn et al., 2004). Likewise, with regards to learning ability, some studies 
report no impairment (Brown et al., 2000; Kim et al., 2003; Munro et al., 2000), while 
others have reported impairments (Brown et al., 2000; Munro et al., 2000). 
Cognitive flexibility and executive functioning have often been measured in 
alcohol samples. Impairments have been reported on the WCST (Beatty et al., 1995; 
Errico et al., 2002; Fama et al., 2004; Goldstein et al., 2004; Williams & Skinner, 
1990), with most studies reporting perseverative behaviour in this population (Lezak, 
Howieson, Loring, Hannay, & Fisher, 2004). Impairments have also been found in 
impulse control and inhibition (Fishbein et al., 2007; Flannery et al., 2007; Selby & 
Azrin, 1998; Tedstone & Coyle, 2004; Townshend & Duka, 2005; Uekermann et al., 
2003), although these have not been reported by all studies (Duka et al., 2003; 
Fishbein et al., 2007). Impairments in cognitive flexibility, as measured on the TMT, 
have been reported by some studies (Alterman et al., 1990; Goldstein et al., 2004; 
Selby & Azrin, 1998; Zinn et al., 2004), with others reporting no impairment (Munro 
et al., 2000). Impairments in problem solving and abstract reasoning have been 
reported by several studies (Beatty et al., 1995; Brown et al., 2000; Dawson & Grant, 
2000; Fishbein et al., 2007; Glass et al., 2000; Sparadeo & Butters, 1983; Tedstone & 
Coyle, 2004; Uekermann et al., 2003; Williams & Skinner, 1990; Zinn et al., 2004). 
Other studies have reported no impairments (Beatty et al., 1995; Brown et al., 2000; 
Flannery et al., 2007; Williams & Skinner, 1990).  
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Some studies suggest impairment in psychomotor speed (Beatty et al., 1995; 
Duka et al., 2003; Farquhar et al., 2002; Fishbein et al., 2007; Flannery et al., 2007; 
Selby & Azrin, 1998; Tivis et al., 1995; Zinn et al., 2004), while other studies do not 
(Brown et al., 2000; Kim et al., 2003; Nixon et al., 1998; Selby & Azrin, 1998; Tivis, 
Tivis, & Nixon, 1999; Tivis et al., 1995). 
In summary, the findings regarding the effects of alcohol on cognitive 
functioning are not consistent. For some cognitive abilities there is equal evidence 
both for and against an effect of alcohol use. For other abilities, the majority of studies 
do suggest that excessive alcohol use/abuse results in impairments. Overall these 
studies suggest that alcohol users are likely to experience impairments in memory, as 
well as executive functioning tasks such as problem solving and abstract reasoning, 
although some studies have contested these findings. As with studies involving users 
of other substances, observations of alcohol using populations in treatment, have 
linked these cognitive impairments with poor treatment adherence and retention to 
treatment (Blume, Schmalinga, & Marlatt, 2005; Cooney, Kadden, Litt, & Getter, 
1991; Fals-Stewart et al., 1994; McCrady & Smith, 1986; Rychtarik et al., 2000; 
Tapert, Senses Ozyurt, Myers, & Brown, 2004). 
 As outlined in the Introduction the inconsistent results reported for alcohol 
populations on cognitive measures may be a result of a number of factors. For 
example, frequency, amount, and length of alcohol use may affect the obtained 
results, as may the different measures used to assess these cognitive functions. 
Demographic factors such as previous head injuries, overdoses, or psychiatric 
comorbdity may also affect results. Research does, however, suggest that alcohol 
populations have increased rates of cognitive impairments that are not seen in the 
general population. 
 
As outlined above, Experiment 5 reports on the results of the drug and alcohol 
samples that were recruited parallel to Experiment 4. This study was conducted to see 
if the cognitive deficits found for the methadone samples in Experiment 3 and 
Experiment 4 were unique to individuals on MMT, or if these deficits are associated 
with general alcohol and substance use. In order to compare the samples, the same 
measures that were administered in Experiment 4 were administered in the current 
study. In spite of the lack of findings in Experiment 3 and Experiment 4 regarding 
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adherence, it was decided to continue to measure this in Experiment 5 to allow for 
comparison across the samples.  
In comparing the literature available for this different sample groups with the 
research on individuals in MMT, the suggested impairments in the cognitive 
functioning of alcohol users are most consistently reported. Findings for both alcohol 
and methadone samples suggest that impairments in memory, and aspects of cognitive 
flexibility are likely, although findings also suggest that impairments in attention are 
likely in individuals on MMT. As such, it would be expected that impairments in 
alcohol samples may be more likely, as results have been more consistent with this 
population, although results across the two populations should be similar. 
Findings for polysubstance populations have been less consistent, with no 
consistent results reported to date. Findings do, however, suggest that polysubstance 
users may show greater levels of cognitive impairment compared to other substance 
populations. Research with opiate users, predominantly those using heroin, have also 
been inconsistent, although the impairments reported are similar to those listed for the 
methadone population.  
Given the findings to date, it would be expected that the methadone sample 
obtains similar cognitive functioning results as other drug and alcohol samples, 
although greater impairment may be seen in polysubstance users. The differences 
between samples from these populations are examined further in this study. 
 
 
METHOD 
 
Participants 
A total of 30 individuals recruited from the Community Alcohol and Drug 
Service, Salvation Army Bridge Program, and Needle Exchange Service in Hamilton 
were interviewed, from 36 individuals who initially agreed to be contacted. The 
remaining individuals either declined to be interviewed when they were contacted, did 
not arrive for an arranged interview, or were unable to be contacted. Of the 30 
individuals that were interviewed, one was excluded due to acute cannabis 
intoxication leaving a sample of 29 individuals. 
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 This sample was then divided according to the type of treatment each 
participant was receiving. The final samples were: Alcohol (n=13); Other Drug and 
Alcohol (excluding opiate use) (n=11); and Other Opiates (not in MMT programme) 
(n=5). Further details on these samples are available in the Results section. 
 
Materials 
The psychometric measures administered to each participant in this study were 
identical to those administered in Experiment 4. A description of these measures is 
available in the sections titled Experiment 1 and Experiment 3. 
 
Procedure 
Prior to the commencement of this research, ethical approval was obtained 
from the Psychology Department Human Research Ethics Committee at the 
University of Waikato and the Northern Y Regional Ethics Committee (part of the 
Health and Disability Ethics Committee). 
Participants were recruited from CADS, Salvation Army Bridge Programme, 
and the Needle Exchange Service, all of which were located in Hamilton. Participants 
from CADS were recruited between January 2005 and December 2007, while 
individuals from the Salvation Army Bridge Programme and Needle Exchange 
Service were recruited between January 2007 and December 2007. Individuals 
recruited through the Community Alcohol & Drug Service and the Salvation Army 
Bridge Programme were in treatment programmes for alcohol and/or drug use that 
were provided by these services. Individuals recruited through the Needle Exchange 
were either in treatment at a service within Hamilton, were not in treatment but using 
substances, or had been substance users previously. Participants were recruited via 
information fliers posted at CADS (see Appendix XV), Salvation Army (see 
Appendix XVI), and the Needle Exchange (see Appendix XVII), and through 
information provided by staff to consumers of these services.  
Individuals were eligible to participate in the research if they currently or 
previously used alcohol and/or drugs at the time of the assessment, and were over the 
age of 18 years. Individuals were excluded from the research if the staff at the service 
deemed them to be intoxicated (either alcohol or substance induced) at the time of the 
interview, and/or they had a current major mental illness (judged on a case by case 
basis).  
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All individuals who used the treatment services provided by the Community 
Alcohol and Drug Service and Salvation Army Bridge programme were given the 
opportunity to participate in the research, and provided that they met the stability 
criteria they were invited to take part in the research. As with previous studies, 
exclusion criteria were kept to a minimum to allow for a truer representation of this 
population and to allow for the extraction of meaningful results that will be useful for 
the entire population. Exclusion due to intoxication or substance impairment was 
assessed on the day of the interview, as research suggests that intoxicated individuals 
may not comprehend fully what they are agreeing to participate in (McCrady & Bux 
Jr., 1999).  
Individuals who agreed to take part in the research, were provided with the 
information sheet about the research (see Appendices XVII, XIX, and XX), and once 
they had completed the necessary consent forms (see Appendices XXI, XXII, and 
XXIII), they were administered the neuropsychological tests, and asked a short series 
of questions regarding recent substance/alcohol use, and previous head injuries (see 
Appendix XXIV). The neuropsychological tests were the same as those administered 
in Experiment 4, and were administered in the same order. The TPQ was included as 
part of this study and was administered at the end of the test sequence. All interviews 
were conducted on a one on one basis in a room at CADS, Salvation Army Bridge 
programme, or Needle Exchange Service. Following the completion of the 
assessment, individual participation was recorded for the individuals from CADS in 
their files (see Appendix XIV). 
Individuals were required to consent to a review of their file in order to assess 
their adherence to treatment, and to gain further demographic information. 
Participants were provided with refreshments and tea/coffee for participation in the 
research, as it was considered to be inappropriate to give them a financial incentive.  
 
Adherence Measures 
As mentioned in Experiment 3, many different measures have been used to 
assess adherence to treatment. For the purposes of this study, adherence was assessed 
as outlined below: 
 
• Number of missed keyworker appointments – based on the two most recently 
scheduled appointments. An individual was considered to have missed/not 
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attended a scheduled appointment if they failed to attend the initial scheduled 
appointment or the replacement appointment if one was scheduled within two 
weeks of the original appointment. The percentage of attended appointments 
was based on the last two initial appointments scheduled (if individuals 
attended the replacement appointment they were considered to have completed 
the criteria of having attended the scheduled appointment). This approach was 
used by Gutierrez, Ballesteros, Gonzalez-Oliveros, & Ruiz de Apodaka (1995) 
who used unjustified absence from 5 consecutive or 10 alternative follow-up 
appointments as evidence of non-adherence with treatment.  
 
Demographic Information 
Demographic information was obtained from the short demographic 
questionnaire completed by participants, and through file reviews (e.g. previous drug 
use, DSM diagnoses etc) as this information was collected for all individuals on initial 
assessment at the CADS and at the Salvation Army Bridge programme.  
 
Scoring and data entry 
Scoring and data entry was conducted as outlined in Experiment 3. 
Participants from the CADS and the Salvation Army Bridge programme were given 
the option of receiving feedback on the results of the testing, and, if participants 
agreed, this information was included in their case notes at the respective service also. 
Individuals from the Needle Exchange Service were not provided with feedback on 
their individual results. 
Analysis was conducted using SPSS Version 12, and was based on the same 
psychometric scores as outlined in Experiment 3. The results from the TPQ were 
analysed in the same manner as in Experiment 3.  
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RESULTS 
 
This study was conducted to assess the occurrence of cognitive impairments in 
individuals who reported a history of alcohol, drug and alcohol, or opiate use. The 
samples collected were: an Alcohol sample (n=13); a Drug and Alcohol sample 
(excluding opiate use) (n=11); and an Other Opiates Sample (n=5). All participants 
were recruited through the CADS, the Needle Exchange Service, and the Salvation 
Army Bridge Program in Hamilton, New Zealand. 
As shown in Table 5.1, the Alcohol sample had a mean age of 45.23 years, and 
were predominantly of New Zealand European descent. There were a similar numbers 
of males and females in the sample, and on average the sample had completed the 
equivalent of 6th Form or Year 12/NCEA Level 2. The Alcohol sample had been in 
this episode of treatment for a mean of 5 ½ months, and four of the individuals had 
received treatment for alcohol and/or drug concerns previously, with a mean number 
of treatment episodes of 1.17. Of the sample, 8 had used other substances previously, 
but none of the Alcohol sample reported current use of other substances.  
 The Drug and Alcohol sample had a mean age of 33.00 years and were 
predominantly of New Zealand European descent. There were a greater number of 
males than females in the sample, and on average the sample had completed the 
equivalent of 5th Form or Year 11/NCEA Level 1. The Drug and Alcohol sample had 
been in this episode of treatment for a mean of 8 months, and three of the individuals 
had received treatment for alcohol and/or drug concerns previously, with a mean 
number of treatment episodes of 0.82.  
 The Other Opiate sample consisted of three individuals in treatment who used 
opiates other than methadone, and two individuals who had used opiates previously 
but were not in treatment at the time of assessment. The Other Opiate sample had a 
mean age of 39.00 years, were predominantly of New Zealand European descent and 
had completed the equivalent of Form 7 or Year 13/NCEA Level 3. 
The results for each of the samples are reported separately in the following 
section, and are followed by between group comparisons. 
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Alcohol Sample 
As discussed previously, the Alcohol sample consisted of 13 individuals 
recruited from the Community Alcohol and Drug Service. One participant was 
excluded from the analysis of the Stroop due to colour-blindness, while the same 
participant and one other participant did not complete the WCST-A.  
Prior to any analysis, Shapiro-Wilks tests were conducted on the data to assess 
for normality. Results from this analysis suggested that the data for the WMS-III-A 
Family Pictures I (W = 0.850, df = 13) and Trail Making B Percentile Score (W = 
0.811, df = 13) were significantly different from the normal distribution. 
Subsequently, transformations were conducted on these measures, and square-root 
transformations normalised the distribution of scores for the WMS-III-A Family 
Pictures I subtest. The data from the TMT Part B were unable to be normalised. As 
such, the results for the TMT Part B should be interpreted with caution.  
A series of one sample t-tests was conducted to compare the scores of these 
participants with the normative data provided in the administration manuals for each 
test, with the exception of the Trail Making Test. The Trail Making Test data were 
compared to the normative data provided by Tombaugh (2004) as discussed in 
Experiment 1. 
The one sample t-tests showed significant differences between the obtained 
and the normative data for a number of measures. A summary of these results is 
presented in Table 5.2. Significantly lower scores were found compared to the 
normative sample on the WMS-III-A Family Pictures I and II subtests and Immediate 
Memory score, and Stroop Colour T-Score. Medium effect sizes were obtained on all 
measures of the WMS-III-A with the exception of the Logical Memory I and II 
subtests, and the Stroop Colour T-Score. Results from the Alcohol sample on all other 
measures were not significantly different from the normative sample at p < 0.05. 
A comparison of the obtained results to the normative standard deviation 
ranges provided for each measure showed that, while the Alcohol sample differed 
significantly from the normative data on a number of measures, the mean scores for 
all measures fell within one standard deviation of the test norm for the majority of 
measures. This indicates that the results on these measures were not clinically 
significant. A summary of the mean and standard deviation scores for each measure 
are provided in Table 5.3. 
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The data from the Alcohol sample were examined for each participant to 
assess the clinical level of impairment (i.e. one and two standard deviations below the 
normative mean). Outlined in Table 5.4 is the number of individuals who were 
impaired on each of the measures at either one or two standard deviations from the 
normative mean. The exception to this is the TMT where only one standard deviation 
(16th Percentile) was used. Participants are numbered according to the order in which 
they were recruited.  
 This analysis showed that 2 participants obtained scores more than two 
standard deviations below the normative mean on most measures of the WMS-III-A. 
These 2 participants, as well as another 2 participants, obtained scores one standard 
deviation below the normative means on both the TMT Part A and Part B. 
 
Relation between demographic and psychometric test results 
As for previous experiments, the relation between psychometric results and 
gender, handedness, years of education, head injuries and overdoses were assessed. 
Table 5.5 shows that years of education was positively correlated with the WMS-III-A 
Family Pictures II subtest, Immediate Memory and Total Memory measures. Number 
of overdoses was positively correlated with WCST-A Perseverative Errors. Gender, 
handedness and number of head injuries were not correlated with any of the measures. 
 
Other Drug Use 
Of the 13 individuals in the Alcohol sample, 11 participants reported no use of 
other substances in the last 48 hours. The remaining 2 participants reported use of 
benzodiazepines. As only two participants reported using other substances, no formal 
analysis was conducted comparing the results of these two groups. Comparison of the 
means, as shown in Table 5.6, showed that the benzodiazepine group obtained poorer 
results on the WMS-III-A Delayed Memory and Total Memory scores, TMT part B 
Percentile Score, and Stroop Colour T-Score, and higher scores on all measures of the 
WCST-A with the exception of the Nonperseverative Errors measure. 
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Satisfaction with Treatment 
Scores on the TPQ for the Alcohol sample showed high levels of satisfaction 
with treatment (31.67, SD 5.91, range 21-40), and, in general, provided praise for the 
staff and service provision on the personal opinion section. The few exceptions to this 
included one participant who felt that scripts were not processed quickly enough, and 
another who felt that comorbid psychiatric disorders were not addressed as adequately 
as they could be by the treatment services. 
An analysis of the individual TPQ questions indicated mean scores above 3 
(indicating greater treatment satisfaction) on all but two questions: ‘I have not liked 
all of the treatment sessions I have attended (2.58, SD 1.34) and ‘I have not had 
enough time to sort out my problems’ (2.50, SD 1.00). Analysis using the two factors 
identified by Marsden et al (2000) found slightly higher mean scores on the staff 
perceptions factor (16.42, SD 2.61) versus the program perceptions factor (15.42, SD 
3.48). 
Pearson Correlations were conducted to assess the relation between time in 
treatment and treatment satisfaction as measured by the TPQ. No significant 
correlations were found between time in treatment and the TPQ Score (r = -0.392), 
TPQ Staff Perceptions (r = -0.356), or TPQ Program Perceptions (r = -0.394). 
 
Neuropsychological Performance & Treatment Adherence 
Adherence to treatment in the Alcohol sample was measured by attendance at 
scheduled keyworker appointments, and individuals were deemed to have complied if 
they had attended their two most recent keyworker appointments. Within the Alcohol 
sample, 11 participants had attended their two most recent appointments while the 
remaining 2 had attended one of the two most recent appointments.  
To assess the difference between the means of the two groups (those who 
attended two appointments versus those who attended one appointment) on the 
psychometric results, a series of Mann-Whitney U tests was conducted. The results of 
the WCST-A and the TPQ were not included in the analysis as the 2 participants that 
had attended one of their last two appointments did not complete this measure. The 
Stroop was also excluded as only 1 of the 2 participants had completed this measure.  
As shown in Table 5.7, the 2 participants who had attended one of the two 
most recent appointments obtained significantly poorer scores on the WMS-III-A 
Logical Memory I and II subtest. Large effect sizes were obtained on all measures of 
 
182 
 
 
the WMS-III-A with the exception of the Family Pictures I and II subtests, and on the 
TMT Part B Percentile Score. The two groups did not differ on any of the other 
psychometric measures. 
Comparison of the results for the 1 participant who did complete the Stroop 
compared to the rest of the sample showed that this participant obtained a lower 
Stroop Colour T-Score, but comparable scores on the other Stroop measures.
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Drug and Alcohol Sample 
As mentioned earlier, the Drug and Alcohol sample consisted of 11 
individuals recruited from the Community Alcohol & Drug Service and the Salvation 
Army Bridge Program. The participants completed all of the measures with the 
exception of one participant who did not complete the WCST-A as they found the test 
‘too difficult’. This participant completed all of the remaining assessments. 
Prior to any analysis, Shapiro-Wilkes tests were conducted on the data to 
assess for normality. Results from this analysis suggested that the data for the TMT 
Part B Percentile Score (W = 0.809, df = 11, p < 0.05) were significantly different 
from the normal distribution. Subsequently, transformations were conducted on this 
measure however the data were unable to normalised. As there are no non-parametric 
equivalents to the one sample t-test this data were compared to the normative data 
using the standard one sample t-test. As such the results for the TMT Part B should be 
interpreted with caution. 
A series of one sample t-tests was conducted to compare the results obtained 
with the normative data provided in the administration manuals for each test, with the 
exception of the TMT. The TMT data were compared to the normative data provided 
by Tombaugh (2004) as discussed in Experiment 1. 
The one sample t-tests showed significant differences between the obtained 
and the normative data for a number of measures. A summary of these results is 
presented in Table 5.8. The Drug and Alcohol sample obtained significantly lower 
scores compared to the normative sample on all measures of the WMS-III-A, and all 
measure of the WCST-A. Medium effect sizes were obtained on the TMT Part B 
Percentile Score, and WCST-A Perseverative Responses and Perseverative Errors, 
while large effect sizes were obtained on all measures of the WMS-III-A, and all other 
measures of the WCST-A. Results from the Drug and Alcohol sample on all other 
measures were not significantly different from the normative sample. 
A comparison of the obtained results to the normative standard deviation 
ranges provided for each measure showed that, while the Drug and Alcohol sample 
differed significantly from the normative data on a number of measures, the mean 
scores for most of the measures fell within one standard deviation of the normative 
mean. The scores for all measures of the WMS-III-A, with the exception of Logical 
Memory II and Family Pictures II, and the WCST-A Total Number of Errors and 
Nonperseverative Errors, fell more that one standard deviation below the normative 
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mean. A summary of the mean and standard deviation scores for each measure are 
provided in Table 5.3.  
The Drug and Alcohol sample data were examined on a case by case basis to 
assess overall impairment at one and two standard deviations below the normative 
mean. Outlined in Table 5.4 is the number of individuals who obtained scores either 
one or two standard deviations below the normative mean on each measure. Obtained 
scores on the TMT are compared at ones standard deviation (16th Percentile) only. 
Individual participants were numbered according to the order in which they were 
recruited for this sample. 
This analysis showed that 2 participants obtained scores that fell more than 
two standard deviations below the normative mean on all of the WMS-III-A 
measures, while an additional 2 participants obtained results more than two standard 
deviations below the normative data on several of the WMS-III-A measures. Two of 
the 11 participants obtained scores one standard deviation below the normative mean 
on both the TMT Part A and Part B, and an additional 3 participants obtained scores 
that fell more than one standard deviation below the normative mean on the TMT Part 
B. Participants 3 and 4 obtained results in the impaired range (more than one standard 
deviation below the normative mean) on all psychometric tests. 
 
Relation between demographic and psychometric test results 
As with previous samples, Pearson Correlations were calculated for the 
psychometric measures and years of education, handedness, gender, head injuries and 
overdoses. Table 5.9 shows that gender was positively correlated with the WMS-III-A 
Logical Memory II subtest (females obtained greater scores). Academic achievement, 
handedness, number of head injuries, and number of overdoses were not correlated 
with any of the psychometric measures. 
 
Satisfaction with Treatment 
The TPQ results for the Drug and Alcohol sample showed high levels of 
satisfaction with treatment (31.82, SD 4.916, range 25-39) and generally praised the 
staff and service provision. The exceptions to this were 1 participant who thought that 
the methadone maintenance treatment program and the drug and alcohol treatment 
service should be provided as separate services, and another who said that 
appointments were often cancelled by staff members. 
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An analysis of the individual TPQ scores indicated mean scores above 3 
(indicating greater treatment satisfaction) on all questions with the exception of: ‘The 
staff have not always understood the kind of help I wanted’ (2.91, SD 0.944), ‘The 
staff and I have had different ideas about what my treatment objectives should be’ 
(2.45, SD 1.37), and ‘I have not had enough time to sort out my problems’ (2.45, SD 
1.29). Analysis using the two factors identified by Marsden et al. (2000) found similar 
mean scores on bother the staff perceptions factor (16.09, SD 1.81) and the program 
perceptions factor (15.73, SD 3.55). 
Pearson Correlations were calculated to assess the relation between time in 
treatment and treatment satisfaction as measured by the TPQ. No significant 
correlations were found between time in treatment and the TPQ Score (r 0.071), TPQ 
Staff Perceptions (r 0.312), or TPQ Program Perceptions (r -0.061). 
 
Neuropsychological Performance & Treatment Adherence 
Adherence to treatment in the Drug and Alcohol sample was measured by 
attendance as scheduled keyworker appointments, and individuals were deemed to 
have complied if they had attended their two most recent appointments. Within the 
Drug and Alcohol sample, 10 of the 11 participants had attended their two most recent 
appointments, while the remaining participant had attended one of the two most recent 
appointments.  
As only 1 participant did not attend 100% of their appointments, analysis was 
not conducted for the Drug and Alcohol sample to assess the relation between 
neuropsychological performance and treatment adherence. Examination of the data 
did suggest, however, that this participant did not obtain scores that were noticeably 
lower than the remainder of the sample. 
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Other Opiate Sample 
As mentioned earlier, the Other Opiate sample consisted of 5 individuals 
recruited from the Community Alcohol & Drug Service, Salvation Army Bridge 
Program, and Needle Exchange Service. This sample did not complete the Treatment 
Perceptions Questionnaire as not all of the sample were in treatment at the time of the 
assessment.  
Prior to any analysis, Shapiro-Wilks tests were conducted on the data to assess 
for normality. Results from these analyses showed that the data for the Family 
Pictures I subtest from the WMS-III-A (W = 0.753, df = 5, p < 0.05) and the TMT 
Part B Percentile Score (W = 0.754, df = 5, p < 0.05) were significantly different from 
the normal distribution. Subsequently, transformations were conducted on these 
measures, however, these transformations did not succeed in normalising these data. 
As there are no non-parametric equivalents to the one sample t-test, the data were 
compared using the standard one sample t-test. As such the results for the Family 
Pictures I subtest and the TMT Part B Percentile Score should be interpreted with 
caution. 
A series of one sample t-tests was conducted to compare the results obtained 
with the normative data provided in the administration manuals for each test, with the 
exception of the Trail Making Test. The Trail Making Test data were compared to the 
normative data provided by Tombaugh (2004) as discussed in Experiment 1. 
The one sample t-tests showed significant differences between the obtained 
and the normative data for a number of measures. A summary of these results is 
presented in Table 5.10. The Other Opiate sample obtained significantly lower scores 
compared to the normative sample on the Family Pictures I and II subtests, and 
Immediate and Total Memory scores of the WMS-III-A, and all measures of the 
WCST-A. Medium effect sizes was obtained on the WMS-III-A Logical Memory II 
subtest and TMT Part B Percentile Score, while large effect sizes were obtained on all 
other measures of the WMS-III-A, the Stroop Colour T-Score and all measures of the 
WCST-A. Results from the Other Opiate sample on all other measures were not 
statistically different from the normative sample. 
A comparison of the obtained results to the normative standard deviation 
ranges provided for each measure showed that, while the Other Opiate sample 
differed significantly from the normative data on a number of measures, the mean 
scores fell within one standard deviation of the test norm for the majority of measures. 
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Obtained scores on all the measures of the WMS-III-A, with the exception of Family 
Picture I, and all measures of the WCST-A, fell more than one standard deviations 
below the normative means. The mean and standard deviation scores for each 
psychometric test are provided in Table 5.3. 
The Other Opiate sample data were examined on a case by case basis to assess 
overall impairment at one and two standard deviations below the normative mean. 
Outlined in Table 5.4 is the number of individuals who were impaired on each of the 
measures at either one or two standard deviations below the normative mean. 
Obtained scores for the TMT are only assessed at one standard deviation (16th 
Percentile). Participants are numbered according to the order in which they were 
recruited for this sample. 
This analysis showed that 1 participant obtained scores more than two 
standard deviations below the normative mean on all measures, with the exception of 
the WMS-III-A Family Pictures I and II subtests and all measures of the Stroop. The 
remaining participants obtained scores more than one standard deviation below the 
normative mean on most measures with the exception of the TMT Part A Percentile 
Score. Participant 4 obtained impaired results on all psychometric tests (this 
participant did not complete the Stroop).  
 
Relation between demographic and psychometric test results 
As with previous samples, the relation between psychometric results and 
gender, handedness, years of education, head injuries and overdoses was assessed. 
Table 5.11 shows that gender was positively correlated with the WMS-III-A Family 
Picture I and II subtest (females obtained greater scores). Years of education was 
positively correlated with the WMS-III-A Logical Memory I and II subtests and 
Delayed and Total Scores. Number of overdoses was positively correlated with the 
TMT Part B Score (as number of overdoses increases, the obtained score on TMT Part 
B improved). Number of head injuries was not found to correlate with any of the 
psychometric measures. 
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Neuropsychological Performance across samples 
The three samples (Alcohol, Drug and Alcohol, and Other Opiate) were 
compared to one another to identify any patterns in impairments across the different 
substances. Additionally, the three samples were compared to the Combined 
Methadone sample, which consisted of those participants recruited in Experiments 3 
and Experiment 4.  
A series of one-way ANOVAs assessed the difference between the samples 
with regards to age and years of education, while a chi squared test for independence 
was used to assess the difference between the samples with regards to gender and 
ethnicity.  
As shown in Table 5.12, age was significantly different between at least two of 
the samples, while years of education did not significantly differ across the groups. 
Post-hoc analysis showed that age in the Alcohol sample differed from the Drug and 
Alcohol and Combined Methadone samples. As shown in Table 5.13, the results for 
the chi squared test for independence showed gender and ethnicity were not related to 
sample membership.  
A series of one-way ANOVAs and Kruskal Wallis tests were conducted to 
assess the difference between the samples. Kruskal Wallis tests were conducted when 
one or more of the samples differed significantly from the normative distribution. As 
shown in Table 5.12 and Table 5.14, statistically significant differences between at 
least two of the groups were obtained on the WCST-A Total Number of Errors and 
Conceptual Level Responses. Post-hoc analysis showed that the Other Opiate sample 
obtained significantly lower scores on both of these measures compared to the 
Alcohol sample. No other significant differences were found between the four 
samples. 
In addition to comparing the obtained scores on the neuropsychological 
measures, a series of one-way ANOVAs were conducted to assess the difference 
between the Alcohol, Drug and Alcohol, and Combined Methadone samples on the 
TPQ. The Other Opiate sample was not included in this analysis as they did not 
complete the TPQ. As shown in Table 5.15, obtained scores on all of the TPQ 
measures differed significantly between at least two of the samples. Post-hoc analysis 
showed that the Combined Methadone sample obtained significantly lower mean 
scores on the Treatment Perceptions Questionnaire Total, Staff Perceptions and 
Program Perceptions scores compared to the Alcohol, and Drug and Alcohol samples. 
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Table 5.13
Chi-Squared tests comparing demographic characteristics of Alcohol, 
Drug and Alcohol, Other Opiate, and Combined Methadone Samples
X  2 Asymp. Sig
Alcohol & Drug and Alcohol Samples
Gender 0.743 NS
Ethnicity 3.055 NS
Alcohol & Other Opiate Samples
Gender 0.277 NS
Ethnicity 2.215 NS
Alcohol & Combine Methadone Sample
Gender 0.563 NS
Ethnicity 1.682 NS
Drug and Alcohol & Other Opiate Sample
Gender 0.019 NS
Ethnicity 3.588 NS
Drug and Alcohol & Combine Methadone Sample
Gender 0.084 NS
Ethnicity 4.556 NS
Other Opiate & Combined Methadone Sample
Gender 0.003 NS
Ethnicity 1.037 NS
* Significant at p< 0.05
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DISCUSSION 
 
Experiment 5 was conducted to assess the cognitive functioning of individuals 
who were not in MMT, but who had a history of alcohol and drug use. The intention 
was to see if the cognitive deficits found for in the MMT samples described in 
Experiment 3 and Experiment 4 were unique to individuals on MMT, or were evident 
in other drug and alcohol populations. In addition, this study aimed to assess the 
cognitive functioning of drug and alcohol populations in New Zealand compared to 
overseas research findings. 
 Several samples were recruited for this study, and these included 13 
individuals in treatment for alcohol use, 11 individuals in treatment for drug and 
alcohol use, and 5 individuals who were past or present opiate users (not in 
methadone maintenance). The findings for each of the respective samples are outlined 
in the following section. 
 
Wechsler Memory Scale-III-Abbreviated 
All three samples in the current study obtained lower scores than the 
normative data on the WMS-III-A, with lower scores reported most often on the 
Family Pictures I and II subtests, and on the Immediate Memory score. In addition, 
individual analysis showed that approximately half of the individuals in the Alcohol, 
and Drug and Alcohol samples obtained results in the impaired range (more than one 
standard deviation below the normative mean), and 3 of the 5 individuals in the Other 
Opiate sample obtained results in the impaired range on the Family Pictures I and II 
subtests. 
These results suggest that the portion of the sample with scores more than one 
standard deviation below the normative mean are likely to have difficulty with both 
short and long-term visual and verbal/working memory. Impairment in these areas is 
likely to impact upon their ability to recall information in their everyday lives, as well 
as remembering and later recalling information in treatment settings. Results from the 
Alcohol sample support this relation, as poorer scores on the WMS-III-A Logical 
Memory I and II subtest, as well as on the TMT Part B Percentile Score were 
associated with poorer adherence.  
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In interpreting findings from these samples, it should be noted that scores on 
the WMS-III-A were found to correlate with years of education in the Alcohol and 
Other Opiate samples. Previous research has reported similar findings in regards to 
the WMS and academic achievement (Stanton, Savageau, Aucion, Jenkins, & 
Zyzanski, 1984). This finding may suggest that memory ability may be improved 
through training, and training may improve adherence and retention in these 
populations. Alternatively, this finding may also suggest that those with better 
memory skill are more likely to achieve higher educational qualifications. 
 A comparison of the results obtained for the three samples in this study, with 
those obtained for the Combined Methadone sample found no differences in the 
scores obtained on the WMS-III-A. Examination of mean scores for the samples 
showed lower mean scores for both the Drug and Alcohol and Other Opiate samples 
on the WMS-III-A compared to the Alcohol sample and the Methadone sample (with 
the exception of the delayed memory measures for the Methadone sample). The 
Methadone sample also obtained lower mean scores on the delayed memory measures 
compared to the Alcohol sample. These results suggest that memory deficits are more 
prevalent in drug and alcohol and other opiate samples, and the individuals in 
methadone maintenance have particular difficulty with delayed memory.  
 
Wisconsin Card Sorting Test-Abbreviated 
Mean scores for the Alcohol sample on the WCST-A were comparable to the 
normative means, and most individuals obtained scores that fell within the normative 
range on each of the given measures. These results contrast with the literature that has 
reported impairments on the WCST in alcohol populations (Beatty et al., 1995; Errico 
et al., 2002; Fama et al., 2004; Goldstein et al., 2004; Williams & Skinner, 1990). 
These results suggest that the current Alcohol sample did not experience significant 
impairment in problem solving and abstract thinking. Therefore, the participants in 
this Alcohol sample are unlikely to have difficulty solving problems, or thinking 
about material in an abstract way (Kongs, Thompson, Iverson, & Heaton, 2000; Lezak 
et al., 2004).  
The disparity between the current findings and those found in previous 
research may be attributable to differences in the populations being studies. For 
example, studies have examined different frequency of use, amount consumed, and 
history of use, as well as individuals during and following detoxification from alcohol 
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(Beatty et al., 1995; Errico et al., 2002; Fama et al., 2004; Goldstein et al., 2004; 
Williams & Skinner, 1990). These factors were not assessed in the current sample so 
it if difficult to identify the reason for the obtained results. 
Both the Drug and Alcohol, and Other Opiate samples obtained lower scores 
on the WCST-A compared to the normative data. The Drug and Alcohol sample 
obtained mean scores that fell more than one standard deviation below the normative 
mean on the Total Number of Errors and Nonperseverative Errors, while the Other 
Opiate sample obtained scores that fell more than one standard deviation below the 
normative mean on all WCST-A measures. The results for the Drug and Alcohol 
sample suggest some impairment in problem solving and abstract reasoning, with 
50% of the sample obtained impaired results on aspects of this test. Additionally, the 
results suggest that several participants had difficulties with working memory and 
understanding sorting principles, however, no perseveration was evident across the 
sample. Impairments in these areas are likely to result in difficulties solving problems 
in daily life, which may also affect successful progress in treatment (Lezak et al., 
2004). 
 Individual results for the Other Opiate sample showed that 3 of the 4 
participants who completed the WCST-A obtained results in the impaired range on 
Number of Categories Completed, and all 4 participants obtained results in the 
impaired range on Conceptual Level Reponses. These results suggest that the sample 
lacked understanding of the sorting principles in the WCST-A, and had difficulties 
identifying solutions in problem solving. Results in the impaired range (more than one 
standard deviation below the normative mean) were also noted on the Perseverative 
Responses and Perseverative Errors measures, with 2 and 3 individuals obtaining 
scores in the impaired ranges of these measures respectively. This suggests that the 
Other Opiate sample did not use the feedback given on incorrect responses to modify 
their behaviour. As with the Drug and Alcohol sample, impairments in these areas are 
likely to negatively impact on daily functioning. 
Comparison of the three samples showed that the greatest scores on the 
WCST-A were obtained by the Alcohol, with a large difference in scores between the 
Alcohol and Other Opiate samples. Interestingly, the Alcohol sample was also the 
oldest of the sample suggesting that problem solving ability may improve with age or 
practice over time. Comparisons between the other samples showed no significant 
findings on the measures of the WCST-A. This suggests that the greatest impairment 
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in problem solving ability is seen in other opiate users, followed by drug and alcohol 
users, with alcohol users showing the least impairment.  
The difference in scores obtained by the samples, while not statistically 
significant for all measures of the WCST-A, suggests that problem solving ability 
may be more impaired in some drug and alcohol populations. Interestingly, the 
methadone and other opiate sample obtained mean scores that differed by a large 
degree on the Total Number of Errors and Conceptual Level Responses measures. 
Given that individuals on MMT are previous illicit opiate users, this finding may 
suggest that while illicit opiate use impairs functioning, both in current and previous 
users, methadone may improve problem solving ability in individuals currently in an 
MMT programme. However, as identified in Experiment 3, long term methadone 
maintenance also appears to be associated with a possible impairment in problem 
solving ability.  Future research may wish to examine these findings. 
 
Trail Making Test 
 In the current study, mean results for all three samples were within one 
standard deviation of the normative mean for the TMT. These findings suggest that 
the three samples were not impaired in attention or cognitive flexibility. Individual 
results did, however, show that a number of participants in each sample obtained 
results more than one standard deviation below the normative mean on the TMT Part 
A and Part B. Four participants in the Alcohol sample obtained results in this range on 
both the TMT Part A and Part B; 1 participant on the TMT Part A and 5 participants 
on the TMT Part B in the Drug and Alcohol sample; and 3 participants on the TMT 
Part B in the Other Opiate sample. 
The findings the TMT Part A for these individuals suggests they are likely to 
have difficult with simple attention, while results more than one standard deviation 
below the normative mean on the TMT Part B suggest impairments in divided 
attention and cognitive flexibility. Impairments in these areas are likely to have an 
effect on their ability to participate in treatment, and to function effectively in their 
daily lives. Additionally, difficulties in attention are likely to be related to the 
impairments in memory that were reported in all of the samples (Lezak et al., 2004). 
 The findings on the TMT for the Other Opiate sample should be interpreted 
with particular caution, as a positive correlation was found between overdoses and the 
TMT Part B score. This suggests that as the number of overdoses increases, greater 
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(better) scores are obtained on TMT Part B. This finding is surprising given that the 
TMT is considered to be a measure of organic brain damage (Reitan, 1986; 
Tombaugh, 2004). 
 The three samples in the current study obtained similar results to the 
methadone samples in Experiments 3 and 4. Less than one-third of the participants in 
the Combined Methadone sample had impairments in simple attention, while over 
60% had impairments in divide attention and cognitive flexibility. The findings 
suggest that attentional impairments are not specific to individuals in MMT, with 
impairments on the TMT Part B observed most often. As discussed in Experiment 4, 
individuals with impairments in divided attention are more likely to have difficulty 
paying attention to several tasks at once, and it is recommended that information is 
provided in a simplified format.  
 
Stroop Colour & Word Test 
Results for the three samples were comparable to the normative means on all 
measures of the Stroop, with the exception of the Alcohol sample which obtained a 
lower mean Stroop Colour T-Score. Previously, research in cocaine users has 
suggested that impairments in colour naming may be a result of colour vision 
impairment in acute withdrawal (Kelley, Yeager, Pepper, & Beversdorf, 2005). 
However, it seems unlikely that this would account for the results of the Alcohol 
sample as none of the individuals reported symptoms of withdrawal, or were going 
through a withdrawal process at the time of assessment. Golden and Freshwater 
(2002) have also suggested that impairment in colour naming may be a result of 
impairments in the temporal-occipital region of the right hemisphere, although 
research has not assessed this link thoroughly.  
Overall, results on the Stroop for all three samples suggest the participants do 
not have difficulty with impulse control or inhibition. As such, it would be expected 
that individuals in the three samples are able to control their impulsivity, and that rule 
violations and other acts often attributed to impulsivity would be lower in this sample. 
These findings contrast with previous research that suggests impairments in inhibition 
and impulse control may account for continued alcohol and substance use (Verdejo-
Garcia et al., 2004).  
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 The findings for the three samples in this study on the Stroop are similar to 
those reported in the methadone samples in Experiment 3 and 4. Overall, the results 
for all samples suggest no impairments in inhibition or impulse control.  
 
Treatment Perceptions Questionnaire 
The TPQ was administered to the Alcohol and Drug and Alcohol samples in 
the current study. On this measure, both samples reported high levels of treatment 
satisfaction, and participants in both samples provided praise for the staff and service 
provision. 
Compared to the Combined Methadone sample, both of the samples in this 
study obtained significantly higher scores on the TPQ (indicating greater treatment 
satisfaction). This suggests that treatment dissatisfaction is associated specifically 
with aspects of the MMT program, rather than the general service provision provided 
by CADS and the Salvation Army Bridge Programme. The lower levels of treatment 
satisfaction in the methadone samples is comparable to the literature in this area 
(Deering et al., 2003; National Treatment Agency for Substance Misuse, 2007; 
Simpson, Joe, & Brown, 1997; Strang et al., 2000; Villafranca, McKellar, Trafton, & 
Humphreys, 2005). This suggests that while the methadone samples were less 
satisfied with the CADS treatment service in Hamilton, this low level of satisfaction is 
associated with MMT programmes in general.  
 
Neuropsychological Performance & Treatment Adherence 
Previous research has suggested a link between cognitive impairment in 
alcohol dependent sample and poor treatment adherence (Blume et al., 2005; Cooney 
et al., 1991; Fals-Stewart et al., 1994; Kadden, Cooney, Getter, & Litt, 1989; 
McCrady & Smith, 1986; Rychtarik et al., 2000; Tapert et al., 2004). In the current 
study, only the treatment adherence of the Alcohol sample was assessed formally. 
Poorer treatment adherence in the Alcohol sample was associated with impairments 
on the WMS-III-A Logical Memory I and II subtests, and the TMT Part B Percentile 
Score. The relationship found between treatment adherence and the WMS-III-A 
Logical Memory I and Logical Memory II scores is similar to that reported by Blume 
et al (2005) who found an association between verbal and delayed memory scores on 
the WMS-R and motivation in treatment. 
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The findings for the Alcohol sample suggest that poorer treatment adherence is 
associated with impairments in verbal memory. However, caution should be taken in 
interpreting this result as this was a small sample, and only 2 participants did not 
attend 100% of their scheduled appointments. The greater attendance rates seen in the 
Alcohol sample in the current study corresponds with the literature which has shown 
that individuals in treatment for alcohol have higher levels of adherence (Veach, 
Remley, Kippers, & Sorg, 2000). 
The relation between cognitive impairment and treatment adherence in the 
Drug and Alcohol sample was not formally assessed, as 10 of the 11 participants had 
attended 100% of their two most recent appointments. While no formal analysis was 
conducted, comparison of the data showed that the one participant who had missed an 
appointment did not obtain scores that were noticeably lower than the remainder of 
the sample. This finding suggests that cognitive impairments, as measured in this 
study are not associated with attendance at keyworker appointments in the drug and 
alcohol population.  
The findings for the Alcohol sample in the current study contrast with those 
reported in Experiment 3 and Experiment 4. The results from Experiment 3 suggested 
that poorer treatment adherence was associated with lower levels of treatment 
satisfaction. This differs from the results found for both methadone samples, where 
there was an association between poorer treatment adherence and better psychometric 
test scores. However, it should be noted that the measures associated with poorer 
adherence, while similar, differed across the two methadone samples.  
 
Limitations 
In this study, participants were recruited form CADS, the Salvation Army 
Bridge Programme, and the Needle Exchange Service in Hamilton. Participation in 
the research was available to all individuals who were attending these services 
provided they met the inclusion/exclusion criteria. Individuals from the Community 
Alcohol and Drug Service were recruited between January 2005 and December 2007, 
while the individuals from the Salvation Army Bridge Program and Needle Exchange 
were recruited between January 2007 and December 2007. All participants were 
recruited through information fliers posted at CADS, and through information 
provided by staff to consumers of these services. While the research was available to 
almost all individuals in these services, only 36 individuals agreed to be contacted. Of 
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this 36, 30 completed the research, however, one was excluded from the research due 
to acute cannabis intoxication. As such, the three samples are relatively small, and for 
several reasons may not be representative of the population as a whole.  
Firstly, individuals were recruited on a voluntary basis so would only include 
those individuals who visited the services, or who heard about the research from other 
individuals. Secondly, while 36 individuals agreed to be contacted with regards to 
participation in the research, only those individuals who arrived for the appointments 
could be interviewed. As discussed in Experiments 3 and 4, comparison with 
individuals who did not arrive for their appointments, and a comparison with the 
greater populations would have helped to determine whether the samples were a true 
representation of the populations being studies. As such, the obtained Alcohol and 
Drug and Alcohol samples in this study may only include individuals who attend 
treatment services regularly, and this may be indicative of less severe impairment 
(although this is difficult to determine). The Needle Exchange was included as a 
recruitment location in this study in the aim of recruiting individuals who did not 
attend their appointments at the treatment services, however, none of the participants 
in the Alcohol or Drug and Alcohol samples were recruited through this service. 
Another limitation of the current study was the limitations surrounding the use 
of incentives in attracting participants. Previous research with drug and alcohol 
populations has suggested that financial incentives could be considered as coercion to 
participate as financial incentives could be used to aid continued drug seeking 
behaviour (Cunningham, 1998; Galanter & Kleber, 1999; McCrady & Bux Jr., 1999). 
Despite this, the majority of drug and alcohol research studies provide incentives for 
participation. Being unable to offer any incentives may have decreased the likelihood 
that these individuals would be willing to participate in research.  
One final limitation was the difficultly in identifying adherence to treatment. 
As mentioned in the previous studies, due to the limitations of the information that is 
collected routinely by CADS, adherence was measured by attendance at 
appointments. Therefore, the adherence criteria used in this study may not be a true 
representation of adherence at these treatment services. A link between cognitive 
impairment and treatment adherence may exist, but may not have been found in this 
study due to limitations with the adherence measure.  
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Strengths 
While there were a number of limitations in the current study, there were also 
a number of strengths. The current study assessed the cognitive functioning of several 
different drug and alcohol populations in New Zealand in addition to the methadone 
samples obtained in earlier studies. Little research has been conducted in New 
Zealand previously that has assesses the cognitive functioning of drug and alcohol 
populations, despite evidence that different rates and types of substance use occur in 
New Zealand compared to other countries. Therefore, this research provides 
information about the cognitive impairments of drug and alcohol users in the New 
Zealand populations. 
 As mentioned previously, individuals were not excluded from the current 
unless they were deemed to be intoxicated, or were considered to be mentally unstable 
at the time of assessment. Only one individual was excluded based on these criteria, 
as they were acutely intoxicated at the time of assessment. The minimum exclusion 
criteria used in this study, and in the previous methadone samples, allowed for a truer 
representation of the population being sampled, while also controlling for 
confounding variables such as head injuries and overdoses. As research suggests that 
such variables are common in drug and alcohol populations,  the exclusion of 
individuals with these confounding variables would have reduced the applicability of 
the current findings to the larger drug and alcohol population in New Zealand.  
 The current research also included psychometric measures that have been well 
validated in overseas populations. In addition, Experiment 1 which was conducted to 
assess the utility of the psychometrics in New Zealand, found that the normative data 
for these psychometric measures is applicable within the New Zealand setting. 
Previous research has, at times, used measures that have not been well validated, or 
have not been normed on a representative sample. As such, the psychometric 
measures used in the current research are an improvement on some studies that have 
been reported previously. However, as noted earlier, the small samples sizes do limit 
the application of the findings.  
 
Overall Findings 
 
In the current study, the cognitive functioning of alcohol users, drug and 
alcohol users, and other opiate users were assessed. These results were additionally 
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compared to the results obtained by the methadone samples in order to assess whether 
the impairments found in Experiments 3 and 4 were specific to individuals in MMT, 
or were related to general alcohol and substance use. 
Overall, the findings suggest that all individuals who use alcohol and drugs, 
including those in MMT, have difficulty recalling information in a visual format, and 
recalling information in the short-term. Impairments in these areas may have some 
impact on attendance at appointments, as the association between the WMS-III-A 
Logical Memory I and II subtest and adherence in the Alcohol sample suggests.  
No consistent impairments were reported in the attentional abilities of any of 
the samples, including the methadone samples, however, an analysis of individual 
results showed that a larger number of participants obtained results in the impaired 
range on the TMT Part B Percentile Score. This finding suggests greater difficulty 
with tasks requiring divided attention, and cognitive flexibility which may impact on 
the ability to attend to information in daily life as well as in treatment sessions. In 
addition, scores on the TMT Part B were found to be associated with poorer 
adherence in the Alcohol sample suggesting that divided attention may play a role in 
attendance at appointments.  
One of the most unexpected findings was that all of the samples obtained 
results on the Stroop that were comparable to the normative data. This suggests that 
participants did not have difficulty with controlling impulses, which would suggests 
that these samples would have lower rates of continued substance use or reported 
violent or threatening behaviour. These behaviours may, however, be associated with 
other factors (such as dependence) which may reduce impulse control ability.   
 Obtained results on the WCST-A were inconsistent, with poorer performance 
found for the Drug and Alcohol, Other Opiate, and Methadone samples, but not the 
Alcohol sample. Individual results showed that all samples had participants that 
obtained results in the impaired range. Overall, these findings suggest that drug and 
alcohol use, and opiate use (both methadone and other opiates) is associated with 
greater impairments in problem solving ability. In particular, individuals appear to 
make more errors in problem solving, and have difficulty identifying the correct 
solution to a problem. Impairments on the WCST-A are likely to be associated with 
difficulties in daily life, and also in implementing treatment strategies, however, the 
current study did not find an association between impairment on their measures and 
attendance at appointments.  
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 As mentioned previously, greater treatment satisfaction was found in the 
Alcohol and Drug and Alcohol samples compared to the Combined Methadone 
sample. This finding suggests that treatment dissatisfaction is associated specifically 
with aspects of the MMT program (i.e. prescription of methadone), rather than the 
general service provision provided by these services. This may suggest a need to 
revise aspects of the MMT programme at CADS, although it is noted that national 
guidelines and regulations limit the changes that can be made. Specifically, issues 
such as the inconsistency with which rules are applied, and how decisions are made 
about a clients treatment need to be addressed. 
 
Recommendations 
 Based on the findings from these studies, a number of recommendations can 
be made. Firstly, given that a large number of the individuals in these studies obtained 
lower scores on the measures of memory and problem solving, changes to treatment 
services that accommodate these deficits may be beneficial. For example, providing 
treatment information in several formats, and repetition of this information across 
sessions may promote retention. Reminders regarding appointments may also increase 
adherence in these populations, although it is noted that adherence in the Alcohol and 
Drug and Alcohol sample were better than that seen in the Combined Methadone 
sample. Additionally, skills could be taught in regards to problem solving, and 
working through everyday issues in treatment sessions may promote the use of these 
skills outside of treatment. 
 Further research is also needed to assess the cognitive functioning of these 
populations. While the current study consisted of small samples, the findings do 
suggest impairments in these populations. Further research may be able to elaborate 
on the findings of this research, and examine the link between cognitive impairments 
and adherence to treatment further.  
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GENERAL DISCUSSION 
 
 
  The aim of this research was to explore the cognitive deficits of several 
different drug and alcohol samples in New Zealand, and to assess the association 
between cognitive outcomes and adherence to treatment. Specifically, the research 
included individuals in Methadone Maintenance Treatment (MMT), and individuals 
with a history of alcohol, drug and alcohol, and other opiate use. In order to conduct 
this research, a number of preliminary steps were conducted. 
Firstly, a sample of university students who reported no regular alcohol or 
drug use was recruited from the University of Waikato in Hamilton to determine the 
appropriateness of overseas psychometric norms for use in the New Zealand context. 
The findings of this study (Experiment 1) showed that the normative data provided for 
each of the psychometric measures was applicable in a New Zealand setting. As such, 
the psychometric measures were used in later studies. Additionally, the results of this 
study suggest that the normative data for the administered psychometric tests can be 
used in other research, and in clinical settings within New Zealand. 
In parallel to Experiment 1, a sample of university student who reported 
regular alcohol and/or substance use were recruited from the University of Waikato to 
explore the cognitive deficits of non-dependent alcohol and cannabis users. 
Individuals in this sample were initially recruited as part of Experiment 1 but were 
excluded from this sample based on their alcohol and/or substance use. The findings 
of this study suggested that there was no impairment in the cognitive functioning of 
university students who consume alcohol regularly, however, increased frequency of 
alcohol use was associated with decreased performance on a problem solving task. 
Cannabis use was associated with poorer problem solving ability, and a greater 
frequency of cannabis use was associated with poorer memory functioning.  
The findings for Experiment 2 suggest that while impairments in cognitive 
functioning are seen in longer-term cannabis and alcohol users, these same 
impairments were not apparent in university students with casual use. Frequency of 
use was, however, related to poorer performance on several measures suggesting that 
there is a link between cognitive impairments and alcohol/cannabis use that may 
become more apparent should the university students continue with their current use 
patterns. Additionally, the findings from Experiment 2 showed that the administered 
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psychometric measures were sensitive to the effects of alcohol and drug use in casual 
users.  
 Experiment 3 was conducted to explore the cognitive deficits of a group of 
opiate dependent participants enrolled in MMT, and used the same measures 
administered in Experiment 1. In addition, this study examined the link between 
cognitive functioning and treatment adherence. Findings from this study suggested 
poorer memory, divided attention and cognitive flexibility, and mathematical ability 
in the MMT sample compared to the normative data, however, the mean sample 
scores were within one standard deviation of the normative mean. A relation was also 
found between treatment adherence and satisfaction with treatment, with lower 
satisfaction related to poorer adherence. Cohen’s effect sizes suggested that scores on 
the measures of long-term verbal memory, academic ability with the exception of 
spelling, impulse control, depression, verbal intelligence, and some aspects of 
problem solving were associated with adherence. Surprisingly, however, those 
individuals with poorer adherence obtained better scores on these measures which 
contradicts previous research and suggests a link between poor adherence and 
cognitive impairment. This unusual finding may have been a factor of the adherence 
measure used in this study, although it may have also been attributable to the biased 
sample. 
As mentioned earlier, the findings of Experiment 3 were tentative as the 
sample consisted of only 15 individuals on the MMT programme at CADS in 
Hamilton. Recruitment of participants for this study was particularly poor, and as 
such, following this study the research approach was revised. For follow-up studies 
the number of administered measured was reduced, which subsequently reduced the 
administration time of the battery; additional recruitment locations were also added in 
an attempt to increase the number of participants who volunteered for the research 
(including those who did not regularly attend appointments at CADS); and the 
population being studied was expanded to also include individuals with a history of 
alcohol and drug use who were not on the MMT programme. These changes to the 
research approach resulted in two further samples – an additional sample of 
individuals in MMT, and a sample of drug and alcohol users who were not in MMT. 
 Experiment 4 reported on the Second Methadone sample obtained through 
recruitment at CADS and at the Needle Exchange in Hamilton. Despite the changes to 
the research approach, this sample was also small (14 participants) although findings 
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paralleled those found for the initial methadone sample in Experiment 3. The one 
exception to this was the there was no relation between any of the administered 
measures and adherence to treatment (although effect sizes did suggest possible 
relations). Cohen’s effect sizes in this sample also suggested that poorer adherence 
was associated with better scores on long-term visual memory, simple attention, and 
aspects on problem solving ability, although the effect sizes suggested different 
associations compared to those found in Experiment 3.  
 In parallel to Experiment 4, Experiment 5 explored the cognitive deficits of 
drug and alcohol participants including a sample of individuals in treatment for 
alcohol use, a sample in treatment for drug and alcohol use, and a sample of 
individuals who used, or had a history of, opiates other than methadone (both in an 
out of treatment). This study was conducted with the intention of seeing if the 
cognitive deficits found for both the MMT samples were unique to individuals on 
MMT, or were evident in other drug and alcohol populations. The findings from this 
study showed that all samples had poor memory ability, in particular visual memory; 
and that a large number of individuals in the samples had impairments in divided 
attention and cognitive flexibility. These results were similar to those obtained by the 
methadone samples in Experiments 3 and 4. In addition, the samples were comparable 
to the methadone samples in that no impairment was found in inhibition and impulse 
control, although the samples differed in problem solving ability. On the measure of 
problem solving, the alcohol sample showed the least impairment, followed by the 
methadone, drug and alcohol, and other opiate samples in that order.  
 A comparison of the data from the samples in Experiment 5 to the data of the 
methadone samples showed that treatment satisfaction was significantly lower in the 
Methadone sample compared to both the Alcohol and Drug and Alcohol samples. 
This suggested that treatment dissatisfaction is related to specific aspects of MMT. 
For example, issues with daily dosing, and the implementation of treatment rules and 
regulations were commonly raised as issues of contention. These findings were, 
however, not specifically attributable to the MMT programme at CADS as previous 
research has reported similarly rates of satisfaction in other MMT populations 
(Deering et al., 2003; National Treatment Agency for Substance Misuse, 2007; 
Simpson, Joe, & Brown, 1997; Strang et al., 2000; Villafranca, McKellar, Trafton, & 
Humphreys, 2005). Therefore, a review of the delivery of MMT services is warranted 
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to assess the reasons for poor satisfaction further, and to identify changes that could 
be implemented to resolve these issues. 
Based on the findings from the methadone samples in Experiments 3 and 4, 
and the drug and alcohol samples collected in Experiment 5 a number of 
recommendations were made. Firstly, given the cognitive impairments that were 
shown in these samples it was recommended that services adapt their treatment 
approach to accommodate these deficits. For example, simplifying information to 
reduce attentional difficulties associated with divided attention, repeating information 
within and across sessions to help with recall of this information, and teaching 
approaches to solving problems may reduce the impact of deficits in these areas. In 
addition, it was recommended that providing reminders regarding appointments may 
improve treatment adherence in treatment services, and also result in better treatment 
outcomes.  
 Specifically in regards to methadone maintenance treatment, a number of 
additional recommendations were made based on the results of the TPQ. On the TPQ, 
the methadone samples were found to be significantly less satisfied with treatment, 
with participants outlining a number of areas in which treatment could be improved. 
Based on these comments it was recommended that treatment services address the 
inconsistency with which rules are applied (e.g. number of takeaway doses, 
consequences for not applying with treatment regulations), and that individuals in 
MMT are included in decisions regarding their treatment. 
 The relation between the adherence and psychometric tests results in the 
current research did not follow the pattern expected for the methadone samples. While 
the findings from Experiment 3 suggested that poorer adherence was associated with 
lower levels of treatment satisfaction, this finding was not replicated in Experiment 4. 
Results for both methadone samples suggested that poor adherence was associated 
with better test performance, although the two samples did not obtain the same results 
with regards to the measures on which individuals had better performance. Therefore, 
the results for the methadone samples suggest that the adherence measure in the 
current research may not have represented adherence to treatment effectively, or 
alternatively, that the samples did not capture those individuals who did not attend 
appointments.  
Adherence as measured for the Alcohol sample did, however, show that 
poorer adherence was associated with impairments in verbal memory, and sustained 
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attention, although the sample contained few individuals with poor adherence. The 
relation between treatment adherence and psychometric measures for the Alcohol 
sample suggest that adherence to treatment in drug and alcohol samples other than 
MMT may be measurable by the adherence measures used in this research. 
Overall, findings for this research suggest that individuals in MMT 
programmes do have cognitive deficits; however, these deficits do not appear to be 
specific to those individuals in MMT programmes, as similar impairments were found 
in other drug and alcohol samples. When the results for the methadone samples in the 
present research were compared to overseas samples, the current methadone samples 
generally obtained scores that were less suggestive of clinically significant 
impairment. The findings for the methadone samples in this research suggest that 
there may be differences in the impairments seen in MMT populations in New 
Zealand, and that any impairments that are identified, may not be as severe as those 
found overseas. Future research with larger samples would be able to examine the 
findings of this research further. 
One possible reason for the noted differences between the current methadone 
samples and those studied overseas is the variation in substances that are available. As 
mentioned previously, the incidence of heroin use is substantially lower than that seen 
in overseas countries, while the rates of cannabis use have been reported as higher 
(Field & Casswell, 1999; New Zealand Health Information Service, 2001; Wilkins, 
Casswell, Bhatta, & Pledger, 2002). Other demographic factors may have influenced 
the findings of the present study. For example, the higher premorbid IQ levels 
reported in the initial methadone sample may suggest better premorbid functioning 
rates that overseas which may mean that decreases in functioning are not as 
noticeable.  
As mentioned previously, there were a number of issues encountered in the 
present research. While these have been discussed briefly following each of the 
Experiments, these are discussed in more detail in the following section. 
Throughout the research, difficulties with recruitment were encountered. 
Recruited samples were smaller than anticipated, despite recruitment over several 
years and changes to the research approach which aimed to increase participation. 
Specifically, the small number of individuals recruited in Experiments 3, 4 and 5 may 
be attributable to a number of factors. During the recruitment periods of this research 
there were a number of changes to the staff at CADS. The newly employed staff were 
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not always aware of the research, and staff changes also created disruption for the 
individuals in this service. As a result of the keyworker changes, the individuals may 
have been less likely to volunteer to participate in the present research.  
Alternatively, the recruitment difficulties may simply indicate that alcohol and 
drug populations, and specifically MMT populations, do not readily volunteer for 
research. Individuals in these populations may be uninterested in research, or 
concerned that participation would lead to the identification of impairments in their 
functioning, and potential stigma associated with these impairments. Equally, a 
distrust of researchers and concern over how the findings of the research would be 
used, or difficulties attending appointments in order to participate in the research may 
have contributed to the poor recruitment rate. 
Previous research studies have used incentives to encourage research 
participation, or have incorporated research into the existing treatment programmes. 
These approaches appear to be more successful in recruiting participants, and as such, 
may be a more effective approach to the recruitment of individuals within the drug 
and alcohol field. However, issues have been raised regarding the use of incentives in 
participant recruitment. In the current research, minimal incentives (i.e., coffee and 
biscuits) were offered to increase participation in the research. This limitation was put 
in place by the Ethical Committees that approved this research, due, in part, to 
previous research findings which have suggested that financial incentives for 
participation could be considered as coercion as they may aid the continued drug 
seeking behaviour of many substance using individuals (Cunningham, 1998; Galanter 
& Kleber, 1999; McCrady & Bux Jr., 1999). Therefore, the lack of monetary 
incentives offer in this research, may have contributed to the recruitment difficulties. 
Incorporation of the research into the treatment programmes that participants were 
enrolled in was not within the scope of this research. 
The findings, in relation to treatment adherence, for the participants recruited 
for this research may have been biased, as only those individuals who arrived for 
assessment appointments were able to be interviewed,. Therefore, the samples may 
represent only those individuals who regularly attend treatment appointments. 
Inclusion of the Needle Exchange in Experiment 3 was unsuccessful in rectifying this 
imbalance. 
In addition to the potentially biased sample, the measures of adherence used in 
this research may have affected the findings, and the lack of significant findings when 
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treatment adherence was assessed in relation to the psychometric measures. In the 
current research, adherence in the MMT sample was assessed by attendance at 
doctor’s appointments and number of missed methadone doses. These two adherence 
measures were chosen as this information was the only information routinely 
collected by CADS. Given that adherence to treatment incorporates aspects other than 
attendance at appointments, the measure of adherence used in this research is likely to 
have under-reported adherence in this sample. In addition, the number of missed 
doses as an adherence measure was found to be ineffective as none of the methadone 
participants had missed a dose of methadone within the last month. Again, this may 
suggest a bias in the sample, or it could be that individuals who miss methadone doses 
are not retained in the MMT programme. Given the limitations with both the 
adherence measures, and sample sizes in the current research, future research is 
warranted, with larger samples and with more robust adherence measures. At present, 
a large variety of adherence measures are used when researching this area. This lack 
of consistency across these studies makes this a difficult task. Therefore, future 
research that aims to develop a robust measure of treatment adherence for use with 
drug and alcohol populations would address this issue. 
In addition to the issues surrounding the effectiveness of the adherence 
measures, the validity of the results obtained on two of the psychometric measures 
used in this research are questionable. While the majority of psychometric measures 
used in the present research were effective in identifying deficits associated with 
alcohol and/or substance use, the findings on the BAI and BDI-II raised some 
concerns. While the findings in Experiment 3 using the BAI and BDI-II suggested that 
the initial methadone sample had elevated rates of both anxiety and depression 
compared to the normative population, a review of the literature, and discussions with 
the participants in this study highlighted that a number of the common side effects of 
methadone resemble symptomology assessed by these measures. For example, the 
BAI assesses symptoms of sweating, difficulty breathing, dizziness or light-
headedness, and the BDI-II similarly assesses aspects such as changes in sleep 
patterns, and loss of interest in sex. All of these are commonly reported side-effects of 
methadone. Thus, it is difficult to determine if the reported symptoms on the BAI and 
BDI-II represent symptoms of anxiety and depression, or the result of the methadone 
treatment. Additionally, this finding suggests that high rates of benzodiazepine 
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prescription for this population may be the result of methadone side-effects that have 
been misdiagnosed as anxiety. 
Overall, the findings from this research suggest that cognitive impairments are 
associated with drug and alcohol use in the New Zealand population. The current 
research, however, failed to find a relationship between these cognitive impairments 
and adherence to treatment in all but the Alcohol sample. As these findings contrast 
with those found previously in research overseas, further research is needed to explore 
these results in a New Zealand population. Additionally, future research could look at 
the difference between the demographics, and drug and alcohol use of New Zealand 
and overseas samples, and how these differences may account for the differing results.  
The findings of the present study also suggest other directions for future 
research. In particular, future research could address the issues surrounding 
participant research, and aim to develop methods that allow a larger, and more 
representative sample of the population to be obtained; the need for a reliable and 
robust measure of adherence to treatment; and the limitations of using some 
psychometric measures with drug and alcohol populations. 
With regard to treatment satisfaction, the current research has highlighted 
issues that need to be addressed within the current treatment settings, and considered 
in the development of new treatment options.  
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APPENDIX I 
 
Research Participants Needed! 
 
Ever wondered what tests psychologists use? Or just wanted to see what 
research students do? If so read on …. 
 
Hi, my name is Susan and I am a PhD student at the University of Waikato. I 
am looking for people who would be willing to complete some tests 
designed to test memory, attention, language and other cognitive functions. 
In other words, the tests examine how you remember things (like times, 
dates, experiences), how you plan and organise your time, how you solve 
problems, and how good your attention span is etc. I will also be asking 
some questions about your medical status, psychological status, drug and 
alcohol history and if you have ever had any head injuries. 
 
Participation in this research would require approximately 2 hours of your 
time to complete a number of psychometric tests which you would get 
course credit for (up to 5%) if you are in 102 or 103.  
 
If you are interested in participating in this research you can leave your 
name and contact details on this sign up sheet at the Psychology office. If 
you have any questions first you can email me on sjy1@waikato.ac.nz or 
leave a message at (07) 838 4080 ext. 4755. Alternately, you can contact my 
supervisors (Mary Foster and Nicola Starkey) if you have any questions or 
you can contact the convenor of the Research and Ethics Committee at the 
University of Waikato if you have any concerns about this research. 
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APPENDIX II 
 
 
Consent Form 
 
Testing of memory, attention, language and other 
cognitive areas 
 
 
I have read and I understand the information sheet for volunteers taking part in the study 
designed to test memory, attention, language and other cognitive functions. I have been 
given the opportunity to discuss the research. I am satisfied with the answers I have been 
given. I have also been given a copy of the information sheet with contact details of the 
researcher if I wish to ask any questions at a later stage. 
 
I understand that taking part in this research is voluntary (my choice) and that I may 
withdraw from the study at any time. I understand that my participation in this study is 
confidential and that no material which can identify me will be used in any reports on this 
study. 
 
 
 
I  ______________________________________ hereby consent to take part in this 
research. 
 
 
Signed __________________________________ Date ____________________ 
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APPENDIX III 
 
 
Demographic Information 
 
Gender: 
 
Age: 
 
Ethnicity: 
 
Handedness: 
 
Academic achievement: 
 -  highest level attained: 
 
Number of Languages spoken (and is English first/second/third) 
 
 
 
Medical Information 
 
Do you have any major medical conditions? (eye conditions, hearing difficulties) 
 
Are you taking any prescription medication on a regular basis? 
 
Have you previously been hospitalised for a medical condition? If yes: 
 
- what for and how long? 
 
- any surgery (e.g. open heart) 
 
Have you previously had any head injuries? If yes: 
 
how many? 
 
How long were you unconscious? 
 
Did you require hospitalisation? 
 
Have you ever been treated for psychological or emotional problems? If yes: 
 
- diagnosis if known 
- was this in the last 30 days? 
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Drug and Alcohol Information 
 
Are you presently using any substance or alcohol on a regular basis? If yes, what? 
 
e.g.  
 
   Ever Used Age of First Use Frequency of Use 
 
Alcohol 
 
Opioids  
 
Benzodiazepines 
 
Cannabis 
 
Hallucinogenics 
 
Inhalants 
 
Nicotine 
 
Amphetamines 
 
Other 
 
If yes, how many times in the past week? 
 
If yes, how many times in the past 24 hours? 
 
Have you previously, or continue to receive treatment for drugs or alcohol? 
 
Have you ever had to be hospitalised due to an overdose resulting from alcohol or 
substance use? If yes: 
 
What substance did you overdose on? 
 
Did you become unconscious? If yes, for how long? 
 
How long were you required to stay in hospital? 
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APPENDIX IV 
 
 
 
Testing of memory, attention, language and 
other cognitive areas 
 
 
 
Thank-you for participating in this research. If you decide at a later stage that you have 
any further questions about this research you can email me on sjy1@waikato.ac.nz or 
leave a message at (07) 838 4080 ext. 4755. Alternately, you can contact my supervisors 
(Mary Foster and Nicola Starkey) if you have any questions or you can contact the 
convenor of the Research and Ethics Committee at the University of Waikato if you have 
any concerns about this research. 
 
Alternately, if you have any questions or concerns about  
• your own drug and/or alcohol use 
• someone else’s drug and/or alcohol use 
• your own mental health 
• someone else’s mental health 
  
You can contact  
• Community Alcohol and Drug Service, 40 Clarence Street (07) 839 4352 
• The Drug Helpline (0800) 787 797 
• Webhealth – www.webhealth.co.nz  
 
And thanks again for participating in this research. 
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PPENDIX V 
 
Using Recreational Drugs? 
 
Do you currently use any recreational drugs? 
If so read on …. 
 
Hi, my name is Susan and I am a PhD student at the University of 
Waikato. I am looking for people who currently use recreational drugs who would be 
willing to complete some tests designed to measure memory, attention and other 
cognitive functions. In other words, the tests examine areas like how you remember 
things (like times, dates, experiences), how you plan and organise your time, how you 
solve problems, and how good you attention span is. I will also be asking questions about 
your medical status, psychological status, drug and alcohol history and if you have 
had any head injuries. 
 
Participation in this research would require approximately 45 minutes of your time to 
complete a number of psychological tests which you would get 1 course credit for if you 
are in 102 or in 103. 
If you are interested in participating in this research you can: 
- leave your name and contact details on the sign up sheet at the 
Psychology office 
- you can email me on sjy1@waikato.ac.nz 
- you can call me on (07) 838 4755 
- Or just pop past K1.04 and ask for Susan. 
 
Other queries regarding this research can also be directed to Mary Foster & Nicola 
Starkey, or you can contact the convenor of the Research and Ethics Committee at the 
University of Waikato if you have any concerns regarding the research. 
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APPENDIX VI 
 
Community Alcohol & Drug Service - METHADONE CONTRACT 
 
Clients: 
When you join the Methadone Programme you agree to certain conditions. Please read 
the following information carefully, if you have any questions please ask the Centre staff. 
 
Starting the programme: 
 
I …………………………………………………………… agree 
 
To provide my true name and address (residential & postal) with ID – either a passport or 
birth certificate. 
To being observed for up to four hours after the first dose of Methadone. 
To consume on Pharmacy premises daily for at least 3 months. 
To undergo routine examination and blood tests and urinanalysis as required on 
admission.  
 
Appointments: 
 
I ………………………………………………………….. agree 
To keep all appointments with Doctors and Counsellors. 
 
What if I am unable to keep an appointment? 
 
It is your responsibility to ring the Centre within 48 hours and make another time. 
 
What if I miss a 3 monthly review appointment? 
 
It is your responsibility to advise the centre at least 48 hours beforehand if you are unable 
to attend. Should you miss the appointment without giving the necessary notice you will 
be required to consume methadone daily until you attend your next appointment.  
 
What if I miss 2 consecutive appointments? 
 
Your prescription will be stopped. The Medical officer is required by law to see you at 
least every three months in order to prescribe Methadone. If you fail to attend a review 
appointment, your Methadone prescription will be stopped on the day of your next 
appointment. 
Centre staff can be reached during office hours 8.30 – 5pm. 
If you want to leave a message after hours use the Centre night answer phone. Do not 
ring staff at home or other places of work such as Doctor’s surgeries. 
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Centre staff agree to: 
 
Treat you in a professional and courteous manner. 
Give you medical and counselling appointments. 
Provide you with HIV/AIDS testing (with your consent) as well as general medical 
testing, including Hepatitis C and B testing. 
Arrange long term transfers to other centres -  as long as you give appropriate notice and 
as long as you are accepted by the Centre (there are no guarantees) 
Discuss changes in your Methadone dosage with you. 
Keep personal details confidential – any information about you will only be shared with 
health professionals when it is necessary for your treatment. We need your permission to 
share information with anybody else unless there is significant risk to you or others. 
 
Appropriate Behaviour at the Centre: 
 
Centre staff have undertaken to treat you in a polite and professional manner. 
 
I ……………………………………………….………….. agree that my behaviour at the 
centre will be courteous and co-operative.  
 
Any from of violence towards Centre staff, or other clients at the Centre, will not be 
tolerated. If you behave in a violent way (this includes verbal threats) your case will be 
reviewed and you may be discharged from the programme. 
 
Theft of property or damage to property in, or around the centre will not be tolerated 
either. If you behave in this way your contract will be reviewed and you may be 
discharged from the programme. 
 
Takeaway Methadone: 
 
I …………………………………………………………… agree 
 
Not to inject the takeaway Methadone or to supply the takeaway methadone to anyone 
else. (To ensure methadone is kept in a safe place and out of reach of children) 
To accept responsibility for my takeaway Methadone, I understand that if the Methadone 
is dropped, stolen, vomited or lost – it will not be replaced. 
To give Centre staff 48 hours notice if I want takeaway Methadone, and 2 weeks notice 
for a planned holiday. I understand that the whole team makes decisions about who may 
get takeaways. This decision will depend on my general progress and whether I have 
used takehome Methadone safely in the past. 
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Ongoing Treatment: 
 
I ……………………………………………………………. agree 
 
Not to sell or exchange drugs, or set up drug deals on centre premises and pharmacy 
premises.  
Not to use intoxicating drugs in or around centre property (this includes smoking 
cannabis) 
No dogs on service premises. 
Not to get intoxicating drugs from other Doctors. If I do, my contract will be reviewed 
and I may be discharged from the programme. 
To provide urine samples as required. Sometimes these will need to be provided under 
observation. 
To tell Centre staff if my address (Residential and Postal) and telephone number change. 
Not to be involved in serious drug related criminal activities, this includes burglary of 
chemist/Dr Surgery, serious drug related charges etc. (see involuntary discharge section). 
Evidence of this may result in countdown and discharge from the programme. 
 
Taking your Methadone at a pharmacy: 
 
The pharmacist agrees to carry out the dispensing of Methadone prescriptions in a polite, 
professional manner. 
 
I …………………………………………………………… agree    
 
To let the pharmacist supervise me taking the Methadone in the pharmacy. 
To regularly pick up Methadone at the pharmacy. 
 
Failure to pick up for two consecutive days will result in your script being cancelled: 
 
You must tell the centre if you won’t be picking up your methadone. If you don’t do this, 
and don’t attend the pharmacy for two days in a row, the pharmacist will be advised not 
to give you any more. 
 
Not to discuss my Methadone dosage ad pickup arrangements with the pharmacist (ask 
centre staff) 
To behave in an acceptable manner in the pharmacy 
 
What will happen if I don’t behave in an acceptable manner? 
 
The pharmacist will inform the Centre and/or the police of any disorderly behaviour in 
the pharmacy. The pharmacist also has the right to refuse to dispense your Methadone. If 
the pharmacist refuses to dispense your Methadone it’s your responsibility to find another 
listed pharmacy who would be prepared to do it. 
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Disorderly behaviour includes threats, verbal abuse, shop lifting, violence, drug diversion 
or any other type of behaviour which would be unacceptably disruptive or offensive to 
staff or customers. 
 
Do not go to the pharmacy intoxicated by drugs or alcohol 
 
What will happen if I do go to the pharmacy intoxicated? 
 
The pharmacist won’t give you your Methadone. The Pharmacist will telephone the clinic 
and tell staff what has happened and direct you back to the clinic.  
 
If you fail to keep this contract the Team will review your contract which may result in 
count down and discharge from the programme. 
 
 
 
 
 
 
Clients Signature: ..………………………………….. Date: …………………… 
 
 
 
 
Doctors Signature: ………………………………….. Date: …………………… 
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APPENDIX VII 
 
New Research at CADS!!! 
 
Hi, my name is Susan and I am a PhD student at the University of Waikato. I am wanting 
to do research with individuals on the Methadone Maintenance Treatment program 
(MMT). What this means is that we would like you to participate in some tests to see how 
you remember things (like times, dates, experiences), how you plan and organise your 
time, how you solve problems, and how good your attention span is etc.  
 
Research in this area suggests that some people on methadone programs may have 
trouble with various aspects of thinking and decision making.  Other research has found 
that some methadone users have trouble with their attention span, remembering things 
(like what someone’s name was they have just met), and have difficulty solving 
problems. Another group of researchers found that the methadone users they studies 
seemed to show problems with planning (like deciding what order to do things in) and 
organisation (making sure you get everything done on time, making it to appointments on 
time).  
 
Research suggests that these problems with how well you can do tasks may interfere with 
your daily life and how well you feel that your life is going. As you can see, there’s lots 
of conflicting evidence, and it’s really difficulty to try and work out the reasons why 
some people have difficulties and some don’t. 
 
We want to try and figure out what problems the methadone population is having in 
Hamilton and would like to get people to do tests to find this out. We also want to see if 
any of these difficulties (like not remembering things) are linked to not turning up to 
appointments, collecting scripts, or staying on the methadone program.  
 
The type of tests we want to use are not scary (no blood tests, no heavy machinery!), and 
are things like problem solving tasks, memory skills, and pencil and paper tests (a bit like 
school, but we won’t be giving you a grade on it). We would also like to know what you 
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think of the methadone program and if you think there is anything we could do to 
improve it. Hopefully all this will take no more than two hours, but if you have some 
spare time (as this part will require more of your time) we would also like to ask you 
some questions about your mood, previous drug use, medical history, legal history and 
employment history.   
 
We hope that this research will help us to better understand people on methadone and 
make services more accessible. In addition, it is hoped that this research will help 
individuals by identifying difficulties they have and suggesting changes to present 
services to help in these areas. 
 
We would like to know what you think about the research, if you have any concerns and 
if you think people on the methadone program would be interested in taking part. You 
can contact Susan or Vicki through CADS (07 839 4352). If you are interested in taking 
part in this research you can ask any of the staff at CADS about how to sign up. 
 
 
REFRESHMENTS AVAILABLE 
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APPENDIX VIII 
 
Testing of memory, attention, language and other  
cognitive areas of individuals on Methadone  
Maintenance Treatment. 
 
 
About the research: 
Hi, my name is Susan and I am a PhD student at the University of Waikato. I am wanting 
to do research with individuals on the Methadone Maintenance Treatment program 
(MMT). What this means is that we would like you to participate in some tests to see how 
you remember things (like times, dates, experiences), how you plan and organise your 
time, how you solve problems, and how good your attention span is etc.  In addition, we 
would like to get your opinion on reasons for not making appointments, difficulties 
making use of keyworker sessions, and managing your methadone. It will take 
approximately 2 hours of your time to participate in this research. 
 
In addition to this (for those people that are interested and have the time) we would like 
to ask you questions about your mood, previous drug use, medical history, legal history 
and employment history. 
 
The type of tests we want to use are not scary (no blood tests, no heavy machinery!), and 
are things like problem solving tasks, memory skills, and pencil and paper tests (a bit like 
school, but we won’t be giving you a grade on it). We also want to know what you think 
of the methadone program and if you think there is anything we could do to improve it.  
 
We hope that this research will help us to better understand people on methadone and 
make services more accessible. In addition, it is hoped that this research will help 
individuals by identifying difficulties they have and suggesting changes to present 
services to help in these areas. 
 
Your participation: 
You do not have to take part in this research at all if you do not want to.  You can also do 
part of the study but do not have to do all of it. At any time in the study, you can change 
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your mind and not answer questions or choose not participate. Participation or non-
participation in the research will not adversely affect any present or future treatment that 
you receive. In other words if you don’t want to be part of the research you will keep 
receiving your methadone just like before.  
 
All the information you tell us will remain confidential, although with your consent may 
be discussed with staff at CADS. However, if you tell us that you are thinking of hurting 
yourself or someone else we will have to talk to other staff members about this. Whatever 
you tell us will not affect whether or not you can or cannot get services, so your honesty 
is appreciated. 
 
Results of the study: 
We will discuss a summary of the results of your testing with you if you would like. 
Also, if it is okay with you we would like to discuss you results with other staff members 
at CADS and put the results of your testing in your case notes. 
 
All results from this study will be anonomised, and individuals will not be identifiable, as 
the results will be reported on as a group.  Results from this research will be published, 
presented at conferences, and also presented at the Methadone Consumer Group meeting. 
A summary report at the end of the research can be provided for access by CADS 
consumers if you would like. 
 
How to contact us: 
If you are not happy about anything relating to this study or if you want to discuss your 
participation in the study, please contact Susan Yates c/o Community Alcohol and Drug 
Service, Hamilton on (07) 839 4352.  Alternately, you can contact Vicki Barratt c/o the 
same phone number or Mary Foster/Nicola Starkey at the University of Waikato at (07) 
838-4466. If you are wanting to discuss or voice any concerns about the research you can 
also contact the Health Advocacy on 0800 423638. 
 
Approval:  
This study has receiving ethical approval from The University of Waikato Ethics 
Committee and the Waikato Ethics Committee. 
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APPENDIX IX 
 
Testing of memory, attention, language and other 
cognitive areas of individuals on Methadone 
Maintenance Treatment. 
 
 
 
I have read and I understand the information sheet for volunteers taking part in the study designed 
to test memory, attention, language and other cognitive functions. I have been given the 
opportunity to discuss the research. I am satisfied with the answers I have been given. I have also 
been given an information sheet with contact details of the researcher if I wish to ask any 
questions at a later stage. 
 
I agree for the researcher to review my relevant medical records and case notes for the sole 
purpose of gaining information for this study and to conduct a follow-up study in approximately 6 
months time. I also understand that the researcher will record in my case notes that I have 
participated in this research.  
 
I understand that taking part in this research is voluntary (my choice) and that I may withdraw 
from the study at any time and that this will in no way affect my present, or any future treatment. 
I understand that my participation in this study is confidential and that no material that can 
identify me will be used in any reports on this study. 
 
As part of the research I understand that I will participate in some testing of things like memory, 
attention, and language. I would like to be informed of the results of my testing         YES/NO 
I agree for the results of my testing to be included in my case notes          YES/NO 
I agree for my GP or other current provider to be informed of the results of my participation in 
the research                          YES/NO 
 
I ___________________________________________ hereby consent to take part in this 
research. 
 
Signed _____________________________   Date ________________ 
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Demographic Information 
Participant No: ___________________  Date of Interview: ____________ 
Time of Administration: ____________  Time on MMT: ______________ 
Present methadone dose: ____________  Gender: __________    
Age: __________     Ethnicity: ___________________  
Academic achievement: _____________  Handedness: _________________ 
 
Medical Information 
Have you previously had any head injuries? __________ 
- How many? ____________ 
- How long were you unconscious? ____________ 
- Severity/did you require hospitalisation? ____________ 
 
Drug & Alcohol Use 
Age at onset of drug use:__________  Age at onset of opioid use: ____________ 
      Length of time using opiates: __________ 
Have you ever overdoses: _________  
- How many? ______________ 
- Severity/did you require hospitalisation? ____________________ 
Use of substances in last 48 hours (other than methadone): ________________________ 
 
Psychiatric 
Curent Diagnoses: 
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Date __________________ 
 
To Whom It May Concern: 
 
Please note that ___________________________________ has recently participated in a 
research project conducted at Community Alcohol/Drug Service designed to assess the 
cognitive functioning of individuals receiving Methadone Maintenance Treatment. As 
part of the research they completed the following test: 
 
Wechsler Memory Scale-III-abbreviated     
Trail Making Test      
Stroop Color and Word Test   
Wisconsin Card Sorting Test-abbreviated    
Wechsler Individual Achievement Test-II-abbreviated  
Beck Depression Inventory-II    
Beck Anxiety Inventory      
National Test of Adult Reading  
 
If participants agreed to a record of their results being kept by Community Alcohol/Drug 
Service these results will be available at the end of the Research for review by qualified 
professionals.  
 
Has the participant agreed for a record of their results to be kept on file at Community 
Alcohol/Drug Service        YES/NO 
 
Should you have any questions regarding the results prior to the completion of this 
research please contact Susan Yates on (07) 838 4755. 
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APPENDIX XII 
 
 
Testing of memory, attention and other cognitive areas of 
individuals on Methadone Maintenance Treatment 
 
 
About the research: 
Hi, my name is Susan and I am a PhD student at the University of Waikato. I am wanting 
to do research with individuals on the Methadone Maintenance Treatment program 
(MMT). What this means is that we would like you to participate in some tests to see how 
you remember things (like times, dates, experiences), how you plan and organise your 
time, how you solve problems, and how good your attention span is etc. In addition, we 
would like to ask you questions about your previous drug use and previous treatment for 
drug and alcohol use that you may have received. It will take approximately 45 minutes 
of your time to participate in this research. 
 
The type of tests we want to use are not scary (no blood tests, no heavy machinery!), but 
are things like problem solving tasks, memory skills, and pencil and paper tests (a bit like 
school, but we won’t give you a grade on it!). We also would like to know what you think 
of the treatment services available at the Community Alcohol & Drug Service and if you 
think there is anything we could do to improve it. 
 
We hope this research will help us better understand people who use substances and 
make treatment services more accessible. In addition, it is hoped that this research will 
help individuals by identifying difficulties they are having and suggesting changes to 
present services to help in these areas. 
 
Your participation: 
You do not have to take part in this research at all if you do not want to. You can also do 
part of the study but do not have to do all of it. At any time in the study, you can change 
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your mind and not answer questions or chose not to participate. Participation or non-
participation in the research will not adversely affect any present or future treatment that 
you receive. In other words if you don’t want to be part of this research you will continue 
receiving the same treatment that you already receive. 
 
All the information you tell us will remain confidential, although with your consent may 
be discussed with staff at CADS. Whatever you tell us will not affect whether or not you 
can or cannot get services, so your honesty is appreciated. 
 
Results of the study: 
We will discuss a summary of the results of your testing with you if you would like. 
Also, if it is okay with you we would like to discuss the results with other staff members 
at CADS and put the results of your testing in your case notes. 
 
All results will otherwise be anonomised, and individuals will not be identifiable, as 
results will be reported on as a group. Results from this research will be published, 
presented at conferences, and also presented at the Methadone Consumer group meeting, 
A summary report at the end of the research can be provided at the end of the research 
can be provided for access by CADS consumers if you would like. 
 
How to contact us: 
If you are not happy about anything related to this study, or if you want to discuss your 
participation in this study please contact Susan Yates on (07) 838 4755. Alternatively you 
can contact Mary Foster or Nicola Starkey at the University of Waikato on (07) 838 
4466. If you are wanting to discuss or voice any concerns about the research you can also 
contact Health Advocacy on 0800 423 638. 
 
Approval: 
This study has received ethical approval from the University of Waikato Ethics 
Committee and the Northern Y Regional Ethics Committee.  
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Testing of memory, attention and other cognitive areas of 
individuals on Methadone Maintenance Treatment 
 
 
I have read and I understand the information sheet for volunteers taking part in the study 
designed to test memory, attention, language and other cognitive functions. I have been 
given the opportunity to discuss the research. I am satisfied with the answers I have been 
given. I have also been given an information sheet with contact details of the researcher if 
I wish to ask any questions at a later stage. 
 
I agree for the researcher to review my relevant medical records and case notes for the 
sole purpose of gaining information for this study. I also understand that the researcher 
will record in my case notes that I have participated in this research.  
 
I understand that taking part in this research is voluntary (my choice) and that I may 
withdraw from the study at any time and that this will in no way affect my present, or any 
future treatment. I understand that my participation in this study is confidential and that 
no material that can identify me will be used in any reports on this study. 
 
As part of the research I understand that I will participate in some testing of things like 
memory, attention, and language. I would like to be informed of the results of my testing  
        YES/NO 
I agree for the results of my testing to be included in my case notes          YES/NO 
I agree for my GP or other current provider to be informed of the results of my 
participation in the research                         YES/NO 
 
I ___________________________________________ hereby consent to take part in this 
research. 
 
Signed _____________________________   Date ________________
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Date ________________ 
 
To Whom It May Concern: 
 
Please note that _____________________________________ has recently participated 
in a research project conducted at the Community Alcohol & Drug Service in Hamilton 
designed to assess the cognitive functioning of alcohol and substance users. As part of the 
research they completed the following tests: 
 
Wechsler Memory Scale-III-Abbreviated 
Trail Making Test 
Stoop Colour & Word Test 
Wisconsin Card Sorting Test 
 
If participants agreed to a record of their results being kept by the Community Alcohol & 
Drug Service, these results will be available at the end of the research for review by 
qualified professionals. 
 
Has the participant agreed for a record of their results to be kept on file at the Community 
Alcohol & Drug Service                   YES/NO 
 
Should you have any questions regarding the results prior to the completion of this 
research please contact Susan Yates on (07) 838 4755. 
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Hi, my name is Susan and I am a PhD student at the University of Waikato. I am wanting to do 
research with individuals who attend the Community Alcohol & Drug Service in Hamilton. What 
this means is that we would like you to participate in some tests to see how you remember things 
(like times, dates, experiences), how you plan and organise your time, how you solve problems, 
and how good your attention span is etc. In addition, we would like to ask you questions about 
your previous drug use and previous and current treatment for drug and alcohol use. It will take 
approximately 45 minutes of your time to participate in this research. 
 
Research in the drug and alcohol field suggests that individuals who use substances may 
experience difficulties with remembering things, planning and organising their time, and solving 
problems. As such we want to try and figure out what problems the substance using population is 
having in Hamilton and would like to get people to do tests to find this out. We also want to see if 
any of these difficulties (like not remembering things) are linked to not turning up to 
appointments, collecting scripts or staying in treatment. 
 
The type of tests we want to use are not scary (no blood tests, no heavy machinery!), but are 
things like problem solving tasks, memory skills, and pencil and paper tests (a bit like school, but 
we won’t give you a grade on it!). People have actually said these are quiet fun to participate in. 
Participation in this research would require approximately 45 minutes of your time, and drinks 
and food will be provided for those that are interested. 
 
We hope this research will help us better understand people who use substances and make 
treatment services more accessible. In addition, it is hoped that this research will help individuals 
by identifying difficulties they are having and suggesting changes to present services to help in 
these areas. 
 
If you would like to find out more about the research, or if you would be interested in taking part 
you can contact Susan on (07) 838 4755. If you have any concerns about the research you can 
also contact the Health Advocacy Service on Health 0800 423 638 or the convenor of the 
Research and Ethics Committee at the University of Waikato (Dr Robert Isler, phone: 838 4466 
ext. 8401, e-mail r.isler@waikato.ac.nz).    
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Research Participants Needed  
 
Hi, my name is Susan and I am a PhD student at the University of Waikato. I am wanting 
to do research with individuals who attend the Salvation Army in Hamilton. What this 
means is that we would like you to participate in some tests to see how you remember 
things (like times, dates, experiences), how you plan and organise your time, how you 
solve problems, and how good your attention span is etc. In addition, we would like to 
ask you questions about your previous drug use and previous and current treatment for 
drug and alcohol use. It will take approximately 45 minutes of your time to participate in 
this research. 
 
The type of tests we want to use are not scary (no blood tests, no heavy machinery!), but 
are things like problem solving tasks, memory skills, and pencil and paper tests (a bit like 
school, but we won’t give you a grade on it!). People have actually said they are quiet fun 
to participate in. Participation in this research would require approximately 45 minutes of 
your time, and drinks and food will be provided for those that are interested. 
 
We would like to know what you think about the research, or if you would be interested 
in taking part you can contact Susan on (07) 838 4755. Alternatively, if you have any 
concerns regarding the research you can contact the Health Advocacy Service on 0800 
423 638 or the convenor of the Research and Ethics Committee at the University of 
Waikato (Dr Robert Isler, phone: 838 4466 ext. 8401, e-mail r.isler@waikato.ac.nz).   
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Research Participants Needed 
 
Hi, my name is Susan and I am a PhD student at the University of Waikato. I am wanting to do 
research with individuals who attend the Needle Exchange Service in Hamilton. What this means 
is that we would like you to participate in some tests to see how you remember things (like times, 
dates, experiences), how you plan and organise your time, how you solve problems, and how 
good your attention span is etc.  
In addition, we would like to ask you questions about your previous drug use and previous 
treatment for drug and alcohol use that you may have received. It will take approximately 45 
minutes of your time to participate in this research. 
 
Research in the drug and alcohol field suggests that individuals who use substances may 
experience difficulties with remembering things, planning and organising their time, and solving 
problems. As such we want to try and figure out what problems the substance using population is 
having in Hamilton and would like to get people to do tests to find this out.  
 
The type of tests we want to use are not scary (no blood tests, no heavy machinery!), but are 
things like problem solving tasks, memory skills, and pencil and paper tests (a bit like school, but 
we won’t give you a grade on it!). People have actually said these are quiet fun to participate in. 
Participation in this research would require approximately 45 minutes of your time, and drinks 
and food will be provided for those that are interested. 
 
We hope this research will help us better understand people who use substances and make 
treatment services more accessible. In addition, it is hoped that this research will help individuals 
by identifying difficulties they are having and suggesting changes to present services to help in 
these areas. 
 
If you would like to find out more about the research, or if you would be interested in taking part 
you can contact Susan on (07) 838 4755. If you have any concerns about the research you can 
contact the Health Advocacy Service on Health 0800 423 638 or the convenor of the Research 
and Ethics Committee at the University of Waikato (Dr Robert Isler, phone: 838 4466 ext. 8401, 
e-mail r.isler@waikato.ac.nz).   
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APPENDIX XVIII 
 
Testing of memory, attention and other cognitive areas of 
individuals attending the Community Alcohol & Drug 
Service 
 
About the research: 
Hi, my name is Susan and I am a PhD student at the University of Waikato. I am wanting 
to do research with individuals who attend the Community Alcohol & Drug Service in 
Hamilton. What this means is that we would like you to participate in some tests to see 
how you remember things (like times, dates, experiences), how you plan and organise 
your time, how you solve problems, and how good your attention span is etc. In addition, 
we would like to ask you questions about your previous drug use and previous treatment 
for drug and alcohol use that you may have received. It will take approximately 45 
minutes of your time to participate in this research. 
 
The type of tests we want to use are not scary (no blood tests, no heavy machinery!), but 
are things like problem solving tasks, memory skills, and pencil and paper tests (a bit like 
school, but we won’t give you a grade on it!). We also would like to know what you think 
of the treatment services available at the Community Alcohol & Drug Service and if you 
think there is anything we could do to improve it. 
 
We hope this research will help us better understand people who use substances and 
make treatment services more accessible. In addition, it is hoped that this research will 
help individuals by identifying difficulties they are having and suggesting changes to 
present services to help in these areas. 
 
Your participation: 
You do not have to take part in this research at all if you do not want to. You can also do 
part of the study but do not have to do all of it. At any time in the study, you can change 
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your mind and not answer questions or chose not to participate. Participation or non-
participation in the research will not adversely affect any present or future treatment that 
you receive. In other words if you don’t want to be part of this research you will continue 
receiving the same treatment that you already receive. 
 
All the information you tell us will remain confidential, although with your consent may 
be discussed with staff at CADS. Whatever you tell us will not affect whether or not you 
can or cannot get services, so your honesty is appreciated. 
 
Results of the study: 
We will discuss a summary of the results of your testing with you if you would like. 
Also, if it is okay with you we would like to discuss the results with other staff members 
at CADS and put the results of your testing in your case notes. 
 
All results will otherwise be anonomised, and individuals will not be identifiable, as 
results will be reported on as a group. Results from this research will be published, 
presented at conferences, and also presented at the Methadone Consumer group meeting, 
A summary report at the end of the research can be provided at the end of the research 
can be provided for access by CADS consumers if you would like. 
 
How to contact us: 
If you are not happy about anything related to this study, or if you want to discuss your 
participation in this study please contact Susan Yates on (07) 838 4755. Alternatively you 
can contact Mary Foster or Nicola Starkey at the University of Waikato on (07) 838 
4466. If you are wanting to discuss or voice any concerns about the research you can also 
contact Health Advocacy on 0800 423 638. 
 
Approval: 
This study has received ethical approval from the University of Waikato Ethics 
Committee and the Northern Y Regional Ethics Committee.  
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Testing of memory, attention and other cognitive areas of 
individuals attending the Salvation Army 
 
 
 
About the research: 
Hi, my name is Susan and I am a PhD student at the University of Waikato. I am wanting 
to do research with individuals who attend the Salvation Army in Hamilton. What this 
means is that we would like you to participate in some tests to see how you remember 
things (like times, dates, experiences), how you plan and organise your time, how you 
solve problems, and how good your attention span is etc. In addition, we would like to 
ask you questions about your previous drug use and previous treatment for drug and 
alcohol use that you may have received. It will take approximately 45 minutes of your 
time to participate in this research. 
 
The type of tests we want to use are not scary (no blood tests, no heavy machinery!), but 
are things like problem solving tasks, memory skills, and pencil and paper tests (a bit like 
school, but we won’t give you a grade on it!). People have actually said these are quiet 
fun to participate in. 
 
Your participation: 
You do not have to take part in this research at all if you do not want to. You can also do 
part of the study but do not have to do all of it. At any time in the study, you can change 
your mind and not answer questions or chose not to participate. Participation or non-
participation in the research will not adversely affect any present or future treatment that 
you receive. In other words if you don’t want to be part of this research you will continue 
receiving the same treatment that you already receive. 
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All the information you tell us will remain confidential. Whatever you tell us will not 
affect whether or not you can or cannot get services, so your honesty is appreciated. 
 
Results of the study: 
We will discuss a summary of the results of your testing with you if you would like. All 
results will otherwise be anonomised, and individuals will not be identifiable, as results 
will be reported on as a group. Results from this research will be published, presented at 
conferences, and also presented at the Methadone Consumer group meeting, A summary 
report at the end of the research can be provided at the end of the research if you would 
like. 
 
How to contact us: 
If you are not happy about anything related to this study, or if you want to discuss your 
participation in this study please contact Susan Yates on (07) 838 4755. Alternatively you 
can contact Mary Foster or Nicola Starkey at the University of Waikato on (07) 838 
4466. If you are wanting to discuss or voice any concerns about the research you can also 
contact Health Advocacy on 0800 423 638 or the convenor of the Research and Ethics 
Committee at the University of Waikato (Dr Robert Isler, phone: 838 4466 ext. 8401, e-
mail r.isler@waikato.ac.nz).   
 
Approval: 
This study has received ethical approval from the Research and Ethics Committee at the 
University of Waikato and the Northern Y Regional Ethics Committee.  
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APPENDIX XX 
 
Testing of memory, attention and other cognitive areas 
of individuals attending the 
Needle Exchange Service 
 
 
About the research: 
Hi, my name is Susan and I am a PhD student at the University of Waikato. I am wanting 
to do research with individuals who attend the Needle Exchange Service in Hamilton. 
What this means is that we would like you to participate in some tests to see how you 
remember things (like times, dates, experiences), how you plan and organise your time, 
how you solve problems, and how good your attention span is etc. In addition, we would 
like to ask you questions about your previous drug use and previous treatment for drug 
and alcohol use that you may have received. It will take approximately 45 minutes of 
your time to participate in this research. 
 
The type of tests we want to use are not scary (no blood tests, no heavy machinery!), but 
are things like problem solving tasks, memory skills, and pencil and paper tests (a bit like 
school, but we won’t give you a grade on it!).  
 
We hope this research will help us better understand people who use substances and 
make treatment services more accessible. In addition, it is hoped that this research will 
help individuals by identifying difficulties they are having and suggesting changes to 
present services to help in these areas. 
 
Your participation: 
You do not have to take part in this research at all if you do not want to. You can also do 
part of the study but do not have to do all of it. At any time in the study, you can change 
your mind and not answer questions or chose not to participate. Participation or non-
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participation in the research will not adversely affect any present or future treatment that 
you receive.  
 
All the information you tell us will remain confidential. Whatever you tell us will not 
affect whether or not you can or cannot get services so your honesty is appreciated. 
 
Results of the study: 
We will discuss a summary of the results of your testing with you if you would like. All 
results will otherwise be anonomised, and individuals will not be identifiable, as results 
will be reported on as a group. Results from this research will be published, presented at 
conferences, and also presented at the Methadone Consumer group meeting, A summary 
report at the end of the research can be provided at the end of the research if you would 
like. 
 
How to contact us: 
If you are not happy about anything related to this study, or if you want to discuss your 
participation in this study please contact Susan Yates on (07) 838 4755. Alternatively you 
can contact Mary Foster or Nicola Starkey at the University of Waikato on (07) 838 
4466. If you are wanting to discuss or voice any concerns about the research you can also 
contact Health Advocacy on 0800 423 638. 
 
Approval: 
This study has received ethical approval from the University of Waikato Ethics 
Committee and the Northern Y Regional Ethics Committee. 
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APPENDIX XXI 
 
Testing of memory, attention and other cognitive areas of 
individuals attending the  
Community Alcohol & Drug Service 
 
I have read and I understand the information sheet provided to volunteers taking part in this study 
designed to test memory, attention and other cognitive functions. I have been given the 
opportunity to discuss the research I am satisfied with the answers I have been given. I have also 
been given an information sheet with the contact details of the researcher if I wish to ask any 
questions at a later stage. 
 
I agree for the researcher to review my relevant medical records and case notes for the sol 
purpose of gaining information for this study. I also understand that the researcher will record in 
my case notes that I have participated in this research. 
 
I understand that taking part in this research is voluntary (my choice) and that I may withdraw 
from the study at any time and that this will in no way adversely affect my present, or future 
treatment. I understand that my participation in this study is confidential and that no material that 
can identify me will be used in any reports on this study. 
 
As part of the research I understand that I will participate in some testing of things like memory 
and attention. I would like to receive feedback regarding the testing 
         YES/NO 
I agree for the results of my testing to be included in my case notes             YES/NO 
 
I agree for my GP or other current provider to be informed of the results of my participation in 
the research                                              YES/NO 
 
I __________________________________________ hereby consent to take part in this research.  
 
Signed _____________________________   Date ________________ 
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Testing of memory, attention and other cognitive areas of 
individuals attending the Salvation Army 
 
 
I have read and I understand the information sheet provided to volunteers taking part in 
this study designed to test memory, attention and other cognitive functions. I have been 
given the opportunity to discuss the research I am satisfied with the answers I have been 
given. I have also been given an information sheet with the contact details of the 
researcher if I wish to ask any questions at a later stage. 
 
I understand that taking part in this research is voluntary (my choice) and that I may 
withdraw from the study at any time and that this will in no way adversely affect my 
present, or future treatment. I understand that my participation in this study is 
confidential and that no material that can identify me will be used in any reports on this 
study. 
 
As part of the research I understand that I will participate in some testing of things like 
memory and attention. I would like to receive feedback regarding the testing 
         YES/NO 
I agree for the results of my testing to be included in my case notes           YES/NO 
 
I agree for my GP or other current provider to be informed of the results of my 
participation in the research                                  YES/NO 
 
I __________________________________________ hereby consent to take part in this 
research.  
 
Signed _____________________________   Date ________________ 
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Testing of memory, attention and other cognitive areas 
of individuals attending the  
Needle Exchange Service 
 
 
I have read and I understand the information sheet provided to volunteers taking part in 
this study designed to test memory, attention and other cognitive functions. I have been 
given the opportunity to discuss the research I am satisfied with the answers I have been 
given. I have also been given an information sheet with the contact details of the 
researcher if I wish to ask any questions at a later stage. 
 
I understand that taking part in this research is voluntary (my choice) and that I may 
withdraw from the study at any time. I understand that my participation in this study is 
confidential and that no material that can identify me will be used in any reports on this 
study. 
 
 
I __________________________________________ hereby consent to take part in this 
research.  
 
 
Signed _____________________________   Date ________________ 
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Demographic Information 
Participant Number: _______________  Date of Interview: ______________ 
Location: ________________________  Gender: _______________   
Age: ______________    Ethnicity: _____________________  
Academic achievement: _____________  Handedness: ___________________ 
 
If on MMT 
Time of Administration: ____________  Time on MMT: ______________ 
Present methadone dose: ____________ 
 
Medical Information 
Have you previously had any head injuries? __________ 
- How many? ____________ 
- How long were you unconscious? ____________ 
- Severity/did you require hospitalisation? ____________ 
 
Drug & Alcohol Use 
Age at onset of drug use:__________  Age at onset of opioid use: ____________ 
      Length of time using opiates: __________ 
Have you ever overdoses: _________  
- How many? ______________ 
- Severity/did you require hospitalisation? ____________________ 
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Current Treatment 
Current Service receiving treatment from: 
⁪ Community Alcohol & Drug Service 
⁪ Salvation Army Bridge Program 
⁪ Other: ________________________ 
⁪ Not currently in treatment 
 
Receiving treatment for: 
________________________________________________________________________ 
 
Current drug use (type and frequency of use) 
________________________________________________________________________ 
 
Use of substances in last 48 hours: 
________________________________________________________________________ 
 
Psychiatric 
Curent Diagnoses: 
 
 
 
 
 
